

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s). If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Requests: cder_mpl2p_wp016, cder_mpl2p_wp022, cder_mpl1p_wp034

Request IDs: cder_mpl2p_wp016_nsdv_v02, cder_mpl2p_wp022_nsdv_v01, cder_mpl1p_wp034_nsdv_v01

Request Description: In this report we examined the association between exposure to hydrochlorothiazide (HCTZ)-containing products and incidence of non-melanoma skin cancer (NMSC) in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, Version 7.0.3, with Propensity Score Analysis module and ad hoc programming.

Data Source: We distributed this request to 17 Sentinel Data Partners. The study period included data from January 1, 2000 to August 31, 2018. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We conducted a retrospective new-user cohort study where we evaluated the occurrence of basal cell carcinoma and squamous cell carcinoma following initiation of HCTZ or the comparator drugs: angiotensin-converting enzyme inhibitors (ACEIs). We conducted 1:1 propensity score-matched analysis comparing individuals initiating HCTZ or ACEI using the nearest neighbor approach. We also evaluated a dose-response relation between cumulative use of HCTZ and basal cell carcinoma and squamous cell carcinoma. This was a Type 2 analysis using the Propensity Score Analysis module in the Query Request Package (QRP) documentation with additional ad hoc programming.

Exposure and Comparator: We defined the exposure of interest, new use of HCTZ-containing products, and the comparator of interest, new use of ACEI monotherapy or non-HCTZ ACEI combination products, using outpatient dispensing data and National Drug Codes (NDCs). New use was defined as no evidence of the exposure or comparator in the 183 days prior to the index dispensing. See Appendix B for a list of generic drug names used to define exposures in this request.

Cohort Eligibility Criteria: We required members included in the cohort to be continuously enrolled in health plans with both medical and drug coverage for at least 183 days prior to their first qualifying (index) dispensing date, during which gaps in coverage of up to 45 days were allowed. Our cohort included individuals newly initiating HCTZ or ACEI who had no evidence of a cancer diagnosis, use of any chemotherapeutic agent, or radiation therapy in the 183 days prior to index dispensing. We also excluded individuals who had evidence of the outcome or exposure to both HCTZ and ACEI on the index dispensing date. Only the first qualifying treatment episode of HCTZ or ACEI was assessed; cohort re-entry was not allowed. We included the following age groups in the cohort: 0-48, 50-59, 60-74, and 75+ years.

Outcomes of Interest: The two outcomes of interest included under NMSC were basal cell carcinoma and squamous cell carcinoma. Each outcome was investigated separately. Our outcome definition required a diagnosis code for the cancer of interest in any care setting accompanied by evidence of tumor removal or topical chemotherapy on the same day as the diagnosis or in the 30 days following diagnosis. The day of diagnosis was designated as the date that the outcome occurred. We defined outcomes of squamous cell carcinoma and basal cell carcinoma using NDCs, International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes, International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) diagnosis codes, and Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes. Please see Appendix C for a list of diagnosis and procedure codes used to define the outcomes in this request. Please see Appendix D for a list of generic and brand drug names used to define outcomes in this request.

Follow-up: Follow-up began on the day after the index dispensing and continued until the outcome occurred or the first occurrence of any of the following censoring events: 1) disenrollment; 2) death; 3) end of query period (August 31, 2018); 4) end of Data Partner data availability; 5) diagnosis of any non-NMSC cancer; or 6) use of chemotherapy or radiation therapy. Follow-up time was extended beyond discontinuation of treatment with the use of ad hoc programming. Censoring criteria was defined using NDCs, CPT-4 procedure codes, ICD-9-CM diagnosis codes, and ICD-10-CM diagnosis codes. Please see Appendix E for a list of diagnosis and procedure codes used to define censoring criteria in this request. Please see Appendix F for a list of generic and brand drug names used to define censoring criteria in this request.

Overview for Requests: cder_mpl2p_wp016, cder_mpl2p_wp022, cder_mpl1p_wp034

Baseline Characteristics: We assessed the following characteristics at baseline: age, sex, calendar year, naevi, mole removal, immunosuppressive conditions, xeroderma pigmentosum, photosensitizing drugs, alcohol use, actinic keratosis, Bowen's disease, human papillomavirus, Arsenic exposure, diabetes, drugs with antineoplastic effects, healthcare utilization, prior combined comorbidity raw score, and exposure to ultraviolet radiation. These characteristics were measured either on the day of index dispensing (age, calendar year) or in the 183 days prior. These characteristics were defined using diagnosis (ICD-9-CM, ICD-10-CM), procedure (ICD-9-CM, ICD-10-CM, CPT, HCPCS), and drug (NDC) codes. Please see Appendix G and H for the full list used. Exposure to ultraviolet radiation was determined based on data from the National Weather Service and categorized into: low, moderate, high, very high, or extremely high based on the convention used by the World Health Organization to report ultraviolet index.

Cumulative Dose Calculation: We calculated the cumulative dose of exposure to any HCTZ-containing product starting from the day of index dispensing until the end of follow-up time. Dose was calculated by multiplying the amount supplied of the dispensing by the strength of HCTZ in the product dispensed. Cumulative dose represented the sum of doses associated with all HCTZ-containing dispensings in the follow-up period. For dispensings with amount supplied values outside of the expected range of 1-365, the amount supplied value was replaced with the days supplied. Exceptions to this replacement applied to the following custom values of amount supplied: 600, 900, 1800, 6000, 9000, 18000; these values were replaced with the custom amount supplied values of 60, 90, 180, 60, 90, and 180, respectively. We categorized cumulative dose as: <10,000mg, 10,000–24,999mg, 25,000–49,999mg, 50,000–74,999mg, 75,000–99,999mg, ≥100,000mg, and ≥ 50,000mg. Follow-up time in each cumulative dose category was reset when individuals accrued enough exposure to move to a higher cumulative dose group. We reported frequencies of cumulative at-risk times, cumulative dispensed days, and the final dispensing strength of HCTZ, overall and by cumulative HCTZ dose group.

Analysis: For each comparison, we used Cox proportional hazards regression models to estimate hazard ratios and corresponding 95% confidence intervals for the unmatched analyses and the unconditional matched analyses. Subgroups of effect estimation included: age, sex, and race. For the dose-response analyses, we estimated age and data partner site-adjusted incidence rate ratios for each cumulative HCTZ dose group relative to ACEI using a generalized linear model with log-link and Poisson distribution within the 1:1 propensity score-matched population.

Sensitivity Analyses: We performed the following sensitivity analyses modifying parameters used in ascertaining outcomes of basal cell carcinoma and squamous cell carcinoma. We expanded the time window following cancer diagnosis where we examined evidence for tumor removal or chemotherapy from 30 days to 1) 60 days; and 2) 180 days. We also introduced a blackout period of 2 years following index dispensing during which time any occurrence of NMSC in HCTZ or ACEI was excluded.

Limitations: Algorithms used to define exposures, outcomes, and covariates are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitations in mind.

Please see the Appendices I and J for the specifications of parameters used in the analyses for this request.

Notes: Please contact the Sentinel Operations Center Query Fulfillment Team (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of Contents

<u>Table 1a</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (Unmatched, Aggregated), Ratio: 1:1, Caliper:0.05
<u>Table 1b</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (Matched, Aggregated), Ratio: 1:1, Caliper:0.05
<u>Table 1c</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (Unmatched, Aggregated), Ratio: 1:1, Caliper:0.05
<u>Table 1d</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (Matched, Aggregated), Ratio: 1:1, Caliper:0.05
<u>Table 1e</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Overall
<u>Table 1f</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: <10,000mg
<u>Table 1g</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 10,000-24,999mg
<u>Table 1h</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 25,000-49,999mg
<u>Table 1i</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 50,000-74,999mg
<u>Table 1j</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 75,000-99,999mg
<u>Table 1k</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=100,000mg
<u>Table 1l</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=50,000mg
<u>Table 1m</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Overall
<u>Table 1n</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: <10,000mg

Table of Contents

<u>Table 1o</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 10,000-24,999mg
<u>Table 1p</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 25,000-49,999mg
<u>Table 1q</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 50,000-74,999mg
<u>Table 1r</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 75,000-99,999mg
<u>Table 1s</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=100,000mg
<u>Table 1t</u>	Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=50,000mg
<u>Table 2</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Overall
<u>Table 3</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Sex
<u>Table 4</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Age Group
<u>Table 5</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Race
<u>Table 6</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, Overall
<u>Table 7</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Sex
<u>Table 8</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Age Group
<u>Table 9</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Race
<u>Table 10</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Analysis Type
<u>Table 11</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Sex
<u>Table 12</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Age Group
<u>Table 13</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Race

Table of Contents

<u>Table 14</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Analysis Type
<u>Table 15</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Sex
<u>Table 16</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Age Group
<u>Table 17</u>	Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Race
<u>Table 18</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Analysis Type
<u>Table 19</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Sex
<u>Table 20</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Age Group
<u>Table 21</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Race
<u>Table 22</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Analysis Type
<u>Table 23</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Sex
<u>Table 24</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Age Group
<u>Table 25</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Race
<u>Table 26</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Analysis Type
<u>Table 27</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Sex
<u>Table 28</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Age Group
<u>Table 29</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Race
<u>Table 30</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Analysis Type
<u>Table 31</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Sex
<u>Table 32</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Age Group
<u>Table 33</u>	Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Race

Table of Contents

<u>Table 34</u>	Site and Age adjusted Effect Estimates for Basal Cell Carcinoma with Dose-specific Follow-up Time in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, All Races, by Hydrochlorothiazide (HCTZ) cumulative dose
<u>Table 35</u>	Site and Age adjusted Effect Estimates for Basal Cell Carcinoma with Dose-specific Follow-up Time in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, White Race Only, by Hydrochlorothiazide (HCTZ) cumulative dose
<u>Table 36</u>	Site and Age adjusted Effect Estimates for Squamous Cell Carcinoma with Dose-specific Follow-up Time in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, All Races, by Hydrochlorothiazide (HCTZ) cumulative dose
<u>Table 37</u>	Site and Age adjusted Effect Estimates for Squamous Cell Carcinoma with Dose-specific Follow-up Time in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, White Race Only, by Hydrochlorothiazide (HCTZ) cumulative dose
<u>Table 38</u>	Number of Matched Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome, by Exposure and Days Dispensed
<u>Table 39</u>	Distribution of Hydrochlorothiazide (HCTZ) Dispensings for Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome, by Pill Strength and Cumulative Dose Category
<u>Table 40</u>	Number of Matched Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome, by Exposure and Days Dispensed
<u>Table 41</u>	Distribution of Hydrochlorothiazide (HCTZ) Dispensings for Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome, by Pill Strength and Cumulative Dose Category
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (April 12, 2019)
<u>Appendix B</u>	List of Generic Drug Names Used to Define the Exposure and Comparator in this Request
<u>Appendix C</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request
<u>Appendix D</u>	List of Generic and Brand Drug Names Used to Define Outcomes in this Request
<u>Appendix E</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Censoring Criteria in this Request
<u>Appendix F</u>	List of Generic and Brand Drug Names Used to Define Censoring Criteria in this Request
<u>Appendix G</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request
<u>Appendix H</u>	List of Generic and Brand Drug Names Used to Define Covariates in this Request
<u>Appendix I</u>	Specifications used to Define Parameters for Outcome 1 (Basal Cell Carcinoma) in this Request
<u>Appendix J</u>	Specifications used to Define Parameters for Outcome 2 (Squamous Cell Carcinoma) in this Request
<u>Appendix K</u>	Design Diagram for this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (Unmatched, Aggregated), Ratio: 1:1, Caliper:0.05

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients	6,959,086	100.0%	7,417,942	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean Age (years)	59.8	13	61.6	13.6	-1.813	-0.137
Age (years)	Number	Percent	Number	Percent		
0-49	1,925,761	27.7%	1,754,358	23.7%	4.022	0.092
50-59	1,537,829	22.1%	1,577,347	21.3%	0.834	0.02
60-74	2,308,436	33.2%	2,557,657	34.5%	-1.308	-0.028
75+	1,187,060	17.1%	1,528,580	20.6%	-3.549	-0.091
Sex						
Female	4,278,186	61.5%	3,469,657	46.8%	14.702	0.298
Male	2,680,900	38.5%	3,948,285	53.2%	-14.702	-0.298
Year						
2000	47,411	0.7%	37,352	0.5%	0.536	0.026
2001	85,339	1.2%	67,132	0.9%	0.976	0.037
2002	82,646	1.2%	71,242	1.0%	0.276	0.01
2003	97,660	1.4%	84,788	1.1%	0.262	0.009
2004	93,239	1.3%	74,996	1.0%	0.968	0.036
2005	79,437	1.1%	69,255	0.9%	0.275	0.011
2006	154,582	2.2%	111,949	1.5%	1.252	0.055
2007	230,985	3.3%	169,461	2.3%	1.803	0.072
2008	388,647	5.6%	318,010	4.3%	1.179	0.044
2009	477,770	6.9%	422,681	5.7%	0.712	0.024
2010	643,173	9.2%	655,595	8.8%	0.388	0.013
2011	794,782	11.4%	876,148	11.8%	-0.419	-0.013
2012	721,550	10.4%	818,864	11.0%	-0.671	-0.022
2013	711,528	10.2%	829,575	11.2%	-0.959	-0.031
2014	670,311	9.6%	825,455	11.1%	-1.496	-0.049
2015	652,391	9.4%	786,664	10.6%	-1.23	-0.041
2016	645,630	9.3%	774,474	10.4%	-1.162	-0.039
2017	296,162	4.3%	328,338	4.4%	-1.073	-0.042
2018	85,843	1.2%	95,963	1.3%	-0.382	-0.022

Table 1a. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (Unmatched, Aggregated), Ratio: 1:1, Caliper:0.05

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	194,993	2.8%	202,301	2.7%	0.075	0.005
Alcohol Use	64,945	0.9%	110,932	1.5%	-0.562	-0.051
Antineoplastic Effects	3,135,003	45.0%	3,965,006	53.5%	-8.403	-0.169
Arsenic Exposure	95	0.0%	121	0.0%	0	-0.001
Diabetes	1,303,595	18.7%	2,658,680	35.8%	-17.109	-0.391
Human papillomavirus	15,636	0.2%	9,668	0.1%	0.094	0.022
Immunosuppressive: Chronic pulmonary	818,485	11.8%	1,164,329	15.7%	-3.935	-0.115
Immunosuppressive: Connective Tissue Disease	120,473	1.7%	133,577	1.8%	-0.07	-0.005
Immunosuppressive: CVD	777,807	11.2%	1,931,277	26.0%	-14.858	-0.389
Immunosuppressive: Glucocorticoids	1,987,513	28.6%	2,035,009	27.4%	1.126	0.025
Immunosuppressive: HIV	23,615	0.3%	33,084	0.4%	-0.107	-0.017
Immunosuppressive: Immune Disorders	6,909	0.1%	9,562	0.1%	-0.03	-0.009
Immunosuppressive: Moderate/Severe Renal Disease	37,557	0.5%	216,952	2.9%	-2.385	-0.184
Immunosuppressive: Severe Skin disease	6,815	0.1%	19,276	0.3%	-0.162	-0.038
Immunosuppressive: Transplant	12,655	0.2%	50,150	0.7%	-0.494	-0.076
Immunosuppressive: Treatment for Immune Disorders	621,843	8.9%	604,615	8.2%	0.785	0.028
Immunosuppressive: White Blood Cell Disease	3,302	0.0%	6,398	0.1%	-0.039	-0.015
Mole Removal	59,979	0.9%	56,865	0.8%	0.095	0.011
Naevi	52,905	0.8%	45,911	0.6%	0.141	0.017
Photosensitizing: Aminoquinolines	37,656	0.5%	37,611	0.5%	0.034	0.005
Photosensitizing: Amiodarone	35,412	0.5%	130,347	1.8%	-1.248	-0.118
Photosensitizing: Macrolides	854,963	12.3%	870,074	11.7%	0.556	0.017
Photosensitizing: Methoxypsoralen	80	0.0%	74	0.0%	0	0
Photosensitizing: Retinoids	2,905	0.0%	1,710	0.0%	0.019	0.01
Photosensitizing: Tetracycline	13,216	0.2%	11,708	0.2%	0.032	0.008
UV Radiation: Extreme	4,914	0.1%	3,681	0.0%	0.021	0.009
UV Radiation: High	3,001,262	43.1%	2,899,661	39.1%	4.037	0.082
UV Radiation: Low	8,485	0.1%	12,389	0.2%	-0.045	-0.012
UV Radiation: Moderate	2,732,675	39.3%	3,163,459	42.6%	-3.378	-0.069
UV Radiation: Unknown	100,902	1.4%	100,857	1.4%	0.09	0.008
UV Radiation: Very High	1,110,848	16.0%	1,237,895	16.7%	-0.725	-0.02
Xeroderma pigmentosum	496	0.0%	311	0.0%	0.003	0.004

Table 1a. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (Unmatched, Aggregated), Ratio: 1:1, Caliper:0.05

	HCTZ		ACEI		Covariate Balance	
	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Health Service Utilization Intensity:						
Prior Combined Comorbidity Raw Score	0	1.4	0.9	2.2	-0.808	-0.435
Mean Number of Ambulatory Encounters (AV)	6.7	6.9	7.4	7.8	-0.705	-0.096
Mean Number of Emergency Room Encounters (ED)	0.3	0.8	0.4	1	-0.107	-0.113
Mean Number of Inpatient Hospital Encounters (IP)	0.1	0.4	0.3	0.7	-0.194	-0.326
Mean Number of Non-Acute Institutional Encounters (IS)	0	0.3	0.1	0.5	-0.06	-0.144
Mean Number of Other Ambulatory Encounters (OA)	1.6	3.9	3.2	7.4	-1.594	-0.269
Mean Number of Filled Prescriptions	13.6	13.9	16	16.3	-2.384	-0.158
Mean Number of Generics	6.3	4.3	7.1	4.7	-0.824	-0.182

Table 1b. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (Matched, Aggregated), Ratio: 1:1, Caliper:0.05

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients	5,211,321	74.9%	5,211,321	70.3%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean Age (years)	60.7	13	60.7	13.3	0.015	0.001
Age (years)	Number	Percent	Number	Percent		
0-49	1,332,378	25.6%	1,322,000	25.4%	0.199	0.005
50-59	1,107,392	21.2%	1,135,100	21.8%	-0.532	-0.013
60-74	1,813,053	34.8%	1,779,209	34.1%	0.649	0.014
75+	958,498	18.4%	975,012	18.7%	-0.317	-0.008
Sex						
Female	2,736,163	52.5%	2,768,027	53.1%	-0.611	-0.012
Male	2,475,158	47.5%	2,443,294	46.9%	0.611	0.012
Year						
2000	25,302	0.5%	25,037	0.5%	0.045	0.002
2001	44,850	0.9%	44,903	0.9%	-0.009	0
2002	46,355	0.9%	46,050	0.9%	0.052	0.002
2003	52,102	1.0%	52,026	1.0%	0.013	0
2004	49,634	1.0%	49,608	1.0%	0.004	0
2005	44,039	0.8%	43,674	0.8%	0.055	0.002
2006	82,156	1.6%	82,532	1.6%	-0.023	-0.001
2007	131,852	2.5%	132,344	2.5%	-0.024	-0.001
2008	255,090	4.9%	253,045	4.9%	0.065	0.002
2009	333,271	6.4%	332,164	6.4%	0.035	0.001
2010	483,044	9.3%	482,370	9.3%	0.013	0
2011	621,205	11.9%	620,637	11.9%	0.011	0
2012	572,146	11.0%	571,490	11.0%	0.013	0
2013	571,797	11.0%	571,491	11.0%	0.006	0
2014	550,546	10.6%	550,445	10.6%	0.002	0
2015	530,670	10.2%	531,053	10.2%	-0.007	0
2016	520,025	10.0%	522,831	10.0%	-0.054	-0.002
2017	228,800	4.4%	230,886	4.4%	-0.066	-0.003
2018	68,437	1.3%	68,735	1.3%	-0.014	-0.001

Table 1b. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (Matched, Aggregated), Ratio: 1:1, Caliper:0.05

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	151,216	2.9%	150,762	2.9%	0.009	0.001
Alcohol Use	55,099	1.1%	54,842	1.1%	0.005	0
Antineoplastic Effects	2,518,785	48.3%	2,509,393	48.2%	0.18	0.004
Arsenic Exposure	72	0.0%	67	0.0%	0	0
Diabetes	1,268,567	24.3%	1,267,131	24.3%	0.028	0.001
Human papillomavirus	8,480	0.2%	8,531	0.2%	-0.001	0
Immunosuppressive: Chronic pulmonary	654,848	12.6%	655,038	12.6%	-0.004	0
Immunosuppressive: Connective Tissue Disease	90,349	1.7%	90,078	1.7%	0.005	0
Immunosuppressive: CVD	755,132	14.5%	749,282	14.4%	0.112	0.003
Immunosuppressive: Glucocorticoids	1,446,093	27.7%	1,446,220	27.8%	-0.002	0
Immunosuppressive: HIV	20,493	0.4%	20,419	0.4%	0.001	0
Immunosuppressive: Immune Disorders	5,218	0.1%	5,355	0.1%	-0.003	-0.001
Immunosuppressive: Moderate/Severe Renal Disease	37,410	0.7%	44,315	0.9%	-0.132	-0.015
Immunosuppressive: Severe Skin disease	6,361	0.1%	6,674	0.1%	-0.006	-0.002
Immunosuppressive: Transplant	12,470	0.2%	13,794	0.3%	-0.025	-0.005
Immunosuppressive: Treatment for Immune Disorders	441,748	8.5%	441,360	8.5%	0.007	0
Immunosuppressive: White Blood Cell Disease	2,829	0.1%	2,902	0.1%	-0.001	-0.001
Mole Removal	43,066	0.8%	42,912	0.8%	0.003	0
Naevi	35,479	0.7%	35,618	0.7%	-0.003	0
Photosensitizing: Aminoquinolines	27,184	0.5%	27,304	0.5%	-0.002	0
Photosensitizing: Amiodarone	34,585	0.7%	36,131	0.7%	-0.03	-0.004
Photosensitizing: Macrolides	619,985	11.9%	619,355	11.9%	0.012	0
Photosensitizing: Methoxypsoralen	52	0.0%	52	0.0%	0	0
Photosensitizing: Retinoids	1,481	0.0%	1,465	0.0%	0	0
Photosensitizing: Tetracycline	8,438	0.2%	8,419	0.2%	0	0
UV Radiation: Extreme	3,355	0.1%	3,190	0.1%	0.003	0.001
UV Radiation: High	2,090,902	40.1%	2,091,975	40.1%	-0.021	0
UV Radiation: Low	7,618	0.1%	7,539	0.1%	0.002	0
UV Radiation: Moderate	2,161,323	41.5%	2,158,936	41.4%	0.046	0.001
UV Radiation: Unknown	71,818	1.4%	71,660	1.4%	0.003	0
UV Radiation: Very High	876,305	16.8%	878,021	16.8%	-0.033	-0.001
Xeroderma pigmentosum	258	0.0%	244	0.0%	0	0

Table 1b. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (Matched, Aggregated), Ratio: 1:1, Caliper:0.05

Health Service Utilization Intensity:	HCTZ		ACEI		Covariate Balance	
	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Prior Combined Comorbidity Raw Score	0.2	1.5	0.2	1.6	-0.013	-0.008
Mean Number of Ambulatory Encounters (AV)	6.8	6.9	6.8	7.2	-0.013	-0.002
Mean Number of Emergency Room Encounters (ED)	0.3	0.9	0.3	0.8	-0.004	-0.005
Mean Number of Inpatient Hospital Encounters (IP)	0.1	0.5	0.1	0.4	-0.006	-0.014
Mean Number of Non-Acute Institutional Encounters (IS)	0	0.3	0	0.3	-0.002	-0.008
Mean Number of Other Ambulatory Encounters (OA)	1.8	4.3	1.9	4.3	-0.056	-0.013
Mean Number of Filled Prescriptions	14.2	14.4	14.2	14.7	0.008	0.001
Mean Number of Generics	6.4	4.4	6.4	4.4	0	0

Table 1c. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (Unmatched, Aggregated), Ratio: 1:1, Caliper:0.05

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients	6,959,086	100.0%	7,417,942	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean Age (years)	59.8	13	61.6	13.6	-1.813	-0.137
Age (years)	Number	Percent	Number	Percent		
0-49	1,925,761	27.7%	1,754,358	23.7%	4.022	0.092
50-59	1,537,829	22.1%	1,577,347	21.3%	0.834	0.02
60-74	2,308,436	33.2%	2,557,657	34.5%	-1.308	-0.028
75+	1,187,060	17.1%	1,528,580	20.6%	-3.549	-0.091
Sex						
Female	4,278,186	61.5%	3,469,657	46.8%	14.702	0.298
Male	2,680,900	38.5%	3,948,285	53.2%	-14.702	-0.298
Year						
2000	47,411	0.7%	37,352	0.5%	0.536	0.026
2001	85,339	1.2%	67,132	0.9%	0.976	0.037
2002	82,646	1.2%	71,242	1.0%	0.276	0.01
2003	97,660	1.4%	84,788	1.1%	0.262	0.009
2004	93,239	1.3%	74,996	1.0%	0.968	0.036
2005	79,437	1.1%	69,255	0.9%	0.275	0.011
2006	154,582	2.2%	111,949	1.5%	1.252	0.055
2007	230,985	3.3%	169,461	2.3%	1.803	0.072
2008	388,647	5.6%	318,010	4.3%	1.179	0.044
2009	477,770	6.9%	422,681	5.7%	0.712	0.024
2010	643,173	9.2%	655,595	8.8%	0.388	0.013
2011	794,782	11.4%	876,148	11.8%	-0.419	-0.013
2012	721,550	10.4%	818,864	11.0%	-0.671	-0.022
2013	711,528	10.2%	829,575	11.2%	-0.959	-0.031
2014	670,311	9.6%	825,455	11.1%	-1.496	-0.049
2015	652,391	9.4%	786,664	10.6%	-1.23	-0.041
2016	645,630	9.3%	774,474	10.4%	-1.162	-0.039
2017	296,162	4.3%	328,338	4.4%	-1.073	-0.042
2018	85,843	1.2%	95,963	1.3%	-0.382	-0.022

Table 1c. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (Unmatched, Aggregated), Ratio: 1:1, Caliper:0.05

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	194,993	2.8%	202,301	2.7%	0.075	0.005
Alcohol Use	64,945	0.9%	110,932	1.5%	-0.562	-0.051
Antineoplastic Effects	3,135,003	45.0%	3,965,006	53.5%	-8.403	-0.169
Arsenic Exposure	95	0.0%	121	0.0%	0	-0.001
Diabetes	1,303,595	18.7%	2,658,680	35.8%	-17.109	-0.391
Human papillomavirus	15,636	0.2%	9,668	0.1%	0.094	0.022
Immunosuppressive: Chronic pulmonary	818,485	11.8%	1,164,329	15.7%	-3.935	-0.115
Immunosuppressive: Connective Tissue Disease	120,473	1.7%	133,577	1.8%	-0.07	-0.005
Immunosuppressive: CVD	777,807	11.2%	1,931,277	26.0%	-14.858	-0.389
Immunosuppressive: Glucocorticoids	1,987,513	28.6%	2,035,009	27.4%	1.126	0.025
Immunosuppressive: HIV	23,615	0.3%	33,084	0.4%	-0.107	-0.017
Immunosuppressive: Immune Disorders	6,909	0.1%	9,562	0.1%	-0.03	-0.009
Immunosuppressive: Moderate/Severe Renal Disease	37,557	0.5%	216,952	2.9%	-2.385	-0.184
Immunosuppressive: Severe Skin disease	6,815	0.1%	19,276	0.3%	-0.162	-0.038
Immunosuppressive: Transplant	12,655	0.2%	50,150	0.7%	-0.494	-0.076
Immunosuppressive: Treatment for Immune Disorders	621,843	8.9%	604,615	8.2%	0.785	0.028
Immunosuppressive: White Blood Cell Disease	3,302	0.0%	6,398	0.1%	-0.039	-0.015
Mole Removal	59,979	0.9%	56,865	0.8%	0.095	0.011
Naevi	52,905	0.8%	45,911	0.6%	0.141	0.017
Photosensitizing: Aminoquinolines	37,656	0.5%	37,611	0.5%	0.034	0.005
Photosensitizing: Amiodarone	35,412	0.5%	130,347	1.8%	-1.248	-0.118
Photosensitizing: Macrolides	854,963	12.3%	870,074	11.7%	0.556	0.017
Photosensitizing: Methoxypsoralen	80	0.0%	74	0.0%	0	0
Photosensitizing: Retinoids	2,905	0.0%	1,710	0.0%	0.019	0.01
Photosensitizing: Tetracycline	13,216	0.2%	11,708	0.2%	0.032	0.008
UV Radiation: Extreme	4,914	0.1%	3,681	0.0%	0.021	0.009
UV Radiation: High	3,001,262	43.1%	2,899,661	39.1%	4.037	0.082
UV Radiation: Low	8,485	0.1%	12,389	0.2%	-0.045	-0.012
UV Radiation: Moderate	2,732,675	39.3%	3,163,459	42.6%	-3.378	-0.069
UV Radiation: Unknown	100,902	1.4%	100,857	1.4%	0.09	0.008
UV Radiation: Very High	1,110,848	16.0%	1,237,895	16.7%	-0.725	-0.02
Xeroderma pigmentosum	496	0.0%	311	0.0%	0.003	0.004

Table 1c. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (Unmatched, Aggregated), Ratio: 1:1, Caliper:0.05

	HCTZ		ACEI		Covariate Balance	
	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Health Service Utilization Intensity:						
Prior Combined Comorbidity Raw Score	0	1.4	0.9	2.2	-0.808	-0.435
Mean Number of Ambulatory Encounters (AV)	6.7	6.9	7.4	7.8	-0.705	-0.096
Mean Number of Emergency Room Encounters (ED)	0.3	0.8	0.4	1	-0.107	-0.113
Mean Number of Inpatient Hospital Encounters (IP)	0.1	0.4	0.3	0.7	-0.194	-0.326
Mean Number of Non-Acute Institutional Encounters (IS)	0	0.3	0.1	0.5	-0.06	-0.144
Mean Number of Other Ambulatory Encounters (OA)	1.6	3.9	3.2	7.4	-1.594	-0.269
Mean Number of Filled Prescriptions	13.6	13.9	16	16.3	-2.384	-0.158
Mean Number of Generics	6.3	4.3	7.1	4.7	-0.824	-0.182

Table 1d. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (Matched, Aggregated), Ratio: 1:1, Caliper:0.05

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients	5,211,321	74.9%	5,211,321	70.3%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean Age (years)	60.7	13	60.7	13.3	0.015	0.001
Age (years)	Number	Percent	Number	Percent		
0-49	1,332,378	25.6%	1,322,000	25.4%	0.199	0.005
50-59	1,107,392	21.2%	1,135,100	21.8%	-0.532	-0.013
60-74	1,813,053	34.8%	1,779,209	34.1%	0.649	0.014
75+	958,498	18.4%	975,012	18.7%	-0.317	-0.008
Sex						
Female	2,736,163	52.5%	2,768,027	53.1%	-0.611	-0.012
Male	2,475,158	47.5%	2,443,294	46.9%	0.611	0.012
Year						
2000	25,302	0.5%	25,037	0.5%	0.045	0.002
2001	44,850	0.9%	44,903	0.9%	-0.009	0
2002	46,355	0.9%	46,050	0.9%	0.052	0.002
2003	52,102	1.0%	52,026	1.0%	0.013	0
2004	49,634	1.0%	49,608	1.0%	0.004	0
2005	44,039	0.8%	43,674	0.8%	0.055	0.002
2006	82,156	1.6%	82,532	1.6%	-0.023	-0.001
2007	131,852	2.5%	132,344	2.5%	-0.024	-0.001
2008	255,090	4.9%	253,045	4.9%	0.065	0.002
2009	333,271	6.4%	332,164	6.4%	0.035	0.001
2010	483,044	9.3%	482,370	9.3%	0.013	0
2011	621,205	11.9%	620,637	11.9%	0.011	0
2012	572,146	11.0%	571,490	11.0%	0.013	0
2013	571,797	11.0%	571,491	11.0%	0.006	0
2014	550,546	10.6%	550,445	10.6%	0.002	0
2015	530,670	10.2%	531,053	10.2%	-0.007	0
2016	520,025	10.0%	522,831	10.0%	-0.054	-0.002
2017	228,800	4.4%	230,886	4.4%	-0.066	-0.003
2018	68,437	1.3%	68,735	1.3%	-0.014	-0.001

Table 1d. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (Matched, Aggregated), Ratio: 1:1, Caliper:0.05

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	151,216	2.9%	150,762	2.9%	0.009	0.001
Alcohol Use	55,099	1.1%	54,842	1.1%	0.005	0
Antineoplastic Effects	2,518,785	48.3%	2,509,393	48.2%	0.18	0.004
Arsenic Exposure	72	0.0%	67	0.0%	0	0
Diabetes	1,268,567	24.3%	1,267,131	24.3%	0.028	0.001
Human papillomavirus	8,480	0.2%	8,531	0.2%	-0.001	0
Immunosuppressive: Chronic pulmonary	654,848	12.6%	655,038	12.6%	-0.004	0
Immunosuppressive: Connective Tissue Disease	90,349	1.7%	90,078	1.7%	0.005	0
Immunosuppressive: CVD	755,132	14.5%	749,282	14.4%	0.112	0.003
Immunosuppressive: Glucocorticoids	1,446,093	27.7%	1,446,220	27.8%	-0.002	0
Immunosuppressive: HIV	20,493	0.4%	20,419	0.4%	0.001	0
Immunosuppressive: Immune Disorders	5,218	0.1%	5,355	0.1%	-0.003	-0.001
Immunosuppressive: Moderate/Severe Renal Disease	37,410	0.7%	44,315	0.9%	-0.132	-0.015
Immunosuppressive: Severe Skin disease	6,361	0.1%	6,674	0.1%	-0.006	-0.002
Immunosuppressive: Transplant	12,470	0.2%	13,794	0.3%	-0.025	-0.005
Immunosuppressive: Treatment for Immune Disorders	441,748	8.5%	441,360	8.5%	0.007	0
Immunosuppressive: White Blood Cell Disease	2,829	0.1%	2,902	0.1%	-0.001	-0.001
Mole Removal	43,066	0.8%	42,912	0.8%	0.003	0
Naevi	35,479	0.7%	35,618	0.7%	-0.003	0
Photosensitizing: Aminoquinolines	27,184	0.5%	27,304	0.5%	-0.002	0
Photosensitizing: Amiodarone	34,585	0.7%	36,131	0.7%	-0.03	-0.004
Photosensitizing: Macrolides	619,985	11.9%	619,355	11.9%	0.012	0
Photosensitizing: Methoxypsoralen	52	0.0%	52	0.0%	0	0
Photosensitizing: Retinoids	1,481	0.0%	1,465	0.0%	0	0
Photosensitizing: Tetracycline	8,438	0.2%	8,419	0.2%	0	0
UV Radiation: Extreme	3,355	0.1%	3,190	0.1%	0.003	0.001
UV Radiation: High	2,090,902	40.1%	2,091,975	40.1%	-0.021	0
UV Radiation: Low	7,618	0.1%	7,539	0.1%	0.002	0
UV Radiation: Moderate	2,161,323	41.5%	2,158,936	41.4%	0.046	0.001
UV Radiation: Unknown	71,818	1.4%	71,660	1.4%	0.003	0
UV Radiation: Very High	876,305	16.8%	878,021	16.8%	-0.033	-0.001
Xeroderma pigmentosum	258	0.0%	244	0.0%	0	0

Table 1d. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (Matched, Aggregated), Ratio: 1:1, Caliper:0.05

Health Service Utilization Intensity:	HCTZ		ACEI		Covariate Balance	
	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Prior Combined Comorbidity Raw Score	0.2	1.5	0.2	1.6	-0.013	-0.008
Mean Number of Ambulatory Encounters (AV)	6.8	6.9	6.8	7.2	-0.013	-0.002
Mean Number of Emergency Room Encounters (ED)	0.3	0.9	0.3	0.8	-0.004	-0.005
Mean Number of Inpatient Hospital Encounters (IP)	0.1	0.5	0.1	0.4	-0.006	-0.014
Mean Number of Non-Acute Institutional Encounters (IS)	0	0.3	0	0.3	-0.002	-0.008
Mean Number of Other Ambulatory Encounters (OA)	1.8	4.3	1.9	4.3	-0.056	-0.013
Mean Number of Filled Prescriptions	14.2	14.4	14.2	14.7	0.008	0.001
Mean Number of Generics	6.4	4.4	6.4	4.4	0	0

Table 1e. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Overall

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients ¹	5,192,912	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	60.7	13.0	60.7	13.3	0.015	0.001
Mean age at end of follow-up (years)	63.2	13.1	63.1	13.4	0.030	0.002
Age (years)	Number	Percent	Number	Percent		
0-49	1,327,501	25.6%	1,317,226	25.4%	0.198	0.005
50-59	1,102,894	21.2%	1,130,393	21.8%	-0.530	-0.013
60-74	1,807,465	34.8%	1,773,915	34.2%	0.646	0.014
75+	955,052	18.4%	971,378	18.7%	-0.314	-0.008
Sex						
Female	2,726,320	52.5%	2,758,086	53.1%	-0.612	-0.012
Male	2,466,592	47.5%	2,434,826	46.9%	0.612	0.012
Race/Ethnicity						
American Indian or Alaska Native	16,172	0.3%	25,722	0.5%	-0.184	-0.029
Asian	119,655	2.3%	109,049	2.1%	0.204	0.014
Black or African American	539,989	10.4%	336,082	6.5%	3.927	0.142
Native Hawaiian or Other Pacific Islander	13,857	0.3%	14,146	0.3%	-0.006	-0.001
Unknown	2,261,540	43.6%	2,266,810	43.7%	-0.101	-0.002
White	2,241,699	43.2%	2,441,103	47.0%	-3.840	-0.077
Hispanic Origin	140,381	2.7%	152,340	2.9%	-0.230	-0.014
Year						
2000	24,870	0.5%	24,601	0.5%	0.005	0.001
2001	43,860	0.8%	43,913	0.8%	-0.001	-0.000
2002	45,503	0.9%	45,213	0.9%	0.006	0.001
2003	51,010	1.0%	50,960	1.0%	0.001	0.000
2004	47,265	0.9%	47,202	0.9%	0.001	0.000
2005	42,953	0.8%	42,556	0.8%	0.008	0.001
2006	80,467	1.5%	80,884	1.6%	-0.008	-0.001
2007	130,915	2.5%	131,415	2.5%	-0.010	-0.001
2008	254,058	4.9%	252,046	4.9%	0.039	0.002
2009	332,065	6.4%	331,001	6.4%	0.020	0.001
2010	480,959	9.3%	480,257	9.2%	0.014	0.000
2011	620,206	11.9%	619,642	11.9%	0.011	0.000
2012	571,117	11.0%	570,459	11.0%	0.013	0.000
2013	570,848	11.0%	570,505	11.0%	0.007	0.000
2014	549,672	10.6%	549,548	10.6%	0.002	0.000
2015	530,051	10.2%	530,434	10.2%	-0.007	-0.000
2016	519,856	10.0%	522,655	10.1%	-0.054	-0.002
2017	228,800	7.2%	230,886	7.3%	-0.066	-0.003
2018	68,437	3.2%	68,735	3.2%	-0.014	-0.001

Table 1e. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Overall

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	150,879	2.9%	150,435	2.9%	0.009	0.001
Alcohol Use	54,883	1.1%	54,647	1.1%	0.005	0.000
Antineoplastic Effects	2,511,689	48.4%	2,502,392	48.2%	0.179	0.004
Arsenic Exposure	72	0.0%	67	0.0%	0.000	0.000
Diabetes	1,266,180	24.4%	1,264,787	24.4%	0.027	0.001
Human papillomavirus	8,446	0.2%	8,494	0.2%	-0.001	-0.000
Immunosuppressive: CVD	753,769	14.5%	747,851	14.4%	0.114	0.003
Immunosuppressive: Chronic Pulmonary	653,301	12.6%	653,486	12.6%	-0.004	-0.000
Immunosuppressive: Connective Tissue Disease	90,145	1.7%	89,857	1.7%	0.006	0.000
Immunosuppressive: Moderate/Severe Renal Disease	37,346	0.7%	44,225	0.9%	-0.132	-0.015
Immunosuppressive: Transplant	12,453	0.2%	13,775	0.3%	-0.025	-0.005
Immunosuppressive: Severe Skin Disease	6,350	0.1%	6,664	0.1%	-0.006	-0.002
Immunosuppressive: Glucocorticoids	1,442,496	27.8%	1,442,636	27.8%	-0.003	-0.000
Immunosuppressive: HIV	20,477	0.4%	20,405	0.4%	0.001	0.000
Immunosuppressive: Immune Disorders	5,210	0.1%	5,349	0.1%	-0.003	-0.001
Immunosuppressive: White Blood Cell Disease	2,827	0.1%	2,899	0.1%	-0.001	-0.001
Immunosuppressive: Treatment for Immune Disorders	441,049	8.5%	440,681	8.5%	0.007	0.000
Mole Removal	42,922	0.8%	42,771	0.8%	0.003	0.000
Naevi	35,351	0.7%	35,482	0.7%	-0.003	-0.000
Photosensitizing: Aminoquinolines	27,094	0.5%	27,212	0.5%	-0.002	-0.000
Photosensitizing: Amiodarone	34,555	0.7%	36,095	0.7%	-0.030	-0.004
Photosensitizing: Macrolides	618,708	11.9%	618,058	11.9%	0.013	0.000
Photosensitizing: Methoxypsoralen	50	0.0%	50	0.0%	0.000	0.000
Photosensitizing: Retinoids	1,463	0.0%	1,453	0.0%	0.000	0.000
Photosensitizing: Tetracycline	8,381	0.2%	8,366	0.2%	0.000	0.000
Xeroderma pigmentosum	257	0.0%	243	0.0%	0.000	0.000

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

Table 1f. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: <10,000mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients ¹	5,192,912	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	60.7	13.0	60.7	13.3	0.015	0.001
Mean age at end of follow-up (years)	63.2	13.1	63.1	13.4	0.030	0.002
Age (years)	Number	Percent	Number	Percent		
0-49	1,327,501	25.6%	1,317,226	25.4%	0.198	0.005
50-59	1,102,894	21.2%	1,130,393	21.8%	-0.530	-0.013
60-74	1,807,465	34.8%	1,773,915	34.2%	0.646	0.014
75+	955,052	18.4%	971,378	18.7%	-0.314	-0.008
Sex						
Female	2,726,320	52.5%	2,758,086	53.1%	-0.612	-0.012
Male	2,466,592	47.5%	2,434,826	46.9%	0.612	0.012
Race/Ethnicity						
American Indian or Alaska Native	16,172	0.3%	25,722	0.5%	-0.184	-0.029
Asian	119,655	2.3%	109,049	2.1%	0.204	0.014
Black or African American	539,989	10.4%	336,082	6.5%	3.927	0.142
Native Hawaiian or Other Pacific Islander	13,857	0.3%	14,146	0.3%	-0.006	-0.001
Unknown	2,261,540	43.6%	2,266,810	43.7%	-0.101	-0.002
White	2,241,699	43.2%	2,441,103	47.0%	-3.840	-0.077
Hispanic Origin	140,381	2.7%	152,340	2.9%	-0.230	-0.014
Year						
2000	24,870	0.5%	24,601	0.5%	0.005	0.001
2001	43,860	0.8%	43,913	0.8%	-0.001	-0.000
2002	45,503	0.9%	45,213	0.9%	0.006	0.001
2003	51,010	1.0%	50,960	1.0%	0.001	0.000
2004	47,265	0.9%	47,202	0.9%	0.001	0.000
2005	42,953	0.8%	42,556	0.8%	0.008	0.001
2006	80,467	1.5%	80,884	1.6%	-0.008	-0.001
2007	130,915	2.5%	131,415	2.5%	-0.010	-0.001
2008	254,058	4.9%	252,046	4.9%	0.039	0.002
2009	332,065	6.4%	331,001	6.4%	0.020	0.001
2010	480,959	9.3%	480,257	9.2%	0.014	0.000
2011	620,206	11.9%	619,642	11.9%	0.011	0.000
2012	571,117	11.0%	570,459	11.0%	0.013	0.000
2013	570,848	11.0%	570,505	11.0%	0.007	0.000
2014	549,672	10.6%	549,548	10.6%	0.002	0.000
2015	530,051	10.2%	530,434	10.2%	-0.007	-0.000
2016	519,856	10.0%	522,655	10.1%	-0.054	-0.002
2017	228,800	7.2%	230,886	7.3%	-0.066	-0.003
2018	68,437	3.2%	68,735	3.2%	-0.014	-0.001

Table 1f. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: <10,000mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	150,879	2.9%	150,435	2.9%	0.009	0.001
Alcohol Use	54,883	1.1%	54,647	1.1%	0.005	0.000
Antineoplastic Effects	2,511,689	48.4%	2,502,392	48.2%	0.179	0.004
Arsenic Exposure	72	0.0%	67	0.0%	0.000	0.000
Diabetes	1,266,180	24.4%	1,264,787	24.4%	0.027	0.001
Human papillomavirus	8,446	0.2%	8,494	0.2%	-0.001	-0.000
Immunosuppressive: CVD	753,769	14.5%	747,851	14.4%	0.114	0.003
Immunosuppressive: Chronic Pulmonary	653,301	12.6%	653,486	12.6%	-0.004	-0.000
Immunosuppressive: Connective Tissue Disease	90,145	1.7%	89,857	1.7%	0.006	0.000
Immunosuppressive: Moderate/Severe Renal Disease	37,346	0.7%	44,225	0.9%	-0.132	-0.015
Immunosuppressive: Transplant	12,453	0.2%	13,775	0.3%	-0.025	-0.005
Immunosuppressive: Severe Skin Disease	6,350	0.1%	6,664	0.1%	-0.006	-0.002
Immunosuppressive: Glucocorticoids	1,442,496	27.8%	1,442,636	27.8%	-0.003	-0.000
Immunosuppressive: HIV	20,477	0.4%	20,405	0.4%	0.001	0.000
Immunosuppressive: Immune Disorders	5,210	0.1%	5,349	0.1%	-0.003	-0.001
Immunosuppressive: White Blood Cell Disease	2,827	0.1%	2,899	0.1%	-0.001	-0.001
Immunosuppressive: Treatment for Immune Disorders	441,049	8.5%	440,681	8.5%	0.007	0.000
Mole Removal	42,922	0.8%	42,771	0.8%	0.003	0.000
Naevi	35,351	0.7%	35,482	0.7%	-0.003	-0.000
Photosensitizing: Aminoquinolines	27,094	0.5%	27,212	0.5%	-0.002	-0.000
Photosensitizing: Amiodarone	34,555	0.7%	36,095	0.7%	-0.030	-0.004
Photosensitizing: Macrolides	618,708	11.9%	618,058	11.9%	0.013	0.000
Photosensitizing: Methoxypsoralen	50	0.0%	50	0.0%	0.000	0.000
Photosensitizing: Retinoids	1,463	0.0%	1,453	0.0%	0.000	0.000
Photosensitizing: Tetracycline	8,381	0.2%	8,366	0.2%	0.000	0.000
Xeroderma pigmentosum	257	0.0%	243	0.0%	0.000	0.000

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

Table 1g. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 10,000-24,999mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	1,329,225	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	63.7	11.9	60.7	13.3	2.924	0.231
Mean age at end of follow-up (years)	66.2	12.1	63.1	13.4	3.037	0.238
Age (years)	Number	Percent	Number	Percent		
0-49	231,978	17.5%	1,317,226	25.4%	-7.914	-0.194
50-59	295,094	22.2%	1,130,393	21.8%	0.432	0.010
60-74	520,942	39.2%	1,773,915	34.2%	5.031	0.105
75+	281,211	21.2%	971,378	18.7%	2.450	0.061
Sex						
Female	703,304	52.9%	2,758,086	53.1%	-0.202	-0.004
Male	625,921	47.1%	2,434,826	46.9%	0.202	0.004
Race/Ethnicity						
American Indian or Alaska Native	4,780	0.4%	25,722	0.5%	-0.136	-0.021
Asian	39,129	2.9%	109,049	2.1%	0.844	0.054
Black or African American	151,939	11.4%	336,082	6.5%	4.959	0.174
Native Hawaiian or Other Pacific Islander	4,808	0.4%	14,146	0.3%	0.089	0.016
Unknown	489,910	36.9%	2,266,810	43.7%	-6.795	-0.139
White	638,659	48.0%	2,441,103	47.0%	1.039	0.021
Hispanic Origin	39,212	2.9%	152,340	2.9%	0.016	0.001
Year						
2000	12,544	0.9%	24,601	0.5%	0.470	0.056
2001	20,873	1.6%	43,913	0.8%	0.725	0.066
2002	21,660	1.6%	45,213	0.9%	0.759	0.068
2003	22,065	1.7%	50,960	1.0%	0.679	0.059
2004	19,173	1.4%	47,202	0.9%	0.533	0.050
2005	17,093	1.3%	42,556	0.8%	0.466	0.046
2006	29,126	2.2%	80,884	1.6%	0.634	0.047
2007	42,778	3.2%	131,415	2.5%	0.688	0.041
2008	68,553	5.2%	252,046	4.9%	0.304	0.014
2009	85,867	6.5%	331,001	6.4%	0.086	0.004
2010	145,866	11.0%	480,257	9.2%	1.725	0.057
2011	197,637	14.9%	619,642	11.9%	2.936	0.086
2012	180,187	13.6%	570,459	11.0%	2.570	0.078
2013	172,314	13.0%	570,505	11.0%	1.977	0.061
2014	148,063	11.1%	549,548	10.6%	0.556	0.018
2015	100,777	7.6%	530,434	10.2%	-2.633	-0.093
2016	38,291	2.9%	522,655	10.1%	-7.192	-0.295
2017	*****	<1%	230,886	7.3%	*****	*****
2018	*****	<1%	68,735	3.2%	*****	*****

Table 1g. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 10,000-24,999mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	31,187	2.3%	150,435	2.9%	-0.551	-0.034
Alcohol Use	9,637	0.7%	54,647	1.1%	-0.327	-0.035
Antineoplastic Effects	673,629	50.7%	2,502,392	48.2%	2.490	0.050
Arsenic Exposure	11	0.0%	67	0.0%	-0.000	-0.001
Diabetes	338,580	25.5%	1,264,787	24.4%	1.116	0.026
Human papillomavirus	1,661	0.1%	8,494	0.2%	-0.039	-0.010
Immunosuppressive: CVD	163,060	12.3%	747,851	14.4%	-2.134	-0.063
Immunosuppressive: Chronic Pulmonary	145,329	10.9%	653,486	12.6%	-1.651	-0.051
Immunosuppressive: Connective Tissue Disease	18,325	1.4%	89,857	1.7%	-0.352	-0.028
Immunosuppressive: Moderate/Severe Renal Disease	7,911	0.6%	44,225	0.9%	-0.256	-0.030
Immunosuppressive: Transplant	2,477	0.2%	13,775	0.3%	-0.079	-0.017
Immunosuppressive: Severe Skin Disease	1,206	0.1%	6,664	0.1%	-0.038	-0.011
Immunosuppressive: Glucocorticoids	331,841	25.0%	1,442,636	27.8%	-2.816	-0.064
Immunosuppressive: HIV	5,238	0.4%	20,405	0.4%	0.001	0.000
Immunosuppressive: Immune Disorders	943	0.1%	5,349	0.1%	-0.032	-0.011
Immunosuppressive: White Blood Cell Disease	511	0.0%	2,899	0.1%	-0.017	-0.008
Immunosuppressive: Treatment for Immune Disorders	97,023	7.3%	440,681	8.5%	-1.187	-0.044
Mole Removal	11,602	0.9%	42,771	0.8%	0.049	0.005
Naevi	8,683	0.7%	35,482	0.7%	-0.030	-0.004
Photosensitizing: Aminoquinolines	6,024	0.5%	27,212	0.5%	-0.071	-0.010
Photosensitizing: Amiodarone	7,334	0.6%	36,095	0.7%	-0.143	-0.018
Photosensitizing: Macrolides	139,391	10.5%	618,058	11.9%	-1.415	-0.045
Photosensitizing: Methoxypsoralen	14	0.0%	50	0.0%	0.000	0.000
Photosensitizing: Retinoids	311	0.0%	1,453	0.0%	-0.005	-0.003
Photosensitizing: Tetracycline	2,508	0.2%	8,366	0.2%	0.028	0.007
Xeroderma pigmentosum	56	0.0%	243	0.0%	-0.000	-0.001

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1h. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 25,000-49,999mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	424,149	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	64.6	11.6	60.7	13.3	3.914	0.313
Mean age at end of follow-up (years)	67.2	11.8	63.1	13.4	4.109	0.326
Age (years)	Number	Percent	Number	Percent		
0-49	61,093	14.4%	1,317,226	25.4%	-10.962	-0.277
50-59	97,509	23.0%	1,130,393	21.8%	1.221	0.029
60-74	168,789	39.8%	1,773,915	34.2%	5.634	0.117
75+	96,758	22.8%	971,378	18.7%	4.106	0.101
Sex						
Female	225,509	53.2%	2,758,086	53.1%	0.055	0.001
Male	198,640	46.8%	2,434,826	46.9%	-0.055	-0.001
Race/Ethnicity						
American Indian or Alaska Native	1,730	0.4%	25,722	0.5%	-0.087	-0.013
Asian	16,627	3.9%	109,049	2.1%	1.820	0.107
Black or African American	49,422	11.7%	336,082	6.5%	5.180	0.181
Native Hawaiian or Other Pacific Islander	2,295	0.5%	14,146	0.3%	0.269	0.042
Unknown	141,310	33.3%	2,266,810	43.7%	-10.336	-0.214
White	212,765	50.2%	2,441,103	47.0%	3.154	0.063
Hispanic Origin	14,841	3.5%	152,340	2.9%	0.565	0.032
Year						
2000	7,748	1.8%	24,601	0.5%	1.353	0.127
2001	12,199	2.9%	43,913	0.8%	2.030	0.151
2002	12,381	2.9%	45,213	0.9%	2.048	0.151
2003	11,185	2.6%	50,960	1.0%	1.656	0.124
2004	10,532	2.5%	47,202	0.9%	1.574	0.122
2005	9,891	2.3%	42,556	0.8%	1.512	0.122
2006	14,315	3.4%	80,884	1.6%	1.817	0.117
2007	19,387	4.6%	131,415	2.5%	2.040	0.110
2008	27,711	6.5%	252,046	4.9%	1.680	0.073
2009	33,239	7.8%	331,001	6.4%	1.463	0.057
2010	58,068	13.7%	480,257	9.2%	4.442	0.140
2011	72,487	17.1%	619,642	11.9%	5.158	0.147
2012	57,945	13.7%	570,459	11.0%	2.676	0.081
2013	46,208	10.9%	570,505	11.0%	-0.092	-0.003
2014	22,510	5.3%	549,548	10.6%	-5.276	-0.196
2015	7,358	1.7%	530,434	10.2%	-8.480	-0.364
2016	963	0.2%	522,655	10.1%	-9.847	-0.457
2017	22	0.0%	230,886	7.3%	-7.250	-0.395
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1h. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 25,000-49,999mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	8,136	1.9%	150,435	2.9%	-0.979	-0.064
Alcohol Use	2,964	0.7%	54,647	1.1%	-0.354	-0.038
Antineoplastic Effects	210,601	49.7%	2,502,392	48.2%	1.464	0.029
Arsenic Exposure	*****	<1%	67	0.0%	*****	*****
Diabetes	101,693	24.0%	1,264,787	24.4%	-0.380	-0.009
Human papillomavirus	503	0.1%	8,494	0.2%	-0.045	-0.012
Immunosuppressive: CVD	43,554	10.3%	747,851	14.4%	-4.133	-0.126
Immunosuppressive: Chronic Pulmonary	40,373	9.5%	653,486	12.6%	-3.066	-0.098
Immunosuppressive: Connective Tissue Disease	4,757	1.1%	89,857	1.7%	-0.609	-0.051
Immunosuppressive: Moderate/Severe Renal Disease	2,362	0.6%	44,225	0.9%	-0.295	-0.035
Immunosuppressive: Transplant	625	0.1%	13,775	0.3%	-0.118	-0.026
Immunosuppressive: Severe Skin Disease	344	0.1%	6,664	0.1%	-0.047	-0.015
Immunosuppressive: Glucocorticoids	98,382	23.2%	1,442,636	27.8%	-4.586	-0.105
Immunosuppressive: HIV	1,592	0.4%	20,405	0.4%	-0.018	-0.003
Immunosuppressive: Immune Disorders	254	0.1%	5,349	0.1%	-0.043	-0.015
Immunosuppressive: White Blood Cell Disease	144	0.0%	2,899	0.1%	-0.022	-0.010
Immunosuppressive: Treatment for Immune Disorders	28,513	6.7%	440,681	8.5%	-1.764	-0.067
Mole Removal	3,739	0.9%	42,771	0.8%	0.058	0.006
Naevi	2,990	0.7%	35,482	0.7%	0.022	0.003
Photosensitizing: Aminoquinolines	1,697	0.4%	27,212	0.5%	-0.124	-0.018
Photosensitizing: Amiodarone	1,902	0.4%	36,095	0.7%	-0.247	-0.033
Photosensitizing: Macrolides	40,563	9.6%	618,058	11.9%	-2.339	-0.076
Photosensitizing: Methoxypsoralen	*****	<1%	50	0.0%	*****	*****
Photosensitizing: Retinoids	117	0.0%	1,453	0.0%	-0.000	-0.000
Photosensitizing: Tetracycline	1,047	0.2%	8,366	0.2%	0.086	0.019
Xeroderma pigmentosum	20	0.0%	243	0.0%	0.000	0.000

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1i. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 50,000-74,999mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients ¹	95,738	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	64.6	11.4	60.7	13.3	3.914	0.316
Mean age at end of follow-up (years)	67.7	11.5	63.1	13.4	4.585	0.367
Age (years)	Number	Percent	Number	Percent		
0-49	11,469	12.0%	1,317,226	25.4%	-13.386	-0.349
50-59	24,215	25.3%	1,130,393	21.8%	3.525	0.083
60-74	39,195	40.9%	1,773,915	34.2%	6.780	0.140
75+	20,859	21.8%	971,378	18.7%	3.082	0.077
Sex						
Female	50,029	52.3%	2,758,086	53.1%	-0.856	-0.017
Male	45,709	47.7%	2,434,826	46.9%	0.856	0.017
Race/Ethnicity						
American Indian or Alaska Native	438	0.5%	25,722	0.5%	-0.038	-0.005
Asian	6,403	6.7%	109,049	2.1%	4.588	0.225
Black or African American	11,089	11.6%	336,082	6.5%	5.111	0.179
Native Hawaiian or Other Pacific Islander	901	0.9%	14,146	0.3%	0.669	0.086
Unknown	27,934	29.2%	2,266,810	43.7%	-14.474	-0.304
White	48,973	51.2%	2,441,103	47.0%	4.145	0.083
Hispanic Origin	4,994	5.2%	152,340	2.9%	2.283	0.116
Year						
2000	4,236	4.4%	24,601	0.5%	3.951	0.258
2001	6,193	6.5%	43,913	0.8%	5.623	0.303
2002	6,492	6.8%	45,213	0.9%	5.910	0.312
2003	5,810	6.1%	50,960	1.0%	5.087	0.279
2004	5,456	5.7%	47,202	0.9%	4.790	0.270
2005	5,063	5.3%	42,556	0.8%	4.469	0.262
2006	5,793	6.1%	80,884	1.6%	4.493	0.237
2007	6,701	7.0%	131,415	2.5%	4.469	0.211
2008	8,335	8.7%	252,046	4.9%	3.852	0.154
2009	9,107	9.5%	331,001	6.4%	3.138	0.116
2010	13,361	14.0%	480,257	9.2%	4.707	0.147
2011	11,083	11.6%	619,642	11.9%	-0.356	-0.011
2012	4,915	5.1%	570,459	11.0%	-5.852	-0.216
2013	2,075	2.2%	570,505	11.0%	-8.819	-0.362
2014	866	0.9%	549,548	10.6%	-9.678	-0.425
2015	*****	<1%	530,434	10.2%	*****	*****
2016	*****	<1%	522,655	10.1%	*****	*****
2017	-	0.0%	230,886	7.3%	-7.258	-
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1i. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 50,000-74,999mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	1,396	1.5%	150,435	2.9%	-1.439	-0.099
Alcohol Use	764	0.8%	54,647	1.1%	-0.254	-0.027
Antineoplastic Effects	44,329	46.3%	2,502,392	48.2%	-1.886	-0.038
Arsenic Exposure	-	0.0%	67	0.0%	-0.001	-
Diabetes	18,202	19.0%	1,264,787	24.4%	-5.344	-0.130
Human papillomavirus	86	0.1%	8,494	0.2%	-0.074	-0.021
Immunosuppressive: CVD	6,626	6.9%	747,851	14.4%	-7.480	-0.244
Immunosuppressive: Chronic Pulmonary	7,198	7.5%	653,486	12.6%	-5.066	-0.169
Immunosuppressive: Connective Tissue	725	0.8%	89,857	1.7%	-0.973	-0.088
Immunosuppressive: Moderate/Severe Renal Disease	463	0.5%	44,225	0.9%	-0.368	-0.045
Immunosuppressive: Transplant	92	0.1%	13,775	0.3%	-0.169	-0.040
Immunosuppressive: Severe Skin Disease	51	0.1%	6,664	0.1%	-0.075	-0.025
Immunosuppressive: Glucocorticoids	20,208	21.1%	1,442,636	27.8%	-6.673	-0.156
Immunosuppressive: HIV	282	0.3%	20,405	0.4%	-0.098	-0.017
Immunosuppressive: Immune Disorders	38	0.0%	5,349	0.1%	-0.063	-0.024
Immunosuppressive: White Blood Cell Disease	20	0.0%	2,899	0.1%	-0.035	-0.018
Immunosuppressive: Treatment for Immune Disorders	5,939	6.2%	440,681	8.5%	-2.283	-0.088
Mole Removal	850	0.9%	42,771	0.8%	0.064	0.007
Naevi	959	1.0%	35,482	0.7%	0.318	0.035
Photosensitizing: Aminoquinolines	345	0.4%	27,212	0.5%	-0.164	-0.025
Photosensitizing: Amiodarone	297	0.3%	36,095	0.7%	-0.385	-0.054
Photosensitizing: Macrolides	7,359	7.7%	618,058	11.9%	-4.215	-0.142
Photosensitizing: Methoxypsoralen	*****	<1%	50	0.0%	*****	*****
Photosensitizing: Retinoids	39	0.0%	1,453	0.0%	0.013	0.007
Photosensitizing: Tetracycline	327	0.3%	8,366	0.2%	0.180	0.036
Xeroderma pigmentosum	*****	<1%	243	0.0%	*****	*****

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1j. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 75,000-99,999mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	32,808	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	65.3	11.3	60.7	13.3	4.551	0.369
Mean age at end of follow-up (years)	68.6	11.4	63.1	13.4	5.496	0.442
Age (years)	Number	Percent	Number	Percent		
0-49	3,063	9.3%	1,317,226	25.4%	-16.030	-0.433
50-59	8,150	24.8%	1,130,393	21.8%	3.074	0.073
60-74	14,429	44.0%	1,773,915	34.2%	9.820	0.202
75+	7,166	21.8%	971,378	18.7%	3.136	0.078
Sex						
Female	17,383	53.0%	2,758,086	53.1%	-0.128	-0.003
Male	15,425	47.0%	2,434,826	46.9%	0.128	0.003
Race/Ethnicity						
American Indian or Alaska Native	196	0.6%	25,722	0.5%	0.102	0.014
Asian	3,191	9.7%	109,049	2.1%	7.626	0.328
Black or African American	3,994	12.2%	336,082	6.5%	5.702	0.197
Native Hawaiian or Other Pacific Islander	422	1.3%	14,146	0.3%	1.014	0.115
Unknown	6,943	21.2%	2,266,810	43.7%	-22.489	-0.495
White	18,062	55.1%	2,441,103	47.0%	8.045	0.161
Hispanic Origin	2,343	7.1%	152,340	2.9%	4.208	0.193
Year						
2000	2,557	7.8%	24,601	0.5%	7.320	0.374
2001	3,621	11.0%	43,913	0.8%	10.191	0.441
2002	3,752	11.4%	45,213	0.9%	10.566	0.451
2003	3,263	9.9%	50,960	1.0%	8.964	0.402
2004	2,948	9.0%	47,202	0.9%	8.077	0.379
2005	2,591	7.9%	42,556	0.8%	7.078	0.352
2006	2,611	8.0%	80,884	1.6%	6.401	0.304
2007	2,603	7.9%	131,415	2.5%	5.403	0.244
2008	2,685	8.2%	252,046	4.9%	3.330	0.135
2009	2,098	6.4%	331,001	6.4%	0.021	0.001
2010	1,412	4.3%	480,257	9.2%	-4.944	-0.198
2011	1,483	4.5%	619,642	11.9%	-7.412	-0.272
2012	842	2.6%	570,459	11.0%	-8.419	-0.340
2013	272	0.8%	570,505	11.0%	-10.157	-0.441
2014	57	0.2%	549,548	10.6%	-10.409	-0.474
2015	13	0.0%	530,434	10.2%	-10.175	-0.474
2016	-	0.0%	522,655	10.1%	-10.075	-
2017	-	0.0%	230,886	7.3%	-7.258	-
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1j. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 75,000-99,999mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	406	1.2%	150,435	2.9%	-1.659	-0.117
Alcohol Use	262	0.8%	54,647	1.1%	-0.254	-0.027
Antineoplastic Effects	14,497	44.2%	2,502,392	48.2%	-4.001	-0.080
Arsenic Exposure	-	0.0%	67	0.0%	-0.001	-
Diabetes	4,883	14.9%	1,264,787	24.4%	-9.472	-0.240
Human papillomavirus	27	0.1%	8,494	0.2%	-0.081	-0.023
Immunosuppressive: CVD	1,624	5.0%	747,851	14.4%	-9.451	-0.324
Immunosuppressive: Chronic Pulmonary	2,074	6.3%	653,486	12.6%	-6.263	-0.215
Immunosuppressive: Connective Tissue Disease	197	0.6%	89,857	1.7%	-1.130	-0.105
Immunosuppressive: Moderate/Severe Renal Disease	126	0.4%	44,225	0.9%	-0.468	-0.060
Immunosuppressive: Transplant	21	0.1%	13,775	0.3%	-0.201	-0.050
Immunosuppressive: Severe Skin Disease	17	0.1%	6,664	0.1%	-0.077	-0.026
Immunosuppressive: Glucocorticoids	6,567	20.0%	1,442,636	27.8%	-7.764	-0.183
Immunosuppressive: HIV	66	0.2%	20,405	0.4%	-0.192	-0.035
Immunosuppressive: Immune Disorders	*****	<1%	5,349	0.1%	*****	*****
Immunosuppressive: White Blood Cell Disease	*****	<1%	2,899	0.1%	*****	*****
Immunosuppressive: Treatment for Immune Disorders	1,959	6.0%	440,681	8.5%	-2.515	-0.097
Mole Removal	316	1.0%	42,771	0.8%	0.140	0.015
Naevi	457	1.4%	35,482	0.7%	0.710	0.070
Photosensitizing: Aminoquinolines	103	0.3%	27,212	0.5%	-0.210	-0.033
Photosensitizing: Amiodarone	75	0.2%	36,095	0.7%	-0.466	-0.069
Photosensitizing: Macrolides	2,023	6.2%	618,058	11.9%	-5.736	-0.201
Photosensitizing: Methoxypsoralen	*****	<1%	50	0.0%	*****	*****
Photosensitizing: Retinoids	15	0.0%	1,453	0.0%	0.018	0.009
Photosensitizing: Tetracycline	142	0.4%	8,366	0.2%	0.272	0.050
Xeroderma pigmentosum	*****	<1%	243	0.0%	*****	*****

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1k. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=100,000mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	13,842	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	66.0	11.1	60.7	13.3	5.305	0.434
Mean age at end of follow-up (years)	69.2	11.0	63.1	13.4	6.107	0.498
Age (years)	Number	Percent	Number	Percent		
0-49	1,034	7.5%	1,317,226	25.4%	-17.896	-0.498
50-59	3,231	23.3%	1,130,393	21.8%	1.574	0.038
60-74	6,464	46.7%	1,773,915	34.2%	12.538	0.258
75+	3,113	22.5%	971,378	18.7%	3.784	0.094
Sex						
Female	7,514	54.3%	2,758,086	53.1%	1.172	0.023
Male	6,328	45.7%	2,434,826	46.9%	-1.172	-0.023
Race/Ethnicity						
American Indian or Alaska Native	79	0.6%	25,722	0.5%	0.075	0.010
Asian	1,591	11.5%	109,049	2.1%	9.394	0.380
Black or African American	1,729	12.5%	336,082	6.5%	6.019	0.207
Native Hawaiian or Other Pacific Islander	207	1.5%	14,146	0.3%	1.223	0.131
Unknown	2,125	15.4%	2,266,810	43.7%	-28.300	-0.653
White	8,111	58.6%	2,441,103	47.0%	11.589	0.234
Hispanic Origin	1,163	8.4%	152,340	2.9%	5.468	0.238
Year						
2000	1,553	11.2%	24,601	0.5%	10.746	0.471
2001	2,181	15.8%	43,913	0.8%	14.911	0.561
2002	2,209	16.0%	45,213	0.9%	15.088	0.565
2003	1,810	13.1%	50,960	1.0%	12.095	0.487
2004	1,542	11.1%	47,202	0.9%	10.231	0.440
2005	1,226	8.9%	42,556	0.8%	8.038	0.381
2006	902	6.5%	80,884	1.6%	4.959	0.254
2007	495	3.6%	131,415	2.5%	1.045	0.061
2008	438	3.2%	252,046	4.9%	-1.689	-0.086
2009	440	3.2%	331,001	6.4%	-3.195	-0.150
2010	517	3.7%	480,257	9.2%	-5.513	-0.225
2011	381	2.8%	619,642	11.9%	-9.180	-0.358
2012	105	0.8%	570,459	11.0%	-10.227	-0.446
2013	31	0.2%	570,505	11.0%	-10.762	-0.481
2014	*****	<1%	549,548	10.6%	*****	*****
2015	*****	<1%	530,434	10.2%	*****	*****
2016	-	0.0%	522,655	10.1%	-10.075	-
2017	-	0.0%	230,886	7.3%	-7.258	-
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1k. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=100,000mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	146	1.1%	150,435	2.9%	-1.842	-0.133
Alcohol Use	113	0.8%	54,647	1.1%	-0.236	-0.025
Antineoplastic Effects	5,896	42.6%	2,502,392	48.2%	-5.594	-0.113
Arsenic Exposure	-	0.0%	67	0.0%	-0.001	-
Diabetes	1,710	12.4%	1,264,787	24.4%	-12.002	-0.314
Human papillomavirus	*****	<1%	8,494	0.2%	*****	*****
Immunosuppressive: CVD	575	4.2%	747,851	14.4%	-10.247	-0.359
Immunosuppressive: Chronic Pulmonary	799	5.8%	653,486	12.6%	-6.812	-0.238
Immunosuppressive: Connective Tissue Disease	75	0.5%	89,857	1.7%	-1.189	-0.112
Immunosuppressive: Moderate/Severe Renal Disease	40	0.3%	44,225	0.9%	-0.563	-0.075
Immunosuppressive: Transplant	*****	<1%	13,775	0.3%	*****	*****
Immunosuppressive: Severe Skin Disease	*****	<1%	6,664	0.1%	*****	*****
Immunosuppressive: Glucocorticoids	2,723	19.7%	1,442,636	27.8%	-8.109	-0.191
Immunosuppressive: HIV	24	0.2%	20,405	0.4%	-0.220	-0.041
Immunosuppressive: Immune Disorders	-	0.0%	5,349	0.1%	-0.103	-
Immunosuppressive: White Blood Cell Disease	*****	<1%	2,899	0.1%	*****	*****
Immunosuppressive: Treatment for Immune Disorders	834	6.0%	440,681	8.5%	-2.461	-0.095
Mole Removal	149	1.1%	42,771	0.8%	0.253	0.026
Naevi	236	1.7%	35,482	0.7%	1.022	0.094
Photosensitizing: Aminoquinolines	47	0.3%	27,212	0.5%	-0.184	-0.028
Photosensitizing: Amiodarone	20	0.1%	36,095	0.7%	-0.551	-0.085
Photosensitizing: Macrolides	770	5.6%	618,058	11.9%	-6.339	-0.226
Photosensitizing: Methoxypsoralen	-	0.0%	50	0.0%	-0.001	-
Photosensitizing: Retinoids	*****	<1%	1,453	0.0%	*****	*****
Photosensitizing: Tetracycline	63	0.5%	8,366	0.2%	0.294	0.053
Xeroderma pigmentosum	*****	<1%	243	0.0%	*****	*****

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=50,000mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients ¹	95,738	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	64.6	11.4	60.7	13.3	3.914	0.316
Mean age at end of follow-up (years)	67.7	11.5	63.1	13.4	4.585	0.367
Age (years)	Number	Percent	Number	Percent		
0-49	11,469	12.0%	1,317,226	25.4%	-13.386	-0.349
50-59	24,215	25.3%	1,130,393	21.8%	3.525	0.083
60-74	39,195	40.9%	1,773,915	34.2%	6.780	0.140
75+	20,859	21.8%	971,378	18.7%	3.082	0.077
Sex						
Female	50,029	52.3%	2,758,086	53.1%	-0.856	-0.017
Male	45,709	47.7%	2,434,826	46.9%	0.856	0.017
Race/Ethnicity						
American Indian or Alaska Native	438	0.5%	25,722	0.5%	-0.038	-0.005
Asian	6,403	6.7%	109,049	2.1%	4.588	0.225
Black or African American	11,089	11.6%	336,082	6.5%	5.111	0.179
Native Hawaiian or Other Pacific Islander	901	0.9%	14,146	0.3%	0.669	0.086
Unknown	27,934	29.2%	2,266,810	43.7%	-14.474	-0.304
White	48,973	51.2%	2,441,103	47.0%	4.145	0.083
Hispanic Origin	4,994	5.2%	152,340	2.9%	2.283	0.116
Year						
2000	4,236	4.4%	24,601	0.5%	3.951	0.258
2001	6,193	6.5%	43,913	0.8%	5.623	0.303
2002	6,492	6.8%	45,213	0.9%	5.910	0.312
2003	5,810	6.1%	50,960	1.0%	5.087	0.279
2004	5,456	5.7%	47,202	0.9%	4.790	0.270
2005	5,063	5.3%	42,556	0.8%	4.469	0.262
2006	5,793	6.1%	80,884	1.6%	4.493	0.237
2007	6,701	7.0%	131,415	2.5%	4.469	0.211
2008	8,335	8.7%	252,046	4.9%	3.852	0.154
2009	9,107	9.5%	331,001	6.4%	3.138	0.116
2010	13,361	14.0%	480,257	9.2%	4.707	0.147
2011	11,083	11.6%	619,642	11.9%	-0.356	-0.011
2012	4,915	5.1%	570,459	11.0%	-5.852	-0.216
2013	2,075	2.2%	570,505	11.0%	-8.819	-0.362
2014	866	0.9%	549,548	10.6%	-9.678	-0.425
2015	*****	<1%	530,434	10.2%	*****	*****
2016	*****	<1%	522,655	10.1%	*****	*****
2017	-	0.0%	230,886	7.3%	-7.258	-
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 11. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=50,000mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	1,396	1.5%	150,435	2.9%	-1.439	-0.099
Alcohol Use	764	0.8%	54,647	1.1%	-0.254	-0.027
Antineoplastic Effects	44,329	46.3%	2,502,392	48.2%	-1.886	-0.038
Arsenic Exposure	-	0.0%	67	0.0%	-0.001	-
Diabetes	18,202	19.0%	1,264,787	24.4%	-5.344	-0.130
Human papillomavirus	86	0.1%	8,494	0.2%	-0.074	-0.021
Immunosuppressive: CVD	6,626	6.9%	747,851	14.4%	-7.480	-0.244
Immunosuppressive: Chronic Pulmonary	7,198	7.5%	653,486	12.6%	-5.066	-0.169
Immunosuppressive: Connective Tissue	725	0.8%	89,857	1.7%	-0.973	-0.088
Immunosuppressive: Moderate/Severe Renal Disease	463	0.5%	44,225	0.9%	-0.368	-0.045
Immunosuppressive: Transplant	92	0.1%	13,775	0.3%	-0.169	-0.040
Immunosuppressive: Severe Skin Disease	51	0.1%	6,664	0.1%	-0.075	-0.025
Immunosuppressive: Glucocorticoids	20,208	21.1%	1,442,636	27.8%	-6.673	-0.156
Immunosuppressive: HIV	282	0.3%	20,405	0.4%	-0.098	-0.017
Immunosuppressive: Immune Disorders	38	0.0%	5,349	0.1%	-0.063	-0.024
Immunosuppressive: White Blood Cell Disease	20	0.0%	2,899	0.1%	-0.035	-0.018
Immunosuppressive: Treatment for Immune Disorders	5,939	6.2%	440,681	8.5%	-2.283	-0.088
Mole Removal	850	0.9%	42,771	0.8%	0.064	0.007
Naevi	959	1.0%	35,482	0.7%	0.318	0.035
Photosensitizing: Aminoquinolines	345	0.4%	27,212	0.5%	-0.164	-0.025
Photosensitizing: Amiodarone	297	0.3%	36,095	0.7%	-0.385	-0.054
Photosensitizing: Macrolides	7,359	7.7%	618,058	11.9%	-4.215	-0.142
Photosensitizing: Methoxypsoralen	*****	<1%	50	0.0%	*****	*****
Photosensitizing: Retinoids	39	0.0%	1,453	0.0%	0.013	0.007
Photosensitizing: Tetracycline	327	0.3%	8,366	0.2%	0.180	0.036
Xeroderma pigmentosum	*****	<1%	243	0.0%	*****	*****

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1m. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Overall

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients ¹	5,192,912	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	60.7	13.0	60.7	13.3	0.015	0.001
Mean age at end of follow-up (years)	63.2	13.1	63.1	13.4	0.030	0.002
Age (years)	Number	Percent	Number	Percent		
0-49	1,327,501	25.6%	1,317,226	25.4%	0.198	0.005
50-59	1,102,894	21.2%	1,130,393	21.8%	-0.530	-0.013
60-74	1,807,465	34.8%	1,773,915	34.2%	0.646	0.014
75+	955,052	18.4%	971,378	18.7%	-0.314	-0.008
Sex						
Female	2,726,320	52.5%	2,758,086	53.1%	-0.612	-0.012
Male	2,466,592	47.5%	2,434,826	46.9%	0.612	0.012
Race/Ethnicity						
American Indian or Alaska Native	16,172	0.3%	25,722	0.5%	-0.184	-0.029
Asian	119,655	2.3%	109,049	2.1%	0.204	0.014
Black or African American	539,989	10.4%	336,082	6.5%	3.927	0.142
Native Hawaiian or Other Pacific Islander	13,857	0.3%	14,146	0.3%	-0.006	-0.001
Unknown	2,261,540	43.6%	2,266,810	43.7%	-0.101	-0.002
White	2,241,699	43.2%	2,441,103	47.0%	-3.840	-0.077
Hispanic Origin	140,381	2.7%	152,340	2.9%	-0.230	-0.014
Year						
2000	24,870	0.5%	24,601	0.5%	0.005	0.001
2001	43,860	0.8%	43,913	0.8%	-0.001	-0.000
2002	45,503	0.9%	45,213	0.9%	0.006	0.001
2003	51,010	1.0%	50,960	1.0%	0.001	0.000
2004	47,265	0.9%	47,202	0.9%	0.001	0.000
2005	42,953	0.8%	42,556	0.8%	0.008	0.001
2006	80,467	1.5%	80,884	1.6%	-0.008	-0.001
2007	130,915	2.5%	131,415	2.5%	-0.010	-0.001
2008	254,058	4.9%	252,046	4.9%	0.039	0.002
2009	332,065	6.4%	331,001	6.4%	0.020	0.001
2010	480,959	9.3%	480,257	9.2%	0.014	0.000
2011	620,206	11.9%	619,642	11.9%	0.011	0.000
2012	571,117	11.0%	570,459	11.0%	0.013	0.000
2013	570,848	11.0%	570,505	11.0%	0.007	0.000
2014	549,672	10.6%	549,548	10.6%	0.002	0.000
2015	530,051	10.2%	530,434	10.2%	-0.007	-0.000
2016	519,856	10.0%	522,655	10.1%	-0.054	-0.002
2017	228,800	7.2%	230,886	7.3%	-0.066	-0.003
2018	68,437	3.2%	68,735	3.2%	-0.014	-0.001

Table 1m. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Overall

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	150,879	2.9%	150,435	2.9%	0.009	0.001
Alcohol Use	54,883	1.1%	54,647	1.1%	0.005	0.000
Antineoplastic Effects	2,511,689	48.4%	2,502,392	48.2%	0.179	0.004
Arsenic Exposure	72	0.0%	67	0.0%	0.000	0.000
Diabetes	1,266,180	24.4%	1,264,787	24.4%	0.027	0.001
Human papillomavirus	8,446	0.2%	8,494	0.2%	-0.001	-0.000
Immunosuppressive: CVD	753,769	14.5%	747,851	14.4%	0.114	0.003
Immunosuppressive: Chronic Pulmonary	653,301	12.6%	653,486	12.6%	-0.004	-0.000
Immunosuppressive: Connective Tissue	90,145	1.7%	89,857	1.7%	0.006	0.000
Immunosuppressive: Moderate/Severe Renal Disease	37,346	0.7%	44,225	0.9%	-0.132	-0.015
Immunosuppressive: Transplant	12,453	0.2%	13,775	0.3%	-0.025	-0.005
Immunosuppressive: Severe Skin Disease	6,350	0.1%	6,664	0.1%	-0.006	-0.002
Immunosuppressive: Glucocorticoids	1,442,496	27.8%	1,442,636	27.8%	-0.003	-0.000
Immunosuppressive: HIV	20,477	0.4%	20,405	0.4%	0.001	0.000
Immunosuppressive: Immune Disorders	5,210	0.1%	5,349	0.1%	-0.003	-0.001
Immunosuppressive: White Blood Cell	2,827	0.1%	2,899	0.1%	-0.001	-0.001
Immunosuppressive: Treatment for Immune Disorders	441,049	8.5%	440,681	8.5%	0.007	0.000
Mole Removal	42,922	0.8%	42,771	0.8%	0.003	0.000
Naevi	35,351	0.7%	35,482	0.7%	-0.003	-0.000
Photosensitizing: Aminoquinolines	27,094	0.5%	27,212	0.5%	-0.002	-0.000
Photosensitizing: Amiodarone	34,555	0.7%	36,095	0.7%	-0.030	-0.004
Photosensitizing: Macrolides	618,708	11.9%	618,058	11.9%	0.013	0.000
Photosensitizing: Methoxypsoralen	50	0.0%	50	0.0%	0.000	0.000
Photosensitizing: Retinoids	1,463	0.0%	1,453	0.0%	0.000	0.000
Photosensitizing: Tetracycline	8,381	0.2%	8,366	0.2%	0.000	0.000
Xeroderma pigmentosum	257	0.0%	243	0.0%	0.000	0.000

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

Table 1n. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: <10,000mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients ¹	5,192,912	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	60.7	13.0	60.7	13.3	0.015	0.001
Mean age at end of follow-up (years)	63.2	13.1	63.1	13.4	0.030	0.002
Age (years)	Number	Percent	Number	Percent		
0-49	1,327,501	25.6%	1,317,226	25.4%	0.198	0.005
50-59	1,102,894	21.2%	1,130,393	21.8%	-0.530	-0.013
60-74	1,807,465	34.8%	1,773,915	34.2%	0.646	0.014
75+	955,052	18.4%	971,378	18.7%	-0.314	-0.008
Sex						
Female	2,726,320	52.5%	2,758,086	53.1%	-0.612	-0.012
Male	2,466,592	47.5%	2,434,826	46.9%	0.612	0.012
Race/Ethnicity						
American Indian or Alaska Native	16,172	0.3%	25,722	0.5%	-0.184	-0.029
Asian	119,655	2.3%	109,049	2.1%	0.204	0.014
Black or African American	539,989	10.4%	336,082	6.5%	3.927	0.142
Native Hawaiian or Other Pacific Islander	13,857	0.3%	14,146	0.3%	-0.006	-0.001
Unknown	2,261,540	43.6%	2,266,810	43.7%	-0.101	-0.002
White	2,241,699	43.2%	2,441,103	47.0%	-3.840	-0.077
Hispanic Origin	140,381	2.7%	152,340	2.9%	-0.230	-0.014
Year						
2000	24,870	0.5%	24,601	0.5%	0.005	0.001
2001	43,860	0.8%	43,913	0.8%	-0.001	-0.000
2002	45,503	0.9%	45,213	0.9%	0.006	0.001
2003	51,010	1.0%	50,960	1.0%	0.001	0.000
2004	47,265	0.9%	47,202	0.9%	0.001	0.000
2005	42,953	0.8%	42,556	0.8%	0.008	0.001
2006	80,467	1.5%	80,884	1.6%	-0.008	-0.001
2007	130,915	2.5%	131,415	2.5%	-0.010	-0.001
2008	254,058	4.9%	252,046	4.9%	0.039	0.002
2009	332,065	6.4%	331,001	6.4%	0.020	0.001
2010	480,959	9.3%	480,257	9.2%	0.014	0.000
2011	620,206	11.9%	619,642	11.9%	0.011	0.000
2012	571,117	11.0%	570,459	11.0%	0.013	0.000
2013	570,848	11.0%	570,505	11.0%	0.007	0.000
2014	549,672	10.6%	549,548	10.6%	0.002	0.000
2015	530,051	10.2%	530,434	10.2%	-0.007	-0.000
2016	519,856	10.0%	522,655	10.1%	-0.054	-0.002
2017	228,800	7.2%	230,886	7.3%	-0.066	-0.003
2018	68,437	3.2%	68,735	3.2%	-0.014	-0.001

Table 1n. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: <10,000mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	150,879	2.9%	150,435	2.9%	0.009	0.001
Alcohol Use	54,883	1.1%	54,647	1.1%	0.005	0.000
Antineoplastic Effects	2,511,689	48.4%	2,502,392	48.2%	0.179	0.004
Arsenic Exposure	72	0.0%	67	0.0%	0.000	0.000
Diabetes	1,266,180	24.4%	1,264,787	24.4%	0.027	0.001
Human papillomavirus	8,446	0.2%	8,494	0.2%	-0.001	-0.000
Immunosuppressive: CVD	753,769	14.5%	747,851	14.4%	0.114	0.003
Immunosuppressive: Chronic Pulmonary	653,301	12.6%	653,486	12.6%	-0.004	-0.000
Immunosuppressive: Connective Tissue	90,145	1.7%	89,857	1.7%	0.006	0.000
Immunosuppressive: Moderate/Severe Renal Disease	37,346	0.7%	44,225	0.9%	-0.132	-0.015
Immunosuppressive: Transplant	12,453	0.2%	13,775	0.3%	-0.025	-0.005
Immunosuppressive: Severe Skin Disease	6,350	0.1%	6,664	0.1%	-0.006	-0.002
Immunosuppressive: Glucocorticoids	1,442,496	27.8%	1,442,636	27.8%	-0.003	-0.000
Immunosuppressive: HIV	20,477	0.4%	20,405	0.4%	0.001	0.000
Immunosuppressive: Immune Disorders	5,210	0.1%	5,349	0.1%	-0.003	-0.001
Immunosuppressive: White Blood Cell	2,827	0.1%	2,899	0.1%	-0.001	-0.001
Immunosuppressive: Treatment for Immune Disorders	441,049	8.5%	440,681	8.5%	0.007	0.000
Mole Removal	42,922	0.8%	42,771	0.8%	0.003	0.000
Naevi	35,351	0.7%	35,482	0.7%	-0.003	-0.000
Photosensitizing: Aminoquinolines	27,094	0.5%	27,212	0.5%	-0.002	-0.000
Photosensitizing: Amiodarone	34,555	0.7%	36,095	0.7%	-0.030	-0.004
Photosensitizing: Macrolides	618,708	11.9%	618,058	11.9%	0.013	0.000
Photosensitizing: Methoxypsoralen	50	0.0%	50	0.0%	0.000	0.000
Photosensitizing: Retinoids	1,463	0.0%	1,453	0.0%	0.000	0.000
Photosensitizing: Tetracycline	8,381	0.2%	8,366	0.2%	0.000	0.000
Xeroderma pigmentosum	257	0.0%	243	0.0%	0.000	0.000

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

Table 1o. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 10,000-24,999mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	1,328,085	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	63.6	11.9	60.7	13.3	2.917	0.231
Mean age at end of follow-up (years)	66.2	12.1	63.1	13.4	3.032	0.238
Age (years)	Number	Percent	Number	Percent		
0-49	231,930	17.5%	1,317,226	25.4%	-7.902	-0.194
50-59	294,981	22.2%	1,130,393	21.8%	0.443	0.011
60-74	520,405	39.2%	1,773,915	34.2%	5.024	0.104
75+	280,769	21.1%	971,378	18.7%	2.435	0.061
Sex						
Female	702,695	52.9%	2,758,086	53.1%	-0.202	-0.004
Male	625,390	47.1%	2,434,826	46.9%	0.202	0.004
Race/Ethnicity						
American Indian or Alaska Native	4,778	0.4%	25,722	0.5%	-0.136	-0.021
Asian	39,125	2.9%	109,049	2.1%	0.846	0.054
Black or African American	151,937	11.4%	336,082	6.5%	4.968	0.175
Native Hawaiian or Other Pacific Islander	4,807	0.4%	14,146	0.3%	0.090	0.016
Unknown	489,655	36.9%	2,266,810	43.7%	-6.783	-0.139
White	637,783	48.0%	2,441,103	47.0%	1.014	0.020
Hispanic Origin	39,191	3.0%	152,340	2.9%	0.017	0.001
Year						
2000	12,544	0.9%	24,601	0.5%	0.471	0.056
2001	20,873	1.6%	43,913	0.8%	0.726	0.066
2002	21,659	1.6%	45,213	0.9%	0.760	0.068
2003	22,066	1.7%	50,960	1.0%	0.680	0.060
2004	19,173	1.4%	47,202	0.9%	0.535	0.050
2005	17,093	1.3%	42,556	0.8%	0.468	0.046
2006	29,126	2.2%	80,884	1.6%	0.635	0.047
2007	42,775	3.2%	131,415	2.5%	0.690	0.041
2008	68,545	5.2%	252,046	4.9%	0.308	0.014
2009	85,850	6.5%	331,001	6.4%	0.090	0.004
2010	145,786	11.0%	480,257	9.2%	1.729	0.057
2011	197,423	14.9%	619,642	11.9%	2.933	0.086
2012	179,934	13.5%	570,459	11.0%	2.563	0.078
2013	172,078	13.0%	570,505	11.0%	1.971	0.061
2014	147,867	11.1%	549,548	10.6%	0.551	0.018
2015	100,687	7.6%	530,434	10.2%	-2.633	-0.093
2016	38,250	2.9%	522,655	10.1%	-7.192	-0.295
2017	*****	<1%	230,886	7.3%	*****	*****
2018	*****	<1%	68,735	3.2%	*****	*****

Table 1o. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 10,000-24,999mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	31,062	2.3%	150,435	2.9%	-0.558	-0.035
Alcohol Use	9,627	0.7%	54,647	1.1%	-0.327	-0.035
Antineoplastic Effects	672,976	50.7%	2,502,392	48.2%	2.484	0.050
Arsenic Exposure	11	0.0%	67	0.0%	-0.000	-0.001
Diabetes	338,285	25.5%	1,264,787	24.4%	1.116	0.026
Human papillomavirus	1,660	0.1%	8,494	0.2%	-0.039	-0.010
Immunosuppressive: CVD	162,877	12.3%	747,851	14.4%	-2.137	-0.063
Immunosuppressive: Chronic Pulmonary	145,227	10.9%	653,486	12.6%	-1.649	-0.051
Immunosuppressive: Connective Tissue	18,308	1.4%	89,857	1.7%	-0.352	-0.028
Immunosuppressive: Moderate/Severe Renal Disease	7,904	0.6%	44,225	0.9%	-0.256	-0.030
Immunosuppressive: Transplant	2,473	0.2%	13,775	0.3%	-0.079	-0.017
Immunosuppressive: Severe Skin Disease	1,207	0.1%	6,664	0.1%	-0.037	-0.011
Immunosuppressive: Glucocorticoids	331,552	25.0%	1,442,636	27.8%	-2.816	-0.064
Immunosuppressive: HIV	5,237	0.4%	20,405	0.4%	0.001	0.000
Immunosuppressive: Immune Disorders	942	0.1%	5,349	0.1%	-0.032	-0.011
Immunosuppressive: White Blood Cell	512	0.0%	2,899	0.1%	-0.017	-0.008
Immunosuppressive: Treatment for Immune Disorders	96,921	7.3%	440,681	8.5%	-1.188	-0.044
Mole Removal	11,581	0.9%	42,771	0.8%	0.048	0.005
Naevi	8,669	0.7%	35,482	0.7%	-0.031	-0.004
Photosensitizing: Aminoquinolines	6,021	0.5%	27,212	0.5%	-0.071	-0.010
Photosensitizing: Amiodarone	7,318	0.6%	36,095	0.7%	-0.144	-0.018
Photosensitizing: Macrolides	139,252	10.5%	618,058	11.9%	-1.417	-0.045
Photosensitizing: Methoxypsoralen	14	0.0%	50	0.0%	0.000	0.000
Photosensitizing: Retinoids	311	0.0%	1,453	0.0%	-0.005	-0.003
Photosensitizing: Tetracycline	2,505	0.2%	8,366	0.2%	0.028	0.007
Xeroderma pigmentosum	56	0.0%	243	0.0%	-0.000	-0.001

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1p. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 25,000-49,999mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	423,639	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	64.6	11.6	60.7	13.3	3.903	0.312
Mean age at end of follow-up (years)	67.2	11.8	63.1	13.4	4.101	0.325
Age (years)	Number	Percent	Number	Percent		
0-49	61,083	14.4%	1,317,226	25.4%	-10.947	-0.277
50-59	97,468	23.0%	1,130,393	21.8%	1.239	0.030
60-74	168,556	39.8%	1,773,915	34.2%	5.627	0.117
75+	96,532	22.8%	971,378	18.7%	4.081	0.101
Sex						
Female	225,241	53.2%	2,758,086	53.1%	0.056	0.001
Male	198,398	46.8%	2,434,826	46.9%	-0.056	-0.001
Race/Ethnicity						
American Indian or Alaska Native	1,730	0.4%	25,722	0.5%	-0.087	-0.013
Asian	16,625	3.9%	109,049	2.1%	1.824	0.107
Black or African American	49,422	11.7%	336,082	6.5%	5.194	0.182
Native Hawaiian or Other Pacific Islander	2,295	0.5%	14,146	0.3%	0.269	0.042
Unknown	141,213	33.3%	2,266,810	43.7%	-10.319	-0.213
White	212,354	50.1%	2,441,103	47.0%	3.118	0.062
Hispanic Origin	14,836	3.5%	152,340	2.9%	0.568	0.032
Year						
2000	7,748	1.8%	24,601	0.5%	1.355	0.127
2001	12,199	2.9%	43,913	0.8%	2.034	0.151
2002	12,380	2.9%	45,213	0.9%	2.052	0.151
2003	11,185	2.6%	50,960	1.0%	1.659	0.125
2004	10,532	2.5%	47,202	0.9%	1.577	0.122
2005	9,892	2.3%	42,556	0.8%	1.516	0.122
2006	14,315	3.4%	80,884	1.6%	1.821	0.118
2007	19,383	4.6%	131,415	2.5%	2.045	0.111
2008	27,702	6.5%	252,046	4.9%	1.685	0.073
2009	33,218	7.8%	331,001	6.4%	1.467	0.057
2010	57,983	13.7%	480,257	9.2%	4.439	0.140
2011	72,342	17.1%	619,642	11.9%	5.144	0.146
2012	57,837	13.7%	570,459	11.0%	2.667	0.081
2013	46,106	10.9%	570,505	11.0%	-0.103	-0.003
2014	22,477	5.3%	549,548	10.6%	-5.277	-0.196
2015	7,354	1.7%	530,434	10.2%	-8.479	-0.364
2016	964	0.2%	522,655	10.1%	-9.847	-0.457
2017	22	0.0%	230,886	7.3%	-7.250	-0.395
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1p. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 25,000-49,999mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	8,117	1.9%	150,435	2.9%	-0.981	-0.064
Alcohol Use	2,961	0.7%	54,647	1.1%	-0.353	-0.038
Antineoplastic Effects	210,307	49.6%	2,502,392	48.2%	1.454	0.029
Arsenic Exposure	*****	<1%	67	0.0%	*****	*****
Diabetes	101,549	24.0%	1,264,787	24.4%	-0.385	-0.009
Human papillomavirus	503	0.1%	8,494	0.2%	-0.045	-0.012
Immunosuppressive: CVD	43,485	10.3%	747,851	14.4%	-4.137	-0.126
Immunosuppressive: Chronic Pulmonary	40,324	9.5%	653,486	12.6%	-3.066	-0.098
Immunosuppressive: Connective Tissue Disease	4,753	1.1%	89,857	1.7%	-0.608	-0.051
Immunosuppressive: Moderate/Severe Renal Disease	2,360	0.6%	44,225	0.9%	-0.295	-0.035
Immunosuppressive: Transplant	623	0.1%	13,775	0.3%	-0.118	-0.026
Immunosuppressive: Severe Skin Disease	345	0.1%	6,664	0.1%	-0.047	-0.014
Immunosuppressive: Glucocorticoids	98,245	23.2%	1,442,636	27.8%	-4.590	-0.105
Immunosuppressive: HIV	1,592	0.4%	20,405	0.4%	-0.017	-0.003
Immunosuppressive: Immune Disorders	252	0.1%	5,349	0.1%	-0.044	-0.015
Immunosuppressive: White Blood Cell Disease	143	0.0%	2,899	0.1%	-0.022	-0.010
Immunosuppressive: Treatment for Immune Disorders	28,472	6.7%	440,681	8.5%	-1.765	-0.067
Mole Removal	3,730	0.9%	42,771	0.8%	0.057	0.006
Naevi	2,991	0.7%	35,482	0.7%	0.023	0.003
Photosensitizing: Aminoquinolines	1,695	0.4%	27,212	0.5%	-0.124	-0.018
Photosensitizing: Amiodarone	1,902	0.4%	36,095	0.7%	-0.246	-0.033
Photosensitizing: Macrolides	40,523	9.6%	618,058	11.9%	-2.336	-0.076
Photosensitizing: Methoxypsoralen	*****	<1%	50	0.0%	*****	*****
Photosensitizing: Retinoids	117	0.0%	1,453	0.0%	-0.000	-0.000
Photosensitizing: Tetracycline	1,049	0.2%	8,366	0.2%	0.087	0.019
Xeroderma pigmentosum	20	0.0%	243	0.0%	0.000	0.000

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1q. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 50,000-74,999mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	95,648	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	64.6	11.4	60.7	13.3	3.907	0.315
Mean age at end of follow-up (years)	67.7	11.5	63.1	13.4	4.582	0.366
Age (years)	Number	Percent	Number	Percent		
0-49	11,465	12.0%	1,317,226	25.4%	-13.379	-0.348
50-59	24,208	25.3%	1,130,393	21.8%	3.541	0.084
60-74	39,151	40.9%	1,773,915	34.2%	6.772	0.140
75+	20,824	21.8%	971,378	18.7%	3.066	0.076
Sex						
Female	49,980	52.3%	2,758,086	53.1%	-0.858	-0.017
Male	45,668	47.7%	2,434,826	46.9%	0.858	0.017
Race/Ethnicity						
American Indian or Alaska Native	438	0.5%	25,722	0.5%	-0.037	-0.005
Asian	6,404	6.7%	109,049	2.1%	4.595	0.226
Black or African American	11,089	11.6%	336,082	6.5%	5.122	0.179
Native Hawaiian or Other Pacific Islander	901	0.9%	14,146	0.3%	0.670	0.086
Unknown	27,904	29.2%	2,266,810	43.7%	-14.478	-0.304
White	48,912	51.1%	2,441,103	47.0%	4.129	0.083
Hispanic Origin	4,990	5.2%	152,340	2.9%	2.283	0.116
Year						
2000	4,236	4.4%	24,601	0.5%	3.955	0.258
2001	6,193	6.5%	43,913	0.8%	5.629	0.303
2002	6,492	6.8%	45,213	0.9%	5.917	0.312
2003	5,811	6.1%	50,960	1.0%	5.094	0.279
2004	5,456	5.7%	47,202	0.9%	4.795	0.271
2005	5,062	5.3%	42,556	0.8%	4.473	0.262
2006	5,793	6.1%	80,884	1.6%	4.499	0.237
2007	6,699	7.0%	131,415	2.5%	4.473	0.211
2008	8,324	8.7%	252,046	4.9%	3.849	0.154
2009	9,098	9.5%	331,001	6.4%	3.138	0.116
2010	13,339	13.9%	480,257	9.2%	4.698	0.147
2011	11,048	11.6%	619,642	11.9%	-0.382	-0.012
2012	4,907	5.1%	570,459	11.0%	-5.855	-0.216
2013	2,073	2.2%	570,505	11.0%	-8.819	-0.362
2014	865	0.9%	549,548	10.6%	-9.678	-0.425
2015	*****	<1%	530,434	10.2%	*****	*****
2016	*****	<1%	522,655	10.1%	*****	*****
2017	-	0.0%	230,886	7.3%	-7.258	-
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1q. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 50,000-74,999mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	1,390	1.5%	150,435	2.9%	-1.444	-0.099
Alcohol Use	762	0.8%	54,647	1.1%	-0.256	-0.027
Antineoplastic Effects	44,288	46.3%	2,502,392	48.2%	-1.885	-0.038
Arsenic Exposure	-	0.0%	67	0.0%	-0.001	-
Diabetes	18,175	19.0%	1,264,787	24.4%	-5.354	-0.130
Human papillomavirus	86	0.1%	8,494	0.2%	-0.074	-0.021
Immunosuppressive: CVD	6,613	6.9%	747,851	14.4%	-7.487	-0.244
Immunosuppressive: Chronic Pulmonary	7,186	7.5%	653,486	12.6%	-5.071	-0.169
Immunosuppressive: Connective Tissue Disease	724	0.8%	89,857	1.7%	-0.973	-0.088
Immunosuppressive: Moderate/Severe Renal Disease	463	0.5%	44,225	0.9%	-0.368	-0.045
Immunosuppressive: Transplant	92	0.1%	13,775	0.3%	-0.169	-0.040
Immunosuppressive: Severe Skin Disease	51	0.1%	6,664	0.1%	-0.075	-0.025
Immunosuppressive: Glucocorticoids	20,185	21.1%	1,442,636	27.8%	-6.677	-0.156
Immunosuppressive: HIV	282	0.3%	20,405	0.4%	-0.098	-0.017
Immunosuppressive: Immune Disorders	38	0.0%	5,349	0.1%	-0.063	-0.024
Immunosuppressive: White Blood Cell Disease	20	0.0%	2,899	0.1%	-0.035	-0.018
Immunosuppressive: Treatment for Immune Disorders	5,938	6.2%	440,681	8.5%	-2.278	-0.087
Mole Removal	850	0.9%	42,771	0.8%	0.065	0.007
Naevi	958	1.0%	35,482	0.7%	0.318	0.035
Photosensitizing: Aminoquinolines	344	0.4%	27,212	0.5%	-0.164	-0.025
Photosensitizing: Amiodarone	296	0.3%	36,095	0.7%	-0.386	-0.055
Photosensitizing: Macrolides	7,352	7.7%	618,058	11.9%	-4.215	-0.142
Photosensitizing: Methoxypsoralen	*****	<1%	50	0.0%	*****	*****
Photosensitizing: Retinoids	38	0.0%	1,453	0.0%	0.012	0.006
Photosensitizing: Tetracycline	327	0.3%	8,366	0.2%	0.181	0.036
Xeroderma pigmentosum	*****	<1%	243	0.0%	*****	*****

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1r. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 75,000-99,999mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent		
Number of unique patients ¹	32,778	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	65.3	11.3	60.7	13.3	4.545	0.368
Mean age at end of follow-up (years)	68.6	11.4	63.1	13.4	5.492	0.442
Age (years)	Number	Percent	Number	Percent		
0-49	3,062	9.3%	1,317,226	25.4%	-16.024	-0.433
50-59	8,147	24.9%	1,130,393	21.8%	3.087	0.073
60-74	14,414	44.0%	1,773,915	34.2%	9.814	0.202
75+	7,155	21.8%	971,378	18.7%	3.123	0.078
Sex						
Female	17,363	53.0%	2,758,086	53.1%	-0.141	-0.003
Male	15,415	47.0%	2,434,826	46.9%	0.141	0.003
Race/Ethnicity						
American Indian or Alaska Native	196	0.6%	25,722	0.5%	0.103	0.014
Asian	3,191	9.7%	109,049	2.1%	7.635	0.328
Black or African American	3,994	12.2%	336,082	6.5%	5.713	0.197
Native Hawaiian or Other Pacific Islander	422	1.3%	14,146	0.3%	1.015	0.116
Unknown	6,936	21.2%	2,266,810	43.7%	-22.491	-0.495
White	18,039	55.0%	2,441,103	47.0%	8.025	0.161
Hispanic Origin	2,343	7.1%	152,340	2.9%	4.214	0.194
Year						
2000	2,557	7.8%	24,601	0.5%	7.327	0.374
2001	3,621	11.0%	43,913	0.8%	10.201	0.442
2002	3,752	11.4%	45,213	0.9%	10.576	0.451
2003	3,262	10.0%	50,960	1.0%	8.970	0.403
2004	2,948	9.0%	47,202	0.9%	8.085	0.379
2005	2,589	7.9%	42,556	0.8%	7.079	0.352
2006	2,607	8.0%	80,884	1.6%	6.396	0.304
2007	2,600	7.9%	131,415	2.5%	5.401	0.244
2008	2,679	8.2%	252,046	4.9%	3.320	0.135
2009	2,094	6.4%	331,001	6.4%	0.014	0.001
2010	1,412	4.3%	480,257	9.2%	-4.941	-0.198
2011	1,474	4.5%	619,642	11.9%	-7.436	-0.273
2012	840	2.6%	570,459	11.0%	-8.423	-0.340
2013	272	0.8%	570,505	11.0%	-10.156	-0.441
2014	58	0.2%	549,548	10.6%	-10.406	-0.474
2015	13	0.0%	530,434	10.2%	-10.175	-0.474
2016	-	0.0%	522,655	10.1%	-10.075	-
2017	-	0.0%	230,886	7.3%	-7.258	-
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1r. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: 75,000-99,999mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	405	1.2%	150,435	2.9%	-1.661	-0.117
Alcohol Use	262	0.8%	54,647	1.1%	-0.253	-0.026
Antineoplastic Effects	14,480	44.2%	2,502,392	48.2%	-4.013	-0.081
Arsenic Exposure	-	0.0%	67	0.0%	-0.001	-
Diabetes	4,874	14.9%	1,264,787	24.4%	-9.486	-0.241
Human papillomavirus	27	0.1%	8,494	0.2%	-0.081	-0.023
Immunosuppressive: CVD	1,622	4.9%	747,851	14.4%	-9.453	-0.324
Immunosuppressive: Chronic Pulmonary	2,069	6.3%	653,486	12.6%	-6.272	-0.216
Immunosuppressive: Connective Tissue Disease	196	0.6%	89,857	1.7%	-1.132	-0.106
Immunosuppressive: Moderate/Severe Renal Disease	126	0.4%	44,225	0.9%	-0.467	-0.060
Immunosuppressive: Transplant	21	0.1%	13,775	0.3%	-0.201	-0.050
Immunosuppressive: Severe Skin Disease	17	0.1%	6,664	0.1%	-0.076	-0.025
Immunosuppressive: Glucocorticoids	6,564	20.0%	1,442,636	27.8%	-7.755	-0.183
Immunosuppressive: HIV	66	0.2%	20,405	0.4%	-0.192	-0.035
Immunosuppressive: Immune Disorders	*****	<1%	5,349	0.1%	*****	*****
Immunosuppressive: White Blood Cell Disease	*****	<1%	2,899	0.1%	*****	*****
Immunosuppressive: Treatment for Immune Disorders	1,958	6.0%	440,681	8.5%	-2.513	-0.097
Mole Removal	316	1.0%	42,771	0.8%	0.140	0.015
Naevi	456	1.4%	35,482	0.7%	0.708	0.070
Photosensitizing: Aminoquinolines	103	0.3%	27,212	0.5%	-0.210	-0.032
Photosensitizing: Amiodarone	75	0.2%	36,095	0.7%	-0.466	-0.069
Photosensitizing: Macrolides	2,018	6.2%	618,058	11.9%	-5.745	-0.201
Photosensitizing: Methoxypsoralen	*****	<1%	50	0.0%	*****	*****
Photosensitizing: Retinoids	15	0.0%	1,453	0.0%	0.018	0.009
Photosensitizing: Tetracycline	142	0.4%	8,366	0.2%	0.272	0.050
Xeroderma pigmentosum	*****	<1%	243	0.0%	*****	*****

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1s. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=100,000mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	13,830	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	66.0	11.1	60.7	13.3	5.301	0.433
Mean age at end of follow-up (years)	69.2	11.0	63.1	13.4	6.106	0.497
Age (years)	Number	Percent	Number	Percent		
0-49	1,034	7.5%	1,317,226	25.4%	-17.889	-0.498
50-59	3,232	23.4%	1,130,393	21.8%	1.601	0.038
60-74	6,453	46.7%	1,773,915	34.2%	12.499	0.257
75+	3,111	22.5%	971,378	18.7%	3.789	0.094
Sex						
Female	7,504	54.3%	2,758,086	53.1%	1.146	0.023
Male	6,326	45.7%	2,434,826	46.9%	-1.146	-0.023
Race/Ethnicity						
American Indian or Alaska Native	79	0.6%	25,722	0.5%	0.076	0.010
Asian	1,591	11.5%	109,049	2.1%	9.404	0.380
Black or African American	1,729	12.5%	336,082	6.5%	6.030	0.207
Native Hawaiian or Other Pacific Islander	207	1.5%	14,146	0.3%	1.224	0.131
Unknown	2,122	15.3%	2,266,810	43.7%	-28.309	-0.653
White	8,102	58.6%	2,441,103	47.0%	11.574	0.233
Hispanic Origin	1,162	8.4%	152,340	2.9%	5.468	0.238
Year						
2000	1,553	11.2%	24,601	0.5%	10.755	0.471
2001	2,181	15.8%	43,913	0.8%	14.924	0.562
2002	2,209	16.0%	45,213	0.9%	15.102	0.565
2003	1,806	13.1%	50,960	1.0%	12.077	0.487
2004	1,539	11.1%	47,202	0.9%	10.219	0.440
2005	1,225	8.9%	42,556	0.8%	8.038	0.381
2006	901	6.5%	80,884	1.6%	4.957	0.254
2007	494	3.6%	131,415	2.5%	1.041	0.061
2008	438	3.2%	252,046	4.9%	-1.687	-0.086
2009	439	3.2%	331,001	6.4%	-3.200	-0.150
2010	516	3.7%	480,257	9.2%	-5.517	-0.225
2011	381	2.8%	619,642	11.9%	-9.178	-0.357
2012	105	0.8%	570,459	11.0%	-10.226	-0.446
2013	31	0.2%	570,505	11.0%	-10.762	-0.481
2014	*****	<1%	549,548	10.6%	*****	*****
2015	*****	<1%	530,434	10.2%	*****	*****
2016	-	0.0%	522,655	10.1%	-10.075	-
2017	-	0.0%	230,886	7.3%	-7.258	-
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1s. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=100,000mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	145	1.0%	150,435	2.9%	-1.848	-0.133
Alcohol Use	113	0.8%	54,647	1.1%	-0.235	-0.024
Antineoplastic Effects	5,892	42.6%	2,502,392	48.2%	-5.586	-0.112
Arsenic Exposure	-	0.0%	67	0.0%	-0.001	-
Diabetes	1,710	12.4%	1,264,787	24.4%	-11.992	-0.314
Human papillomavirus	*****	<1%	8,494	0.2%	*****	*****
Immunosuppressive: CVD	574	4.2%	747,851	14.4%	-10.251	-0.359
Immunosuppressive: Chronic Pulmonary	799	5.8%	653,486	12.6%	-6.807	-0.237
Immunosuppressive: Connective Tissue	75	0.5%	89,857	1.7%	-1.188	-0.112
Immunosuppressive: Moderate/Severe Renal Disease	40	0.3%	44,225	0.9%	-0.562	-0.075
Immunosuppressive: Transplant	*****	<1%	13,775	0.3%	*****	*****
Immunosuppressive: Severe Skin Disease	*****	<1%	6,664	0.1%	*****	*****
Immunosuppressive: Glucocorticoids	2,718	19.7%	1,442,636	27.8%	-8.128	-0.192
Immunosuppressive: HIV	24	0.2%	20,405	0.4%	-0.219	-0.041
Immunosuppressive: Immune Disorders	-	0.0%	5,349	0.1%	-0.103	-
Immunosuppressive: White Blood Cell Disease	*****	<1%	2,899	0.1%	*****	*****
Immunosuppressive: Treatment for Immune Disorders	830	6.0%	440,681	8.5%	-2.485	-0.096
Mole Removal	149	1.1%	42,771	0.8%	0.254	0.026
Naevi	234	1.7%	35,482	0.7%	1.009	0.093
Photosensitizing: Aminoquinolines	47	0.3%	27,212	0.5%	-0.184	-0.028
Photosensitizing: Amiodarone	20	0.1%	36,095	0.7%	-0.550	-0.085
Photosensitizing: Macrolides	769	5.6%	618,058	11.9%	-6.342	-0.226
Photosensitizing: Methoxypsoralen	-	0.0%	50	0.0%	-0.001	-
Photosensitizing: Retinoids	*****	<1%	1,453	0.0%	*****	*****
Photosensitizing: Tetracycline	63	0.5%	8,366	0.2%	0.294	0.053
Xeroderma pigmentosum	*****	<1%	243	0.0%	*****	*****

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1t. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=50,000mg

Characteristic	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Number of unique patients ¹	95,648	100.0%	5,192,912	100.0%	-	-
Demographics	Mean	Standard Deviation	Mean	Standard Deviation	Absolute Difference	Standardized Difference
Mean age at start of dose time group (years)	64.6	11.4	60.7	13.3	3.907	0.315
Mean age at end of follow-up (years)	67.7	11.5	63.1	13.4	4.582	0.366
Age (years)	Number	Percent	Number	Percent		
0-49	11,465	12.0%	1,317,226	25.4%	-13.379	-0.348
50-59	24,208	25.3%	1,130,393	21.8%	3.541	0.084
60-74	39,151	40.9%	1,773,915	34.2%	6.772	0.140
75+	20,824	21.8%	971,378	18.7%	3.066	0.076
Sex						
Female	49,980	52.3%	2,758,086	53.1%	-0.858	-0.017
Male	45,668	47.7%	2,434,826	46.9%	0.858	0.017
Race/Ethnicity						
American Indian or Alaska Native	438	0.5%	25,722	0.5%	-0.037	-0.005
Asian	6,404	6.7%	109,049	2.1%	4.595	0.226
Black or African American	11,089	11.6%	336,082	6.5%	5.122	0.179
Native Hawaiian or Other Pacific Islander	901	0.9%	14,146	0.3%	0.670	0.086
Unknown	27,904	29.2%	2,266,810	43.7%	-14.478	-0.304
White	48,912	51.1%	2,441,103	47.0%	4.129	0.083
Hispanic Origin	4,990	5.2%	152,340	2.9%	2.283	0.116
Year						
2000	4,236	4.4%	24,601	0.5%	3.955	0.258
2001	6,193	6.5%	43,913	0.8%	5.629	0.303
2002	6,492	6.8%	45,213	0.9%	5.917	0.312
2003	5,811	6.1%	50,960	1.0%	5.094	0.279
2004	5,456	5.7%	47,202	0.9%	4.795	0.271
2005	5,062	5.3%	42,556	0.8%	4.473	0.262
2006	5,793	6.1%	80,884	1.6%	4.499	0.237
2007	6,699	7.0%	131,415	2.5%	4.473	0.211
2008	8,324	8.7%	252,046	4.9%	3.849	0.154
2009	9,098	9.5%	331,001	6.4%	3.138	0.116
2010	13,339	13.9%	480,257	9.2%	4.698	0.147
2011	11,048	11.6%	619,642	11.9%	-0.382	-0.012
2012	4,907	5.1%	570,459	11.0%	-5.855	-0.216
2013	2,073	2.2%	570,505	11.0%	-8.819	-0.362
2014	865	0.9%	549,548	10.6%	-9.678	-0.425
2015	*****	<1%	530,434	10.2%	*****	*****
2016	*****	<1%	522,655	10.1%	*****	*****
2017	-	0.0%	230,886	7.3%	-7.258	-
2018	-	0.0%	68,735	3.2%	-3.249	-

Table 1t. Baseline Covariates of New Hydrochlorothiazide (HCTZ) and Angiotensin-Converting Enzyme Inhibitor (ACEI) Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome (All Patients in the Matched Cohort), Time-Varying Dose Group: >=50,000mg

Recorded History during Baseline Period:	HCTZ		ACEI		Covariate Balance	
	Number	Percent	Number	Percent	Absolute Difference	Standardized Difference
Actinic Keratosis	1,390	1.5%	150,435	2.9%	-1.444	-0.099
Alcohol Use	762	0.8%	54,647	1.1%	-0.256	-0.027
Antineoplastic Effects	44,288	46.3%	2,502,392	48.2%	-1.885	-0.038
Arsenic Exposure	-	0.0%	67	0.0%	-0.001	-
Diabetes	18,175	19.0%	1,264,787	24.4%	-5.354	-0.130
Human papillomavirus	86	0.1%	8,494	0.2%	-0.074	-0.021
Immunosuppressive: CVD	6,613	6.9%	747,851	14.4%	-7.487	-0.244
Immunosuppressive: Chronic Pulmonary	7,186	7.5%	653,486	12.6%	-5.071	-0.169
Immunosuppressive: Connective Tissue Disease	724	0.8%	89,857	1.7%	-0.973	-0.088
Immunosuppressive: Moderate/Severe Renal Disease	463	0.5%	44,225	0.9%	-0.368	-0.045
Immunosuppressive: Transplant	92	0.1%	13,775	0.3%	-0.169	-0.040
Immunosuppressive: Severe Skin Disease	51	0.1%	6,664	0.1%	-0.075	-0.025
Immunosuppressive: Glucocorticoids	20,185	21.1%	1,442,636	27.8%	-6.677	-0.156
Immunosuppressive: HIV	282	0.3%	20,405	0.4%	-0.098	-0.017
Immunosuppressive: Immune Disorders	38	0.0%	5,349	0.1%	-0.063	-0.024
Immunosuppressive: White Blood Cell Disease	20	0.0%	2,899	0.1%	-0.035	-0.018
Immunosuppressive: Treatment for Immune Disorders	5,938	6.2%	440,681	8.5%	-2.278	-0.087
Mole Removal	850	0.9%	42,771	0.8%	0.065	0.007
Naevi	958	1.0%	35,482	0.7%	0.318	0.035
Photosensitizing: Aminoquinolines	344	0.4%	27,212	0.5%	-0.164	-0.025
Photosensitizing: Amiodarone	296	0.3%	36,095	0.7%	-0.386	-0.055
Photosensitizing: Macrolides	7,352	7.7%	618,058	11.9%	-4.215	-0.142
Photosensitizing: Methoxypsoralen	*****	<1%	50	0.0%	*****	*****
Photosensitizing: Retinoids	38	0.0%	1,453	0.0%	0.012	0.006
Photosensitizing: Tetracycline	327	0.3%	8,366	0.2%	0.181	0.036
Xeroderma pigmentosum	*****	<1%	243	0.0%	*****	*****

¹One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)											
HCTZ ¹	6,959,086	17,949,221.34	942.07	2.58	43,324	2.41	6.23	-0.37	-0.36	0.96 (0.95, 0.97)	<0.001
ACEI ²	7,417,942	17,565,869.63	864.92	2.37	48,838	2.78	6.58				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05											
HCTZ	5,211,321	12,631,890.88	885.34	2.42	35,112	2.78	6.74	-0.04	-0.06	0.99 (0.97, 1.00)	0.072
ACEI	5,211,321	12,557,937.72	880.16	2.41	35,429	2.82	6.80				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 3. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Sex

Medical Product	Sex	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Male	2,680,900	6,762,065.04	921.27	2.52	20,576	3.04	7.68	-0.22	-0.01	1.03 (1.01, 1.05)	0.003
ACEI ²	Male	3,948,285	9,289,247.42	859.33	2.35	30,346	3.27	7.69				
HCTZ	Female	4,278,186	11,187,156.30	955.10	2.61	22,748	2.03	5.32	-0.20	-0.01	1.04 (1.02, 1.06)	<0.001
ACEI	Female	3,469,657	8,276,622.22	871.28	2.39	18,492	2.23	5.33				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Male	2,427,149	5,800,767.47	872.93	2.39	19,294	3.33	7.95	-0.03	-0.09	0.99 (0.97, 1.01)	0.341
ACEI	Male	2,427,149	5,818,441.31	875.59	2.40	19,516	3.35	8.04				
HCTZ	Female	2,716,796	6,674,000.39	897.26	2.46	15,367	2.30	5.66	-0.07	-0.08	0.98 (0.95, 1.00)	0.027
ACEI	Female	2,716,796	6,576,398.28	884.14	2.42	15,593	2.37	5.74				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 4. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Age Group

Medical Product	Age Group (years)	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	0-49	1,925,761	5,265,133.34	998.61	2.73	2,385	0.45	1.24	-0.06	-0.05	0.92 (0.87, 0.98)	0.007
ACEI ²	0-49	1,754,358	4,453,701.66	927.24	2.54	2,263	0.51	1.29				
HCTZ	50-59	1,537,829	4,202,720.65	998.19	2.73	5,657	1.35	3.68	-0.17	-0.18	0.89 (0.85, 0.92)	<0.001
ACEI	50-59	1,577,347	4,017,519.08	930.30	2.55	6,083	1.51	3.86				
HCTZ	60-74	2,308,436	5,680,777.43	898.84	2.46	19,557	3.44	8.47	-0.24	-0.06	0.96 (0.95, 0.98)	<0.001
ACEI	60-74	2,557,657	5,917,375.18	845.04	2.31	21,813	3.69	8.53				
HCTZ	75+	1,187,060	2,800,589.92	861.72	2.36	15,725	5.61	13.25	-0.26	1.03	0.98 (0.96, 1.01)	0.138
ACEI	75+	1,528,580	3,177,273.72	759.20	2.08	18,679	5.88	12.22				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	0-49	1,268,629	3,221,571.58	927.52	2.54	1,597	0.50	1.26	-0.07	-0.18	0.88 (0.82, 0.94)	<0.001
ACEI	0-49	1,268,629	3,211,010.51	924.48	2.53	1,822	0.57	1.44				
HCTZ	50-59	1,095,379	2,789,548.03	930.16	2.55	4,240	1.52	3.87	-0.15	-0.35	0.91 (0.88, 0.95)	<0.001
ACEI	50-59	1,095,379	2,774,864.48	925.27	2.53	4,628	1.67	4.23				
HCTZ	60-74	1,753,457	4,115,222.77	857.21	2.35	15,564	3.78	8.88	-0.05	-0.09	0.99 (0.97, 1.01)	0.277
ACEI	60-74	1,753,457	4,099,022.10	853.84	2.34	15,723	3.84	8.97				
HCTZ	75+	942,684	2,125,248.80	823.44	2.25	12,838	6.04	13.62	0.02	0.32	1.01 (0.98, 1.03)	0.511
ACEI	75+	942,684	2,082,310.49	806.81	2.21	12,540	6.02	13.30				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 5. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Race

Medical Product	Race	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Unknown	3,130,041	6,941,906.94	810.06	2.22	12,108	1.74	3.87	-0.23	-0.32	0.88 (0.86, 0.90)	<0.001
ACEI ²	Unknown	2,993,689	6,354,560.80	775.30	2.12	12,542	1.97	4.19				
HCTZ	American Indian	21,704	71,805.91	1,208.40	3.31	73	1.02	3.36	0.21	1.12	1.60 (1.17, 2.19)	0.004
ACEI	American Indian	39,611	110,947.43	1,023.04	2.80	89	0.80	2.25				
HCTZ	Asian	180,968	776,538.43	1,567.30	4.29	97	0.12	0.54	0.05	0.22	1.69 (1.21, 2.36)	0.002
ACEI	Asian	172,561	693,893.66	1,468.73	4.02	55	0.08	0.32				
HCTZ	Black	691,611	2,044,738.85	1,079.86	2.96	81	0.04	0.12	0.00	0.01	1.06 (0.76, 1.48)	0.723
ACEI	Black	570,629	1,463,863.45	936.99	2.57	62	0.04	0.11				
HCTZ	Pacific Islander	18,732	86,737.95	1,691.28	4.63	17	0.20	0.91	-0.03	-0.10	0.91 (0.49, 1.68)	0.759
ACEI	Pacific Islander	24,733	112,809.61	1,665.94	4.56	25	0.22	1.01				
HCTZ	White	2,916,030	8,027,493.26	1,005.49	2.75	30,948	3.86	10.61	-0.23	0.64	1.06 (1.04, 1.07)	<0.001
ACEI	White	3,616,719	8,829,794.68	891.71	2.44	36,065	4.08	9.97				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Unknown	2,260,367	4,858,115.56	785.02	2.15	9,273	1.91	4.10	-0.08	-0.17	0.96 (0.93, 0.99)	0.007
ACEI	Unknown	2,260,367	4,861,715.95	785.60	2.15	9,655	1.99	4.27				
HCTZ	American Indian	15,997	47,968.25	1,095.23	3.00	63	1.31	3.94	0.50	1.50	1.58 (1.06, 2.35)	0.025
ACEI	American Indian	15,997	47,894.20	1,093.54	2.99	39	0.81	2.44				
HCTZ	Asian	103,864	409,389.70	1,439.67	3.94	59	0.14	0.57	0.06	0.23	1.72 (1.13, 2.61)	0.011
ACEI	Asian	103,864	412,109.22	1,449.23	3.97	35	0.08	0.34				
HCTZ	Black	336,205	910,749.13	989.43	2.71	40	0.04	0.12	-0.01	-0.02	0.83 (0.55, 1.27)	0.395
ACEI	Black	336,205	909,514.09	988.09	2.71	48	0.05	0.14				
HCTZ	Pacific Islander	13,377	59,888.31	1,635.21	4.48	16	0.27	1.20	0.02	0.07	1.09 (0.54, 2.21)	0.803
ACEI	Pacific Islander	13,377	60,458.64	1,650.78	4.52	15	0.25	1.12				
HCTZ	White	2,246,784	5,711,893.95	928.56	2.54	25,583	4.48	11.39	0.36	0.97	1.09 (1.07, 1.11)	<0.001
ACEI	White	2,246,784	5,686,199.19	924.38	2.53	23,400	4.12	10.41				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 6. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, Overall

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)											
HCTZ ¹	6,959,086	17,948,159.12	942.02	2.58	62,243	3.47	8.94	-0.54	-0.55	0.96 (0.95, 0.97)	<0.001
ACEI ²	7,417,942	17,564,712.93	864.86	2.37	70,463	4.01	9.50				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05											
HCTZ	5,211,321	12,631,044.22	885.28	2.42	50,416	3.99	9.67	-0.09	-0.16	0.98 (0.97, 0.99)	<0.001
ACEI	5,211,321	12,557,100.38	880.10	2.41	51,245	4.08	9.83				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 7. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Sex

Medical Product	Sex	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Male	2,680,900	6,761,572.12	921.21	2.52	28,885	4.27	10.77				
ACEI ²	Male	3,948,285	9,288,558.51	859.27	2.35	43,107	4.64	10.92	-0.37	-0.14	1.02 (1.00, 1.03)	0.046
HCTZ	Female	4,278,186	11,186,587.00	955.05	2.61	33,358	2.98	7.80				
ACEI	Female	3,469,657	8,276,154.42	871.23	2.39	27,356	3.31	7.88	-0.32	-0.09	1.03 (1.01, 1.04)	0.002
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Male	2,427,149	5,800,306.03	872.86	2.39	27,151	4.68	11.19				
ACEI	Male	2,427,149	5,818,001.70	875.52	2.40	27,704	4.76	11.41	-0.08	-0.23	0.98 (0.97, 1.00)	0.031
HCTZ	Female	2,716,796	6,673,626.56	897.21	2.46	22,644	3.39	8.33				
ACEI	Female	2,716,796	6,576,008.58	884.09	2.42	23,070	3.51	8.49	-0.12	-0.16	0.97 (0.95, 0.99)	0.002

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 8. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Age Group

Medical Product	Age Group (years)	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	0-49	1,925,761	5,265,083.14	998.60	2.73	3,516	0.67	1.83				
ACEI ²	0-49	1,754,358	4,453,655.23	927.23	2.54	3,415	0.77	1.95	-0.10	-0.12	0.90 (0.86, 0.95)	<0.001
HCTZ	50-59	1,537,829	4,202,596.38	998.16	2.73	8,264	1.97	5.37				
ACEI	50-59	1,577,347	4,017,354.08	930.26	2.55	9,001	2.24	5.71	-0.27	-0.33	0.88 (0.85, 0.90)	<0.001
HCTZ	60-74	2,308,436	5,680,271.70	898.76	2.46	28,099	4.95	12.17				
ACEI	60-74	2,557,657	5,916,861.49	844.97	2.31	31,698	5.36	12.39	-0.41	-0.22	0.95 (0.94, 0.97)	<0.001
HCTZ	75+	1,187,060	2,800,207.89	861.60	2.36	22,364	7.99	18.84				
ACEI	75+	1,528,580	3,176,842.12	759.10	2.08	26,349	8.29	17.24	-0.31	1.60	0.99 (0.98, 1.01)	0.523
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	0-49	1,268,629	3,221,539.09	927.51	2.54	2,382	0.74	1.88				
ACEI	0-49	1,268,629	3,210,973.39	924.47	2.53	2,746	0.86	2.16	-0.12	-0.29	0.87 (0.82, 0.92)	<0.001
HCTZ	50-59	1,095,379	2,789,455.77	930.13	2.55	6,203	2.22	5.66				
ACEI	50-59	1,095,379	2,774,742.25	925.23	2.53	6,844	2.47	6.25	-0.24	-0.59	0.90 (0.87, 0.93)	<0.001
HCTZ	60-74	1,753,457	4,114,811.08	857.13	2.35	22,321	5.42	12.73				
ACEI	60-74	1,753,457	4,098,663.58	853.76	2.34	22,968	5.60	13.10	-0.18	-0.37	0.97 (0.95, 0.99)	0.001
HCTZ	75+	942,684	2,124,956.60	823.33	2.25	18,282	8.60	19.39				
ACEI	75+	942,684	2,082,013.60	806.69	2.21	17,653	8.48	18.73	0.12	0.67	1.02 (1.00, 1.04)	0.059

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 9. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Race

Medical Product	Race	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Unknown	3,130,041	6,941,640.01	810.03	2.22	17,738	2.56	5.67	-0.37	-0.54	0.87 (0.85, 0.89)	<0.001
ACEI ²	Unknown	2,993,689	6,354,282.42	775.26	2.12	18,584	2.92	6.21				
HCTZ	American Indian	21,704	71,804.60	1,208.38	3.31	101	1.41	4.65	0.39	1.80	1.73 (1.32, 2.27)	<0.001
ACEI	American Indian	39,611	110,944.33	1,023.01	2.80	113	1.02	2.85				
HCTZ	Asian	180,968	776,536.36	1,567.29	4.29	125	0.16	0.69	0.05	0.23	1.49 (1.12, 1.98)	0.006
ACEI	Asian	172,561	693,891.50	1,468.72	4.02	79	0.11	0.46				
HCTZ	Black	691,611	2,044,737.49	1,079.86	2.96	110	0.05	0.16	0.00	0.01	1.05 (0.79, 1.40)	0.74
ACEI	Black	570,629	1,463,862.54	936.99	2.57	83	0.06	0.15				
HCTZ	Pacific Islander	18,732	*****	*****	*****	*****	0.31	*****	-0.03	*****	0.94 (0.57, 1.54)	0.807
ACEI	Pacific Islander	24,733	112,809.00	1,665.93	4.56	38	0.34	1.54				
HCTZ	White	2,916,030	8,026,703.07	1,005.39	2.75	44,142	5.50	15.14	-0.34	0.88	1.06 (1.05, 1.07)	<0.001
ACEI	White	3,616,719	8,828,923.15	891.63	2.44	51,566	5.84	14.26				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Unknown	2,260,367	4,857,907.79	784.98	2.15	13,573	2.79	6.00	-0.15	-0.33	0.95 (0.93, 0.97)	<0.001
ACEI	Unknown	2,260,367	4,861,506.70	785.57	2.15	14,322	2.95	6.34				
HCTZ	American Indian	15,997	47,967.00	1,095.20	3.00	85	1.77	5.31	0.85	*****	1.90 (1.32, 2.73)	<0.001
ACEI	American Indian	15,997	*****	*****	*****	*****	0.92	*****				
HCTZ	Asian	103,864	409,388.58	1,439.66	3.94	81	0.20	0.78	0.08	0.30	1.66 (1.16, 2.36)	0.005
ACEI	Asian	103,864	412,107.85	1,449.23	3.97	50	0.12	0.48				
HCTZ	Black	336,205	910,748.50	989.43	2.71	51	0.06	0.15	-0.02	-0.04	0.78 (0.54, 1.13)	0.195
ACEI	Black	336,205	909,513.32	988.09	2.71	65	0.07	0.19				
HCTZ	Pacific Islander	13,377	*****	*****	*****	*****	0.42	*****	0.05	*****	1.17 (0.66, 2.08)	0.587
ACEI	Pacific Islander	13,377	*****	*****	*****	*****	0.36	*****				
HCTZ	White	2,246,784	5,711,259.86	928.45	2.54	36,483	6.39	16.24	0.49	1.31	1.09 (1.07, 1.10)	<0.001
ACEI	White	2,246,784	5,685,628.23	924.29	2.53	33,538	5.90	14.93				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)											
HCTZ ¹	3,241,938	8,589,178.06	967.69	2.65	17,356	2.02	5.35				
ACEI ²	3,267,035	7,773,695.94	869.09	2.38	18,299	2.35	5.60	-0.33	-0.25	0.95 (0.93, 0.97)	<0.001
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05											
HCTZ	2,339,214	5,631,083.91	879.25	2.41	13,397	2.38	5.73				
ACEI	2,339,214	5,587,023.78	872.37	2.39	13,648	2.44	5.83	-0.06	-0.11	0.98 (0.95, 1.00)	0.041

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 11. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Sex

Medical Product	Sex	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Male	1,208,881	3,204,975.11	968.35	2.65	7,876	2.46	6.52				
ACEI ²	Male	1,702,191	4,127,635.52	885.69	2.42	11,073	2.68	6.51	-0.23	0.01	1.01 (0.98, 1.03)	0.722
HCTZ	Female	2,033,057	5,384,202.95	967.30	2.65	9,480	1.76	4.66				
ACEI	Female	1,564,844	3,646,060.42	851.03	2.33	7,226	1.98	4.62	-0.22	0.05	1.01 (0.98, 1.04)	0.562
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Male	1,058,957	2,594,266.11	894.80	2.45	7,179	2.77	6.78				
ACEI	Male	1,058,957	2,603,647.15	898.04	2.46	7,318	2.81	6.91	-0.04	-0.13	0.98 (0.95, 1.02)	0.31
HCTZ	Female	1,246,956	2,960,797.69	867.26	2.37	6,016	2.03	4.82				
ACEI	Female	1,246,956	2,905,556.03	851.08	2.33	6,187	2.13	4.96	-0.10	-0.14	0.96 (0.93, 0.99)	0.021

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 12. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Age Group

Medical Product	Age Group (years)	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	0-49	897,244	2,684,604.59	1,092.85	2.99	1,345	0.50	1.50	-0.08	-0.07	0.91 (0.84, 0.98)	0.014
ACEI ²	0-49	789,674	2,121,300.91	981.17	2.69	1,237	0.58	1.57				
HCTZ	50-59	734,264	2,121,125.13	1,055.13	2.89	2,834	1.34	3.86	-0.19	-0.14	0.88 (0.84, 0.93)	<0.001
ACEI	50-59	724,825	1,899,438.46	957.16	2.62	2,902	1.53	4.00				
HCTZ	60-74	1,059,638	2,580,272.43	889.40	2.44	7,774	3.01	7.34	-0.30	-0.08	0.95 (0.92, 0.98)	<0.001
ACEI	60-74	1,126,516	2,522,912.22	818.00	2.24	8,351	3.31	7.41				
HCTZ	75+	550,792	1,203,175.91	797.87	2.18	5,403	4.49	9.81	-0.23	0.53	0.98 (0.95, 1.02)	0.331
ACEI	75+	626,020	1,230,044.34	717.67	1.96	5,809	4.72	9.28				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	0-49	566,039	1,525,329.39	984.25	2.69	893	0.59	1.58	-0.07	-0.17	0.90 (0.82, 0.99)	0.022
ACEI	0-49	566,039	1,518,090.63	979.58	2.68	990	0.65	1.75				
HCTZ	50-59	501,385	1,310,599.95	954.75	2.61	1,983	1.51	3.96	-0.18	-0.43	0.90 (0.84, 0.95)	<0.001
ACEI	50-59	501,385	1,302,823.51	949.08	2.60	2,201	1.69	4.39				
HCTZ	60-74	785,128	1,757,628.24	817.67	2.24	5,979	3.40	7.62	-0.10	-0.16	0.97 (0.94, 1.01)	0.154
ACEI	60-74	785,128	1,745,804.98	812.17	2.22	6,108	3.50	7.78				
HCTZ	75+	417,244	854,230.46	747.78	2.05	4,178	4.89	10.01	0.08	0.37	1.02 (0.98, 1.07)	0.323
ACEI	75+	417,244	835,857.40	731.70	2.00	4,022	4.81	9.64				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 13. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Race

Medical Product	Race	Number of New Users	Person Years at Risk	Average	Average	Number of Events	Incidence	Risk per 1000 New Users	Incidence	Difference	Hazard Ratio (95% CI)	Wald P-Value
				Person Days at Risk	Person Years at Risk		Rate per 1000 Years		Rate per 1000 Person Years	Difference in Risk per 1000 New Users		
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Unknown	1,269,688	2,983,448.19	858.25	2.35	5,482	1.84	4.32	-0.23	-0.28	0.88 (0.85, 0.91)	<0.001
ACEI ²	Unknown	1,172,846	2,605,723.93	811.48	2.22	5,390	2.07	4.60				
HCTZ	American Indian	12,505	39,527.44	1,154.53	3.16	37	0.94	2.96	0.32	1.39	1.92 (1.19, 3.09)	0.008
ACEI	American Indian	20,991	53,773.60	935.68	2.56	33	0.61	1.57				
HCTZ	Asian	114,197	499,923.83	1,598.97	4.38	54	0.11	0.47	0.04	0.18	1.72 (1.10, 2.70)	0.018
ACEI	Asian	103,886	434,002.29	1,525.90	4.18	30	0.07	0.29				
HCTZ	Black	369,928	1,050,709.46	1,037.42	2.84	*****	*****	*****	*****	*****	1.12 (0.66, 1.90)	0.682
ACEI	Black	279,629	671,076.15	876.56	2.40	23	0.03	0.08				
HCTZ	Pacific Islander	12,124	58,439.20	1,760.55	4.82	*****	*****	*****	*****	*****	0.63 (0.27, 1.46)	0.282
ACEI	Pacific Islander	15,621	75,774.35	1,771.75	4.85	17	0.22	1.09				
HCTZ	White	1,463,496	3,957,129.94	987.60	2.70	11,740	2.97	8.02	-0.29	0.37	1.05 (1.02, 1.07)	<0.001
ACEI	White	1,674,062	3,933,345.62	858.18	2.35	12,806	3.26	7.65				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Unknown	892,050	2,003,905.13	820.50	2.25	3,999	2.00	4.48	-0.12	-0.27	0.94 (0.90, 0.98)	0.006
ACEI	Unknown	892,050	1,999,632.87	818.75	2.24	4,238	2.12	4.75				
HCTZ	American Indian	8,690	23,691.89	995.80	2.73	26	1.10	2.99	0.43	1.15	1.63 (0.87, 3.03)	0.126
ACEI	American Indian	8,690	23,926.50	1,005.66	2.75	16	0.67	1.84				
HCTZ	Asian	61,940	249,518.43	1,471.37	4.03	36	0.14	0.58	0.06	0.24	1.73 (1.01, 2.96)	0.047
ACEI	Asian	61,940	250,832.81	1,479.12	4.05	21	0.08	0.34				
HCTZ	Black	173,276	430,373.37	907.19	2.48	*****	*****	*****	0.00	0.01	1.10 (0.49, 2.50)	0.814
ACEI	Black	173,276	429,531.01	905.41	2.48	*****	*****	*****				
HCTZ	Pacific Islander	8,400	39,529.36	1,718.82	4.71	*****	*****	*****	-0.02	-0.12	0.92 (0.36, 2.40)	0.871
ACEI	Pacific Islander	8,400	40,594.03	1,765.12	4.83	*****	*****	*****				
HCTZ	White	1,075,757	2,585,046.18	877.70	2.40	9,271	3.59	8.62	0.27	0.72	1.08 (1.05, 1.12)	<0.001
ACEI	White	1,075,757	2,565,805.50	871.16	2.39	8,501	3.31	7.90				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 14. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)											
HCTZ ¹	6,959,086	17,948,766.70	942.05	2.58	55,715	3.10	8.01	-0.48	-0.47	0.96 (0.95, 0.97)	<0.001
ACEI ²	7,417,942	17,565,378.03	864.90	2.37	62,909	3.58	8.48				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05											
HCTZ	5,211,321	12,631,531.32	885.32	2.42	45,160	3.58	8.67	-0.07	-0.13	0.98 (0.97, 0.99)	0.004
ACEI	5,211,321	12,557,573.01	880.13	2.41	45,820	3.65	8.79				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 15. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Sex

Medical Product	Sex	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Male	2,680,900	6,761,849.43	921.24	2.52	26,119	3.86	9.74	-0.30	-0.05	1.02 (1.01, 1.04)	0.004
ACEI ²	Male	3,948,285	9,288,964.04	859.31	2.35	38,653	4.16	9.79				
HCTZ	Female	4,278,186	11,186,917.27	955.08	2.61	29,596	2.65	6.92	-0.29	-0.07	1.03 (1.01, 1.04)	0.004
ACEI	Female	3,469,657	8,276,414.00	871.26	2.39	24,256	2.93	6.99				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Male	2,427,149	5,800,564.70	872.90	2.39	24,529	4.23	10.11	-0.05	-0.16	0.99 (0.97, 1.00)	0.115
ACEI	Male	2,427,149	5,818,253.43	875.56	2.40	24,922	4.28	10.27				
HCTZ	Female	2,716,796	6,673,846.66	897.24	2.46	20,055	3.01	7.38	-0.11	-0.15	0.97 (0.95, 0.99)	0.002
ACEI	Female	2,716,796	6,576,225.97	884.12	2.42	20,473	3.11	7.54				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 16. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Age Group

Medical Product	Age Group (years)	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	0-49	1,925,761	5,265,108.51	998.61	2.73	3,137	0.60	1.63	-0.09	-0.10	0.91 (0.86, 0.95)	<0.001
ACEI ²	0-49	1,754,358	4,453,679.81	927.24	2.54	3,034	0.68	1.73				
HCTZ	50-59	1,537,829	4,202,656.98	998.17	2.73	7,378	1.76	4.80	-0.23	-0.27	0.88 (0.85, 0.91)	<0.001
ACEI	50-59	1,577,347	4,017,447.20	930.28	2.55	7,990	1.99	5.07				
HCTZ	60-74	2,308,436	5,680,553.64	898.80	2.46	25,208	4.44	10.92	-0.34	-0.13	0.96 (0.94, 0.98)	<0.001
ACEI	60-74	2,557,657	5,917,153.46	845.01	2.31	28,271	4.78	11.05				
HCTZ	75+	1,187,060	2,800,447.57	861.68	2.36	19,992	7.14	16.84	-0.29	1.39	0.99 (0.97, 1.01)	0.343
ACEI	75+	1,528,580	3,177,097.56	759.16	2.08	23,614	7.43	15.45				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	0-49	1,268,629	3,221,554.57	927.52	2.54	2,125	0.66	1.68	-0.10	-0.26	0.87 (0.82, 0.92)	<0.001
ACEI	0-49	1,268,629	3,210,993.41	924.47	2.53	2,453	0.76	1.93				
HCTZ	50-59	1,095,379	2,789,502.92	930.15	2.55	5,536	1.98	5.05	-0.20	-0.49	0.91 (0.88, 0.94)	<0.001
ACEI	50-59	1,095,379	2,774,810.55	925.25	2.53	6,075	2.19	5.55				
HCTZ	60-74	1,753,457	4,115,039.18	857.17	2.35	20,040	4.87	11.43	-0.13	-0.25	0.98 (0.96, 1.00)	0.017
ACEI	60-74	1,753,457	4,098,863.85	853.80	2.34	20,477	5.00	11.68				
HCTZ	75+	942,684	2,125,142.02	823.40	2.25	16,345	7.69	17.34	0.07	0.50	1.01 (0.99, 1.04)	0.216
ACEI	75+	942,684	2,082,185.52	806.76	2.21	15,878	7.63	16.84				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 17. Effect Estimates for Basal Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Race

Medical Product	Race	Number of New Users	Person Years at Risk	Average	Average	Number of Events	Incidence	Risk per 1000 New Users	Incidence	Hazard Ratio (95% CI)	Wald P-Value	
				Person Days at Risk	Person Years at Risk		Rate per 1000 Person Years		Rate Difference per 1000 Person Years			
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Unknown	3,130,041	6,941,782.99	810.05	2.22	15,877	2.29	5.07	-0.32	-0.46	0.87 (0.85, 0.89)	<0.001
ACEI ²	Unknown	2,993,689	6,354,436.38	775.28	2.12	16,555	2.61	5.53				
HCTZ	American Indian	21,704	71,805.22	1,208.39	3.31	88	1.23	4.05	0.29	1.43	1.63 (1.22, 2.18)	<0.001
ACEI	American Indian	39,611	110,946.17	1,023.03	2.80	104	0.94	2.63				
HCTZ	Asian	180,968	776,537.02	1,567.29	4.29	116	0.15	0.64	0.05	0.22	1.53 (1.14, 2.05)	0.005
ACEI	Asian	172,561	693,892.14	1,468.72	4.02	72	0.10	0.42				
HCTZ	Black	691,611	2,044,737.88	1,079.86	2.96	101	0.05	0.15	0.00	0.02	1.08 (0.80, 1.46)	0.617
ACEI	Black	570,629	1,463,863.44	936.99	2.57	74	0.05	0.13				
HCTZ	Pacific Islander	18,732	****	*****	*****	*****	0.29	*****				
ACEI	Pacific Islander	24,733	*****	*****	*****	*****	0.29	*****	0.00	*****	1.00 (0.59, 1.68)	0.999
HCTZ	White	2,916,030	8,027,165.91	1,005.45	2.75	39,508	4.92	13.55	-0.30	0.81	1.06 (1.05, 1.07)	<0.001
ACEI	White	3,616,719	8,829,430.67	891.68	2.44	46,071	5.22	12.74				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Unknown	2,260,367	4,858,021.05	785.00	2.15	12,158	2.50	5.38	-0.13	-0.27	0.95 (0.93, 0.98)	<0.001
ACEI	Unknown	2,260,367	4,861,619.44	785.58	2.15	12,776	2.63	5.65				
HCTZ	American Indian	15,997	47,967.62	1,095.22	3.00	75	1.56	4.69	0.69	*****	1.75 (1.20, 2.56)	0.004
ACEI	American Indian	15,997	*****	*****	*****	*****	0.88	*****				
HCTZ	Asian	103,864	409,388.82	1,439.66	3.94	73	0.18	0.70	0.07	0.26	1.63 (1.12, 2.35)	0.01
ACEI	Asian	103,864	412,107.85	1,449.23	3.97	46	0.11	0.44				
HCTZ	Black	336,205	*****	*****	*****	*****	0.05	*****	-0.01	*****	0.86 (0.59, 1.26)	0.443
ACEI	Black	336,205	*****	*****	*****	*****	0.06	*****				
HCTZ	Pacific Islander	13,377	*****	*****	*****	*****	0.38	*****	0.04	*****	1.12 (0.62, 2.03)	0.701
ACEI	Pacific Islander	13,377	*****	*****	*****	*****	0.35	*****				
HCTZ	White	2,246,784	5,711,631.64	928.52	2.54	32,676	5.72	14.54	0.44	1.18	1.09 (1.07, 1.10)	<0.001
ACEI	White	2,246,784	5,685,956.13	924.34	2.53	30,014	5.28	13.36				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 18. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)											
HCTZ ¹	6,959,086	17,936,851.37	941.42	2.58	25,690	1.43	3.69	-0.23	-0.24	0.98 (0.96, 0.99)	0.006
ACEI ²	7,417,942	17,552,302.20	864.25	2.37	29,189	1.66	3.93				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05											
HCTZ	5,211,321	12,622,292.46	884.67	2.42	20,976	1.66	4.03	0.06	0.16	1.04 (1.02, 1.06)	<0.001
ACEI	5,211,321	12,547,769.49	879.45	2.41	20,139	1.60	3.86				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 19. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Sex

Medical Product	Sex	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Male	2,680,900	6,757,251.80	920.62	2.52	11,676	1.73	4.36	-0.13	-0.02	1.05 (1.02, 1.07)	<0.001
ACEI ²	Male	3,948,285	9,281,754.07	858.64	2.35	17,282	1.86	4.38				
HCTZ	Female	4,278,186	11,179,599.57	954.46	2.61	14,014	1.25	3.28	-0.19	-0.16	1.03 (1.01, 1.06)	0.014
ACEI	Female	3,469,657	8,270,548.13	870.64	2.38	11,907	1.44	3.43				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Male	2,427,149	5,796,376.18	872.27	2.39	10,939	1.89	4.51	0.11	0.25	1.06 (1.03, 1.09)	<0.001
ACEI	Male	2,427,149	5,813,638.46	874.87	2.40	10,324	1.78	4.25				
HCTZ	Female	2,716,796	6,668,921.79	896.58	2.45	9,787	1.47	3.60	0.00	0.06	1.01 (0.98, 1.04)	0.65
ACEI	Female	2,716,796	6,571,137.49	883.43	2.42	9,626	1.46	3.54				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 20. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Age Group

Medical Product	Age Group (years)	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	0-49	1,925,761	5,264,324.09	998.46	2.73	580	0.11	0.30	-0.03	-0.06	0.83 (0.74, 0.93)	0.002
ACEI ²	0-49	1,754,358	4,453,093.01	927.12	2.54	628	0.14	0.36				
HCTZ	50-59	1,537,829	4,201,145.13	997.81	2.73	2,083	0.50	1.35	-0.07	-0.10	0.88 (0.83, 0.94)	<0.001
ACEI	50-59	1,577,347	4,015,891.58	929.92	2.55	2,290	0.57	1.45				
HCTZ	60-74	2,308,436	5,674,825.97	897.89	2.46	10,800	1.90	4.68	-0.10	0.06	0.99 (0.96, 1.01)	0.366
ACEI	60-74	2,557,657	5,910,997.62	844.13	2.31	11,824	2.00	4.62				
HCTZ	75+	1,187,060	2,796,556.18	860.48	2.36	12,227	4.37	10.30	-0.18	0.85	0.99 (0.97, 1.01)	0.453
ACEI	75+	1,528,580	3,172,319.99	758.02	2.08	14,447	4.55	9.45				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	0-49	1,268,629	3,221,055.00	927.37	2.54	421	0.13	0.33	-0.01	-0.03	0.92 (0.80, 1.05)	0.205
ACEI	0-49	1,268,629	3,210,519.46	924.34	2.53	458	0.14	0.36				
HCTZ	50-59	1,095,379	2,788,363.71	929.77	2.55	1,537	0.55	1.40	-0.06	-0.13	0.91 (0.85, 0.98)	0.007
ACEI	50-59	1,095,379	2,773,637.86	924.86	2.53	1,682	0.61	1.54				
HCTZ	60-74	1,753,457	4,110,661.64	856.26	2.34	8,625	2.10	4.92	0.09	0.24	1.05 (1.02, 1.08)	0.002
ACEI	60-74	1,753,457	4,094,246.72	852.84	2.33	8,210	2.01	4.68				
HCTZ	75+	942,684	2,122,133.70	822.24	2.25	9,960	4.69	10.57	0.17	0.60	1.04 (1.01, 1.07)	0.003
ACEI	75+	942,684	2,078,796.06	805.45	2.21	9,399	4.52	9.97				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 21. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, by Race

Medical Product	Race	Number of New Users	Person Years at Risk	Average	Average	Number of Events	Incidence	Risk per 1000 New Users	Incidence	Difference	Hazard Ratio (95% CI)	Wald P-Value
				Person Days at Risk	Person Years at Risk		Rate per 1000 Person Years		Rate per 1000 Person Years	in Risk per 1000 New Users		
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Unknown	3,130,041	6,939,154.84	809.74	2.22	5,442	0.78	1.74	-0.11	-0.15	0.87 (0.84, 0.91)	<0.001
ACEI ²	Unknown	2,993,689	6,351,986.33	774.98	2.12	5,663	0.89	1.89				
HCTZ	American Indian	21,704	71,777.11	1,207.92	3.31	32	0.45	1.47	-0.10	-0.04	1.06 (0.68, 1.63)	0.801
ACEI	American Indian	39,611	110,886.71	1,022.48	2.80	60	0.54	1.51				
HCTZ	Asian	180,968	776,483.88	1,567.19	4.29	48	0.06	0.27	-0.03	-0.09	0.74 (0.51, 1.09)	0.126
ACEI	Asian	172,561	693,859.10	1,468.65	4.02	62	0.09	0.36				
HCTZ	Black	691,611	2,044,719.97	1,079.85	2.96	73	0.04	0.11	-0.02	-0.04	0.73 (0.53, 1.00)	0.052
ACEI	Black	570,629	1,463,867.35	937.00	2.57	82	0.06	0.14				
HCTZ	Pacific Islander	18,732	86,735.11	1,691.22	4.63	15	0.17	0.80	0.01	0.07	1.10 (0.55, 2.18)	0.789
ACEI	Pacific Islander	24,733	112,808.70	1,665.93	4.56	18	0.16	0.73				
HCTZ	White	2,916,030	8,017,980.46	1,004.30	2.75	20,080	2.50	6.89	-0.14	0.44	1.08 (1.06, 1.10)	<0.001
ACEI	White	3,616,719	8,818,894.02	890.61	2.44	23,304	2.64	6.44				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Unknown	2,260,367	4,856,080.02	784.69	2.15	4,191	0.86	1.85	0.02	0.03	1.02 (0.98, 1.06)	0.387
ACEI	Unknown	2,260,367	4,859,789.25	785.29	2.15	4,118	0.85	1.82				
HCTZ	American Indian	15,997	47,936.15	1,094.50	3.00	21	0.44	1.31	-0.04	*****	0.95 (0.52, 1.72)	0.859
ACEI	American Indian	15,997	*****	*****	*****	*****	0.48	*****				
HCTZ	Asian	103,864	409,354.23	1,439.54	3.94	29	0.07	0.28	-0.03	-0.12	0.72 (0.44, 1.15)	0.168
ACEI	Asian	103,864	412,096.50	1,449.19	3.97	41	0.10	0.39				
HCTZ	Black	336,205	910,742.36	989.42	2.71	37	0.04	0.11	-0.01	-0.02	0.84 (0.54, 1.30)	0.443
ACEI	Black	336,205	909,512.79	988.09	2.71	44	0.05	0.13				
HCTZ	Pacific Islander	13,377	59,882.78	1,635.06	4.48	13	0.22	0.97	0.08	*****	1.69 (0.70, 4.09)	0.241
ACEI	Pacific Islander	13,377	*****	*****	*****	*****	0.13	*****				
HCTZ	White	2,246,784	5,704,404.33	927.34	2.54	16,633	2.92	7.40	0.37	0.96	1.15 (1.12, 1.17)	<0.001
ACEI	White	2,246,784	5,678,759.46	923.17	2.53	14,473	2.55	6.44				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 22. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)											
HCTZ ¹	6,959,086	17,936,508.22	941.40	2.58	33,962	1.89	4.88	-0.32	-0.36	0.97 (0.96, 0.99)	<0.001
ACEI ²	7,417,942	17,551,920.52	864.23	2.37	38,888	2.22	5.24				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05											
HCTZ	5,211,321	12,622,017.22	884.65	2.42	27,841	2.21	5.34	0.08	0.22	1.04 (1.02, 1.06)	<0.001
ACEI	5,211,321	12,547,518.13	879.43	2.41	26,706	2.13	5.12				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 23. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Sex

Medical Product	Sex	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Male	2,680,900	6,757,094.06	920.60	2.52	15,405	2.28	5.75	-0.21	-0.10	1.04 (1.01, 1.06)	<0.001
ACEI ²	Male	3,948,285	9,281,512.04	858.62	2.35	23,071	2.49	5.84				
HCTZ	Female	4,278,186	11,179,414.16	954.44	2.61	18,557	1.66	4.34	-0.25	-0.22	1.03 (1.01, 1.05)	0.009
ACEI	Female	3,469,657	8,270,408.48	870.62	2.38	15,817	1.91	4.56				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Male	2,427,149	5,796,228.93	872.25	2.39	14,475	2.50	5.96	0.15	0.33	1.06 (1.04, 1.09)	<0.001
ACEI	Male	2,427,149	5,813,494.98	874.84	2.40	13,673	2.35	5.63				
HCTZ	Female	2,716,796	6,668,796.95	896.56	2.45	13,047	1.96	4.80	0.01	0.10	1.01 (0.99, 1.04)	0.337
ACEI	Female	2,716,796	6,571,032.80	883.42	2.42	12,765	1.94	4.70				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 24. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Age Group

Medical Product	Age Group (years)	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	0-49	1,925,761	5,264,312.62	998.46	2.73	799	0.15	0.41	-0.04	-0.07	0.85 (0.77, 0.94)	<0.001
ACEI ²	0-49	1,754,358	4,453,081.89	927.11	2.54	854	0.19	0.49				
HCTZ	50-59	1,537,829	4,201,119.44	997.81	2.73	2,769	0.66	1.80	-0.09	-0.12	0.89 (0.85, 0.94)	<0.001
ACEI	50-59	1,577,347	4,015,860.21	929.91	2.55	3,028	0.75	1.92				
HCTZ	60-74	2,308,436	5,674,664.91	897.87	2.46	14,258	2.51	6.18	-0.16	0.00	0.98 (0.95, 1.00)	0.043
ACEI	60-74	2,557,657	5,910,841.32	844.11	2.31	15,806	2.67	6.18				
HCTZ	75+	1,187,060	2,796,411.25	860.44	2.36	16,136	5.77	13.59	-0.28	1.03	0.99 (0.97, 1.01)	0.178
ACEI	75+	1,528,580	3,172,137.10	757.97	2.08	19,200	6.05	12.56				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	0-49	1,268,629	3,221,044.80	927.37	2.54	588	0.18	0.46	-0.01	-0.02	0.95 (0.85, 1.06)	0.377
ACEI	0-49	1,268,629	3,210,510.21	924.34	2.53	618	0.19	0.49				
HCTZ	50-59	1,095,379	2,788,345.57	929.76	2.55	2,070	0.74	1.89	-0.05	-0.11	0.94 (0.89, 1.00)	0.048
ACEI	50-59	1,095,379	2,773,620.35	924.85	2.53	2,190	0.79	2.00				
HCTZ	60-74	1,753,457	4,110,538.32	856.24	2.34	11,452	2.79	6.53	0.12	0.30	1.05 (1.02, 1.07)	<0.001
ACEI	60-74	1,753,457	4,094,134.75	852.82	2.33	10,923	2.67	6.23				
HCTZ	75+	942,684	2,122,014.54	822.19	2.25	13,147	6.20	13.95	0.21	0.74	1.04 (1.01, 1.07)	0.002
ACEI	75+	942,684	2,078,689.70	805.40	2.21	12,451	5.99	13.21				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 25. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 180-Day Definition, by Race

Medical Product	Race	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Unknown	3,130,041	6,939,102.45	809.74	2.22	7,256	1.05	2.32	-0.15	-0.22	0.87 (0.84, 0.90)	<0.001
ACEI ²	Unknown	2,993,689	6,351,915.81	774.98	2.12	7,587	1.19	2.53				
HCTZ	American Indian	21,704	*****	*****	*****	*****	0.59	*****	-0.07	*****	1.16 (0.79, 1.70)	0.459
ACEI	American Indian	39,611	110,886.29	1,022.47	2.80	73	0.66	1.84				
HCTZ	Asian	180,968	776,482.98	1,567.19	4.29	64	0.08	0.35	-0.02	-0.08	0.82 (0.59, 1.15)	0.244
ACEI	Asian	172,561	693,858.91	1,468.65	4.02	74	0.11	0.43				
HCTZ	Black	691,611	2,044,715.46	1,079.84	2.96	99	0.05	0.14	-0.02	-0.04	0.80 (0.61, 1.06)	0.115
ACEI	Black	570,629	1,463,866.24	937.00	2.57	102	0.07	0.18				
HCTZ	Pacific Islander	18,732	*****	*****	*****	*****	0.21	*****	-0.04	*****	0.85 (0.47, 1.55)	0.604
ACEI	Pacific Islander	24,733	*****	*****	*****	*****	0.25	*****				
HCTZ	White	2,916,030	8,017,695.56	1,004.26	2.75	26,483	3.30	9.08	-0.21	0.50	1.07 (1.05, 1.09)	<0.001
ACEI	White	3,616,719	8,818,584.75	890.58	2.44	31,024	3.52	8.58				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Unknown	2,260,367	4,856,038.80	784.68	2.15	5,634	1.16	2.49	0.03	0.07	1.03 (0.99, 1.07)	0.132
ACEI	Unknown	2,260,367	4,859,734.33	785.28	2.15	5,483	1.13	2.43				
HCTZ	American Indian	15,997	*****	*****	*****	*****	0.54	*****	-0.06	*****	0.92 (0.54, 1.56)	0.753
ACEI	American Indian	15,997	*****	*****	*****	*****	0.61	*****				
HCTZ	Asian	103,864	409,354.13	1,439.54	3.94	40	0.10	0.39	-0.02	*****	0.84 (0.55, 1.28)	0.426
ACEI	Asian	103,864	*****	*****	*****	*****	0.12	*****				
HCTZ	Black	336,205	910,741.59	989.42	2.71	50	0.05	0.15	-0.01	-0.03	0.83 (0.57, 1.21)	0.344
ACEI	Black	336,205	909,512.07	988.09	2.71	60	0.07	0.18				
HCTZ	Pacific Islander	13,377	*****	*****	*****	*****	0.25	*****	0.04	*****	1.20 (0.57, 2.53)	0.623
ACEI	Pacific Islander	13,377	*****	*****	*****	*****	0.22	*****				
HCTZ	White	2,246,784	5,704,175.46	927.30	2.54	22,008	3.86	9.80	0.47	1.24	1.14 (1.12, 1.16)	<0.001
ACEI	White	2,246,784	5,678,583.79	923.14	2.53	19,222	3.38	8.56				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 26. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)											
HCTZ ¹	3,239,301	8,580,721.63	967.53	2.65	9,959	1.16	3.07	-0.16	-0.07	0.99 (0.97, 1.02)	0.582
ACEI ²	3,263,980	7,764,936.13	868.92	2.38	10,269	1.32	3.15				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05											
HCTZ	2,336,908	5,625,973.39	879.32	2.41	7,740	1.38	3.31	0.04	0.12	1.03 (1.00, 1.06)	0.063
ACEI	2,336,908	5,581,469.30	872.36	2.39	7,463	1.34	3.19				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 27. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Sex

Medical Product	Sex	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Male	1,207,806	3,201,765.84	968.24	2.65	4,353	1.36	3.60				
ACEI ²	Male	1,700,474	4,122,781.94	885.54	2.42	6,001	1.46	3.53	-0.10	0.08	1.05 (1.01, 1.09)	0.022
HCTZ	Female	2,031,495	5,378,955.79	967.10	2.65	5,606	1.04	2.76				
ACEI	Female	1,563,506	3,642,154.20	850.84	2.33	4,268	1.17	2.73	-0.13	0.03	1.05 (1.01, 1.09)	0.015
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Male	1,058,413	2,594,154.60	895.22	2.45	3,980	1.53	3.76				
ACEI	Male	1,058,413	2,602,239.52	898.01	2.46	3,792	1.46	3.58	0.08	0.18	1.05 (1.01, 1.10)	0.027
HCTZ	Female	1,245,795	2,957,590.99	867.13	2.37	3,654	1.24	2.93				
ACEI	Female	1,245,795	2,902,155.74	850.87	2.33	3,574	1.23	2.87	0.00	0.06	1.01 (0.96, 1.06)	0.689

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 28. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Age Group

Medical Product	Age Group (years)	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	0-49	897,119	2,683,987.37	1,092.75	2.99	355	0.13	0.40				
ACEI ²	0-49	789,565	2,120,866.06	981.11	2.69	350	0.17	0.44	-0.03	-0.05	0.86 (0.74, 1.00)	0.049
HCTZ	50-59	733,984	2,119,974.24	1,054.96	2.89	1,054	0.50	1.44				
ACEI	50-59	724,494	1,898,338.50	957.04	2.62	1,087	0.57	1.50	-0.08	-0.06	0.89 (0.82, 0.97)	0.006
HCTZ	60-74	1,058,356	2,576,250.34	889.09	2.43	4,387	1.70	4.15				
ACEI	60-74	1,125,127	2,518,683.30	817.64	2.24	4,481	1.78	3.98	-0.08	0.16	1.00 (0.96, 1.04)	0.967
HCTZ	75+	549,842	1,200,509.69	797.48	2.18	4,163	3.47	7.57				
ACEI	75+	624,794	1,227,048.26	717.32	1.96	4,351	3.55	6.96	-0.08	0.61	1.01 (0.97, 1.05)	0.709
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	0-49	565,808	1,524,747.62	984.28	2.69	232	0.15	0.41				
ACEI	0-49	565,808	1,517,554.78	979.64	2.68	257	0.17	0.45	-0.02	-0.04	0.90 (0.75, 1.07)	0.245
HCTZ	50-59	500,354	1,308,758.62	955.37	2.62	737	0.56	1.47				
ACEI	50-59	500,354	1,300,528.07	949.36	2.60	807	0.62	1.61	-0.06	-0.14	0.91 (0.82, 1.00)	0.06
HCTZ	60-74	784,220	1,755,181.51	817.47	2.24	3,373	1.92	4.30				
ACEI	60-74	784,220	1,744,396.68	812.45	2.22	3,182	1.82	4.06	0.10	0.24	1.06 (1.01, 1.11)	0.029
HCTZ	75+	415,947	851,537.28	747.75	2.05	3,201	3.76	7.70				
ACEI	75+	415,947	832,341.40	730.89	2.00	3,009	3.62	7.23	0.14	0.46	1.05 (1.00, 1.10)	0.078

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 29. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 2 Year Blackout, by Race

Medical Product	Race	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Unknown	1,269,188	2,981,532.24	858.03	2.35	2,533	0.85	2.00	-0.05	-0.01	0.93 (0.88, 0.98)	0.007
ACEI ²	Unknown	1,172,306	2,604,060.48	811.34	2.22	2,352	0.90	2.01				
HCTZ	American Indian	12,498	39,505.95	1,154.55	3.16	16	0.41	1.28	*****	*****	1.24 (0.65, 2.37)	0.519
ACEI	American Indian	20,976	53,740.04	935.76	2.56	*****	*****	*****				
HCTZ	Asian	114,185	499,887.69	1,599.02	4.38	34	0.07	0.30	0.00	0.00	1.07 (0.66, 1.75)	0.787
ACEI	Asian	103,885	433,975.22	1,525.82	4.18	31	0.07	0.30				
HCTZ	Black	369,928	1,050,710.51	1,037.42	2.84	38	0.04	0.10	-0.01	0.00	0.95 (0.59, 1.54)	0.836
ACEI	Black	279,629	671,083.34	876.57	2.40	30	0.04	0.11				
HCTZ	Pacific Islander	12,124	58,438.72	1,760.54	4.82	11	0.19	0.91	*****	*****	1.82 (0.73, 4.53)	0.201
ACEI	Pacific Islander	15,620	75,770.83	1,771.79	4.85	*****	*****	*****				
HCTZ	White	1,461,378	3,950,646.51	987.41	2.70	7,327	1.85	5.01	-0.14	0.33	1.09 (1.05, 1.12)	<0.001
ACEI	White	1,671,564	3,926,306.22	857.93	2.35	7,825	1.99	4.68				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Unknown	891,297	2,000,778.62	819.91	2.24	1,836	0.92	2.06	0.02	0.05	1.02 (0.96, 1.09)	0.531
ACEI	Unknown	891,297	1,997,373.19	818.52	2.24	1,794	0.90	2.01				
HCTZ	American Indian	8,662	23,655.98	997.50	2.73	*****	*****	*****	0.13	0.35	1.47 (0.56, 3.88)	0.431
ACEI	American Indian	8,662	24,002.55	1,012.11	2.77	*****	*****	*****				
HCTZ	Asian	61,789	250,893.15	1,483.09	4.06	22	0.09	0.36	0.00	0.02	1.06 (0.58, 1.92)	0.858
ACEI	Asian	61,789	250,654.25	1,481.68	4.06	21	0.08	0.34				
HCTZ	Black	173,635	432,385.51	909.54	2.49	18	0.04	0.10	*****	*****	1.06 (0.54, 2.05)	0.874
ACEI	Black	173,635	430,442.34	905.46	2.48	*****	*****	*****				
HCTZ	Pacific Islander	8,353	39,074.04	1,708.58	4.68	*****	*****	*****	0.18	0.84	3.55 (0.98, 12.89)	0.054
ACEI	Pacific Islander	8,353	39,820.50	1,741.22	4.77	*****	*****	*****				
HCTZ	White	1,074,287	2,581,679.34	877.75	2.40	5,814	2.25	5.41	0.25	0.64	1.13 (1.09, 1.17)	<0.001
ACEI	White	1,074,287	2,562,151.95	871.11	2.38	5,129	2.00	4.77				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 30. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Analysis Type

Medical Product	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)											
HCTZ ¹	6,959,086	17,936,694.78	941.41	2.58	31,491	1.76	4.53	-0.29	-0.32	0.97 (0.96, 0.99)	<0.001
ACEI ²	7,417,942	17,552,123.76	864.24	2.37	35,920	2.05	4.84				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05											
HCTZ	5,211,321	12,622,166.08	884.66	2.42	25,764	2.04	4.94	0.07	0.20	1.04 (1.02, 1.05)	<0.001
ACEI	5,211,321	12,547,650.00	879.44	2.41	24,738	1.97	4.75				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 31. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Sex

Medical Product	Sex	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Male	2,680,900	6,757,182.70	920.61	2.52	14,269	2.11	5.32	-0.18	-0.08	1.04 (1.01, 1.06)	0.001
ACEI ²	Male	3,948,285	9,281,647.42	858.63	2.35	21,316	2.30	5.40				
HCTZ	Female	4,278,186	11,179,512.08	954.45	2.61	17,222	1.54	4.03	-0.23	-0.18	1.03 (1.01, 1.06)	0.004
ACEI	Female	3,469,657	8,270,476.34	870.63	2.38	14,604	1.77	4.21				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Male	2,427,149	5,796,311.82	872.26	2.39	13,387	2.31	5.52	0.13	0.29	1.06 (1.03, 1.08)	<0.001
ACEI	Male	2,427,149	5,813,575.57	874.86	2.40	12,671	2.18	5.22				
HCTZ	Female	2,716,796	6,668,861.56	896.57	2.45	12,077	1.81	4.45	0.01	0.09	1.01 (0.99, 1.04)	0.398
ACEI	Female	2,716,796	6,571,082.02	883.43	2.42	11,827	1.80	4.35				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 32. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Age Group

Medical Product	Age Group (years)	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	0-49	1,925,761	5,264,319.76	998.46	2.73	730	0.14	0.38	-0.04	-0.07	0.84 (0.76, 0.93)	<0.001
ACEI ²	0-49	1,754,358	4,453,085.63	927.11	2.54	787	0.18	0.45				
HCTZ	50-59	1,537,829	4,201,130.97	997.81	2.73	2,602	0.62	1.69	-0.09	-0.10	0.89 (0.85, 0.94)	<0.001
ACEI	50-59	1,577,347	4,015,871.46	929.91	2.55	2,834	0.71	1.80				
HCTZ	60-74	2,308,436	5,674,748.53	897.88	2.46	13,243	2.33	5.74	-0.14	0.02	0.98 (0.96, 1.00)	0.091
ACEI	60-74	2,557,657	5,910,923.96	844.12	2.31	14,624	2.47	5.72				
HCTZ	75+	1,187,060	2,796,495.52	860.46	2.36	14,916	5.33	12.57	-0.24	1.00	0.99 (0.97, 1.01)	0.314
ACEI	75+	1,528,580	3,172,242.71	758.00	2.08	17,675	5.57	11.56				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	0-49	1,268,629	3,221,051.47	927.37	2.54	538	0.17	0.42	-0.01	-0.03	0.94 (0.84, 1.06)	0.298
ACEI	0-49	1,268,629	3,210,512.91	924.34	2.53	572	0.18	0.45				
HCTZ	50-59	1,095,379	2,788,354.43	929.77	2.55	1,938	0.70	1.77	-0.05	-0.12	0.93 (0.88, 0.99)	0.026
ACEI	50-59	1,095,379	2,773,627.39	924.86	2.53	2,070	0.75	1.89				
HCTZ	60-74	1,753,457	4,110,600.95	856.25	2.34	10,618	2.58	6.06	0.11	0.29	1.05 (1.02, 1.08)	<0.001
ACEI	60-74	1,753,457	4,094,191.74	852.83	2.33	10,114	2.47	5.77				
HCTZ	75+	942,684	2,122,082.72	822.22	2.25	12,135	5.72	12.87	0.18	0.67	1.04 (1.01, 1.07)	0.004
ACEI	75+	942,684	2,078,750.11	805.43	2.21	11,507	5.54	12.21				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

Table 33. Effect Estimates for Squamous Cell Carcinoma in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, 60-Day Definition, by Race

Medical Product	Race	Number of New Users	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Incidence Rate per 1000 Person Years	Risk per 1000 New Users	Incidence Rate Difference per 1000 Person Years	Difference in Risk per 1000 New Users	Hazard Ratio (95% CI)	Wald P-Value
Unmatched Analysis (Site-adjusted only)												
HCTZ ¹	Unknown	3,130,041	6,939,124.91	809.74	2.22	6,779	0.98	2.17				
ACEI ²	Unknown	2,993,689	6,351,946.13	774.98	2.12	7,073	1.11	2.36	-0.14	-0.20	0.87 (0.84, 0.90)	<0.001
HCTZ	American Indian	21,704	*****	*****	*****	*****	0.56	*****	-0.04	*****	1.21 (0.81, 1.80)	0.347
ACEI	American Indian	39,611	*****	*****	*****	*****	0.60	*****				
HCTZ	Asian	180,968	776,483.42	1,567.19	4.29	61	0.08	0.34	-0.02	*****	0.86 (0.61, 1.22)	0.397
ACEI	Asian	172,561	*****	*****	*****	*****	0.10	*****				
HCTZ	Black	691,611	2,044,719.02	1,079.85	2.96	85	0.04	0.12	-0.02	*****	0.77 (0.57, 1.03)	0.082
ACEI	Black	570,629	*****	*****	*****	*****	0.06	*****				
HCTZ	Pacific Islander	18,732	*****	*****	*****	*****	0.18	*****	-0.03	*****	0.87 (0.46, 1.64)	0.671
ACEI	Pacific Islander	24,733	*****	*****	*****	*****	0.21	*****				
HCTZ	White	2,916,030	8,017,855.36	1,004.28	2.75	24,510	3.06	8.41	-0.19	0.50	1.07 (1.05, 1.09)	<0.001
ACEI	White	3,616,719	8,818,756.51	890.60	2.44	28,599	3.24	7.91				
1:1 Matched Unconditional Predefined Analysis; Caliper= 0.05												
HCTZ	Unknown	2,260,367	4,856,057.36	784.68	2.15	5,259	1.08	2.33	0.03	0.06	1.03 (0.99, 1.07)	0.157
ACEI	Unknown	2,260,367	4,859,756.23	785.28	2.15	5,122	1.05	2.27				
HCTZ	American Indian	15,997	*****	*****	*****	*****	0.50	*****	-0.04	*****	0.95 (0.54, 1.66)	0.853
ACEI	American Indian	15,997	*****	*****	*****	*****	0.54	*****				
HCTZ	Asian	103,864	*****	*****	*****	*****	0.10	*****	-0.01	*****	0.87 (0.57, 1.34)	0.54
ACEI	Asian	103,864	*****	*****	*****	*****	0.11	*****				
HCTZ	Black	336,205	*****	*****	*****	*****	0.05	*****	-0.01	*****	0.82 (0.55, 1.24)	0.356
ACEI	Black	336,205	*****	*****	*****	*****	0.06	*****				
HCTZ	Pacific Islander	13,377	59,882.78	1,635.06	4.48	13	0.22	0.97	0.04	*****	1.23 (0.55, 2.75)	0.611
ACEI	Pacific Islander	13,377	*****	*****	*****	*****	0.18	*****				
HCTZ	White	2,246,784	5,704,302.03	927.32	2.54	20,326	3.56	9.05	0.44	1.14	1.14 (1.12, 1.17)	<0.001
ACEI	White	2,246,784	5,678,681.98	923.16	2.53	17,757	3.13	7.90				

¹Hydrochlorothiazide

²Angiotensin-converting enzyme inhibitor

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 34. Site and Age adjusted Effect Estimates for Basal Cell Carcinoma with Dose-specific Follow-up Time in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, All Races, by Hydrochlorothiazide (HCTZ) Cumulative Dose^{1,2}

Cumulative HCTZ Dose (mg)	Exposure	Number of New Users ³	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Adjusted Incidence Rate per 1,000 Person years (95% CI)	Adjusted Incidence Rate Ratio (95% CI)	Adjusted Incidence Rate Difference per 1,000 Person Years (95% CI)	Adjusted Risk per 1,000 New Users (95% CI)	Adjusted Risk Ratio (95% CI)
Overall	HCTZ	5,192,912	12,570,987.28	884.20	2.42	35,051	1.11 (1.07, 1.16)			3.17 (3.04, 3.30)	
	ACEI ⁴	5,192,912	12,496,057.15	878.93	2.41	35,357	1.12 (1.08, 1.17)	0.99 (0.97, 1.00)	-0.01 (-0.03, 0.00)	3.20 (3.07, 3.33)	0.99 (0.98, 1.01)
<10000	HCTZ	5,192,912	9,218,315.06	648.38	1.78	26,495	1.09 (1.05, 1.14)			2.28 (2.18, 2.39)	
	ACEI	5,192,912	12,496,057.15	878.93	2.41	35,357	1.11 (1.07, 1.16)	0.98 (0.97, 1.00)	-0.02 (-0.04, -0.00)	3.05 (2.91, 3.18)	0.75 (0.74, 0.76)
10000 - 24999	HCTZ	1,329,225	2,247,897.78	617.69	1.69	6,157	1.02 (0.96, 1.08)			2.02 (1.91, 2.14)	
	ACEI	5,192,912	12,496,057.15	878.93	2.41	35,357	1.13 (1.07, 1.19)	0.90 (0.88, 0.93)	-0.11 (-0.14, -0.08)	3.17 (3.01, 3.34)	0.64 (0.62, 0.66)
25000 - 49999	HCTZ	424,149	809,812.01	697.36	1.91	1,987	1.07 (1.00, 1.15)			2.14 (2.00, 2.29)	
	ACEI	5,192,912	12,496,057.15	878.93	2.41	35,357	1.14 (1.09, 1.21)	0.94 (0.90, 0.98)	-0.07 (-0.12, -0.02)	3.27 (3.10, 3.45)	0.66 (0.63, 0.69)
50000 - 74999	HCTZ	95,738	184,945.17	705.58	1.93	281	0.98 (0.86, 1.12)			1.59 (1.40, 1.80)	
	ACEI	5,192,912	12,496,057.15	878.93	2.41	35,357	1.15 (1.09, 1.21)	0.86 (0.76, 0.96)	-0.17 (-0.28, -0.05)	3.29 (3.11, 3.47)	0.48 (0.43, 0.54)
75000 - 99999	HCTZ	32,808	65,569.82	729.99	2.00	82	1.11 (0.89, 1.39)			1.61 (1.29, 2.02)	
	ACEI	5,192,912	12,496,057.15	878.93	2.41	35,357	1.15 (1.09, 1.22)	0.96 (0.77, 1.20)	-0.04 (-0.29, 0.20)	3.29 (3.12, 3.48)	0.49 (0.39, 0.61)
≥ 100000	HCTZ	13,842	44,447.45	1,172.84	3.21	49	1.28 (0.96, 1.71)			2.57 (1.93, 3.42)	
	ACEI	5,192,912	12,496,057.15	878.93	2.41	35,357	1.15 (1.09, 1.22)	1.12 (0.84, 1.48)	0.13 (-0.23, 0.50)	3.29 (3.11, 3.47)	0.78 (0.59, 1.04)
≥ 50000	HCTZ	95,738	294,962.43	1,125.31	3.08	412	1.07 (0.96, 1.19)			2.32 (2.08, 2.58)	
	ACEI	5,192,912	12,496,057.15	878.93	2.41	35,357	1.15 (1.09, 1.21)	0.93 (0.84, 1.02)	-0.08 (-0.19, 0.02)	3.31 (3.14, 3.50)	0.70 (0.63, 0.77)

¹All effect measures are adjusted for age group and estimated within a 1:1 propensity score-matched cohort.

²Some adjusted risk differences with 95% CI could not be estimated as the model failed to converge.

³One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

⁴Angiotensin-converting enzyme inhibitor

Table 35. Site and Age adjusted Effect Estimates for Basal Cell Carcinoma with Dose-specific Follow-up Time in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, White Race Only, by Hydrochlorothiazide (HCTZ) Cumulative Dose^{1,2}

Cumulative HCTZ Dose (mg)	Exposure	Number of New Users ³	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Adjusted Incidence Rate per 1,000 Person Years (95% CI)	Adjusted Incidence Rate Ratio (95% CI)	Adjusted Incidence Rate Difference per 1,000 Person Years (95% CI)	Adjusted Risk per 1,000 New Users (95% CI)	Adjusted Risk Ratio (95% CI)
Overall	HCTZ	2,241,699	5,690,552.48	927.19	2.54	25,557	1.39 (1.31, 1.47)			4.31 (4.07, 4.57)	
	ACEI ⁴	2,441,103	6,135,119.12	917.97	2.51	25,522	1.29 (1.22, 1.37)	1.08 (1.06, 1.10)	0.10 (0.07, 0.12)	4.00 (3.77, 4.23)	1.08 (1.06, 1.10)
<10000	HCTZ	2,241,699	4,047,555.29	659.49	1.81	19,529	1.39 (1.31, 1.48)			3.10 (2.91, 3.30)	
	ACEI	2,441,103	6,135,119.12	917.97	2.51	25,522	1.28 (1.20, 1.36)	1.09 (1.07, 1.11)	0.12 (0.09, 0.14)	3.76 (3.53, 4.00)	0.82 (0.81, 0.84)
10000 - 24999	HCTZ	638,659	1,080,639.16	618.02	1.69	4,425	1.26 (1.16, 1.36)			2.63 (2.44, 2.84)	
	ACEI	2,441,103	6,135,119.12	917.97	2.51	25,522	1.31 (1.22, 1.41)	0.96 (0.93, 0.99)	-0.06 (-0.10, -0.02)	3.97 (3.69, 4.27)	0.66 (0.64, 0.68)
25000 - 49999	HCTZ	212,765	402,339.80	690.69	1.89	1,335	1.29 (1.18, 1.41)			2.64 (2.41, 2.89)	
	ACEI	2,441,103	6,135,119.12	917.97	2.51	25,522	1.35 (1.26, 1.46)	0.95 (0.90, 1.00)	-0.07 (-0.14, 0.00)	4.21 (3.90, 4.53)	0.63 (0.59, 0.66)
50000 - 74999	HCTZ	48,973	95,752.12	714.14	1.96	163	1.07 (0.90, 1.27)			1.69 (1.43, 2.01)	
	ACEI	2,441,103	6,135,119.12	917.97	2.51	25,522	1.35 (1.25, 1.46)	0.79 (0.68, 0.93)	-0.28 (-0.45, -0.11)	4.21 (3.90, 4.55)	0.40 (0.34, 0.47)
75000 - 99999	HCTZ	18,062	37,187.92	752.01	2.06	62	1.38 (1.07, 1.80)			2.10 (1.62, 2.72)	
	ACEI	2,441,103	6,135,119.12	917.97	2.51	25,522	1.35 (1.25, 1.46)	1.02 (0.80, 1.32)	0.03 (-0.32, 0.38)	4.20 (3.89, 4.54)	0.50 (0.39, 0.64)
≥ 100000	HCTZ	8,111	27,078.18	1,219.37	3.34	43	1.64 (1.21, 2.24)			3.53 (2.59, 4.80)	
	ACEI	2,441,103	6,135,119.12	917.97	2.51	25,522	1.35 (1.25, 1.46)	1.22 (0.90, 1.65)	0.29 (-0.20, 0.79)	4.20 (3.88, 4.53)	0.84 (0.62, 1.14)
≥ 50000	HCTZ	48,973	160,018.22	1,193.45	3.27	268	1.23 (1.07, 1.42)			2.76 (2.40, 3.17)	
	ACEI	2,441,103	6,135,119.12	917.97	2.51	25,522	1.35 (1.24, 1.45)	0.92 (0.81, 1.04)	-0.11 (-0.26, 0.04)	4.23 (3.91, 4.57)	0.65 (0.58, 0.74)

¹All effect measures are adjusted for age group and estimated within a 1:1 propensity score-matched cohort.

²Some adjusted risk differences with 95% CI could not be estimated as the model failed to converge.

³One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

⁴Angiotensin-converting enzyme inhibitor

Table 36. Site and Age adjusted Effect Estimates for Squamous Cell Carcinoma with Dose-specific Follow-up Time in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, All Races, by Hydrochlorothiazide (HCTZ) Cumulative Dose^{1,2}

Cumulative HCTZ Dose (mg)	Exposure	Number of New Users ³	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Adjusted Incidence Rate per 1,000 Person Years (95% CI)	Adjusted Incidence Rate Ratio (95% CI)	Adjusted Incidence Rate Difference per 1,000 Person Years (95% CI)	Adjusted Risk per 1,000 New Users (95% CI)	Adjusted Risk Ratio (95% CI)
Overall	HCTZ	5,192,912	12,561,422.46	883.52	2.42	20,941	0.47 (0.45, 0.50)			1.34 (1.27, 1.42)	1.04 (1.02, 1.06)
	ACEI ⁴	5,192,912	12,485,934.80	878.21	2.40	20,119	0.46 (0.43, 0.48)	1.04 (1.02, 1.06)	0.02 (0.01, 0.03)	1.29 (1.22, 1.37)	1.04 (1.02, 1.06)
<10000	HCTZ	5,192,912	9,212,400.57	647.97	1.77	15,815	0.44 (0.41, 0.47)	1.02 (1.00, 1.04)	0.01 (0.00, 0.02)	0.92 (0.86, 0.98)	0.79 (0.77, 0.80)
	ACEI	5,192,912	12,485,934.80	878.21	2.40	20,119	0.43 (0.41, 0.46)			1.17 (1.10, 1.25)	
10000 - 24999	HCTZ	1,328,085	2,245,341.42	617.51	1.69	3,765	0.42 (0.39, 0.46)	0.95 (0.92, 0.99)	-0.02 (-0.04, -0.01)	0.83 (0.77, 0.91)	0.68 (0.65, 0.70)
	ACEI	5,192,912	12,485,934.80	878.21	2.40	20,119	0.44 (0.41, 0.48)			1.23 (1.14, 1.33)	
25000 - 49999	HCTZ	423,639	808,929.52	697.44	1.91	1,089	0.40 (0.36, 0.44)	0.90 (0.85, 0.96)	-0.04 (-0.07, -0.02)	0.79 (0.71, 0.87)	0.63 (0.59, 0.67)
	ACEI	5,192,912	12,485,934.80	878.21	2.40	20,119	0.44 (0.41, 0.48)			1.26 (1.16, 1.37)	
50000 - 74999	HCTZ	95,648	184,820.55	705.77	1.93	186	0.48 (0.41, 0.57)	1.07 (0.93, 1.24)	0.03 (-0.04, 0.10)	0.75 (0.64, 0.89)	0.59 (0.51, 0.68)
	ACEI	5,192,912	12,485,934.80	878.21	2.40	20,119	0.45 (0.41, 0.49)			1.28 (1.17, 1.40)	
75000 - 99999	HCTZ	32,778	65,500.78	729.88	2.00	59	0.62 (0.47, 0.81)	1.39 (1.07, 1.80)	0.17 (0.01, 0.33)	0.88 (0.68, 1.16)	0.70 (0.54, 0.90)
	ACEI	5,192,912	12,485,934.80	878.21	2.40	20,119	0.45 (0.41, 0.49)			1.26 (1.16, 1.38)	
≥ 100000	HCTZ	13,830	44,429.63	1,173.39	3.21	27	0.58 (0.40, 0.86)	1.32 (0.90, 1.94)	0.14 (-0.08, 0.37)	1.14 (0.77, 1.68)	0.91 (0.62, 1.33)
	ACEI	5,192,912	12,485,934.80	878.21	2.40	20,119	0.44 (0.40, 0.48)			1.26 (1.15, 1.37)	
≥ 50000	HCTZ	95,648	294,750.97	1,125.56	3.08	272	0.54 (0.47, 0.62)	1.19 (1.05, 1.35)	0.09 (0.02, 0.15)	1.10 (0.95, 1.27)	0.85 (0.75, 0.96)
	ACEI	5,192,912	12,485,934.80	878.21	2.40	20,119	0.45 (0.41, 0.49)			1.30 (1.19, 1.42)	

¹All effect measures are adjusted for age group and estimated within a 1:1 propensity score-matched cohort.

²Some adjusted risk differences with 95% CI could not be estimated as the model failed to converge.

³One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

⁴Angiotensin-converting enzyme inhibitor

Table 37. Site and Age adjusted Effect Estimates for Squamous Cell Carcinoma with Dose-specific Follow-up Time in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, White Race Only, by Hydrochlorothiazide (HCTZ) Cumulative Dose^{1,2}

Cumulative HCTZ Dose (mg)	Exposure	Number of New Users ³	Person Years at Risk	Average Person Days at Risk	Average Person Years at Risk	Number of Events	Adjusted Incidence Rate per 1,000 Person Years (95% CI)	Adjusted Incidence Rate Ratio (95% CI)	Adjusted Incidence Rate Difference per 1,000 Person Years (95% CI)	Adjusted Risk per 1,000 New Users (95% CI)	Adjusted Risk Ratio (95% CI)
Overall	HCTZ	2,241,699	5,683,071.38	925.97	2.54	16,615	0.60 (0.55, 0.65)			1.85 (1.69, 2.01)	1.13 (1.11, 1.15)
	ACEI ⁴	2,441,103	6,126,974.48	916.75	2.51	15,847	0.53 (0.49, 0.58)	1.13 (1.10, 1.15)	0.07 (0.05, 0.08)	1.63 (1.50, 1.78)	
<10000	HCTZ	2,241,699	4,042,926.37	658.73	1.80	12,706	0.57 (0.51, 0.62)	1.13 (1.10, 1.16)	0.06 (0.05, 0.08)	1.26 (1.15, 1.39)	0.86 (0.84, 0.88)
	ACEI	2,441,103	6,126,974.48	916.75	2.51	15,847	0.50 (0.46, 0.55)			1.46 (1.33, 1.61)	
10000 - 24999	HCTZ	637,783	1,078,611.25	617.71	1.69	2,925	0.55 (0.49, 0.61)	1.01 (0.97, 1.05)	0.01 (-0.02, 0.03)	1.15 (1.02, 1.29)	0.71 (0.68, 0.74)
	ACEI	2,441,103	6,126,974.48	916.75	2.51	15,847	0.54 (0.48, 0.60)			1.62 (1.45, 1.81)	
25000 - 49999	HCTZ	212,354	401,662.54	690.86	1.89	790	0.48 (0.42, 0.55)	0.92 (0.86, 0.99)	-0.04 (-0.08, -0.01)	0.99 (0.86, 1.14)	0.61 (0.57, 0.66)
	ACEI	2,441,103	6,126,974.48	916.75	2.51	15,847	0.52 (0.46, 0.59)			1.61 (1.43, 1.83)	
50000 - 74999	HCTZ	48,912	95,667.56	714.40	1.96	126	0.60 (0.49, 0.74)	1.12 (0.94, 1.34)	0.07 (-0.04, 0.17)	0.93 (0.75, 1.15)	0.56 (0.47, 0.66)
	ACEI	2,441,103	6,126,974.48	916.75	2.51	15,847	0.54 (0.47, 0.61)			1.67 (1.47, 1.90)	
75000 - 99999	HCTZ	18,039	37,136.76	751.94	2.06	44	0.80 (0.58, 1.10)	1.47 (1.09, 1.99)	0.26 (0.02, 0.50)	1.19 (0.87, 1.64)	0.71 (0.53, 0.96)
	ACEI	2,441,103	6,126,974.48	916.75	2.51	15,847	0.54 (0.48, 0.61)			1.68 (1.48, 1.90)	
≥ 100000	HCTZ	8,102	27,066.88	1,220.21	3.34	24	0.79 (0.52, 1.21)	1.49 (0.99, 2.25)	0.26 (-0.06, 0.59)	1.67 (1.10, 2.53)	1.01 (0.67, 1.52)
	ACEI	2,441,103	6,126,974.48	916.75	2.51	15,847	0.53 (0.47, 0.60)			1.65 (1.45, 1.87)	
≥ 50000	HCTZ	48,912	159,871.21	1,193.84	3.27	194	0.69 (0.57, 0.83)	1.27 (1.10, 1.47)	0.15 (0.04, 0.25)	1.44 (1.20, 1.73)	0.84 (0.73, 0.97)
	ACEI	2,441,103	6,126,974.48	916.75	2.51	15,847	0.54 (0.48, 0.61)			1.71 (1.51, 1.94)	

¹All effect measures are adjusted for age group and estimated within a 1:1 propensity score-matched cohort.

²Some adjusted risk differences with 95% CI could not be estimated as the model failed to converge.

³One small data partner did not contribute data to the cumulative dose analyses (18,409 patients, 133 basal cell carcinoma events, 55 squamous cell carcinoma events).

⁴Angiotensin-converting enzyme inhibitor

Table 38. Number of Matched Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome, by Exposure and Days Dispensed

Matched Users	Cumulative Days Dispensed (years)													
	Total		<1		1 - <2		2 - <3		3 - <4		4 - <5		5+	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
All matched ACEI ¹ users	5,211,321	100.0%	3,422,404	65.7%	836,508	16.1%	417,927	8.0%	234,211	4.5%	134,736	2.6%	165,535	3.2%
All matched HCTZ ² users	5,211,321	100.0%	3,427,781	65.8%	838,625	16.1%	415,794	8.0%	231,313	4.4%	131,974	2.5%	165,834	3.2%
Cumulative HCTZ Dose (mg)														
<10,000	3,874,786	100.0%	3,397,341	87.7%	430,375	11.1%	41,539	1.1%	4,571	0.1%	941	0.0%	19	0.0%
10,000 - 24,999	908,742	100.0%	30,084	3.3%	393,923	43.3%	319,511	35.2%	101,659	11.2%	48,502	5.3%	15,063	1.7%
25,000 - 49,999	330,736	100.0%	*****	<1%	*****	~4%	52,670	15.9%	117,506	35.5%	76,053	23.0%	70,057	21.2%
50,000 - 74,999	63,764	100.0%	*****	<1%	*****	<1%	*****	~3%	7,366	11.6%	3,767	5.9%	50,514	79.2%
75,000 - 99,999	19,267	100.0%	0	0.0%	11	0.1%	145	0.8%	114	0.6%	2,625	13.6%	16,372	85.0%
100,000+	14,026	100.0%	*****	<1%	*****	<1%	*****	<1%	97	0.7%	86	0.6%	13,809	98.5%

¹Angiotensin-converting enzyme inhibitor

²Hydrochlorothiazide

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 39. Distribution of Hydrochlorothiazide (HCTZ) Dispensings for Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Basal Cell Carcinoma Outcome, by Pill Strength and Cumulative Dose Category

	Cumulative Dose Category													
	Overall		Group 1 (<10,000 mg)		Group 2 (10,000-24,999 mg)		Group 3 (25,000-49,999 mg)		Group 4 (50,000-74,999 mg)		Group 5 (75,000-99,999 mg)		Group 6 (100,000+ mg)	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Matched Users														
All matched HCTZ users	5,211,321	100%	3,874,786	100%	908,742	100%	330,736	100%	63,764	100%	19,267	100%	14,026	100%
HCTZ Pill Strength (mg)														
6.25	66,089	1.3%	62,912	1.6%	3,098	0.3%	*****	<1%	*****	<1%	0	0.0%	0	0.0%
12.5	1,909,110	36.6%	1,646,218	42.5%	229,620	25.3%	*****	~10%	*****	~3%	218	1.1%	29	0.2%
15	725	0.0%	*****	<1%	*****	<1%	*****	<1%	*****	<1%	0	0.0%	0	0.0%
25	2,974,576	57.1%	2,038,960	52.6%	615,380	67.7%	258,422	78.1%	45,256	71.0%	11,264	58.5%	5,294	37.7%
30	*****	<1%	0	0.0%	0	0.0%	*****	<1%	0	0.0%	0	0.0%	0	0.0%
50	260,808	5.0%	126,156	3.3%	60,508	6.7%	40,799	12.3%	16,857	26.4%	7,785	40.4%	8,703	62.0%
100	*****	<1%	*****	<1%	*****	<1%	*****	<1%	*****	<1%	0	0.0%	0	0.0%

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 40. Number of Matched Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome, by Exposure and Days Dispensed

Matched Users	Cumulative Days Dispensed (years)													
	Total		<1		1 - <2		2 - <3		3 - <4		4 - <5		5+	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
All matched ACEI ¹ users	5,211,321	100.0%	3,423,791	65.7%	836,343	16.0%	417,584	8.0%	233,873	4.5%	134,509	2.6%	165,221	3.2%
All matched HCTZ ² users	5,211,321	100.0%	3,429,002	65.8%	838,468	16.1%	415,528	8.0%	230,928	4.4%	131,771	2.5%	165,624	3.2%
Cumulative HCTZ Dose (mg)														
<10,000	3,875,928	100.0%	3,398,566	87.7%	430,304	11.1%	41,538	1.1%	4,560	0.1%	941	0.0%	19	0.0%
10,000 - 24,999	908,116	100.0%	30,081	3.3%	393,831	43.4%	319,297	35.2%	101,485	11.2%	48,396	5.3%	15,026	1.7%
25,000 - 49,999	330,312	100.0%	345	0.1%	14,108	4.3%	52,618	15.9%	117,315	35.5%	75,964	23.0%	69,962	21.2%
50,000 - 74,999	63,702	100.0%	*****	<1%	*****	<1%	*****	~3%	7,356	11.5%	3,770	5.9%	50,456	79.2%
75,000 - 99,999	19,250	100.0%	0	0.0%	11	0.1%	145	0.8%	115	0.6%	2,614	13.6%	16,365	85.0%
100,000+	14,013	100.0%	*****	<1%	*****	<1%	*****	<1%	97	0.7%	86	0.6%	13,796	98.5%

¹Angiotensin-converting enzyme inhibitor

²Hydrochlorothiazide

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 41. Distribution of Hydrochlorothiazide (HCTZ) Dispensings for Users in the Sentinel Distributed Database (SDD) between January 1, 2000 and August 31, 2018, Squamous Cell Carcinoma Outcome, by Pill Strength and Cumulative Dose Category

	Cumulative Dose Category													
	Overall		Group 1 (<10,000 mg)		Group 2 (10,000-24,999 mg)		Group 3 (25,000-49,999 mg)		Group 4 (50,000-74,999 mg)		Group 5 (75,000-99,999 mg)		Group 6 (100,000+ mg)	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Matched Users														
All matched HCTZ users	5,211,321	100.0%	3,822,479	100.0%	908,116	100.0%	330,312	100.0%	63,702	100.0%	19,250	100.0%	14,013	100.0%
HCTZ Pill Strength (mg)														
6.25	66,095	1.3%	62,343	1.6%	3,094	0.3%	*****	<1%	*****	<1%	0	0.0%	0	0.0%
12.5	1,909,230	36.6%	1,630,957	42.7%	229,278	25.2%	*****	~10%	*****	~3%	218	1.1%	29	0.2%
15	725	0.0%	*****	<1%	*****	<1%	*****	<1%	*****	<1%	0	0.0%	0	0.0%
25	2,974,468	57.1%	2,005,110	52.5%	615,110	67.7%	258,047	78.1%	45,202	71.0%	11,254	58.5%	5,290	37.8%
30	*****	<1%	0	0.0%	0	0.0%	*****	<1%	0	0.0%	0	0.0%	0	0.0%
50	260,790	5.0%	123,538	3.2%	60,498	6.7%	40,793	12.3%	16,849	26.4%	7,778	40.4%	8,694	62.0%
100	*****	<1%	*****	<1%	*****	<1%	*****	<1%	*****	<1%	0	0.0%	0	0.0%

*Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (April 12, 2019)

DP ID	Start Date ¹	End Date ¹
DP01	6/1/2007	4/30/2018
DP02	1/1/2000	10/31/2017
DP03	1/1/2000	6/30/2018
DP04	1/1/2008	6/30/2018
DP05	1/1/2006	5/31/2018
DP06	1/1/2000	12/31/2017
DP07	1/1/2008	9/30/2017
DP08	1/1/2010	12/31/2016
DP09	1/1/2005	12/17/2017
DP10 ²	1/1/2000	3/31/2016
DP11	1/1/2000	5/31/2015
DP12	1/1/2000	3/31/2018
DP13	1/1/2000	12/31/2017
DP14	1/1/2000	6/30/2018
DP15	1/1/2004	8/31/2018
DP16	1/1/2000	3/31/2018
DP17	1/1/2012	6/30/2017

¹The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.

²This data partner did not contribute data to analyses included in cder_mpl2p_wp022

Appendix B. List of Generic Drug Names Used to Define the Exposure and Comparator in this Request

Generic Name

Hydrochlorothiazide (HCTZ)-Containing Products

aliskiren hemifumarate/amlodipine/hydrochlorothiazide
 aliskiren hemifumarate/hydrochlorothiazide
 amiloride HCl/hydrochlorothiazide
 amlodipine besylate/valsartan/hydrochlorothiazide
 benazepril HCl/hydrochlorothiazide
 bisoprolol fumarate/hydrochlorothiazide
 candesartan cilexetil/hydrochlorothiazide
 captopril/hydrochlorothiazide
 enalapril maleate/hydrochlorothiazide
 eprosartan mesylate/hydrochlorothiazide
 fosinopril sodium/hydrochlorothiazide
 guanethidine sulfate/hydrochlorothiazide
 hydralazine HCl/hydrochlorothiazide
 hydralazine HCl/reserpine/hydrochlorothiazide
 hydrochlorothiazide
 irbesartan/hydrochlorothiazide
 lisinopril/hydrochlorothiazide
 losartan potassium/hydrochlorothiazide
 methyldopa/hydrochlorothiazide
 metoprolol succinate/hydrochlorothiazide
 metoprolol tartrate/hydrochlorothiazide
 moexipril HCl/hydrochlorothiazide
 olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide
 olmesartan medoxomil/hydrochlorothiazide
 propranolol HCl/hydrochlorothiazide
 quinapril HCl/hydrochlorothiazide
 reserpine/hydrochlorothiazide
 spironolactone/hydrochlorothiazide
 telmisartan/hydrochlorothiazide
 timolol maleate/hydrochlorothiazide
 triamterene/hydrochlorothiazide
 valsartan/hydrochlorothiazide

Angiotensin-Converting Enzyme Inhibitors (ACEI) Monotherapy or Non-HCTZ ACEI Combination Products

captopril
 enalapril maleate
 enalapril maleate/diltiazem malate
 enalapril maleate/felodipine
 enalaprilat dihydrate
 fosinopril sodium
 lisinopril
 lisinopril/dietary supplement,comb.10
 perindopril arginine/amlodipine besylate
 perindopril erbumine
 ramipril

Appendix B. List of Generic Drug Names Used to Define the Exposure and Comparator in this Request

Generic Name

trandolapril

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request

Code	Description	Code Category	Code Type
Basal Cell Carcinoma			
173.11	Basal cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.21	Basal cell carcinoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.31	Basal cell carcinoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.41	Basal cell carcinoma of scalp and skin of neck	Diagnosis	ICD-9-CM
173.51	Basal cell carcinoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.61	Basal cell carcinoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.71	Basal cell carcinoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.81	Basal cell carcinoma of other specified sites of skin	Diagnosis	ICD-9-CM
173.91	Basal cell carcinoma of skin, site unspecified	Diagnosis	ICD-9-CM
C44.111	Basal cell carcinoma of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.112	Basal cell carcinoma of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.119	Basal cell carcinoma of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.211	Basal cell carcinoma of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.212	Basal cell carcinoma of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.219	Basal cell carcinoma of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.310	Basal cell carcinoma of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.311	Basal cell carcinoma of skin of nose	Diagnosis	ICD-10-CM
C44.319	Basal cell carcinoma of skin of other parts of face	Diagnosis	ICD-10-CM
C44.41	Basal cell carcinoma of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.510	Basal cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C44.511	Basal cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C44.519	Basal cell carcinoma of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.611	Basal cell carcinoma of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.612	Basal cell carcinoma of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.619	Basal cell carcinoma of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.711	Basal cell carcinoma of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.712	Basal cell carcinoma of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.719	Basal cell carcinoma of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.81	Basal cell carcinoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.91	Basal cell carcinoma of skin, unspecified	Diagnosis	ICD-10-CM
Squamous Cell Carcinoma			
173.12	Squamous cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.22	Squamous cell carcinoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.32	Squamous cell carcinoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.42	Squamous cell carcinoma of scalp and skin of neck	Diagnosis	ICD-9-CM
173.52	Squamous cell carcinoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.62	Squamous cell carcinoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.72	Squamous cell carcinoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.82	Squamous cell carcinoma of other specified sites of skin	Diagnosis	ICD-9-CM
173.92	Squamous cell carcinoma of skin, site unspecified	Diagnosis	ICD-9-CM
C44.121	Squamous cell carcinoma of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request

Code	Description	Code	
		Category	Code Type
C44.122	Squamous cell carcinoma of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.129	Squamous cell carcinoma of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.221	Squamous cell carcinoma of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.222	Squamous cell carcinoma of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.229	Squamous cell carcinoma of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.320	Squamous cell carcinoma of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.321	Squamous cell carcinoma of skin of nose	Diagnosis	ICD-10-CM
C44.329	Squamous cell carcinoma of skin of other parts of face	Diagnosis	ICD-10-CM
C44.42	Squamous cell carcinoma of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.520	Squamous cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C44.521	Squamous cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C44.529	Squamous cell carcinoma of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.621	Squamous cell carcinoma of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.622	Squamous cell carcinoma of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.629	Squamous cell carcinoma of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.721	Squamous cell carcinoma of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.722	Squamous cell carcinoma of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.729	Squamous cell carcinoma of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.82	Squamous cell carcinoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.92	Squamous cell carcinoma of skin, unspecified	Diagnosis	ICD-10-CM
Tumor Removal			
11600	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.5 cm or less	Procedure	CPT-4
11601	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11602	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11603	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11604	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11606	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter over 4.0 cm	Procedure	CPT-4
11620	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less	Procedure	CPT-4
11621	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11622	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11623	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request

Code	Description	Code	
		Category	Code Type
11624	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11626	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm	Procedure	CPT-4
11640	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.5 cm or less	Procedure	CPT-4
11641	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11642	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11643	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11644	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11646	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter over 4.0 cm	Procedure	CPT-4
17260	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 0.5 cm or less	Procedure	CPT-4
17261	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17262	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17263	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17264	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17266	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter over 4.0 cm	Procedure	CPT-4
17270	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less	Procedure	CPT-4
17271	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17272	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17273	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request

Code	Description	Code	
		Category	Code Type
17274	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17276	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter over 4.0 cm	Procedure	CPT-4
17280	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.5 cm or less	Procedure	CPT-4
17281	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17282	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17283	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17284	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17286	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter over 4.0 cm	Procedure	CPT-4
17304	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); first stage, fresh tissue technique, up to 5 specimens	Procedure	CPT-4
17305	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); second stage, fixed or fresh tissue, up to 5 specimens	Procedure	CPT-4
17306	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); third stage, fixed or fresh tissue, up to 5 specimens	Procedure	CPT-4

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request

Code	Description	Code	
		Category	Code Type
17307	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); additional stage(s), up to 5 specimens, each stage	Procedure	CPT-4
17310	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); each additional specimen, after the first 5 specimens, fixed or fresh tissue, any stage (List separately in addition to code for primary procedure)	Procedure	CPT-4
17311	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; first stage, up to 5 tissue blocks	Procedure	CPT-4
17312	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)	Procedure	CPT-4
17313	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks	Procedure	CPT-4
17314	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)	Procedure	CPT-4
17315	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), each additional block after the first 5 tissue blocks, any stage (List separately in addition to code for primary procedure)	Procedure	CPT-4
Radiation			
55859	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request

Code	Description	Code	
		Category	Code Type
55860	Exposure of prostate, any approach, for insertion of radioactive substance;	Procedure	CPT-4
55862	Exposure of prostate, any approach, for insertion of radioactive substance; with lymph node biopsy(s) (limited pelvic lymphadenectomy)	Procedure	CPT-4
55865	Exposure of prostate, any approach, for insertion of radioactive substance; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes	Procedure	CPT-4
55875	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4
76950	Ultrasonic guidance for placement of radiation therapy fields	Procedure	CPT-4
76960	Ultrasonic guidance for placement of radiation therapy fields, except for B-scan echography	Procedure	CPT-4
77280	Therapeutic radiology simulation-aided field setting; simple	Procedure	CPT-4
77285	Therapeutic radiology simulation-aided field setting; intermediate	Procedure	CPT-4
77290	Therapeutic radiology simulation-aided field setting; complex	Procedure	CPT-4
77295	3-dimensional radiotherapy plan, including dose-volume histograms	Procedure	CPT-4
77299	Unlisted procedure, therapeutic radiology clinical treatment planning	Procedure	CPT-4
77300	Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician	Procedure	CPT-4
77305	Teletherapy, isodose plan (whether hand or computer calculated); simple (1 or 2 parallel opposed unmodified ports directed to a single area of interest)	Procedure	CPT-4
77310	Teletherapy, isodose plan (whether hand or computer calculated); intermediate (3 or more treatment ports directed to a single area of interest)	Procedure	CPT-4
77315	Teletherapy, isodose plan (whether hand or computer calculated); complex (mantle or inverted Y, tangential ports, the use of wedges, compensators, complex blocking, rotational beam, or special beam considerations)	Procedure	CPT-4
77321	Special teletherapy port plan, particles, hemibody, total body	Procedure	CPT-4
77326	Brachytherapy isodose plan; simple (calculation made from single plane, 1 to 4 sources/ribbon application, remote afterloading brachytherapy, 1 to 8 sources)	Procedure	CPT-4
77327	Brachytherapy isodose plan; intermediate (multiplane dosage calculations, application involving 5 to 10 sources/ribbons, remote afterloading brachytherapy, 9 to 12 sources)	Procedure	CPT-4
77328	Brachytherapy isodose plan; complex (multiplane isodose plan, volume implant calculations, over 10 sources/ribbons used, special spatial reconstruction, remote afterloading brachytherapy, over 12 sources)	Procedure	CPT-4
77401	Radiation treatment delivery, superficial and/or ortho voltage, per day	Procedure	CPT-4
77402	Radiation treatment delivery, >=1 MeV; simple	Procedure	CPT-4
77403	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 6-10 MeV	Procedure	CPT-4
77404	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 11-19 MeV	Procedure	CPT-4

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request

Code	Description	Code	
		Category	Code Type
77406	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 20 MeV or greater	Procedure	CPT-4
77407	Radiation treatment delivery, =>1 MeV; intermediate	Procedure	CPT-4
77408	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 6-10 MeV	Procedure	CPT-4
77409	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 11-19 MeV	Procedure	CPT-4
77411	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 20 MeV or greater	Procedure	CPT-4
77412	Radiation treatment delivery, =>1 MeV; complex	Procedure	CPT-4
77413	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV	Procedure	CPT-4
77414	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV	Procedure	CPT-4
77416	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater	Procedure	CPT-4
77427	Radiation treatment management, 5 treatments	Procedure	CPT-4
77432	Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)	Procedure	CPT-4
77469	Intraoperative radiation treatment management	Procedure	CPT-4
77470	Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)	Procedure	CPT-4
77499	Unlisted procedure, therapeutic radiology treatment management	Procedure	CPT-4
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)	Procedure	CPT-4
77761	Intracavitary radiation source application; simple	Procedure	CPT-4
77762	Intracavitary radiation source application; intermediate	Procedure	CPT-4
77763	Intracavitary radiation source application; complex	Procedure	CPT-4
77776	Interstitial radiation source application; simple	Procedure	CPT-4
77777	Interstitial radiation source application; intermediate	Procedure	CPT-4
77778	Interstitial radiation source application; complex	Procedure	CPT-4
77781	Remote afterloading high intensity brachytherapy; 1-4 source positions or catheters	Procedure	CPT-4
77782	Remote afterloading high intensity brachytherapy; 5-8 source positions or catheters	Procedure	CPT-4
77783	Remote afterloading high intensity brachytherapy; 9-12 source positions or catheters	Procedure	CPT-4
77784	Remote afterloading high intensity brachytherapy; over 12 source positions or catheters	Procedure	CPT-4
77785	Remote afterloading high dose rate radionuclide brachytherapy; 1 channel	Procedure	CPT-4
77786	Remote afterloading high dose rate radionuclide brachytherapy; 2-12 channels	Procedure	CPT-4
77787	Remote afterloading high dose rate radionuclide brachytherapy; over 12 channels	Procedure	CPT-4
77789	Surface application of low dose rate radionuclide source	Procedure	CPT-4
77799	Unlisted procedure, clinical brachytherapy	Procedure	CPT-4
79005	Radiopharmaceutical therapy, by oral administration	Procedure	CPT-4

Appendix C. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Outcomes in this Request

Code	Description	Code	
		Category	Code Type
79101	Radiopharmaceutical therapy, by intravenous administration	Procedure	CPT-4
79200	Radiopharmaceutical therapy, by intracavitary administration	Procedure	CPT-4
79300	Radiopharmaceutical therapy, by interstitial radioactive colloid administration	Procedure	CPT-4
79400	Radiopharmaceutical therapy, nonthyroid, nonhematologic by intervenous injection	Procedure	CPT-4
79403	Radiopharmaceutical therapy, radiolabeled monoclonal antibody by intravenous infusion	Procedure	CPT-4
79420	Intravascular radiopharmaceutical therapy, particulate	Procedure	CPT-4
79440	Radiopharmaceutical therapy, by intra-articular administration	Procedure	CPT-4
79900	Provision of therapeutic radiopharmaceutical(s)	Procedure	CPT-4
79999	Radiopharmaceutical therapy, unlisted procedure	Procedure	CPT-4

Appendix D. List of Generic and Brand Drug Names Used to Define Outcomes in this Request

Generic Name	Brand Name
Imiquimod	Imiquimod
Imiquimod	Zyclara
Imiquimod	Zyclara
Imiquimod	Zyclara
Imiquimod	Zyclara
Mechlorethamine HCl	Valchlor
Methyl aminolevulinate HCl	Metvixia

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Censoring Criteria in this Request

Code	Description	Code Category	Code Type
Non-Outcome Cancer Diagnosis			
140	Malignant neoplasm of lip	Diagnosis	ICD-9-CM
140.0	Malignant neoplasm of upper lip, vermilion border	Diagnosis	ICD-9-CM
140.1	Malignant neoplasm of lower lip, vermilion border	Diagnosis	ICD-9-CM
140.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-9-CM
140.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-9-CM
140.5	Malignant neoplasm of lip, inner aspect, unspecified as to upper or lower	Diagnosis	ICD-9-CM
140.6	Malignant neoplasm of commissure of lip	Diagnosis	ICD-9-CM
140.8	Malignant neoplasm of other sites of lip	Diagnosis	ICD-9-CM
140.9	Malignant neoplasm of lip, vermilion border, unspecified as to upper or lower	Diagnosis	ICD-9-CM
141	Malignant neoplasm of tongue	Diagnosis	ICD-9-CM
141.0	Malignant neoplasm of base of tongue	Diagnosis	ICD-9-CM
141.1	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-9-CM
141.2	Malignant neoplasm of tip and lateral border of tongue	Diagnosis	ICD-9-CM
141.3	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-9-CM
141.4	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-9-CM
141.5	Malignant neoplasm of junctional zone of tongue	Diagnosis	ICD-9-CM
141.6	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-9-CM
141.8	Malignant neoplasm of other sites of tongue	Diagnosis	ICD-9-CM
141.9	Malignant neoplasm of tongue, unspecified site	Diagnosis	ICD-9-CM
142	Malignant neoplasm of major salivary glands	Diagnosis	ICD-9-CM
142.0	Malignant neoplasm of parotid gland	Diagnosis	ICD-9-CM
142.1	Malignant neoplasm of submandibular gland	Diagnosis	ICD-9-CM
142.2	Malignant neoplasm of sublingual gland	Diagnosis	ICD-9-CM
142.8	Malignant neoplasm of other major salivary glands	Diagnosis	ICD-9-CM
142.9	Malignant neoplasm of salivary gland, unspecified	Diagnosis	ICD-9-CM
143	Malignant neoplasm of gum	Diagnosis	ICD-9-CM
143.0	Malignant neoplasm of upper gum	Diagnosis	ICD-9-CM
143.1	Malignant neoplasm of lower gum	Diagnosis	ICD-9-CM
143.8	Malignant neoplasm of other sites of gum	Diagnosis	ICD-9-CM
143.9	Malignant neoplasm of gum, unspecified site	Diagnosis	ICD-9-CM
144	Malignant neoplasm of floor of mouth	Diagnosis	ICD-9-CM
144.0	Malignant neoplasm of anterior portion of floor of mouth	Diagnosis	ICD-9-CM
144.1	Malignant neoplasm of lateral portion of floor of mouth	Diagnosis	ICD-9-CM
144.8	Malignant neoplasm of other sites of floor of mouth	Diagnosis	ICD-9-CM
144.9	Malignant neoplasm of floor of mouth, part unspecified	Diagnosis	ICD-9-CM
145	Malignant neoplasm of other and unspecified parts of mouth	Diagnosis	ICD-9-CM
145.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-9-CM
145.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-9-CM
145.2	Malignant neoplasm of hard palate	Diagnosis	ICD-9-CM
145.3	Malignant neoplasm of soft palate	Diagnosis	ICD-9-CM

145.4	Malignant neoplasm of uvula	Diagnosis	ICD-9-CM
145.5	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-9-CM
145.6	Malignant neoplasm of retromolar area	Diagnosis	ICD-9-CM
145.8	Malignant neoplasm of other specified parts of mouth	Diagnosis	ICD-9-CM
145.9	Malignant neoplasm of mouth, unspecified site	Diagnosis	ICD-9-CM
146	Malignant neoplasm of oropharynx	Diagnosis	ICD-9-CM
146.0	Malignant neoplasm of tonsil	Diagnosis	ICD-9-CM
146.1	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-9-CM
146.2	Malignant neoplasm of tonsillar pillars (anterior) (posterior)	Diagnosis	ICD-9-CM
146.3	Malignant neoplasm of vallecula	Diagnosis	ICD-9-CM
146.4	Malignant neoplasm of anterior aspect of epiglottis	Diagnosis	ICD-9-CM
146.5	Malignant neoplasm of junctional region of oropharynx	Diagnosis	ICD-9-CM
146.6	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-9-CM
146.7	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-9-CM
146.8	Malignant neoplasm of other specified sites of oropharynx	Diagnosis	ICD-9-CM
146.9	Malignant neoplasm of oropharynx, unspecified site	Diagnosis	ICD-9-CM
147	Malignant neoplasm of nasopharynx	Diagnosis	ICD-9-CM
147.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-9-CM
147.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-9-CM
147.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-9-CM
147.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-9-CM
147.8	Malignant neoplasm of other specified sites of nasopharynx	Diagnosis	ICD-9-CM
147.9	Malignant neoplasm of nasopharynx, unspecified site	Diagnosis	ICD-9-CM
148	Malignant neoplasm of hypopharynx	Diagnosis	ICD-9-CM
148.0	Malignant neoplasm of postcricoid region of hypopharynx	Diagnosis	ICD-9-CM
148.1	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-9-CM
148.2	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-9-CM
148.3	Malignant neoplasm of posterior hypopharyngeal wall	Diagnosis	ICD-9-CM
148.8	Malignant neoplasm of other specified sites of hypopharynx	Diagnosis	ICD-9-CM
148.9	Malignant neoplasm of hypopharynx, unspecified site	Diagnosis	ICD-9-CM
149	Malignant neoplasm of other and ill-defined sites within the lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
149.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-9-CM
149.1	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-9-CM
149.8	Malignant neoplasm of other sites within the lip and oral cavity	Diagnosis	ICD-9-CM
149.9	Malignant neoplasm of ill-defined sites of lip and oral cavity	Diagnosis	ICD-9-CM
150	Malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
150.0	Malignant neoplasm of cervical esophagus	Diagnosis	ICD-9-CM
150.1	Malignant neoplasm of thoracic esophagus	Diagnosis	ICD-9-CM
150.2	Malignant neoplasm of abdominal esophagus	Diagnosis	ICD-9-CM
150.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-9-CM
150.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-9-CM
150.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-9-CM
150.8	Malignant neoplasm of other specified part of esophagus	Diagnosis	ICD-9-CM
150.9	Malignant neoplasm of esophagus, unspecified site	Diagnosis	ICD-9-CM
151	Malignant neoplasm of stomach	Diagnosis	ICD-9-CM
151.0	Malignant neoplasm of cardia	Diagnosis	ICD-9-CM

151.1	Malignant neoplasm of pylorus	Diagnosis	ICD-9-CM
151.2	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-9-CM
151.3	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-9-CM
151.4	Malignant neoplasm of body of stomach	Diagnosis	ICD-9-CM
151.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-9-CM
151.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-9-CM
151.8	Malignant neoplasm of other specified sites of stomach	Diagnosis	ICD-9-CM
151.9	Malignant neoplasm of stomach, unspecified site	Diagnosis	ICD-9-CM
152	Malignant neoplasm of small intestine, including duodenum	Diagnosis	ICD-9-CM
152.0	Malignant neoplasm of duodenum	Diagnosis	ICD-9-CM
152.1	Malignant neoplasm of jejunum	Diagnosis	ICD-9-CM
152.2	Malignant neoplasm of ileum	Diagnosis	ICD-9-CM
152.3	Malignant neoplasm of Meckel's diverticulum	Diagnosis	ICD-9-CM
152.8	Malignant neoplasm of other specified sites of small intestine	Diagnosis	ICD-9-CM
152.9	Malignant neoplasm of small intestine, unspecified site	Diagnosis	ICD-9-CM
153	Malignant neoplasm of colon	Diagnosis	ICD-9-CM
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154	Malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
154.2	Malignant neoplasm of anal canal	Diagnosis	ICD-9-CM
154.3	Malignant neoplasm of anus, unspecified site	Diagnosis	ICD-9-CM
154.8	Malignant neoplasm of other sites of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
155	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.0	Malignant neoplasm of liver, primary	Diagnosis	ICD-9-CM
155.1	Malignant neoplasm of intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.2	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-9-CM
156	Malignant neoplasm of gallbladder and extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.0	Malignant neoplasm of gallbladder	Diagnosis	ICD-9-CM
156.1	Malignant neoplasm of extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.2	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-9-CM
156.8	Malignant neoplasm of other specified sites of gallbladder and extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.9	Malignant neoplasm of biliary tract, part unspecified site	Diagnosis	ICD-9-CM
157	Malignant neoplasm of pancreas	Diagnosis	ICD-9-CM
157.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-9-CM
157.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-9-CM
157.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-9-CM

157.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-9-CM
157.4	Malignant neoplasm of islets of Langerhans	Diagnosis	ICD-9-CM
157.8	Malignant neoplasm of other specified sites of pancreas	Diagnosis	ICD-9-CM
157.9	Malignant neoplasm of pancreas, part unspecified	Diagnosis	ICD-9-CM
158	Malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
158.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-9-CM
158.8	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-9-CM
158.9	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-9-CM
159	Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum	Diagnosis	ICD-9-CM
159.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-9-CM
159.1	Malignant neoplasm of spleen, not elsewhere classified	Diagnosis	ICD-9-CM
159.8	Malignant neoplasm of other sites of digestive system and intra-abdominal organs	Diagnosis	ICD-9-CM
159.9	Malignant neoplasm of ill-defined sites of digestive organs and peritoneum	Diagnosis	ICD-9-CM
160	Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
160.0	Malignant neoplasm of nasal cavities	Diagnosis	ICD-9-CM
160.1	Malignant neoplasm of auditory tube, middle ear, and mastoid air cells	Diagnosis	ICD-9-CM
160.2	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-9-CM
160.3	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-9-CM
160.4	Malignant neoplasm of frontal sinus	Diagnosis	ICD-9-CM
160.5	Malignant neoplasm of sphenoidal sinus	Diagnosis	ICD-9-CM
160.8	Malignant neoplasm of other sites of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
160.9	Malignant neoplasm of site of nasal cavities, middle ear, and accessory sinus, unspecified site	Diagnosis	ICD-9-CM
161	Malignant neoplasm of larynx	Diagnosis	ICD-9-CM
161.0	Malignant neoplasm of glottis	Diagnosis	ICD-9-CM
161.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-9-CM
161.2	Malignant neoplasm of subglottis	Diagnosis	ICD-9-CM
161.3	Malignant neoplasm of laryngeal cartilages	Diagnosis	ICD-9-CM
161.8	Malignant neoplasm of other specified sites of larynx	Diagnosis	ICD-9-CM
161.9	Malignant neoplasm of larynx, unspecified site	Diagnosis	ICD-9-CM
162	Malignant neoplasm of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
162.0	Malignant neoplasm of trachea	Diagnosis	ICD-9-CM
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
163	Malignant neoplasm of pleura	Diagnosis	ICD-9-CM
163.0	Malignant neoplasm of parietal pleura	Diagnosis	ICD-9-CM
163.1	Malignant neoplasm of visceral pleura	Diagnosis	ICD-9-CM
163.8	Malignant neoplasm of other specified sites of pleura	Diagnosis	ICD-9-CM
163.9	Malignant neoplasm of pleura, unspecified site	Diagnosis	ICD-9-CM
164	Malignant neoplasm of thymus, heart, and mediastinum	Diagnosis	ICD-9-CM
164.0	Malignant neoplasm of thymus	Diagnosis	ICD-9-CM

164.1	Malignant neoplasm of heart	Diagnosis	ICD-9-CM
164.2	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-9-CM
164.3	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-9-CM
164.8	Malignant neoplasm of other parts of mediastinum	Diagnosis	ICD-9-CM
164.9	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-9-CM
165	Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs	Diagnosis	ICD-9-CM
165.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-9-CM
165.8	Malignant neoplasm of other sites within the respiratory system and intrathoracic organs	Diagnosis	ICD-9-CM
165.9	Malignant neoplasm of ill-defined sites within the respiratory system	Diagnosis	ICD-9-CM
170	Malignant neoplasm of bone and articular cartilage	Diagnosis	ICD-9-CM
170.0	Malignant neoplasm of bones of skull and face, except mandible	Diagnosis	ICD-9-CM
170.1	Malignant neoplasm of mandible	Diagnosis	ICD-9-CM
170.2	Malignant neoplasm of vertebral column, excluding sacrum and coccyx	Diagnosis	ICD-9-CM
170.3	Malignant neoplasm of ribs, sternum, and clavicle	Diagnosis	ICD-9-CM
170.4	Malignant neoplasm of scapula and long bones of upper limb	Diagnosis	ICD-9-CM
170.5	Malignant neoplasm of short bones of upper limb	Diagnosis	ICD-9-CM
170.6	Malignant neoplasm of pelvic bones, sacrum, and coccyx	Diagnosis	ICD-9-CM
170.7	Malignant neoplasm of long bones of lower limb	Diagnosis	ICD-9-CM
170.8	Malignant neoplasm of short bones of lower limb	Diagnosis	ICD-9-CM
170.9	Malignant neoplasm of bone and articular cartilage, site unspecified	Diagnosis	ICD-9-CM
171	Malignant neoplasm of connective and other soft tissue	Diagnosis	ICD-9-CM
171.0	Malignant neoplasm of connective and other soft tissue of head, face, and neck	Diagnosis	ICD-9-CM
171.2	Malignant neoplasm of connective and other soft tissue of upper limb, including shoulder	Diagnosis	ICD-9-CM
171.3	Malignant neoplasm of connective and other soft tissue of lower limb, including hip	Diagnosis	ICD-9-CM
171.4	Malignant neoplasm of connective and other soft tissue of thorax	Diagnosis	ICD-9-CM
171.5	Malignant neoplasm of connective and other soft tissue of abdomen	Diagnosis	ICD-9-CM
171.6	Malignant neoplasm of connective and other soft tissue of pelvis	Diagnosis	ICD-9-CM
171.7	Malignant neoplasm of connective and other soft tissue of trunk, unspecified site	Diagnosis	ICD-9-CM
171.8	Malignant neoplasm of other specified sites of connective and other soft tissue	Diagnosis	ICD-9-CM
171.9	Malignant neoplasm of connective and other soft tissue, site unspecified	Diagnosis	ICD-9-CM
172	Malignant melanoma of skin	Diagnosis	ICD-9-CM
172.0	Malignant melanoma of skin of lip	Diagnosis	ICD-9-CM
172.1	Malignant melanoma of skin of eyelid, including canthus	Diagnosis	ICD-9-CM
172.2	Malignant melanoma of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
172.3	Malignant melanoma of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
172.4	Malignant melanoma of skin of scalp and neck	Diagnosis	ICD-9-CM
172.5	Malignant melanoma of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
172.6	Malignant melanoma of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
172.7	Malignant melanoma of skin of lower limb, including hip	Diagnosis	ICD-9-CM
172.8	Malignant melanoma of other specified sites of skin	Diagnosis	ICD-9-CM
172.9	Melanoma of skin, site unspecified	Diagnosis	ICD-9-CM
173	Other and unspecified malignant neoplasm of skin	Diagnosis	ICD-9-CM
173.0	Other and unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM
173.00	Unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM

173.01	Basal cell carcinoma of skin of lip	Diagnosis	ICD-9-CM
173.02	Squamous cell carcinoma of skin of lip	Diagnosis	ICD-9-CM
173.09	Other specified malignant neoplasm of skin of lip	Diagnosis	ICD-9-CM
173.1	Other and unspecified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.10	Unspecified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.19	Other specified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.2	Other and unspecified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.20	Unspecified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.29	Other specified malignant neoplasm of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
173.3	Other and unspecified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.30	Unspecified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.39	Other specified malignant neoplasm of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
173.4	Other and unspecified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM
173.40	Unspecified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM
173.49	Other specified malignant neoplasm of scalp and skin of neck	Diagnosis	ICD-9-CM
173.5	Other and unspecified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.50	Unspecified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.59	Other specified malignant neoplasm of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
173.6	Other and unspecified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.60	Unspecified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.69	Other specified malignant neoplasm of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
173.7	Other and unspecified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.70	Unspecified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.79	Other specified malignant neoplasm of skin of lower limb, including hip	Diagnosis	ICD-9-CM
173.8	Other and unspecified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.80	Unspecified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.89	Other specified malignant neoplasm of other specified sites of skin	Diagnosis	ICD-9-CM
173.9	Other and unspecified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM
173.90	Unspecified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM
173.99	Other specified malignant neoplasm of skin, site unspecified	Diagnosis	ICD-9-CM
174	Malignant neoplasm of female breast	Diagnosis	ICD-9-CM
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175	Malignant neoplasm of male breast	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
176	Kaposi's sarcoma	Diagnosis	ICD-9-CM
176.0	Kaposi's sarcoma of skin	Diagnosis	ICD-9-CM
176.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-9-CM

176.2	Kaposi's sarcoma of palate	Diagnosis	ICD-9-CM
176.3	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-9-CM
176.4	Kaposi's sarcoma of lung	Diagnosis	ICD-9-CM
176.5	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-9-CM
176.8	Kaposi's sarcoma of other specified sites	Diagnosis	ICD-9-CM
176.9	Kaposi's sarcoma of unspecified site	Diagnosis	ICD-9-CM
179	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-9-CM
180	Malignant neoplasm of cervix uteri	Diagnosis	ICD-9-CM
180.0	Malignant neoplasm of endocervix	Diagnosis	ICD-9-CM
180.1	Malignant neoplasm of exocervix	Diagnosis	ICD-9-CM
180.8	Malignant neoplasm of other specified sites of cervix	Diagnosis	ICD-9-CM
180.9	Malignant neoplasm of cervix uteri, unspecified site	Diagnosis	ICD-9-CM
181	Malignant neoplasm of placenta	Diagnosis	ICD-9-CM
182	Malignant neoplasm of body of uterus	Diagnosis	ICD-9-CM
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
182.1	Malignant neoplasm of isthmus	Diagnosis	ICD-9-CM
182.8	Malignant neoplasm of other specified sites of body of uterus	Diagnosis	ICD-9-CM
183	Malignant neoplasm of ovary and other uterine adnexa	Diagnosis	ICD-9-CM
183.0	Malignant neoplasm of ovary	Diagnosis	ICD-9-CM
183.2	Malignant neoplasm of fallopian tube	Diagnosis	ICD-9-CM
183.3	Malignant neoplasm of broad ligament of uterus	Diagnosis	ICD-9-CM
183.4	Malignant neoplasm of parametrium of uterus	Diagnosis	ICD-9-CM
183.5	Malignant neoplasm of round ligament of uterus	Diagnosis	ICD-9-CM
183.8	Malignant neoplasm of other specified sites of uterine adnexa	Diagnosis	ICD-9-CM
183.9	Malignant neoplasm of uterine adnexa, unspecified site	Diagnosis	ICD-9-CM
184	Malignant neoplasm of other and unspecified female genital organs	Diagnosis	ICD-9-CM
184.0	Malignant neoplasm of vagina	Diagnosis	ICD-9-CM
184.1	Malignant neoplasm of labia majora	Diagnosis	ICD-9-CM
184.2	Malignant neoplasm of labia minora	Diagnosis	ICD-9-CM
184.3	Malignant neoplasm of clitoris	Diagnosis	ICD-9-CM
184.4	Malignant neoplasm of vulva, unspecified site	Diagnosis	ICD-9-CM
184.8	Malignant neoplasm of other specified sites of female genital organs	Diagnosis	ICD-9-CM
184.9	Malignant neoplasm of female genital organ, site unspecified	Diagnosis	ICD-9-CM
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
186	Malignant neoplasm of testis	Diagnosis	ICD-9-CM
186.0	Malignant neoplasm of undescended testis	Diagnosis	ICD-9-CM
186.9	Malignant neoplasm of other and unspecified testis	Diagnosis	ICD-9-CM
187	Malignant neoplasm of penis and other male genital organs	Diagnosis	ICD-9-CM
187.1	Malignant neoplasm of prepuce	Diagnosis	ICD-9-CM
187.2	Malignant neoplasm of glans penis	Diagnosis	ICD-9-CM
187.3	Malignant neoplasm of body of penis	Diagnosis	ICD-9-CM
187.4	Malignant neoplasm of penis, part unspecified	Diagnosis	ICD-9-CM
187.5	Malignant neoplasm of epididymis	Diagnosis	ICD-9-CM
187.6	Malignant neoplasm of spermatic cord	Diagnosis	ICD-9-CM
187.7	Malignant neoplasm of scrotum	Diagnosis	ICD-9-CM
187.8	Malignant neoplasm of other specified sites of male genital organs	Diagnosis	ICD-9-CM
187.9	Malignant neoplasm of male genital organ, site unspecified	Diagnosis	ICD-9-CM

188	Malignant neoplasm of bladder	Diagnosis	ICD-9-CM
188.0	Malignant neoplasm of trigone of urinary bladder	Diagnosis	ICD-9-CM
188.1	Malignant neoplasm of dome of urinary bladder	Diagnosis	ICD-9-CM
188.2	Malignant neoplasm of lateral wall of urinary bladder	Diagnosis	ICD-9-CM
188.3	Malignant neoplasm of anterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.4	Malignant neoplasm of posterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-9-CM
188.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-9-CM
188.7	Malignant neoplasm of urachus	Diagnosis	ICD-9-CM
188.8	Malignant neoplasm of other specified sites of bladder	Diagnosis	ICD-9-CM
188.9	Malignant neoplasm of bladder, part unspecified	Diagnosis	ICD-9-CM
189	Malignant neoplasm of kidney and other and unspecified urinary organs	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.1	Malignant neoplasm of renal pelvis	Diagnosis	ICD-9-CM
189.2	Malignant neoplasm of ureter	Diagnosis	ICD-9-CM
189.3	Malignant neoplasm of urethra	Diagnosis	ICD-9-CM
189.4	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-9-CM
189.8	Malignant neoplasm of other specified sites of urinary organs	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
190	Malignant neoplasm of eye	Diagnosis	ICD-9-CM
190.0	Malignant neoplasm of eyeball, except conjunctiva, cornea, retina, and choroid	Diagnosis	ICD-9-CM
190.1	Malignant neoplasm of orbit	Diagnosis	ICD-9-CM
190.2	Malignant neoplasm of lacrimal gland	Diagnosis	ICD-9-CM
190.3	Malignant neoplasm of conjunctiva	Diagnosis	ICD-9-CM
190.4	Malignant neoplasm of cornea	Diagnosis	ICD-9-CM
190.5	Malignant neoplasm of retina	Diagnosis	ICD-9-CM
190.6	Malignant neoplasm of choroid	Diagnosis	ICD-9-CM
190.7	Malignant neoplasm of lacrimal duct	Diagnosis	ICD-9-CM
190.8	Malignant neoplasm of other specified sites of eye	Diagnosis	ICD-9-CM
190.9	Malignant neoplasm of eye, part unspecified	Diagnosis	ICD-9-CM
191	Malignant neoplasm of brain	Diagnosis	ICD-9-CM
191.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-9-CM
191.1	Malignant neoplasm of frontal lobe of brain	Diagnosis	ICD-9-CM
191.2	Malignant neoplasm of temporal lobe of brain	Diagnosis	ICD-9-CM
191.3	Malignant neoplasm of parietal lobe of brain	Diagnosis	ICD-9-CM
191.4	Malignant neoplasm of occipital lobe of brain	Diagnosis	ICD-9-CM
191.5	Malignant neoplasm of ventricles of brain	Diagnosis	ICD-9-CM
191.6	Malignant neoplasm of cerebellum NOS	Diagnosis	ICD-9-CM
191.7	Malignant neoplasm of brain stem	Diagnosis	ICD-9-CM
191.8	Malignant neoplasm of other parts of brain	Diagnosis	ICD-9-CM
191.9	Malignant neoplasm of brain, unspecified site	Diagnosis	ICD-9-CM
192	Malignant neoplasm of other and unspecified parts of nervous system	Diagnosis	ICD-9-CM
192.0	Malignant neoplasm of cranial nerves	Diagnosis	ICD-9-CM
192.1	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-9-CM
192.2	Malignant neoplasm of spinal cord	Diagnosis	ICD-9-CM
192.3	Malignant neoplasm of spinal meninges	Diagnosis	ICD-9-CM
192.8	Malignant neoplasm of other specified sites of nervous system	Diagnosis	ICD-9-CM

192.9	Malignant neoplasm of nervous system, part unspecified	Diagnosis	ICD-9-CM
193	Malignant neoplasm of thyroid gland	Diagnosis	ICD-9-CM
194	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
194.0	Malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
194.1	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-9-CM
194.3	Malignant neoplasm of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
194.4	Malignant neoplasm of pineal gland	Diagnosis	ICD-9-CM
194.5	Malignant neoplasm of carotid body	Diagnosis	ICD-9-CM
194.6	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-9-CM
194.8	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
194.9	Malignant neoplasm of endocrine gland, site unspecified	Diagnosis	ICD-9-CM
195	Malignant neoplasm of other and ill-defined sites	Diagnosis	ICD-9-CM
195.0	Malignant neoplasm of head, face, and neck	Diagnosis	ICD-9-CM
195.1	Malignant neoplasm of thorax	Diagnosis	ICD-9-CM
195.2	Malignant neoplasm of abdomen	Diagnosis	ICD-9-CM
195.3	Malignant neoplasm of pelvis	Diagnosis	ICD-9-CM
195.4	Malignant neoplasm of upper limb	Diagnosis	ICD-9-CM
195.5	Malignant neoplasm of lower limb	Diagnosis	ICD-9-CM
195.8	Malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
196	Secondary and unspecified malignant neoplasm of lymph nodes	Diagnosis	ICD-9-CM
196.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
196.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
196.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
196.3	Secondary and unspecified malignant neoplasm of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
196.5	Secondary and unspecified malignant neoplasm of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
196.6	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
196.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
196.9	Secondary and unspecified malignant neoplasm of lymph nodes, site unspecified	Diagnosis	ICD-9-CM
197	Secondary malignant neoplasm of respiratory and digestive systems	Diagnosis	ICD-9-CM
197.0	Secondary malignant neoplasm of lung	Diagnosis	ICD-9-CM
197.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-9-CM
197.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-9-CM
197.3	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-9-CM
197.4	Secondary malignant neoplasm of small intestine including duodenum	Diagnosis	ICD-9-CM
197.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-9-CM
197.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
197.7	Secondary malignant neoplasm of liver	Diagnosis	ICD-9-CM
197.8	Secondary malignant neoplasm of other digestive organs and spleen	Diagnosis	ICD-9-CM
198	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
198.0	Secondary malignant neoplasm of kidney	Diagnosis	ICD-9-CM
198.1	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-9-CM
198.2	Secondary malignant neoplasm of skin	Diagnosis	ICD-9-CM
198.3	Secondary malignant neoplasm of brain and spinal cord	Diagnosis	ICD-9-CM
198.4	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-9-CM

198.5	Secondary malignant neoplasm of bone and bone marrow	Diagnosis	ICD-9-CM
198.6	Secondary malignant neoplasm of ovary	Diagnosis	ICD-9-CM
198.7	Secondary malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
198.8	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
198.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-9-CM
198.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-9-CM
198.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
199	Malignant neoplasm without specification of site	Diagnosis	ICD-9-CM
199.0	Disseminated malignant neoplasm	Diagnosis	ICD-9-CM
199.1	Other malignant neoplasm of unspecified site	Diagnosis	ICD-9-CM
199.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-9-CM
200	Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue	Diagnosis	ICD-9-CM
200.0	Reticulosarcoma	Diagnosis	ICD-9-CM
200.00	Reticulosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.01	Reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.02	Reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.03	Reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.04	Reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.05	Reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.06	Reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.07	Reticulosarcoma of spleen	Diagnosis	ICD-9-CM
200.08	Reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.1	Lymphosarcoma	Diagnosis	ICD-9-CM
200.10	Lymphosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.11	Lymphosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.12	Lymphosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.13	Lymphosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.14	Lymphosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.15	Lymphosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.16	Lymphosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.17	Lymphosarcoma of spleen	Diagnosis	ICD-9-CM
200.18	Lymphosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.2	Burkitt's tumor or lymphoma	Diagnosis	ICD-9-CM
200.20	Burkitt's tumor or lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.21	Burkitt's tumor or lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.22	Burkitt's tumor or lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.23	Burkitt's tumor or lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.24	Burkitt's tumor or lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.25	Burkitt's tumor or lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.26	Burkitt's tumor or lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.27	Burkitt's tumor or lymphoma of spleen	Diagnosis	ICD-9-CM
200.28	Burkitt's tumor or lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.3	Marginal zone lymphoma	Diagnosis	ICD-9-CM
200.30	Marginal zone lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.31	Marginal zone lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.32	Marginal zone lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM

200.33	Marginal zone lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.34	Marginal zone lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.35	Marginal zone lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.36	Marginal zone lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.37	Marginal zone lymphoma, spleen	Diagnosis	ICD-9-CM
200.38	Marginal zone lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.4	Mantle cell lymphoma	Diagnosis	ICD-9-CM
200.40	Mantle cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.41	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.42	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.43	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.44	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.45	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.46	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.47	Mantle cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.48	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.5	Primary central nervous system lymphoma	Diagnosis	ICD-9-CM
200.50	Primary central nervous system lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.51	Primary central nervous system lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.52	Primary central nervous system lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.53	Primary central nervous system lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.54	Primary central nervous system lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.55	Primary central nervous system lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.56	Primary central nervous system lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.57	Primary central nervous system lymphoma, spleen	Diagnosis	ICD-9-CM
200.58	Primary central nervous system lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.6	Anaplastic large cell lymphoma	Diagnosis	ICD-9-CM
200.60	Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.61	Anaplastic large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.62	Anaplastic large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.63	Anaplastic large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.64	Anaplastic large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.65	Anaplastic large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.66	Anaplastic large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.67	Anaplastic large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.68	Anaplastic large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.7	Large cell lymphoma	Diagnosis	ICD-9-CM
200.70	Large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.71	Large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.72	Large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.73	Large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.74	Large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.75	Large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.76	Large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.77	Large cell lymphoma, spleen	Diagnosis	ICD-9-CM

200.78	Large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.8	Other named variants of lymphosarcoma and reticulosarcoma	Diagnosis	ICD-9-CM
200.80	Other named variants, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.81	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.82	Other named variants of lymphosarcoma and reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.83	Other named variants of lymphosarcoma and reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.84	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.85	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.86	Other named variants of lymphosarcoma and reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.87	Other named variants of lymphosarcoma and reticulosarcoma of spleen	Diagnosis	ICD-9-CM
200.88	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201	Hodgkin's disease	Diagnosis	ICD-9-CM
201.0	Hodgkin's paraganuloma	Diagnosis	ICD-9-CM
201.00	Hodgkin's paraganuloma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.01	Hodgkin's paraganuloma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.02	Hodgkin's paraganuloma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.03	Hodgkin's paraganuloma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.04	Hodgkin's paraganuloma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.05	Hodgkin's paraganuloma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.06	Hodgkin's paraganuloma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.07	Hodgkin's paraganuloma of spleen	Diagnosis	ICD-9-CM
201.08	Hodgkin's paraganuloma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.1	Hodgkin's granuloma	Diagnosis	ICD-9-CM
201.10	Hodgkin's granuloma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.11	Hodgkin's granuloma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.12	Hodgkin's granuloma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.13	Hodgkin's granuloma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.14	Hodgkin's granuloma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.15	Hodgkin's granuloma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.16	Hodgkin's granuloma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.17	Hodgkin's granuloma of spleen	Diagnosis	ICD-9-CM
201.18	Hodgkin's granuloma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.2	Hodgkin's sarcoma	Diagnosis	ICD-9-CM
201.20	Hodgkin's sarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.21	Hodgkin's sarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.22	Hodgkin's sarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.23	Hodgkin's sarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.24	Hodgkin's sarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.25	Hodgkin's sarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.26	Hodgkin's sarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM

201.27	Hodgkin's sarcoma of spleen	Diagnosis	ICD-9-CM
201.28	Hodgkin's sarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.4	Hodgkin's disease, lymphocytic-histiocytic predominance	Diagnosis	ICD-9-CM
201.40	Hodgkin's disease, lymphocytic-histiocytic predominance, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.41	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.42	Hodgkin's disease, lymphocytic-histiocytic predominance of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.43	Hodgkin's disease, lymphocytic-histiocytic predominance of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.44	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.45	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.46	Hodgkin's disease, lymphocytic-histiocytic predominance of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.47	Hodgkin's disease, lymphocytic-histiocytic predominance of spleen	Diagnosis	ICD-9-CM
201.48	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.5	Hodgkin's disease, nodular sclerosis	Diagnosis	ICD-9-CM
201.50	Hodgkin's disease, nodular sclerosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.51	Hodgkin's disease, nodular sclerosis, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.52	Hodgkin's disease, nodular sclerosis, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.53	Hodgkin's disease, nodular sclerosis, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.54	Hodgkin's disease, nodular sclerosis, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.55	Hodgkin's disease, nodular sclerosis, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.56	Hodgkin's disease, nodular sclerosis, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.57	Hodgkin's disease, nodular sclerosis, of spleen	Diagnosis	ICD-9-CM
201.58	Hodgkin's disease, nodular sclerosis, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.6	Hodgkin's disease, mixed cellularity	Diagnosis	ICD-9-CM
201.60	Hodgkin's disease, mixed cellularity, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.61	Hodgkin's disease, mixed cellularity, involving lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.62	Hodgkin's disease, mixed cellularity, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.63	Hodgkin's disease, mixed cellularity, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.64	Hodgkin's disease, mixed cellularity, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.65	Hodgkin's disease, mixed cellularity, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.66	Hodgkin's disease, mixed cellularity, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.67	Hodgkin's disease, mixed cellularity, of spleen	Diagnosis	ICD-9-CM
201.68	Hodgkin's disease, mixed cellularity, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.7	Hodgkin's disease, lymphocytic depletion	Diagnosis	ICD-9-CM
201.70	Hodgkin's disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.71	Hodgkin's disease, lymphocytic depletion, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM

201.72	Hodgkin's disease, lymphocytic depletion, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.73	Hodgkin's disease, lymphocytic depletion, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.74	Hodgkin's disease, lymphocytic depletion, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.75	Hodgkin's disease, lymphocytic depletion, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.76	Hodgkin's disease, lymphocytic depletion, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.77	Hodgkin's disease, lymphocytic depletion, of spleen	Diagnosis	ICD-9-CM
201.78	Hodgkin's disease, lymphocytic depletion, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.9	Hodgkin's disease, unspecified type	Diagnosis	ICD-9-CM
201.90	Hodgkin's disease, unspecified type, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.91	Hodgkin's disease, unspecified type, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.92	Hodgkin's disease, unspecified type, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.93	Hodgkin's disease, unspecified type, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.94	Hodgkin's disease, unspecified type, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.95	Hodgkin's disease, unspecified type, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.96	Hodgkin's disease, unspecified type, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.97	Hodgkin's disease, unspecified type, of spleen	Diagnosis	ICD-9-CM
201.98	Hodgkin's disease, unspecified type, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202	Other malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.0	Nodular lymphoma	Diagnosis	ICD-9-CM
202.00	Nodular lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.01	Nodular lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.02	Nodular lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.03	Nodular lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.04	Nodular lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.05	Nodular lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.06	Nodular lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.07	Nodular lymphoma of spleen	Diagnosis	ICD-9-CM
202.08	Nodular lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.1	Mycosis fungoides	Diagnosis	ICD-9-CM
202.10	Mycosis fungoides, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.11	Mycosis fungoides of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.12	Mycosis fungoides of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.13	Mycosis fungoides of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.14	Mycosis fungoides of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.15	Mycosis fungoides of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.16	Mycosis fungoides of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.17	Mycosis fungoides of spleen	Diagnosis	ICD-9-CM
202.18	Mycosis fungoides of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.2	Sezary's disease	Diagnosis	ICD-9-CM
202.20	Sezary's disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.21	Sezary's disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.22	Sezary's disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.23	Sezary's disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.24	Sezary's disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM

202.25	Sezary's disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.26	Sezary's disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.27	Sezary's disease of spleen	Diagnosis	ICD-9-CM
202.28	Sezary's disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.3	Malignant histiocytosis	Diagnosis	ICD-9-CM
202.30	Malignant histiocytosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.31	Malignant histiocytosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.32	Malignant histiocytosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.33	Malignant histiocytosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.34	Malignant histiocytosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.35	Malignant histiocytosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.36	Malignant histiocytosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.37	Malignant histiocytosis of spleen	Diagnosis	ICD-9-CM
202.38	Malignant histiocytosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.4	Leukemic reticuloendotheliosis	Diagnosis	ICD-9-CM
202.40	Leukemic reticuloendotheliosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.41	Leukemic reticuloendotheliosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.42	Leukemic reticuloendotheliosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.43	Leukemic reticuloendotheliosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.44	Leukemic reticuloendotheliosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.45	Leukemic reticuloendotheliosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.46	Leukemic reticuloendotheliosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.47	Leukemic reticuloendotheliosis of spleen	Diagnosis	ICD-9-CM
202.48	Leukemic reticuloendotheliosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.5	Letterer-Siwe disease	Diagnosis	ICD-9-CM
202.50	Letterer-Siwe disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.51	Letterer-Siwe disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.52	Letterer-Siwe disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.53	Letterer-Siwe disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.54	Letterer-Siwe disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.55	Letterer-Siwe disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.56	Letterer-Siwe disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.57	Letterer-Siwe disease of spleen	Diagnosis	ICD-9-CM
202.58	Letterer-Siwe disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.6	Malignant mast cell tumors	Diagnosis	ICD-9-CM
202.60	Malignant mast cell tumors, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.61	Malignant mast cell tumors of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.62	Malignant mast cell tumors of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.63	Malignant mast cell tumors of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.64	Malignant mast cell tumors of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.65	Malignant mast cell tumors of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.66	Malignant mast cell tumors of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.67	Malignant mast cell tumors of spleen	Diagnosis	ICD-9-CM
202.68	Malignant mast cell tumors of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.7	Peripheral T-cell lymphoma	Diagnosis	ICD-9-CM
202.70	Peripheral T-cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.71	Peripheral T-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM

202.72	Peripheral T-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.73	Peripheral T-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.74	Peripheral T-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.75	Peripheral T-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.76	Peripheral T-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.77	Peripheral T-cell lymphoma, spleen	Diagnosis	ICD-9-CM
202.78	Peripheral T-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.8	Other malignant lymphomas	Diagnosis	ICD-9-CM
202.80	Other malignant lymphomas, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.81	Other malignant lymphomas of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.82	Other malignant lymphomas of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.83	Other malignant lymphomas of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.84	Other malignant lymphomas of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.85	Other malignant lymphomas of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.86	Other malignant lymphomas of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.87	Other malignant lymphomas of spleen	Diagnosis	ICD-9-CM
202.88	Other malignant lymphomas of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.9	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.90	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.91	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.92	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.93	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.94	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.95	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.96	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.97	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of spleen	Diagnosis	ICD-9-CM
202.98	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
203	Multiple myeloma and immunoproliferative neoplasms	Diagnosis	ICD-9-CM
203.0	Multiple myeloma	Diagnosis	ICD-9-CM
203.00	Multiple myeloma, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.01	Multiple myeloma in remission	Diagnosis	ICD-9-CM
203.02	Multiple myeloma, in relapse	Diagnosis	ICD-9-CM
203.1	Plasma cell leukemia	Diagnosis	ICD-9-CM
203.10	Plasma cell leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.11	Plasma cell leukemia in remission	Diagnosis	ICD-9-CM
203.12	Plasma cell leukemia, in relapse	Diagnosis	ICD-9-CM
203.8	Other immunoproliferative neoplasms	Diagnosis	ICD-9-CM

203.80	Other immunoproliferative neoplasms, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.81	Other immunoproliferative neoplasms in remission	Diagnosis	ICD-9-CM
203.82	Other immunoproliferative neoplasms, in relapse	Diagnosis	ICD-9-CM
204	Lymphoid leukemia	Diagnosis	ICD-9-CM
204.0	Acute lymphoid leukemia	Diagnosis	ICD-9-CM
204.00	Acute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.01	Acute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.02	Acute lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.1	Chronic lymphoid leukemia	Diagnosis	ICD-9-CM
204.10	Chronic lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.11	Chronic lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.12	Chronic lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.2	Subacute lymphoid leukemia	Diagnosis	ICD-9-CM
204.20	Subacute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.21	Subacute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.22	Subacute lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.8	Other lymphoid leukemia	Diagnosis	ICD-9-CM
204.80	Other lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.81	Other lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.82	Other lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.9	Unspecified lymphoid leukemia	Diagnosis	ICD-9-CM
204.90	Unspecified lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.91	Unspecified lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.92	Unspecified lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
205	Myeloid leukemia	Diagnosis	ICD-9-CM
205.0	Acute myeloid leukemia	Diagnosis	ICD-9-CM
205.00	Acute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.01	Acute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.02	Acute myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.1	Chronic myeloid leukemia	Diagnosis	ICD-9-CM
205.10	Chronic myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.11	Chronic myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.12	Chronic myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.2	Subacute myeloid leukemia	Diagnosis	ICD-9-CM
205.20	Subacute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.21	Subacute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.22	Subacute myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.3	Myeloid sarcoma	Diagnosis	ICD-9-CM
205.30	Myeloid sarcoma, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.31	Myeloid sarcoma in remission	Diagnosis	ICD-9-CM
205.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-9-CM
205.8	Other myeloid leukemia	Diagnosis	ICD-9-CM
205.80	Other myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.81	Other myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.82	Other myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.9	Unspecified myeloid leukemia	Diagnosis	ICD-9-CM

205.90	Unspecified myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.91	Unspecified myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.92	Unspecified myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
206	Monocytic leukemia	Diagnosis	ICD-9-CM
206.0	Acute monocytic leukemia	Diagnosis	ICD-9-CM
206.00	Acute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.01	Acute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.02	Acute monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.1	Chronic monocytic leukemia	Diagnosis	ICD-9-CM
206.10	Chronic monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.11	Chronic monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.12	Chronic monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.2	Subacute monocytic leukemia	Diagnosis	ICD-9-CM
206.20	Subacute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.21	Subacute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.22	Subacute monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.8	Other monocytic leukemia	Diagnosis	ICD-9-CM
206.80	Other monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.81	Other monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.82	Other monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.9	Unspecified monocytic leukemia	Diagnosis	ICD-9-CM
206.90	Unspecified monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.91	Unspecified monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.92	Unspecified monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
207	Other specified leukemia	Diagnosis	ICD-9-CM
207.0	Acute erythremia and erythroleukemia	Diagnosis	ICD-9-CM
207.00	Acute erythremia and erythroleukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.01	Acute erythremia and erythroleukemia in remission	Diagnosis	ICD-9-CM
207.02	Acute erythremia and erythroleukemia, in relapse	Diagnosis	ICD-9-CM
207.1	Chronic erythremia	Diagnosis	ICD-9-CM
207.10	Chronic erythremia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.11	Chronic erythremia in remission	Diagnosis	ICD-9-CM
207.12	Chronic erythremia, in relapse	Diagnosis	ICD-9-CM
207.2	Megakaryocytic leukemia	Diagnosis	ICD-9-CM
207.20	Megakaryocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.21	Megakaryocytic leukemia in remission	Diagnosis	ICD-9-CM
207.22	Megakaryocytic leukemia, in relapse	Diagnosis	ICD-9-CM
207.8	Other specified leukemia	Diagnosis	ICD-9-CM
207.80	Other specified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.81	Other specified leukemia in remission	Diagnosis	ICD-9-CM
207.82	Other specified leukemia, in relapse	Diagnosis	ICD-9-CM
208	Leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.0	Acute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.00	Acute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.01	Acute leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM

208.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.1	Chronic leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.10	Chronic leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.11	Chronic leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.2	Subacute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.20	Subacute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.21	Subacute leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.22	Subacute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.8	Other leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.80	Other leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.81	Other leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.82	Other leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.9	Unspecified leukemia	Diagnosis	ICD-9-CM
208.90	Unspecified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.91	Unspecified leukemia in remission	Diagnosis	ICD-9-CM
208.92	Unspecified leukemia, in relapse	Diagnosis	ICD-9-CM
209	Neuroendocrine tumors	Diagnosis	ICD-9-CM
209.0	Malignant carcinoid tumors of the small intestine	Diagnosis	ICD-9-CM
209.00	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-9-CM
209.01	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-9-CM
209.02	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-9-CM
209.03	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-9-CM
209.1	Malignant carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-9-CM
209.10	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-9-CM
209.11	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-9-CM
209.12	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-9-CM
209.13	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-9-CM
209.14	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-9-CM
209.15	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-9-CM
209.16	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-9-CM
209.17	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-9-CM
209.2	Malignant carcinoid tumors of other and unspecified sites	Diagnosis	ICD-9-CM
209.20	Malignant carcinoid tumor of unknown primary site	Diagnosis	ICD-9-CM
209.21	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-9-CM
209.22	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-9-CM
209.23	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-9-CM
209.24	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-9-CM
209.25	Malignant carcinoid tumor of foregut, not otherwise specified	Diagnosis	ICD-9-CM
209.26	Malignant carcinoid tumor of midgut, not otherwise specified	Diagnosis	ICD-9-CM
209.27	Malignant carcinoid tumor of hindgut, not otherwise specified	Diagnosis	ICD-9-CM
209.29	Malignant carcinoid tumor of other sites	Diagnosis	ICD-9-CM
209.3	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-9-CM
209.30	Malignant poorly differentiated neuroendocrine carcinoma, any site	Diagnosis	ICD-9-CM

209.31	Merkel cell carcinoma of the face	Diagnosis	ICD-9-CM
209.32	Merkel cell carcinoma of the scalp and neck	Diagnosis	ICD-9-CM
209.33	Merkel cell carcinoma of the upper limb	Diagnosis	ICD-9-CM
209.34	Merkel cell carcinoma of the lower limb	Diagnosis	ICD-9-CM
209.35	Merkel cell carcinoma of the trunk	Diagnosis	ICD-9-CM
209.36	Merkel cell carcinoma of other sites	Diagnosis	ICD-9-CM
209.4	Benign carcinoid tumors of the small intestine	Diagnosis	ICD-9-CM
209.40	Benign carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-9-CM
209.41	Benign carcinoid tumor of the duodenum	Diagnosis	ICD-9-CM
209.42	Benign carcinoid tumor of the jejunum	Diagnosis	ICD-9-CM
209.43	Benign carcinoid tumor of the ileum	Diagnosis	ICD-9-CM
209.5	Benign carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-9-CM
209.50	Benign carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-9-CM
209.51	Benign carcinoid tumor of the appendix	Diagnosis	ICD-9-CM
209.52	Benign carcinoid tumor of the cecum	Diagnosis	ICD-9-CM
209.53	Benign carcinoid tumor of the ascending colon	Diagnosis	ICD-9-CM
209.54	Benign carcinoid tumor of the transverse colon	Diagnosis	ICD-9-CM
209.55	Benign carcinoid tumor of the descending colon	Diagnosis	ICD-9-CM
209.56	Benign carcinoid tumor of the sigmoid colon	Diagnosis	ICD-9-CM
209.57	Benign carcinoid tumor of the rectum	Diagnosis	ICD-9-CM
209.6	Benign carcinoid tumors of other and unspecified sites	Diagnosis	ICD-9-CM
209.60	Benign carcinoid tumor of unknown primary site	Diagnosis	ICD-9-CM
209.61	Benign carcinoid tumor of the bronchus and lung	Diagnosis	ICD-9-CM
209.62	Benign carcinoid tumor of the thymus	Diagnosis	ICD-9-CM
209.63	Benign carcinoid tumor of the stomach	Diagnosis	ICD-9-CM
209.64	Benign carcinoid tumor of the kidney	Diagnosis	ICD-9-CM
209.65	Benign carcinoid tumor of foregut, not otherwise specified	Diagnosis	ICD-9-CM
209.66	Benign carcinoid tumor of midgut, not otherwise specified	Diagnosis	ICD-9-CM
209.67	Benign carcinoid tumor of hindgut, not otherwise specified	Diagnosis	ICD-9-CM
209.69	Benign carcinoid tumor of other sites	Diagnosis	ICD-9-CM
209.7	Secondary neuroendocrine tumors	Diagnosis	ICD-9-CM
209.70	Secondary neuroendocrine tumor, unspecified site	Diagnosis	ICD-9-CM
209.71	Secondary neuroendocrine tumor of distant lymph nodes	Diagnosis	ICD-9-CM
209.72	Secondary neuroendocrine tumor of liver	Diagnosis	ICD-9-CM
209.73	Secondary neuroendocrine tumor of bone	Diagnosis	ICD-9-CM
209.74	Secondary neuroendocrine tumor of peritoneum	Diagnosis	ICD-9-CM
209.75	Secondary Merkel cell carcinoma	Diagnosis	ICD-9-CM
209.79	Secondary neuroendocrine tumor of other sites	Diagnosis	ICD-9-CM
230	Carcinoma in situ of digestive organs	Diagnosis	ICD-9-CM
230.0	Carcinoma in situ of lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
230.1	Carcinoma in situ of esophagus	Diagnosis	ICD-9-CM
230.2	Carcinoma in situ of stomach	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
230.5	Carcinoma in situ of anal canal	Diagnosis	ICD-9-CM
230.6	Carcinoma in situ of anus, unspecified	Diagnosis	ICD-9-CM
230.7	Carcinoma in situ of other and unspecified parts of intestine	Diagnosis	ICD-9-CM

230.8	Carcinoma in situ of liver and biliary system	Diagnosis	ICD-9-CM
230.9	Carcinoma in situ of other and unspecified digestive organs	Diagnosis	ICD-9-CM
231	Carcinoma in situ of respiratory system	Diagnosis	ICD-9-CM
231.0	Carcinoma in situ of larynx	Diagnosis	ICD-9-CM
231.1	Carcinoma in situ of trachea	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
231.8	Carcinoma in situ of other specified parts of respiratory system	Diagnosis	ICD-9-CM
231.9	Carcinoma in situ of respiratory system, part unspecified	Diagnosis	ICD-9-CM
232	Carcinoma in situ of skin	Diagnosis	ICD-9-CM
232.0	Carcinoma in situ of skin of lip	Diagnosis	ICD-9-CM
232.1	Carcinoma in situ of eyelid, including canthus	Diagnosis	ICD-9-CM
232.2	Carcinoma in situ of skin of ear and external auditory canal	Diagnosis	ICD-9-CM
232.3	Carcinoma in situ of skin of other and unspecified parts of face	Diagnosis	ICD-9-CM
232.4	Carcinoma in situ of scalp and skin of neck	Diagnosis	ICD-9-CM
232.5	Carcinoma in situ of skin of trunk, except scrotum	Diagnosis	ICD-9-CM
232.6	Carcinoma in situ of skin of upper limb, including shoulder	Diagnosis	ICD-9-CM
232.7	Carcinoma in situ of skin of lower limb, including hip	Diagnosis	ICD-9-CM
232.8	Carcinoma in situ of other specified sites of skin	Diagnosis	ICD-9-CM
232.9	Carcinoma in situ of skin, site unspecified	Diagnosis	ICD-9-CM
233	Carcinoma in situ of breast and genitourinary system	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
233.1	Carcinoma in situ of cervix uteri	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
233.3	Carcinoma in situ, other and unspecified female genital organs	Diagnosis	ICD-9-CM
233.30	Carcinoma in situ, unspecified female genital organ	Diagnosis	ICD-9-CM
233.31	Carcinoma in situ, vagina	Diagnosis	ICD-9-CM
233.32	Carcinoma in situ, vulva	Diagnosis	ICD-9-CM
233.39	Carcinoma in situ, other female genital organ	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
233.5	Carcinoma in situ of penis	Diagnosis	ICD-9-CM
233.6	Carcinoma in situ of other and unspecified male genital organs	Diagnosis	ICD-9-CM
233.7	Carcinoma in situ of bladder	Diagnosis	ICD-9-CM
233.9	Carcinoma in situ of other and unspecified urinary organs	Diagnosis	ICD-9-CM
234	Carcinoma in situ of other and unspecified sites	Diagnosis	ICD-9-CM
234.0	Carcinoma in situ of eye	Diagnosis	ICD-9-CM
234.8	Carcinoma in situ of other specified sites	Diagnosis	ICD-9-CM
234.9	Carcinoma in situ, site unspecified	Diagnosis	ICD-9-CM
235	Neoplasm of uncertain behavior of digestive and respiratory systems	Diagnosis	ICD-9-CM
235.0	Neoplasm of uncertain behavior of major salivary glands	Diagnosis	ICD-9-CM
235.1	Neoplasm of uncertain behavior of lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
235.2	Neoplasm of uncertain behavior of stomach, intestines, and rectum	Diagnosis	ICD-9-CM
235.3	Neoplasm of uncertain behavior of liver and biliary passages	Diagnosis	ICD-9-CM
235.4	Neoplasm of uncertain behavior of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
235.5	Neoplasm of uncertain behavior of other and unspecified digestive organs	Diagnosis	ICD-9-CM
235.6	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-9-CM
235.7	Neoplasm of uncertain behavior of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
235.8	Neoplasm of uncertain behavior of pleura, thymus, and mediastinum	Diagnosis	ICD-9-CM

235.9	Neoplasm of uncertain behavior of other and unspecified respiratory organs	Diagnosis	ICD-9-CM
236	Neoplasm of uncertain behavior of genitourinary organs	Diagnosis	ICD-9-CM
236.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-9-CM
236.1	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-9-CM
236.2	Neoplasm of uncertain behavior of ovary	Diagnosis	ICD-9-CM
236.3	Neoplasm of uncertain behavior of other and unspecified female genital organs	Diagnosis	ICD-9-CM
236.4	Neoplasm of uncertain behavior of testis	Diagnosis	ICD-9-CM
236.5	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-9-CM
236.6	Neoplasm of uncertain behavior of other and unspecified male genital organs	Diagnosis	ICD-9-CM
236.7	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-9-CM
236.9	Neoplasm of uncertain behavior of other and unspecified urinary organs	Diagnosis	ICD-9-CM
236.90	Neoplasm of uncertain behavior of urinary organ, unspecified	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
236.99	Neoplasm of uncertain behavior of other and unspecified urinary organs	Diagnosis	ICD-9-CM
237	Neoplasm of uncertain behavior of endocrine glands and nervous system	Diagnosis	ICD-9-CM
237.0	Neoplasm of uncertain behavior of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
237.1	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-9-CM
237.2	Neoplasm of uncertain behavior of adrenal gland	Diagnosis	ICD-9-CM
237.3	Neoplasm of uncertain behavior of paraganglia	Diagnosis	ICD-9-CM
237.4	Neoplasm of uncertain behavior of other and unspecified endocrine glands	Diagnosis	ICD-9-CM
237.5	Neoplasm of uncertain behavior of brain and spinal cord	Diagnosis	ICD-9-CM
237.6	Neoplasm of uncertain behavior of meninges	Diagnosis	ICD-9-CM
237.7	Neurofibromatosis	Diagnosis	ICD-9-CM
237.70	Neurofibromatosis, unspecified	Diagnosis	ICD-9-CM
237.71	Neurofibromatosis, Type 1 (von Recklinghausen's disease)	Diagnosis	ICD-9-CM
237.72	Neurofibromatosis, Type 2 (acoustic neurofibromatosis)	Diagnosis	ICD-9-CM
237.73	Schwannomatosis	Diagnosis	ICD-9-CM
237.79	Other neurofibromatosis	Diagnosis	ICD-9-CM
237.9	Neoplasm of uncertain behavior of other and unspecified parts of nervous system	Diagnosis	ICD-9-CM
238	Neoplasm of uncertain behavior of other and unspecified sites and tissues	Diagnosis	ICD-9-CM
238.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-9-CM
238.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-9-CM
238.2	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-9-CM
238.3	Neoplasm of uncertain behavior of breast	Diagnosis	ICD-9-CM
238.4	Neoplasm of uncertain behavior of polycythemia vera	Diagnosis	ICD-9-CM
238.5	Neoplasm of uncertain behavior of histiocytic and mast cells	Diagnosis	ICD-9-CM
238.6	Neoplasm of uncertain behavior of plasma cells	Diagnosis	ICD-9-CM
238.7	Other lymphatic and hematopoietic tissues	Diagnosis	ICD-9-CM
238.71	Essential thrombocythemia	Diagnosis	ICD-9-CM
238.72	Low grade myelodysplastic syndrome lesions	Diagnosis	ICD-9-CM
238.73	High grade myelodysplastic syndrome lesions	Diagnosis	ICD-9-CM
238.74	Myelodysplastic syndrome with 5q deletion	Diagnosis	ICD-9-CM
238.75	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-9-CM
238.76	Myelofibrosis with myeloid metaplasia	Diagnosis	ICD-9-CM
238.77	Post-transplant lymphoproliferative disorder [PTLD]	Diagnosis	ICD-9-CM
238.79	Other lymphatic and hematopoietic tissues	Diagnosis	ICD-9-CM
238.8	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-9-CM

238.9	Neoplasm of uncertain behavior, site unspecified	Diagnosis	ICD-9-CM
239	Neoplasms of unspecified nature	Diagnosis	ICD-9-CM
239.0	Neoplasm of unspecified nature of digestive system	Diagnosis	ICD-9-CM
239.1	Neoplasm of unspecified nature of respiratory system	Diagnosis	ICD-9-CM
239.2	Neoplasms of unspecified nature of bone, soft tissue, and skin	Diagnosis	ICD-9-CM
239.3	Neoplasm of unspecified nature of breast	Diagnosis	ICD-9-CM
239.4	Neoplasm of unspecified nature of bladder	Diagnosis	ICD-9-CM
239.5	Neoplasm of unspecified nature of other genitourinary organs	Diagnosis	ICD-9-CM
239.6	Neoplasm of unspecified nature of brain	Diagnosis	ICD-9-CM
239.7	Neoplasm of unspecified nature of endocrine glands and other parts of nervous system	Diagnosis	ICD-9-CM
239.8	Neoplasm of unspecified nature of other specified sites	Diagnosis	ICD-9-CM
239.81	Neoplasms of unspecified nature, retina and choroid	Diagnosis	ICD-9-CM
239.89	Neoplasms of unspecified nature, other specified sites	Diagnosis	ICD-9-CM
239.9	Neoplasm of unspecified nature, site unspecified	Diagnosis	ICD-9-CM
C00.0	Malignant neoplasm of external upper lip	Diagnosis	ICD-10-CM
C00.1	Malignant neoplasm of external lower lip	Diagnosis	ICD-10-CM
C00.2	Malignant neoplasm of external lip, unspecified	Diagnosis	ICD-10-CM
C00.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-10-CM
C00.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-10-CM
C00.5	Malignant neoplasm of lip, unspecified, inner aspect	Diagnosis	ICD-10-CM
C00.6	Malignant neoplasm of commissure of lip, unspecified	Diagnosis	ICD-10-CM
C00.8	Malignant neoplasm of overlapping sites of lip	Diagnosis	ICD-10-CM
C00.9	Malignant neoplasm of lip, unspecified	Diagnosis	ICD-10-CM
C01	Malignant neoplasm of base of tongue	Diagnosis	ICD-10-CM
C02.0	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-10-CM
C02.1	Malignant neoplasm of border of tongue	Diagnosis	ICD-10-CM
C02.2	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-10-CM
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-10-CM
C02.4	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-10-CM
C02.8	Malignant neoplasm of overlapping sites of tongue	Diagnosis	ICD-10-CM
C02.9	Malignant neoplasm of tongue, unspecified	Diagnosis	ICD-10-CM
C03.0	Malignant neoplasm of upper gum	Diagnosis	ICD-10-CM
C03.1	Malignant neoplasm of lower gum	Diagnosis	ICD-10-CM
C03.9	Malignant neoplasm of gum, unspecified	Diagnosis	ICD-10-CM
C04.0	Malignant neoplasm of anterior floor of mouth	Diagnosis	ICD-10-CM
C04.1	Malignant neoplasm of lateral floor of mouth	Diagnosis	ICD-10-CM
C04.8	Malignant neoplasm of overlapping sites of floor of mouth	Diagnosis	ICD-10-CM
C04.9	Malignant neoplasm of floor of mouth, unspecified	Diagnosis	ICD-10-CM
C05.0	Malignant neoplasm of hard palate	Diagnosis	ICD-10-CM
C05.1	Malignant neoplasm of soft palate	Diagnosis	ICD-10-CM
C05.2	Malignant neoplasm of uvula	Diagnosis	ICD-10-CM
C05.8	Malignant neoplasm of overlapping sites of palate	Diagnosis	ICD-10-CM
C05.9	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-10-CM
C06.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-10-CM
C06.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-10-CM
C06.2	Malignant neoplasm of retromolar area	Diagnosis	ICD-10-CM

C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth	Diagnosis	ICD-10-CM
C06.9	Malignant neoplasm of mouth, unspecified	Diagnosis	ICD-10-CM
C07	Malignant neoplasm of parotid gland	Diagnosis	ICD-10-CM
C08.0	Malignant neoplasm of submandibular gland	Diagnosis	ICD-10-CM
C08.1	Malignant neoplasm of sublingual gland	Diagnosis	ICD-10-CM
C08.9	Malignant neoplasm of major salivary gland, unspecified	Diagnosis	ICD-10-CM
C09.0	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-10-CM
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)	Diagnosis	ICD-10-CM
C09.8	Malignant neoplasm of overlapping sites of tonsil	Diagnosis	ICD-10-CM
C09.9	Malignant neoplasm of tonsil, unspecified	Diagnosis	ICD-10-CM
C10.0	Malignant neoplasm of vallecula	Diagnosis	ICD-10-CM
C10.1	Malignant neoplasm of anterior surface of epiglottis	Diagnosis	ICD-10-CM
C10.2	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-10-CM
C10.3	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-10-CM
C10.4	Malignant neoplasm of branchial cleft	Diagnosis	ICD-10-CM
C10.8	Malignant neoplasm of overlapping sites of oropharynx	Diagnosis	ICD-10-CM
C10.9	Malignant neoplasm of oropharynx, unspecified	Diagnosis	ICD-10-CM
C11.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-10-CM
C11.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.8	Malignant neoplasm of overlapping sites of nasopharynx	Diagnosis	ICD-10-CM
C11.9	Malignant neoplasm of nasopharynx, unspecified	Diagnosis	ICD-10-CM
C12	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-10-CM
C13.0	Malignant neoplasm of postcricoid region	Diagnosis	ICD-10-CM
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-10-CM
C13.2	Malignant neoplasm of posterior wall of hypopharynx	Diagnosis	ICD-10-CM
C13.8	Malignant neoplasm of overlapping sites of hypopharynx	Diagnosis	ICD-10-CM
C13.9	Malignant neoplasm of hypopharynx, unspecified	Diagnosis	ICD-10-CM
C14.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-10-CM
C14.2	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-10-CM
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM
C16.0	Malignant neoplasm of cardia	Diagnosis	ICD-10-CM
C16.1	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-10-CM
C16.2	Malignant neoplasm of body of stomach	Diagnosis	ICD-10-CM
C16.3	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-10-CM
C16.4	Malignant neoplasm of pylorus	Diagnosis	ICD-10-CM
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.8	Malignant neoplasm of overlapping sites of stomach	Diagnosis	ICD-10-CM
C16.9	Malignant neoplasm of stomach, unspecified	Diagnosis	ICD-10-CM

C17.0	Malignant neoplasm of duodenum	Diagnosis	ICD-10-CM
C17.1	Malignant neoplasm of jejunum	Diagnosis	ICD-10-CM
C17.2	Malignant neoplasm of ileum	Diagnosis	ICD-10-CM
C17.3	Meckel's diverticulum, malignant	Diagnosis	ICD-10-CM
C17.8	Malignant neoplasm of overlapping sites of small intestine	Diagnosis	ICD-10-CM
C17.9	Malignant neoplasm of small intestine, unspecified	Diagnosis	ICD-10-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C21.0	Malignant neoplasm of anus, unspecified	Diagnosis	ICD-10-CM
C21.1	Malignant neoplasm of anal canal	Diagnosis	ICD-10-CM
C21.2	Malignant neoplasm of cloacogenic zone	Diagnosis	ICD-10-CM
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	Diagnosis	ICD-10-CM
C22.0	Liver cell carcinoma	Diagnosis	ICD-10-CM
C22.1	Intrahepatic bile duct carcinoma	Diagnosis	ICD-10-CM
C22.2	Hepatoblastoma	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
C22.9	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-10-CM
C23	Malignant neoplasm of gallbladder	Diagnosis	ICD-10-CM
C24.0	Malignant neoplasm of extrahepatic bile duct	Diagnosis	ICD-10-CM
C24.1	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-10-CM
C24.8	Malignant neoplasm of overlapping sites of biliary tract	Diagnosis	ICD-10-CM
C24.9	Malignant neoplasm of biliary tract, unspecified	Diagnosis	ICD-10-CM
C25.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-10-CM
C25.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-10-CM
C25.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-10-CM
C25.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-10-CM
C25.4	Malignant neoplasm of endocrine pancreas	Diagnosis	ICD-10-CM
C25.7	Malignant neoplasm of other parts of pancreas	Diagnosis	ICD-10-CM
C25.8	Malignant neoplasm of overlapping sites of pancreas	Diagnosis	ICD-10-CM
C25.9	Malignant neoplasm of pancreas, unspecified	Diagnosis	ICD-10-CM
C26.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-10-CM
C26.1	Malignant neoplasm of spleen	Diagnosis	ICD-10-CM
C26.9	Malignant neoplasm of ill-defined sites within the digestive system	Diagnosis	ICD-10-CM
C30.0	Malignant neoplasm of nasal cavity	Diagnosis	ICD-10-CM

C30.1	Malignant neoplasm of middle ear	Diagnosis	ICD-10-CM
C31.0	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-10-CM
C31.1	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-10-CM
C31.2	Malignant neoplasm of frontal sinus	Diagnosis	ICD-10-CM
C31.3	Malignant neoplasm of sphenoid sinus	Diagnosis	ICD-10-CM
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses	Diagnosis	ICD-10-CM
C31.9	Malignant neoplasm of accessory sinus, unspecified	Diagnosis	ICD-10-CM
C32.0	Malignant neoplasm of glottis	Diagnosis	ICD-10-CM
C32.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-10-CM
C32.2	Malignant neoplasm of subglottis	Diagnosis	ICD-10-CM
C32.3	Malignant neoplasm of laryngeal cartilage	Diagnosis	ICD-10-CM
C32.8	Malignant neoplasm of overlapping sites of larynx	Diagnosis	ICD-10-CM
C32.9	Malignant neoplasm of larynx, unspecified	Diagnosis	ICD-10-CM
C33	Malignant neoplasm of trachea	Diagnosis	ICD-10-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
C37	Malignant neoplasm of thymus	Diagnosis	ICD-10-CM
C38.0	Malignant neoplasm of heart	Diagnosis	ICD-10-CM
C38.1	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-10-CM
C38.2	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-10-CM
C38.3	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-10-CM
C38.4	Malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.01	Malignant neoplasm of scapula and long bones of right upper limb	Diagnosis	ICD-10-CM
C40.02	Malignant neoplasm of scapula and long bones of left upper limb	Diagnosis	ICD-10-CM
C40.10	Malignant neoplasm of short bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.11	Malignant neoplasm of short bones of right upper limb	Diagnosis	ICD-10-CM
C40.12	Malignant neoplasm of short bones of left upper limb	Diagnosis	ICD-10-CM
C40.20	Malignant neoplasm of long bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.21	Malignant neoplasm of long bones of right lower limb	Diagnosis	ICD-10-CM

C40.22	Malignant neoplasm of long bones of left lower limb	Diagnosis	ICD-10-CM
C40.30	Malignant neoplasm of short bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.31	Malignant neoplasm of short bones of right lower limb	Diagnosis	ICD-10-CM
C40.32	Malignant neoplasm of short bones of left lower limb	Diagnosis	ICD-10-CM
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb	Diagnosis	ICD-10-CM
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb	Diagnosis	ICD-10-CM
C41.0	Malignant neoplasm of bones of skull and face	Diagnosis	ICD-10-CM
C41.1	Malignant neoplasm of mandible	Diagnosis	ICD-10-CM
C41.2	Malignant neoplasm of vertebral column	Diagnosis	ICD-10-CM
C41.3	Malignant neoplasm of ribs, sternum and clavicle	Diagnosis	ICD-10-CM
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx	Diagnosis	ICD-10-CM
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified	Diagnosis	ICD-10-CM
C43.0	Malignant melanoma of lip	Diagnosis	ICD-10-CM
C43.10	Malignant melanoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C43.11	Malignant melanoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C43.12	Malignant melanoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C43.20	Malignant melanoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C43.21	Malignant melanoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C43.22	Malignant melanoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C43.30	Malignant melanoma of unspecified part of face	Diagnosis	ICD-10-CM
C43.31	Malignant melanoma of nose	Diagnosis	ICD-10-CM
C43.39	Malignant melanoma of other parts of face	Diagnosis	ICD-10-CM
C43.4	Malignant melanoma of scalp and neck	Diagnosis	ICD-10-CM
C43.51	Malignant melanoma of anal skin	Diagnosis	ICD-10-CM
C43.52	Malignant melanoma of skin of breast	Diagnosis	ICD-10-CM
C43.59	Malignant melanoma of other part of trunk	Diagnosis	ICD-10-CM
C43.60	Malignant melanoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.61	Malignant melanoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.62	Malignant melanoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.70	Malignant melanoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C43.71	Malignant melanoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C43.72	Malignant melanoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C43.8	Malignant melanoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C43.9	Malignant melanoma of skin, unspecified	Diagnosis	ICD-10-CM
C44.00	Unspecified malignant neoplasm of skin of lip	Diagnosis	ICD-10-CM
C44.01	Basal cell carcinoma of skin of lip	Diagnosis	ICD-10-CM
C44.02	Squamous cell carcinoma of skin of lip	Diagnosis	ICD-10-CM
C44.09	Other specified malignant neoplasm of skin of lip	Diagnosis	ICD-10-CM
C44.101	Unspecified malignant neoplasm of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C44.102	Unspecified malignant neoplasm of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.109	Unspecified malignant neoplasm of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.191	Other specified malignant neoplasm of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM

C44.192	Other specified malignant neoplasm of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
C44.199	Other specified malignant neoplasm of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
C44.201	Unspecified malignant neoplasm of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.202	Unspecified malignant neoplasm of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.209	Unspecified malignant neoplasm of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.291	Other specified malignant neoplasm of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C44.292	Other specified malignant neoplasm of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
C44.299	Other specified malignant neoplasm of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
C44.300	Unspecified malignant neoplasm of skin of unspecified part of face	Diagnosis	ICD-10-CM
C44.301	Unspecified malignant neoplasm of skin of nose	Diagnosis	ICD-10-CM
C44.309	Unspecified malignant neoplasm of skin of other parts of face	Diagnosis	ICD-10-CM
C44.390	Other specified malignant neoplasm of skin of unspecified parts of face	Diagnosis	ICD-10-CM
C44.391	Other specified malignant neoplasm of skin of nose	Diagnosis	ICD-10-CM
C44.399	Other specified malignant neoplasm of skin of other parts of face	Diagnosis	ICD-10-CM
C44.40	Unspecified malignant neoplasm of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.49	Other specified malignant neoplasm of skin of scalp and neck	Diagnosis	ICD-10-CM
C44.500	Unspecified malignant neoplasm of anal skin	Diagnosis	ICD-10-CM
C44.501	Unspecified malignant neoplasm of skin of breast	Diagnosis	ICD-10-CM
C44.509	Unspecified malignant neoplasm of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.590	Other specified malignant neoplasm of anal skin	Diagnosis	ICD-10-CM
C44.591	Other specified malignant neoplasm of skin of breast	Diagnosis	ICD-10-CM
C44.599	Other specified malignant neoplasm of skin of other part of trunk	Diagnosis	ICD-10-CM
C44.601	Unspecified malignant neoplasm of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.602	Unspecified malignant neoplasm of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.609	Unspecified malignant neoplasm of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.691	Other specified malignant neoplasm of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.692	Other specified malignant neoplasm of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.699	Other specified malignant neoplasm of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C44.701	Unspecified malignant neoplasm of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.702	Unspecified malignant neoplasm of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.709	Unspecified malignant neoplasm of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.791	Other specified malignant neoplasm of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C44.792	Other specified malignant neoplasm of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
C44.799	Other specified malignant neoplasm of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
C44.80	Unspecified malignant neoplasm of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.89	Other specified malignant neoplasm of overlapping sites of skin	Diagnosis	ICD-10-CM
C44.90	Unspecified malignant neoplasm of skin, unspecified	Diagnosis	ICD-10-CM
C44.99	Other specified malignant neoplasm of skin, unspecified	Diagnosis	ICD-10-CM
C45.0	Mesothelioma of pleura	Diagnosis	ICD-10-CM
C45.1	Mesothelioma of peritoneum	Diagnosis	ICD-10-CM
C45.2	Mesothelioma of pericardium	Diagnosis	ICD-10-CM
C45.7	Mesothelioma of other sites	Diagnosis	ICD-10-CM
C45.9	Mesothelioma, unspecified	Diagnosis	ICD-10-CM

C46.0	Kaposi's sarcoma of skin	Diagnosis	ICD-10-CM
C46.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-10-CM
C46.2	Kaposi's sarcoma of palate	Diagnosis	ICD-10-CM
C46.3	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-10-CM
C46.4	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-10-CM
C46.50	Kaposi's sarcoma of unspecified lung	Diagnosis	ICD-10-CM
C46.51	Kaposi's sarcoma of right lung	Diagnosis	ICD-10-CM
C46.52	Kaposi's sarcoma of left lung	Diagnosis	ICD-10-CM
C46.7	Kaposi's sarcoma of other sites	Diagnosis	ICD-10-CM
C46.9	Kaposi's sarcoma, unspecified	Diagnosis	ICD-10-CM
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck	Diagnosis	ICD-10-CM
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip	Diagnosis	ICD-10-CM
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip	Diagnosis	ICD-10-CM
C47.3	Malignant neoplasm of peripheral nerves of thorax	Diagnosis	ICD-10-CM
C47.4	Malignant neoplasm of peripheral nerves of abdomen	Diagnosis	ICD-10-CM
C47.5	Malignant neoplasm of peripheral nerves of pelvis	Diagnosis	ICD-10-CM
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified	Diagnosis	ICD-10-CM
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified	Diagnosis	ICD-10-CM
C48.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-10-CM
C48.1	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-10-CM
C48.2	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-10-CM
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck	Diagnosis	ICD-10-CM
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip	Diagnosis	ICD-10-CM
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip	Diagnosis	ICD-10-CM
C49.3	Malignant neoplasm of connective and soft tissue of thorax	Diagnosis	ICD-10-CM
C49.4	Malignant neoplasm of connective and soft tissue of abdomen	Diagnosis	ICD-10-CM
C49.5	Malignant neoplasm of connective and soft tissue of pelvis	Diagnosis	ICD-10-CM
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified	Diagnosis	ICD-10-CM
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue	Diagnosis	ICD-10-CM
C49.9	Malignant neoplasm of connective and soft tissue, unspecified	Diagnosis	ICD-10-CM

C49.A0	Gastrointestinal stromal tumor, unspecified site	Diagnosis	ICD-10-CM
C49.A1	Gastrointestinal stromal tumor of esophagus	Diagnosis	ICD-10-CM
C49.A2	Gastrointestinal stromal tumor of stomach	Diagnosis	ICD-10-CM
C49.A3	Gastrointestinal stromal tumor of small intestine	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
C49.A9	Gastrointestinal stromal tumor of other sites	Diagnosis	ICD-10-CM
C4A.0	Merkel cell carcinoma of lip	Diagnosis	ICD-10-CM
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.11	Merkel cell carcinoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.12	Merkel cell carcinoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.21	Merkel cell carcinoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.22	Merkel cell carcinoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.30	Merkel cell carcinoma of unspecified part of face	Diagnosis	ICD-10-CM
C4A.31	Merkel cell carcinoma of nose	Diagnosis	ICD-10-CM
C4A.39	Merkel cell carcinoma of other parts of face	Diagnosis	ICD-10-CM
C4A.4	Merkel cell carcinoma of scalp and neck	Diagnosis	ICD-10-CM
C4A.51	Merkel cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C4A.52	Merkel cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C4A.59	Merkel cell carcinoma of other part of trunk	Diagnosis	ICD-10-CM
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C4A.71	Merkel cell carcinoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C4A.72	Merkel cell carcinoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C4A.8	Merkel cell carcinoma of overlapping sites	Diagnosis	ICD-10-CM
C4A.9	Merkel cell carcinoma, unspecified	Diagnosis	ICD-10-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM

C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
C51.0	Malignant neoplasm of labium majus	Diagnosis	ICD-10-CM
C51.1	Malignant neoplasm of labium minus	Diagnosis	ICD-10-CM
C51.2	Malignant neoplasm of clitoris	Diagnosis	ICD-10-CM
C51.8	Malignant neoplasm of overlapping sites of vulva	Diagnosis	ICD-10-CM
C51.9	Malignant neoplasm of vulva, unspecified	Diagnosis	ICD-10-CM
C52	Malignant neoplasm of vagina	Diagnosis	ICD-10-CM
C53.0	Malignant neoplasm of endocervix	Diagnosis	ICD-10-CM
C53.1	Malignant neoplasm of exocervix	Diagnosis	ICD-10-CM
C53.8	Malignant neoplasm of overlapping sites of cervix uteri	Diagnosis	ICD-10-CM
C53.9	Malignant neoplasm of cervix uteri, unspecified	Diagnosis	ICD-10-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM

C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
C55	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-10-CM
C56.1	Malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C56.2	Malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C56.9	Malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C57.00	Malignant neoplasm of unspecified fallopian tube	Diagnosis	ICD-10-CM
C57.01	Malignant neoplasm of right fallopian tube	Diagnosis	ICD-10-CM
C57.02	Malignant neoplasm of left fallopian tube	Diagnosis	ICD-10-CM
C57.10	Malignant neoplasm of unspecified broad ligament	Diagnosis	ICD-10-CM
C57.11	Malignant neoplasm of right broad ligament	Diagnosis	ICD-10-CM
C57.12	Malignant neoplasm of left broad ligament	Diagnosis	ICD-10-CM
C57.20	Malignant neoplasm of unspecified round ligament	Diagnosis	ICD-10-CM
C57.21	Malignant neoplasm of right round ligament	Diagnosis	ICD-10-CM
C57.22	Malignant neoplasm of left round ligament	Diagnosis	ICD-10-CM
C57.3	Malignant neoplasm of parametrium	Diagnosis	ICD-10-CM
C57.4	Malignant neoplasm of uterine adnexa, unspecified	Diagnosis	ICD-10-CM
C57.7	Malignant neoplasm of other specified female genital organs	Diagnosis	ICD-10-CM
C57.8	Malignant neoplasm of overlapping sites of female genital organs	Diagnosis	ICD-10-CM
C57.9	Malignant neoplasm of female genital organ, unspecified	Diagnosis	ICD-10-CM
C58	Malignant neoplasm of placenta	Diagnosis	ICD-10-CM
C60.0	Malignant neoplasm of prepuce	Diagnosis	ICD-10-CM
C60.1	Malignant neoplasm of glans penis	Diagnosis	ICD-10-CM
C60.2	Malignant neoplasm of body of penis	Diagnosis	ICD-10-CM
C60.8	Malignant neoplasm of overlapping sites of penis	Diagnosis	ICD-10-CM
C60.9	Malignant neoplasm of penis, unspecified	Diagnosis	ICD-10-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
C62.00	Malignant neoplasm of unspecified undescended testis	Diagnosis	ICD-10-CM
C62.01	Malignant neoplasm of undescended right testis	Diagnosis	ICD-10-CM
C62.02	Malignant neoplasm of undescended left testis	Diagnosis	ICD-10-CM
C62.10	Malignant neoplasm of unspecified descended testis	Diagnosis	ICD-10-CM
C62.11	Malignant neoplasm of descended right testis	Diagnosis	ICD-10-CM
C62.12	Malignant neoplasm of descended left testis	Diagnosis	ICD-10-CM
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C63.00	Malignant neoplasm of unspecified epididymis	Diagnosis	ICD-10-CM
C63.01	Malignant neoplasm of right epididymis	Diagnosis	ICD-10-CM
C63.02	Malignant neoplasm of left epididymis	Diagnosis	ICD-10-CM
C63.10	Malignant neoplasm of unspecified spermatic cord	Diagnosis	ICD-10-CM
C63.11	Malignant neoplasm of right spermatic cord	Diagnosis	ICD-10-CM
C63.12	Malignant neoplasm of left spermatic cord	Diagnosis	ICD-10-CM
C63.2	Malignant neoplasm of scrotum	Diagnosis	ICD-10-CM

C63.7	Malignant neoplasm of other specified male genital organs	Diagnosis	ICD-10-CM
C63.8	Malignant neoplasm of overlapping sites of male genital organs	Diagnosis	ICD-10-CM
C63.9	Malignant neoplasm of male genital organ, unspecified	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C65.1	Malignant neoplasm of right renal pelvis	Diagnosis	ICD-10-CM
C65.2	Malignant neoplasm of left renal pelvis	Diagnosis	ICD-10-CM
C65.9	Malignant neoplasm of unspecified renal pelvis	Diagnosis	ICD-10-CM
C66.1	Malignant neoplasm of right ureter	Diagnosis	ICD-10-CM
C66.2	Malignant neoplasm of left ureter	Diagnosis	ICD-10-CM
C66.9	Malignant neoplasm of unspecified ureter	Diagnosis	ICD-10-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM
C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
C68.0	Malignant neoplasm of urethra	Diagnosis	ICD-10-CM
C68.1	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-10-CM
C68.8	Malignant neoplasm of overlapping sites of urinary organs	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
C69.00	Malignant neoplasm of unspecified conjunctiva	Diagnosis	ICD-10-CM
C69.01	Malignant neoplasm of right conjunctiva	Diagnosis	ICD-10-CM
C69.02	Malignant neoplasm of left conjunctiva	Diagnosis	ICD-10-CM
C69.10	Malignant neoplasm of unspecified cornea	Diagnosis	ICD-10-CM
C69.11	Malignant neoplasm of right cornea	Diagnosis	ICD-10-CM
C69.12	Malignant neoplasm of left cornea	Diagnosis	ICD-10-CM
C69.20	Malignant neoplasm of unspecified retina	Diagnosis	ICD-10-CM
C69.21	Malignant neoplasm of right retina	Diagnosis	ICD-10-CM
C69.22	Malignant neoplasm of left retina	Diagnosis	ICD-10-CM
C69.30	Malignant neoplasm of unspecified choroid	Diagnosis	ICD-10-CM
C69.31	Malignant neoplasm of right choroid	Diagnosis	ICD-10-CM
C69.32	Malignant neoplasm of left choroid	Diagnosis	ICD-10-CM
C69.40	Malignant neoplasm of unspecified ciliary body	Diagnosis	ICD-10-CM
C69.41	Malignant neoplasm of right ciliary body	Diagnosis	ICD-10-CM
C69.42	Malignant neoplasm of left ciliary body	Diagnosis	ICD-10-CM
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.51	Malignant neoplasm of right lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.52	Malignant neoplasm of left lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.60	Malignant neoplasm of unspecified orbit	Diagnosis	ICD-10-CM
C69.61	Malignant neoplasm of right orbit	Diagnosis	ICD-10-CM
C69.62	Malignant neoplasm of left orbit	Diagnosis	ICD-10-CM

C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa	Diagnosis	ICD-10-CM
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa	Diagnosis	ICD-10-CM
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa	Diagnosis	ICD-10-CM
C69.90	Malignant neoplasm of unspecified site of unspecified eye	Diagnosis	ICD-10-CM
C69.91	Malignant neoplasm of unspecified site of right eye	Diagnosis	ICD-10-CM
C69.92	Malignant neoplasm of unspecified site of left eye	Diagnosis	ICD-10-CM
C70.0	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C70.1	Malignant neoplasm of spinal meninges	Diagnosis	ICD-10-CM
C70.9	Malignant neoplasm of meninges, unspecified	Diagnosis	ICD-10-CM
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-10-CM
C71.1	Malignant neoplasm of frontal lobe	Diagnosis	ICD-10-CM
C71.2	Malignant neoplasm of temporal lobe	Diagnosis	ICD-10-CM
C71.3	Malignant neoplasm of parietal lobe	Diagnosis	ICD-10-CM
C71.4	Malignant neoplasm of occipital lobe	Diagnosis	ICD-10-CM
C71.5	Malignant neoplasm of cerebral ventricle	Diagnosis	ICD-10-CM
C71.6	Malignant neoplasm of cerebellum	Diagnosis	ICD-10-CM
C71.7	Malignant neoplasm of brain stem	Diagnosis	ICD-10-CM
C71.8	Malignant neoplasm of overlapping sites of brain	Diagnosis	ICD-10-CM
C71.9	Malignant neoplasm of brain, unspecified	Diagnosis	ICD-10-CM
C72.0	Malignant neoplasm of spinal cord	Diagnosis	ICD-10-CM
C72.1	Malignant neoplasm of cauda equina	Diagnosis	ICD-10-CM
C72.20	Malignant neoplasm of unspecified olfactory nerve	Diagnosis	ICD-10-CM
C72.21	Malignant neoplasm of right olfactory nerve	Diagnosis	ICD-10-CM
C72.22	Malignant neoplasm of left olfactory nerve	Diagnosis	ICD-10-CM
C72.30	Malignant neoplasm of unspecified optic nerve	Diagnosis	ICD-10-CM
C72.31	Malignant neoplasm of right optic nerve	Diagnosis	ICD-10-CM
C72.32	Malignant neoplasm of left optic nerve	Diagnosis	ICD-10-CM
C72.40	Malignant neoplasm of unspecified acoustic nerve	Diagnosis	ICD-10-CM
C72.41	Malignant neoplasm of right acoustic nerve	Diagnosis	ICD-10-CM
C72.42	Malignant neoplasm of left acoustic nerve	Diagnosis	ICD-10-CM
C72.50	Malignant neoplasm of unspecified cranial nerve	Diagnosis	ICD-10-CM
C72.59	Malignant neoplasm of other cranial nerves	Diagnosis	ICD-10-CM
C72.9	Malignant neoplasm of central nervous system, unspecified	Diagnosis	ICD-10-CM
C73	Malignant neoplasm of thyroid gland	Diagnosis	ICD-10-CM
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.01	Malignant neoplasm of cortex of right adrenal gland	Diagnosis	ICD-10-CM
C74.02	Malignant neoplasm of cortex of left adrenal gland	Diagnosis	ICD-10-CM
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.11	Malignant neoplasm of medulla of right adrenal gland	Diagnosis	ICD-10-CM
C74.12	Malignant neoplasm of medulla of left adrenal gland	Diagnosis	ICD-10-CM
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.91	Malignant neoplasm of unspecified part of right adrenal gland	Diagnosis	ICD-10-CM
C74.92	Malignant neoplasm of unspecified part of left adrenal gland	Diagnosis	ICD-10-CM
C75.0	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-10-CM
C75.1	Malignant neoplasm of pituitary gland	Diagnosis	ICD-10-CM
C75.2	Malignant neoplasm of craniopharyngeal duct	Diagnosis	ICD-10-CM
C75.3	Malignant neoplasm of pineal gland	Diagnosis	ICD-10-CM

C75.4	Malignant neoplasm of carotid body	Diagnosis	ICD-10-CM
C75.5	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-10-CM
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified	Diagnosis	ICD-10-CM
C75.9	Malignant neoplasm of endocrine gland, unspecified	Diagnosis	ICD-10-CM
C76.0	Malignant neoplasm of head, face and neck	Diagnosis	ICD-10-CM
C76.1	Malignant neoplasm of thorax	Diagnosis	ICD-10-CM
C76.2	Malignant neoplasm of abdomen	Diagnosis	ICD-10-CM
C76.3	Malignant neoplasm of pelvis	Diagnosis	ICD-10-CM
C76.40	Malignant neoplasm of unspecified upper limb	Diagnosis	ICD-10-CM
C76.41	Malignant neoplasm of right upper limb	Diagnosis	ICD-10-CM
C76.42	Malignant neoplasm of left upper limb	Diagnosis	ICD-10-CM
C76.50	Malignant neoplasm of unspecified lower limb	Diagnosis	ICD-10-CM
C76.51	Malignant neoplasm of right lower limb	Diagnosis	ICD-10-CM
C76.52	Malignant neoplasm of left lower limb	Diagnosis	ICD-10-CM
C76.8	Malignant neoplasm of other specified ill-defined sites	Diagnosis	ICD-10-CM
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck	Diagnosis	ICD-10-CM
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes	Diagnosis	ICD-10-CM
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes	Diagnosis	ICD-10-CM
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions	Diagnosis	ICD-10-CM
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified	Diagnosis	ICD-10-CM
C78.00	Secondary malignant neoplasm of unspecified lung	Diagnosis	ICD-10-CM
C78.01	Secondary malignant neoplasm of right lung	Diagnosis	ICD-10-CM
C78.02	Secondary malignant neoplasm of left lung	Diagnosis	ICD-10-CM
C78.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-10-CM
C78.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C78.30	Secondary malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM
C78.39	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-10-CM
C78.4	Secondary malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C78.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-10-CM
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct	Diagnosis	ICD-10-CM
C78.80	Secondary malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
C78.89	Secondary malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.10	Secondary malignant neoplasm of unspecified urinary organs	Diagnosis	ICD-10-CM
C79.11	Secondary malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C79.19	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-10-CM
C79.2	Secondary malignant neoplasm of skin	Diagnosis	ICD-10-CM
C79.31	Secondary malignant neoplasm of brain	Diagnosis	ICD-10-CM

C79.32	Secondary malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C79.40	Secondary malignant neoplasm of unspecified part of nervous system	Diagnosis	ICD-10-CM
C79.49	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-10-CM
C79.51	Secondary malignant neoplasm of bone	Diagnosis	ICD-10-CM
C79.52	Secondary malignant neoplasm of bone marrow	Diagnosis	ICD-10-CM
C79.60	Secondary malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C79.61	Secondary malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C79.62	Secondary malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C79.70	Secondary malignant neoplasm of unspecified adrenal gland	Diagnosis	ICD-10-CM
C79.71	Secondary malignant neoplasm of right adrenal gland	Diagnosis	ICD-10-CM
C79.72	Secondary malignant neoplasm of left adrenal gland	Diagnosis	ICD-10-CM
C79.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-10-CM
C79.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
C79.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.9	Secondary malignant neoplasm of unspecified site	Diagnosis	ICD-10-CM
C7A.00	Malignant carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
C7A.010	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
C7A.011	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM
C7A.012	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.020	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
C7A.021	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
C7A.022	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
C7A.023	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
C7A.024	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
C7A.025	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
C7A.026	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.090	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
C7A.091	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
C7A.092	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
C7A.093	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
C7A.094	Malignant carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
C7A.095	Malignant carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
C7A.098	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.1	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-10-CM
C7A.8	Other malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7B.00	Secondary carcinoid tumors, unspecified site	Diagnosis	ICD-10-CM
C7B.01	Secondary carcinoid tumors of distant lymph nodes	Diagnosis	ICD-10-CM
C7B.02	Secondary carcinoid tumors of liver	Diagnosis	ICD-10-CM
C7B.03	Secondary carcinoid tumors of bone	Diagnosis	ICD-10-CM
C7B.04	Secondary carcinoid tumors of peritoneum	Diagnosis	ICD-10-CM
C7B.09	Secondary carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7B.1	Secondary Merkel cell carcinoma	Diagnosis	ICD-10-CM
C7B.8	Other secondary neuroendocrine tumors	Diagnosis	ICD-10-CM
C80.0	Disseminated malignant neoplasm, unspecified	Diagnosis	ICD-10-CM

C80.1	Malignant (primary) neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-10-CM
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.27	Mixed cellularity Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM

C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.70	Other Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.71	Other Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.72	Other Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.73	Other Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.74	Other Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.75	Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.76	Other Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.77	Other Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.78	Other Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.79	Other Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.90	Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.97	Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.00	Follicular lymphoma grade I, unspecified site	Diagnosis	ICD-10-CM
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.07	Follicular lymphoma grade I, spleen	Diagnosis	ICD-10-CM
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.10	Follicular lymphoma grade II, unspecified site	Diagnosis	ICD-10-CM
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.17	Follicular lymphoma grade II, spleen	Diagnosis	ICD-10-CM
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.20	Follicular lymphoma grade III, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.27	Follicular lymphoma grade III, unspecified, spleen	Diagnosis	ICD-10-CM
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.30	Follicular lymphoma grade IIIa, unspecified site	Diagnosis	ICD-10-CM
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.37	Follicular lymphoma grade IIIa, spleen	Diagnosis	ICD-10-CM
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.40	Follicular lymphoma grade IIIb, unspecified site	Diagnosis	ICD-10-CM
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.47	Follicular lymphoma grade IIIb, spleen	Diagnosis	ICD-10-CM
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.50	Diffuse follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.57	Diffuse follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM

C82.60	Cutaneous follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.67	Cutaneous follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.80	Other types of follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.87	Other types of follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.90	Follicular lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.97	Follicular lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.00	Small cell B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.07	Small cell B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.10	Mantle cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM

C83.17	Mantle cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.19	Mantle cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.30	Diffuse large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.37	Diffuse large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.57	Lymphoblastic (diffuse) lymphoma, spleen	Diagnosis	ICD-10-CM
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.70	Burkitt lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.72	Burkitt lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.76	Burkitt lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.77	Burkitt lymphoma, spleen	Diagnosis	ICD-10-CM
C83.78	Burkitt lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.79	Burkitt lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.80	Other non-follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.87	Other non-follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.00	Mycosis fungoides, unspecified site	Diagnosis	ICD-10-CM
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.02	Mycosis fungoides, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.03	Mycosis fungoides, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.06	Mycosis fungoides, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.07	Mycosis fungoides, spleen	Diagnosis	ICD-10-CM
C84.08	Mycosis fungoides, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.09	Mycosis fungoides, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.10	Sezary disease, unspecified site	Diagnosis	ICD-10-CM
C84.11	Sezary disease, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.12	Sezary disease, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.13	Sezary disease, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.14	Sezary disease, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.16	Sezary disease, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.17	Sezary disease, spleen	Diagnosis	ICD-10-CM
C84.18	Sezary disease, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.19	Sezary disease, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.40	Peripheral T-cell lymphoma, not classified, unspecified site	Diagnosis	ICD-10-CM
C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.47	Peripheral T-cell lymphoma, not classified, spleen	Diagnosis	ICD-10-CM
C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site	Diagnosis	ICD-10-CM
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen	Diagnosis	ICD-10-CM

C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site	Diagnosis	ICD-10-CM
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen	Diagnosis	ICD-10-CM
C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen	Diagnosis	ICD-10-CM
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.A1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site	Diagnosis	ICD-10-CM
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.Z7	Other mature T/NK-cell lymphomas, spleen	Diagnosis	ICD-10-CM
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.10	Unspecified B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM

C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.17	Unspecified B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.87	Other specified types of non-Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.97	Non-Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C86.0	Extranodal NK/T-cell lymphoma, nasal type	Diagnosis	ICD-10-CM
C86.1	Hepatosplenic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.2	Enteropathy-type (intestinal) T-cell lymphoma	Diagnosis	ICD-10-CM
C86.3	Subcutaneous panniculitis-like T-cell lymphoma	Diagnosis	ICD-10-CM

C86.4	Blastic NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.5	Angioimmunoblastic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.6	Primary cutaneous CD30-positive T-cell proliferations	Diagnosis	ICD-10-CM
C88.2	Heavy chain disease	Diagnosis	ICD-10-CM
C88.3	Immunoproliferative small intestinal disease	Diagnosis	ICD-10-CM
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]	Diagnosis	ICD-10-CM
C88.8	Other malignant immunoproliferative diseases	Diagnosis	ICD-10-CM
C88.9	Malignant immunoproliferative disease, unspecified	Diagnosis	ICD-10-CM
C90.00	Multiple myeloma not having achieved remission	Diagnosis	ICD-10-CM
C90.01	Multiple myeloma in remission	Diagnosis	ICD-10-CM
C90.02	Multiple myeloma in relapse	Diagnosis	ICD-10-CM
C90.10	Plasma cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C90.11	Plasma cell leukemia in remission	Diagnosis	ICD-10-CM
C90.12	Plasma cell leukemia in relapse	Diagnosis	ICD-10-CM
C90.20	Extramedullary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.21	Extramedullary plasmacytoma in remission	Diagnosis	ICD-10-CM
C90.22	Extramedullary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C90.30	Solitary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.31	Solitary plasmacytoma in remission	Diagnosis	ICD-10-CM
C90.32	Solitary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C91.00	Acute lymphoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.01	Acute lymphoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C91.02	Acute lymphoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.11	Chronic lymphocytic leukemia of B-cell type in remission	Diagnosis	ICD-10-CM
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse	Diagnosis	ICD-10-CM
C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.31	Prolymphocytic leukemia of B-cell type, in remission	Diagnosis	ICD-10-CM
C91.32	Prolymphocytic leukemia of B-cell type, in relapse	Diagnosis	ICD-10-CM
C91.40	Hairy cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.41	Hairy cell leukemia, in remission	Diagnosis	ICD-10-CM
C91.42	Hairy cell leukemia, in relapse	Diagnosis	ICD-10-CM
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission	Diagnosis	ICD-10-CM
C91.51	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission	Diagnosis	ICD-10-CM
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse	Diagnosis	ICD-10-CM
C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.61	Prolymphocytic leukemia of T-cell type, in remission	Diagnosis	ICD-10-CM
C91.62	Prolymphocytic leukemia of T-cell type, in relapse	Diagnosis	ICD-10-CM
C91.90	Lymphoid leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C91.91	Lymphoid leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C91.92	Lymphoid leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission	Diagnosis	ICD-10-CM
C91.A1	Mature B-cell leukemia Burkitt-type, in remission	Diagnosis	ICD-10-CM
C91.A2	Mature B-cell leukemia Burkitt-type, in relapse	Diagnosis	ICD-10-CM
C91.Z0	Other lymphoid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.Z1	Other lymphoid leukemia, in remission	Diagnosis	ICD-10-CM

C91.Z2	Other lymphoid leukemia, in relapse	Diagnosis	ICD-10-CM
C92.00	Acute myeloblastic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.01	Acute myeloblastic leukemia, in remission	Diagnosis	ICD-10-CM
C92.02	Acute myeloblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission	Diagnosis	ICD-10-CM
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission	Diagnosis	ICD-10-CM
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse	Diagnosis	ICD-10-CM
C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission	Diagnosis	ICD-10-CM
C92.21	Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission	Diagnosis	ICD-10-CM
C92.22	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse	Diagnosis	ICD-10-CM
C92.30	Myeloid sarcoma, not having achieved remission	Diagnosis	ICD-10-CM
C92.31	Myeloid sarcoma, in remission	Diagnosis	ICD-10-CM
C92.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-10-CM
C92.40	Acute promyelocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.41	Acute promyelocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.42	Acute promyelocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.50	Acute myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.51	Acute myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.52	Acute myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission	Diagnosis	ICD-10-CM
C92.61	Acute myeloid leukemia with 11q23-abnormality in remission	Diagnosis	ICD-10-CM
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse	Diagnosis	ICD-10-CM
C92.90	Myeloid leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C92.91	Myeloid leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C92.92	Myeloid leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission	Diagnosis	ICD-10-CM
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission	Diagnosis	ICD-10-CM
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse	Diagnosis	ICD-10-CM
C92.Z0	Other myeloid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C92.Z1	Other myeloid leukemia, in remission	Diagnosis	ICD-10-CM
C92.Z2	Other myeloid leukemia, in relapse	Diagnosis	ICD-10-CM
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.01	Acute monoblastic/monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.02	Acute monoblastic/monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.10	Chronic myelomonocytic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C93.11	Chronic myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.12	Chronic myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.31	Juvenile myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.32	Juvenile myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.90	Monocytic leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C93.91	Monocytic leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C93.92	Monocytic leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C93.Z0	Other monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.Z1	Other monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.Z2	Other monocytic leukemia, in relapse	Diagnosis	ICD-10-CM

C94.00	Acute erythroid leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C94.01	Acute erythroid leukemia, in remission	Diagnosis	ICD-10-CM
C94.02	Acute erythroid leukemia, in relapse	Diagnosis	ICD-10-CM
C94.20	Acute megakaryoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.21	Acute megakaryoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C94.22	Acute megakaryoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.30	Mast cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.31	Mast cell leukemia, in remission	Diagnosis	ICD-10-CM
C94.32	Mast cell leukemia, in relapse	Diagnosis	ICD-10-CM
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission	Diagnosis	ICD-10-CM
C94.41	Acute panmyelosis with myelofibrosis, in remission	Diagnosis	ICD-10-CM
C94.42	Acute panmyelosis with myelofibrosis, in relapse	Diagnosis	ICD-10-CM
C94.6	Myelodysplastic disease, not classified	Diagnosis	ICD-10-CM
C94.80	Other specified leukemias not having achieved remission	Diagnosis	ICD-10-CM
C94.81	Other specified leukemias, in remission	Diagnosis	ICD-10-CM
C94.82	Other specified leukemias, in relapse	Diagnosis	ICD-10-CM
C95.00	Acute leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.01	Acute leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.10	Chronic leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.11	Chronic leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.90	Leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C95.91	Leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C95.92	Leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.20	Malignant mast cell neoplasm, unspecified	Diagnosis	ICD-10-CM
C96.21	Aggressive systemic mastocytosis	Diagnosis	ICD-10-CM
C96.22	Mast cell sarcoma	Diagnosis	ICD-10-CM
C96.29	Other malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.4	Sarcoma of dendritic cells (accessory cells)	Diagnosis	ICD-10-CM
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
C96.A	Histiocytic sarcoma	Diagnosis	ICD-10-CM
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D00.00	Carcinoma in situ of oral cavity, unspecified site	Diagnosis	ICD-10-CM
D00.01	Carcinoma in situ of labial mucosa and vermilion border	Diagnosis	ICD-10-CM
D00.02	Carcinoma in situ of buccal mucosa	Diagnosis	ICD-10-CM
D00.03	Carcinoma in situ of gingiva and edentulous alveolar ridge	Diagnosis	ICD-10-CM
D00.04	Carcinoma in situ of soft palate	Diagnosis	ICD-10-CM
D00.05	Carcinoma in situ of hard palate	Diagnosis	ICD-10-CM
D00.06	Carcinoma in situ of floor of mouth	Diagnosis	ICD-10-CM
D00.07	Carcinoma in situ of tongue	Diagnosis	ICD-10-CM
D00.08	Carcinoma in situ of pharynx	Diagnosis	ICD-10-CM
D00.1	Carcinoma in situ of esophagus	Diagnosis	ICD-10-CM
D00.2	Carcinoma in situ of stomach	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM

D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
D01.3	Carcinoma in situ of anus and anal canal	Diagnosis	ICD-10-CM
D01.40	Carcinoma in situ of unspecified part of intestine	Diagnosis	ICD-10-CM
D01.49	Carcinoma in situ of other parts of intestine	Diagnosis	ICD-10-CM
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D01.7	Carcinoma in situ of other specified digestive organs	Diagnosis	ICD-10-CM
D01.9	Carcinoma in situ of digestive organ, unspecified	Diagnosis	ICD-10-CM
D02.0	Carcinoma in situ of larynx	Diagnosis	ICD-10-CM
D02.1	Carcinoma in situ of trachea	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
D02.3	Carcinoma in situ of other parts of respiratory system	Diagnosis	ICD-10-CM
D02.4	Carcinoma in situ of respiratory system, unspecified	Diagnosis	ICD-10-CM
D03.0	Melanoma in situ of lip	Diagnosis	ICD-10-CM
D03.10	Melanoma in situ of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D03.11	Melanoma in situ of right eyelid, including canthus	Diagnosis	ICD-10-CM
D03.12	Melanoma in situ of left eyelid, including canthus	Diagnosis	ICD-10-CM
D03.20	Melanoma in situ of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
D03.21	Melanoma in situ of right ear and external auricular canal	Diagnosis	ICD-10-CM
D03.22	Melanoma in situ of left ear and external auricular canal	Diagnosis	ICD-10-CM
D03.30	Melanoma in situ of unspecified part of face	Diagnosis	ICD-10-CM
D03.39	Melanoma in situ of other parts of face	Diagnosis	ICD-10-CM
D03.4	Melanoma in situ of scalp and neck	Diagnosis	ICD-10-CM
D03.51	Melanoma in situ of anal skin	Diagnosis	ICD-10-CM
D03.52	Melanoma in situ of breast (skin) (soft tissue)	Diagnosis	ICD-10-CM
D03.59	Melanoma in situ of other part of trunk	Diagnosis	ICD-10-CM
D03.60	Melanoma in situ of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.61	Melanoma in situ of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.62	Melanoma in situ of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.70	Melanoma in situ of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
D03.71	Melanoma in situ of right lower limb, including hip	Diagnosis	ICD-10-CM
D03.72	Melanoma in situ of left lower limb, including hip	Diagnosis	ICD-10-CM
D03.8	Melanoma in situ of other sites	Diagnosis	ICD-10-CM
D03.9	Melanoma in situ, unspecified	Diagnosis	ICD-10-CM
D04.0	Carcinoma in situ of skin of lip	Diagnosis	ICD-10-CM
D04.10	Carcinoma in situ of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D04.11	Carcinoma in situ of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
D04.12	Carcinoma in situ of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
D04.20	Carcinoma in situ of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
D04.21	Carcinoma in situ of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
D04.22	Carcinoma in situ of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
D04.30	Carcinoma in situ of skin of unspecified part of face	Diagnosis	ICD-10-CM
D04.39	Carcinoma in situ of skin of other parts of face	Diagnosis	ICD-10-CM
D04.4	Carcinoma in situ of skin of scalp and neck	Diagnosis	ICD-10-CM
D04.5	Carcinoma in situ of skin of trunk	Diagnosis	ICD-10-CM
D04.60	Carcinoma in situ of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM

D04.61	Carcinoma in situ of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.62	Carcinoma in situ of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.70	Carcinoma in situ of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
D04.71	Carcinoma in situ of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
D04.72	Carcinoma in situ of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
D04.8	Carcinoma in situ of skin of other sites	Diagnosis	ICD-10-CM
D04.9	Carcinoma in situ of skin, unspecified	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D06.0	Carcinoma in situ of endocervix	Diagnosis	ICD-10-CM
D06.1	Carcinoma in situ of exocervix	Diagnosis	ICD-10-CM
D06.7	Carcinoma in situ of other parts of cervix	Diagnosis	ICD-10-CM
D06.9	Carcinoma in situ of cervix, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
D07.1	Carcinoma in situ of vulva	Diagnosis	ICD-10-CM
D07.2	Carcinoma in situ of vagina	Diagnosis	ICD-10-CM
D07.30	Carcinoma in situ of unspecified female genital organs	Diagnosis	ICD-10-CM
D07.39	Carcinoma in situ of other female genital organs	Diagnosis	ICD-10-CM
D07.4	Carcinoma in situ of penis	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
D07.60	Carcinoma in situ of unspecified male genital organs	Diagnosis	ICD-10-CM
D07.61	Carcinoma in situ of scrotum	Diagnosis	ICD-10-CM
D07.69	Carcinoma in situ of other male genital organs	Diagnosis	ICD-10-CM
D09.0	Carcinoma in situ of bladder	Diagnosis	ICD-10-CM
D09.10	Carcinoma in situ of unspecified urinary organ	Diagnosis	ICD-10-CM
D09.19	Carcinoma in situ of other urinary organs	Diagnosis	ICD-10-CM
D09.20	Carcinoma in situ of unspecified eye	Diagnosis	ICD-10-CM
D09.21	Carcinoma in situ of right eye	Diagnosis	ICD-10-CM
D09.22	Carcinoma in situ of left eye	Diagnosis	ICD-10-CM
D09.3	Carcinoma in situ of thyroid and other endocrine glands	Diagnosis	ICD-10-CM
D09.8	Carcinoma in situ of other specified sites	Diagnosis	ICD-10-CM
D09.9	Carcinoma in situ, unspecified	Diagnosis	ICD-10-CM
D25.0	Submucous leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.1	Intramural leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.2	Subserosal leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.9	Leiomyoma of uterus, unspecified	Diagnosis	ICD-10-CM
D37.01	Neoplasm of uncertain behavior of lip	Diagnosis	ICD-10-CM

D37.02	Neoplasm of uncertain behavior of tongue	Diagnosis	ICD-10-CM
D37.030	Neoplasm of uncertain behavior of the parotid salivary glands	Diagnosis	ICD-10-CM
D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands	Diagnosis	ICD-10-CM
D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands	Diagnosis	ICD-10-CM
D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified	Diagnosis	ICD-10-CM
D37.04	Neoplasm of uncertain behavior of the minor salivary glands	Diagnosis	ICD-10-CM
D37.05	Neoplasm of uncertain behavior of pharynx	Diagnosis	ICD-10-CM
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity	Diagnosis	ICD-10-CM
D37.1	Neoplasm of uncertain behavior of stomach	Diagnosis	ICD-10-CM
D37.2	Neoplasm of uncertain behavior of small intestine	Diagnosis	ICD-10-CM
D37.3	Neoplasm of uncertain behavior of appendix	Diagnosis	ICD-10-CM
D37.4	Neoplasm of uncertain behavior of colon	Diagnosis	ICD-10-CM
D37.5	Neoplasm of uncertain behavior of rectum	Diagnosis	ICD-10-CM
D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D37.8	Neoplasm of uncertain behavior of other specified digestive organs	Diagnosis	ICD-10-CM
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified	Diagnosis	ICD-10-CM
D38.0	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-10-CM
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	Diagnosis	ICD-10-CM
D38.2	Neoplasm of uncertain behavior of pleura	Diagnosis	ICD-10-CM
D38.3	Neoplasm of uncertain behavior of mediastinum	Diagnosis	ICD-10-CM
D38.4	Neoplasm of uncertain behavior of thymus	Diagnosis	ICD-10-CM
D38.5	Neoplasm of uncertain behavior of other respiratory organs	Diagnosis	ICD-10-CM
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified	Diagnosis	ICD-10-CM
D39.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-10-CM
D39.10	Neoplasm of uncertain behavior of unspecified ovary	Diagnosis	ICD-10-CM
D39.11	Neoplasm of uncertain behavior of right ovary	Diagnosis	ICD-10-CM
D39.12	Neoplasm of uncertain behavior of left ovary	Diagnosis	ICD-10-CM
D39.2	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-10-CM
D39.8	Neoplasm of uncertain behavior of other specified female genital organs	Diagnosis	ICD-10-CM
D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified	Diagnosis	ICD-10-CM
D3A.00	Benign carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
D3A.010	Benign carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
D3A.011	Benign carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM
D3A.012	Benign carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
D3A.019	Benign carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
D3A.020	Benign carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
D3A.021	Benign carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
D3A.022	Benign carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
D3A.023	Benign carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
D3A.024	Benign carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
D3A.025	Benign carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
D3A.026	Benign carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
D3A.029	Benign carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
D3A.090	Benign carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
D3A.091	Benign carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
D3A.092	Benign carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
D3A.093	Benign carcinoid tumor of the kidney	Diagnosis	ICD-10-CM

D3A.094	Benign carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
D3A.095	Benign carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
D3A.096	Benign carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
D3A.098	Benign carcinoid tumors of other sites	Diagnosis	ICD-10-CM
D3A.8	Other benign neuroendocrine tumors	Diagnosis	ICD-10-CM
D40.0	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-10-CM
D40.10	Neoplasm of uncertain behavior of unspecified testis	Diagnosis	ICD-10-CM
D40.11	Neoplasm of uncertain behavior of right testis	Diagnosis	ICD-10-CM
D40.12	Neoplasm of uncertain behavior of left testis	Diagnosis	ICD-10-CM
D40.8	Neoplasm of uncertain behavior of other specified male genital organs	Diagnosis	ICD-10-CM
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D41.3	Neoplasm of uncertain behavior of urethra	Diagnosis	ICD-10-CM
D41.4	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-10-CM
D41.8	Neoplasm of uncertain behavior of other specified urinary organs	Diagnosis	ICD-10-CM
D41.9	Neoplasm of uncertain behavior of unspecified urinary organ	Diagnosis	ICD-10-CM
D42.0	Neoplasm of uncertain behavior of cerebral meninges	Diagnosis	ICD-10-CM
D42.1	Neoplasm of uncertain behavior of spinal meninges	Diagnosis	ICD-10-CM
D42.9	Neoplasm of uncertain behavior of meninges, unspecified	Diagnosis	ICD-10-CM
D43.0	Neoplasm of uncertain behavior of brain, supratentorial	Diagnosis	ICD-10-CM
D43.1	Neoplasm of uncertain behavior of brain, infratentorial	Diagnosis	ICD-10-CM
D43.2	Neoplasm of uncertain behavior of brain, unspecified	Diagnosis	ICD-10-CM
D43.3	Neoplasm of uncertain behavior of cranial nerves	Diagnosis	ICD-10-CM
D43.4	Neoplasm of uncertain behavior of spinal cord	Diagnosis	ICD-10-CM
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system	Diagnosis	ICD-10-CM
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified	Diagnosis	ICD-10-CM
D44.0	Neoplasm of uncertain behavior of thyroid gland	Diagnosis	ICD-10-CM
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland	Diagnosis	ICD-10-CM
D44.11	Neoplasm of uncertain behavior of right adrenal gland	Diagnosis	ICD-10-CM
D44.12	Neoplasm of uncertain behavior of left adrenal gland	Diagnosis	ICD-10-CM
D44.2	Neoplasm of uncertain behavior of parathyroid gland	Diagnosis	ICD-10-CM
D44.3	Neoplasm of uncertain behavior of pituitary gland	Diagnosis	ICD-10-CM
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct	Diagnosis	ICD-10-CM
D44.5	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-10-CM
D44.6	Neoplasm of uncertain behavior of carotid body	Diagnosis	ICD-10-CM
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia	Diagnosis	ICD-10-CM
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland	Diagnosis	ICD-10-CM
D45	Polycythemia vera	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM

D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.01	Cutaneous mastocytosis	Diagnosis	ICD-10-CM
D47.02	Systemic mastocytosis	Diagnosis	ICD-10-CM
D47.09	Other mast cell neoplasms of uncertain behavior	Diagnosis	ICD-10-CM
D47.1	Chronic myeloproliferative disease	Diagnosis	ICD-10-CM
D47.3	Essential (hemorrhagic) thrombocythemia	Diagnosis	ICD-10-CM
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)	Diagnosis	ICD-10-CM
D47.Z2	Castleman disease	Diagnosis	ICD-10-CM
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-10-CM
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-10-CM
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
D48.3	Neoplasm of uncertain behavior of retroperitoneum	Diagnosis	ICD-10-CM
D48.4	Neoplasm of uncertain behavior of peritoneum	Diagnosis	ICD-10-CM
D48.5	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-10-CM
D48.60	Neoplasm of uncertain behavior of unspecified breast	Diagnosis	ICD-10-CM
D48.61	Neoplasm of uncertain behavior of right breast	Diagnosis	ICD-10-CM
D48.62	Neoplasm of uncertain behavior of left breast	Diagnosis	ICD-10-CM
D48.7	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-10-CM
D48.9	Neoplasm of uncertain behavior, unspecified	Diagnosis	ICD-10-CM
D49.0	Neoplasm of unspecified behavior of digestive system	Diagnosis	ICD-10-CM
D49.1	Neoplasm of unspecified behavior of respiratory system	Diagnosis	ICD-10-CM
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin	Diagnosis	ICD-10-CM
D49.3	Neoplasm of unspecified behavior of breast	Diagnosis	ICD-10-CM
D49.4	Neoplasm of unspecified behavior of bladder	Diagnosis	ICD-10-CM
D49.511	Neoplasm of unspecified behavior of right kidney	Diagnosis	ICD-10-CM
D49.512	Neoplasm of unspecified behavior of left kidney	Diagnosis	ICD-10-CM
D49.519	Neoplasm of unspecified behavior of unspecified kidney	Diagnosis	ICD-10-CM
D49.59	Neoplasm of unspecified behavior of other genitourinary organ	Diagnosis	ICD-10-CM
D49.6	Neoplasm of unspecified behavior of brain	Diagnosis	ICD-10-CM
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system	Diagnosis	ICD-10-CM
D49.81	Neoplasm of unspecified behavior of retina and choroid	Diagnosis	ICD-10-CM
D49.89	Neoplasm of unspecified behavior of other specified sites	Diagnosis	ICD-10-CM

D49.9	Neoplasm of unspecified behavior of unspecified site	Diagnosis	ICD-10-CM
Q85.00	Neurofibromatosis, unspecified	Diagnosis	ICD-10-CM
Q85.01	Neurofibromatosis, type 1	Diagnosis	ICD-10-CM
Q85.02	Neurofibromatosis, type 2	Diagnosis	ICD-10-CM
Q85.03	Schwannomatosis	Diagnosis	ICD-10-CM
Q85.09	Other neurofibromatosis	Diagnosis	ICD-10-CM

Radiation

55859	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4
55860	Exposure of prostate, any approach, for insertion of radioactive substance;	Procedure	CPT-4
55862	Exposure of prostate, any approach, for insertion of radioactive substance; with lymph node biopsy(s) (limited pelvic lymphadenectomy)	Procedure	CPT-4
55865	Exposure of prostate, any approach, for insertion of radioactive substance; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes	Procedure	CPT-4
55875	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4
76950	Ultrasonic guidance for placement of radiation therapy fields	Procedure	CPT-4
76960	Ultrasonic guidance for placement of radiation therapy fields, except for B-scan echography	Procedure	CPT-4
77280	Therapeutic radiology simulation-aided field setting; simple	Procedure	CPT-4
77285	Therapeutic radiology simulation-aided field setting; intermediate	Procedure	CPT-4
77290	Therapeutic radiology simulation-aided field setting; complex	Procedure	CPT-4
77295	3-dimensional radiotherapy plan, including dose-volume histograms	Procedure	CPT-4
77299	Unlisted procedure, therapeutic radiology clinical treatment planning	Procedure	CPT-4
77300	Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician	Procedure	CPT-4
77305	Teletherapy, isodose plan (whether hand or computer calculated); simple (1 or 2 parallel opposed unmodified ports directed to a single area of interest)	Procedure	CPT-4
77310	Teletherapy, isodose plan (whether hand or computer calculated); intermediate (3 or more treatment ports directed to a single area of interest)	Procedure	CPT-4
77315	Teletherapy, isodose plan (whether hand or computer calculated); complex (mantle or inverted Y, tangential ports, the use of wedges, compensators, complex blocking, rotational beam, or special beam considerations)	Procedure	CPT-4
77321	Special teletherapy port plan, particles, hemibody, total body	Procedure	CPT-4
77326	Brachytherapy isodose plan; simple (calculation made from single plane, 1 to 4 sources/ribbon application, remote afterloading brachytherapy, 1 to 8 sources)	Procedure	CPT-4
77327	Brachytherapy isodose plan; intermediate (multiplane dosage calculations, application involving 5 to 10 sources/ribbons, remote afterloading brachytherapy, 9 to 12 sources)	Procedure	CPT-4
77328	Brachytherapy isodose plan; complex (multiplane isodose plan, volume implant calculations, over 10 sources/ribbons used, special spatial reconstruction, remote afterloading brachytherapy, over 12 sources)	Procedure	CPT-4
77401	Radiation treatment delivery, superficial and/or ortho voltage, per day	Procedure	CPT-4
77402	Radiation treatment delivery, >=1 MeV; simple	Procedure	CPT-4

77403	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 6-10 MeV	Procedure	CPT-4
77404	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 11-19 MeV	Procedure	CPT-4
77406	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 20 MeV or greater	Procedure	CPT-4
77407	Radiation treatment delivery, =>1 MeV; intermediate	Procedure	CPT-4
77408	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 6-10 MeV	Procedure	CPT-4
77409	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 11-19 MeV	Procedure	CPT-4
77411	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 20 MeV or greater	Procedure	CPT-4
77412	Radiation treatment delivery, =>1 MeV; complex	Procedure	CPT-4
77413	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV	Procedure	CPT-4
77414	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV	Procedure	CPT-4
77416	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater	Procedure	CPT-4
77427	Radiation treatment management, 5 treatments	Procedure	CPT-4
77432	Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)	Procedure	CPT-4
77469	Intraoperative radiation treatment management	Procedure	CPT-4
77470	Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)	Procedure	CPT-4
77499	Unlisted procedure, therapeutic radiology treatment management	Procedure	CPT-4
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)	Procedure	CPT-4
77761	Intracavitary radiation source application; simple	Procedure	CPT-4
77762	Intracavitary radiation source application; intermediate	Procedure	CPT-4
77763	Intracavitary radiation source application; complex	Procedure	CPT-4
77776	Interstitial radiation source application; simple	Procedure	CPT-4
77777	Interstitial radiation source application; intermediate	Procedure	CPT-4
77778	Interstitial radiation source application; complex	Procedure	CPT-4
77781	Remote afterloading high intensity brachytherapy; 1-4 source positions or catheters	Procedure	CPT-4
77782	Remote afterloading high intensity brachytherapy; 5-8 source positions or catheters	Procedure	CPT-4
77783	Remote afterloading high intensity brachytherapy; 9-12 source positions or catheters	Procedure	CPT-4
77784	Remote afterloading high intensity brachytherapy; over 12 source positions or catheters	Procedure	CPT-4
77785	Remote afterloading high dose rate radionuclide brachytherapy; 1 channel	Procedure	CPT-4
77786	Remote afterloading high dose rate radionuclide brachytherapy; 2-12 channels	Procedure	CPT-4
77787	Remote afterloading high dose rate radionuclide brachytherapy; over 12 channels	Procedure	CPT-4
77789	Surface application of low dose rate radionuclide source	Procedure	CPT-4
77799	Unlisted procedure, clinical brachytherapy	Procedure	CPT-4



79005	Radiopharmaceutical therapy, by oral administration	Procedure	CPT-4
79101	Radiopharmaceutical therapy, by intravenous administration	Procedure	CPT-4
79200	Radiopharmaceutical therapy, by intracavitary administration	Procedure	CPT-4
79300	Radiopharmaceutical therapy, by interstitial radioactive colloid administration	Procedure	CPT-4
79400	Radiopharmaceutical therapy, nonthyroid, nonhematologic by intervenous injection	Procedure	CPT-4
79403	Radiopharmaceutical therapy, radiolabeled monoclonal antibody by intravenous infusion	Procedure	CPT-4
79420	Intravascular radiopharmaceutical therapy, particulate	Procedure	CPT-4
79440	Radiopharmaceutical therapy, by intra-articular administration	Procedure	CPT-4
79900	Provision of therapeutic radiopharmaceutical(s)	Procedure	CPT-4
79999	Radiopharmaceutical therapy, unlisted procedure	Procedure	CPT-4

Appendix F. List of Generic and Brand Drug Names Used to Define Censoring Criteria in this Request

Generic Name	Brand Name
Aldesleukin	Proleukin
Alemtuzumab	Campath
Alemtuzumab	Lemtrada
Altretamine	Hexalen
Arsenic trioxide	Arsenic Trioxide
Arsenic trioxide	Trisenox
Asparaginase	Elspar
Asparaginase (Erwinia chrysanthemi)	Erwinaze
Azacitidine	Azacitidine
Azacitidine	Vidaza
Bendamustine HCl	Bendamustine
Bendamustine HCl	Bendeka
Bendamustine HCl	Treanda
Bevacizumab	Avastin
Bevacizumab	Bevacizumab
Bexarotene	Bexarotene
Bexarotene	Targretin
Bleomycin sulfate	Blenoxane
Bleomycin sulfate	Bleo 15k
Bleomycin sulfate	Bleomycin
Bortezomib	Bortezomib
Bortezomib	Velcade
Brentuximab vedotin	Adcetris
Busulfan	Busulfan
Busulfan	Busulfex
Busulfan	Myleran
Cabazitaxel	Jevtana
Capecitabine	Capecitabine
Capecitabine	Xeloda
Carboplatin	Carboplatin
Carboplatin	Paraplatin
Carfilzomib	Kyprolis
Carmustine	Bicnu
Carmustine	Carmustine
Carmustine in polifeprosan 20	Gliadel Wafer
Cetuximab	Erbitux
Chlorambucil	Leukeran
Cisplatin	Cisplatin
Cisplatin	Platinol AQ
Cladribine	Cladribine
Cladribine	Leustatin
Clindamycin phosphate/tretinoin	Clindamycin-Tretinoin
Clindamycin phosphate/tretinoin	Veltin
Clindamycin phosphate/tretinoin	Ziana
Clofarabine	Clofarabine

Appendix F. List of Generic and Brand Drug Names Used to Define Censoring Criteria in this Request

Generic Name	Brand Name
Clofarabine	Clolar
Cyclophosphamide	Cyclophosphamide
Cyclophosphamide	Cytoxan
Cyclophosphamide	Cytoxan Lyophilized
Cyclophosphamide	Neosar
Cytarabine	Cytarabine
Cytarabine	Cytosar-U
Cytarabine	Tarabine PFS
Cytarabine liposome/PF	Depocyt (PF)
Cytarabine/PF	Cytarabine (PF)
Dacarbazine	Dacarbazine
Dacarbazine	Dtic-Dome
Dactinomycin	Cosmegen
Dactinomycin	Dactinomycin
Dasatinib	Sprycel
Daunorubicin citrate liposomal	Daunoxome
Daunorubicin HCl	Cerubidine
Daunorubicin HCl	Daunorubicin
Daunorubicin/cytarabine liposomal	Vyxeos
Decitabine	Dacogen
Decitabine	Decitabine
Denileukin diftitox	Ontak
Diluent for ixabepilone (castor oil/alcohol)	Diluent For Ixempra (15 Mg)
Diluent for ixabepilone (castor oil/alcohol)	Diluent For Ixempra (45 Mg)
Docetaxel	Docefrez
Docetaxel	Docetaxel
Docetaxel	Taxotere
Doxorubicin HCl	Adriamycin
Doxorubicin HCl	Adriamycin PFS
Doxorubicin HCl	Adriamycin Rdf
Doxorubicin HCl	Doxorubicin
Doxorubicin HCl	Rubex
Doxorubicin HCl pegylated liposomal	Doxil
Doxorubicin HCl pegylated liposomal	Doxorubicin, Peg-Liposomal
Doxorubicin HCl pegylated liposomal	Lipodox
Doxorubicin HCl pegylated liposomal	Lipodox 50
Epirubicin HCl	Ellence
Epirubicin HCl	Epirubicin
Eribulin mesylate	Halaven
Erlotinib HCl	Tarceva
Estramustine phosphate sodium	Emcyt
Etoposide	Etoposide
Etoposide	Toposar
Etoposide	Vepesid
Etoposide phosphate	Etopophos

Appendix F. List of Generic and Brand Drug Names Used to Define Censoring Criteria in this Request

Generic Name	Brand Name
Everolimus	Afinitor
Everolimus	Afinitor Disperz
Everolimus	Zortress
Floxuridine	Floxuridine
Floxuridine	Fudr
Fludarabine phosphate	Fludara
Fludarabine phosphate	Fludarabine
Fludarabine phosphate	Oforta
Fluocinolone acetonide/tretinoin/hydroquinone	Tri-Luma
Fluorouracil	Adrucil
Fluorouracil	Fluorouracil
Gefitinib	Iressa
Gemcitabine HCl	Gemcitabine
Gemcitabine HCl	Gemzar
Gemtuzumab ozogamicin	Mylotarg
Ibrutinib	Imbruvica
Idarubicin HCl	Idamycin
Idarubicin HCl	Idamycin PFS
Idarubicin HCl	Idarubicin
Ifosfamide	Ifex
Ifosfamide	Ifosfamide
Ifosfamide/mesna	Ifex/Mesnex
Ifosfamide/mesna	Ifosfamide-Mesna
Imatinib mesylate	Gleevec
Imatinib mesylate	Imatinib
Ipilimumab	Yervoy
Irinotecan HCl	Camptosar
Irinotecan HCl	Irinotecan
Irinotecan liposomal	Onivyde
Isotretinoin	Absorica
Isotretinoin	Accutane
Isotretinoin	Amnesteem
Isotretinoin	Claravis
Isotretinoin	Isotretinoin
Isotretinoin	Myorisan
Isotretinoin	Sotret
Isotretinoin	Zenatane
Ixabepilone	Ixempra
Lapatinib ditosylate	Tykerb
Lomustine	Ceenu
Lomustine	Gleostine
Lomustine	Lomustine
Mechlorethamine HCl	Mustargen
Melphalan	Alkeran
Melphalan	Melphalan

Appendix F. List of Generic and Brand Drug Names Used to Define Censoring Criteria in this Request

Generic Name	Brand Name
Melphalan HCl	Alkeran
Melphalan HCl	Melphalan HCl
Melphalan HCl/betadex sulfobutyl ether sodium	Evomela
Mercaptopurine	Mercaptopurine
Mercaptopurine	Purinethol
Mercaptopurine	Purixan
Methotrexate	Xatmep
Methotrexate sodium	Methotrexate (Anti-Rheumatic)
Methotrexate sodium	Methotrexate Sodium
Methotrexate sodium	Rheumatrex
Methotrexate sodium	Trexall
Methotrexate sodium/PF	Methotrexate LPF
Methotrexate sodium/PF	Methotrexate Sodium (PF)
Methotrexate/PF	Otrexup (PF)
Methotrexate/PF	Rasuvo (PF)
Mitomycin	Mitomycin
Mitomycin	Mitosol
Mitomycin	Mutamycin
Mitotane	Lysodren
Mitoxantrone HCl	Mitoxantrone
Mitoxantrone HCl	Novantrone
Nelarabine	Arranon
Nilotinib HCl	Tasigna
Obinutuzumab	Gazyva
Ofatumumab	Arzerra
Omacetaxine mepesuccinate	Synribo
Oxaliplatin	Eloxatin
Oxaliplatin	Oxaliplatin
Paclitaxel	Onxol
Paclitaxel	Paclitaxel
Paclitaxel	Taxol
Paclitaxel protein-bound	Abraxane
Panitumumab	Vectibix
Pazopanib HCl	Votrient
Pegaspargase	Oncaspar
Pemetrexed disodium	Alimta
Pentostatin	Nipent
Pentostatin	Pentostatin
Pertuzumab	Perjeta
Plicamycin	Mithracin
Pomalidomide	Pomalyst
Ponatinib HCl	Iclusig
Pralatrexate	Folotyng
Procarbazine HCl	Matulane
Rituximab	Rituxan

Appendix F. List of Generic and Brand Drug Names Used to Define Censoring Criteria in this Request

Generic Name	Brand Name
Rituximab/hyaluronidase, human recombinant	Rituxan Hycela
Romidepsin	Istodax
Romidepsin	Romidepsin
Sipuleucel-t/lactated ringers solution	Provenge
Sorafenib tosylate	Nexavar
Streptozocin	Zanosar
Sunitinib malate	Sutent
Temozolomide	Temodar
Temozolomide	Temozolomide
Temsirolimus	Temsirolimus
Temsirolimus	Torisel
Teniposide	Teniposide
Teniposide	Vumon
Thioguanine	Tabloid
Thiotepa	Tepadina
Thiotepa	Thioplex
Thiotepa	Thiotepa
Topotecan HCl	Hycamtin
Topotecan HCl	Topotecan
Tositumomab iodine-131 (with maltose)	Bexxar 131 Iodine
Tretinoin	Altinac
Tretinoin	Altreno
Tretinoin	Atralin
Tretinoin	Avita
Tretinoin	Retin-A
Tretinoin	Tretinoin
Tretinoin	Tretinoin (Chemotherapy)
Tretinoin	Tretin-X
Tretinoin	Vesanoid
Tretinoin microspheres	Retin-A Micro
Tretinoin microspheres	Retin-A Micro Pump
Tretinoin microspheres	Tretinoin Microspheres
Tretinoin/emollient base	Refissa
Tretinoin/emollient base	Renova
Tretinoin/emollient base	Tretinoin (Emollient)
Tretinoin/emollient combination no.9/skin cleanser no.1	Tretin-X Cream Kit
Tretinoin/emollient combination no.9/skin cleanser no.1/gel	Tretin-X (Gel)
Tretinoin/menthol/zinc oxide/silicone, adhesive	Dermapak Plus
Tretinoin/mequinol	Solage
Vinblastine sulfate	Velban
Vinblastine sulfate	Vinblastine
Vincristine sulfate	Oncovin
Vincristine sulfate	Vincasar PFS
Vincristine sulfate	Vincristine
Vincristine sulfate liposomal	Marqibo

Appendix F. List of Generic and Brand Drug Names Used to Define Censoring Criteria in this Request

Generic Name	Brand Name
Vinorelbine tartrate	Navelbine
Vinorelbine tartrate	Vinorelbine
Vorinostat	Zolanza

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
L57.0	Actinic keratosis	Diagnosis	ICD-10-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
O35.4XX0	Maternal care for (suspected) damage to fetus from alcohol, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.4XX1	Maternal care for (suspected) damage to fetus from alcohol, fetus 1	Diagnosis	ICD-10-CM
O35.4XX2	Maternal care for (suspected) damage to fetus from alcohol, fetus 2	Diagnosis	ICD-10-CM
O35.4XX3	Maternal care for (suspected) damage to fetus from alcohol, fetus 3	Diagnosis	ICD-10-CM
O35.4XX4	Maternal care for (suspected) damage to fetus from alcohol, fetus 4	Diagnosis	ICD-10-CM
O35.4XX5	Maternal care for (suspected) damage to fetus from alcohol, fetus 5	Diagnosis	ICD-10-CM
O35.4XX9	Maternal care for (suspected) damage to fetus from alcohol, other fetus	Diagnosis	ICD-10-CM
P04.3	Newborn affected by maternal use of alcohol	Diagnosis	ICD-10-CM
Q86.0	Fetal alcohol syndrome (dysmorphic)	Diagnosis	ICD-10-CM
T57.0	Toxic effect of arsenic and its compounds	Diagnosis	ICD-10-CM
T57.0X	Toxic effect of arsenic and its compounds	Diagnosis	ICD-10-CM
T57.0X1	Toxic effect of arsenic and its compounds, accidental (unintentional)	Diagnosis	ICD-10-CM
T57.0X1A	Toxic effect of arsenic and its compounds, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T57.0X1D	Toxic effect of arsenic and its compounds, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T57.0X1S	Toxic effect of arsenic and its compounds, accidental (unintentional), sequela	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T57.0X2	Toxic effect of arsenic and its compounds, intentional self-harm	Diagnosis	ICD-10-CM
T57.0X2A	Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T57.0X2D	Toxic effect of arsenic and its compounds, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T57.0X2S	Toxic effect of arsenic and its compounds, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T57.0X3	Toxic effect of arsenic and its compounds, assault	Diagnosis	ICD-10-CM
T57.0X3A	Toxic effect of arsenic and its compounds, assault, initial encounter	Diagnosis	ICD-10-CM
T57.0X3D	Toxic effect of arsenic and its compounds, assault, subsequent encounter	Diagnosis	ICD-10-CM
T57.0X3S	Toxic effect of arsenic and its compounds, assault, sequela	Diagnosis	ICD-10-CM
T57.0X4	Toxic effect of arsenic and its compounds, undetermined	Diagnosis	ICD-10-CM
T57.0X4A	Toxic effect of arsenic and its compounds, undetermined, initial encounter	Diagnosis	ICD-10-CM
T57.0X4D	Toxic effect of arsenic and its compounds, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T57.0X4S	Toxic effect of arsenic and its compounds, undetermined, sequela	Diagnosis	ICD-10-CM
Z77.010	Contact with and (suspected) exposure to arsenic	Diagnosis	ICD-10-CM
E1010	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E1011	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E1021	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E1022	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E1029	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10319	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E103211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E103212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E103213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E103219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E103291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E103292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E103293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E103299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E103311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E103312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E103313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E103319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E103391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E103392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E103393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E103399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E103411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E103412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E103413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E103419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E103491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E103492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E103493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E103499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E103511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E103512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E103513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E103519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E103521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E103522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E103523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E103529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E103531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E103532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E103533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E103539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E103541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E103542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E103543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E103549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E103551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E103552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E103553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E103559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E103591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E103592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E103593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E103599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E1036	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E1037X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E1037X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E1037X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E1037X9	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E1039	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E1040	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E1041	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E1042	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E1043	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E1044	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E1049	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E1051	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E1052	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E1059	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10620	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10621	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10622	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10628	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10638	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10649	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E1065	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E1069	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E108	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E109	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
O24.414	Gestational diabetes mellitus in pregnancy, insulin controlled	Diagnosis	ICD-10-CM
O24.415	Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.419	Gestational diabetes mellitus in pregnancy, unspecified control	Diagnosis	ICD-10-CM
O24.425	Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
O24.429	Gestational diabetes mellitus in childbirth, unspecified control	Diagnosis	ICD-10-CM
O24.434	Gestational diabetes mellitus in the puerperium, insulin controlled	Diagnosis	ICD-10-CM
O24.435	Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs	Diagnosis	ICD-10-CM
O24.439	Gestational diabetes mellitus in the puerperium, unspecified control	Diagnosis	ICD-10-CM
O24011	Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24012	Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24013	Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24019	Pre-existing type 1 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O2402	Pre-existing type 1 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
O2403	Pre-existing type 1 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
O24111	Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24112	Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24113	Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24119	Pre-existing type 2 diabetes mellitus, in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O2412	Pre-existing type 2 diabetes mellitus, in childbirth	Diagnosis	ICD-10-CM
O2413	Pre-existing type 2 diabetes mellitus, in the puerperium	Diagnosis	ICD-10-CM
O24311	Unspecified pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24312	Unspecified pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24313	Unspecified pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24319	Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O2432	Unspecified pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O2433	Unspecified pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24811	Other pre-existing diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24812	Other pre-existing diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24813	Other pre-existing diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24819	Other pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O2482	Other pre-existing diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O2483	Other pre-existing diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
O24911	Unspecified diabetes mellitus in pregnancy, first trimester	Diagnosis	ICD-10-CM
O24912	Unspecified diabetes mellitus in pregnancy, second trimester	Diagnosis	ICD-10-CM
O24913	Unspecified diabetes mellitus in pregnancy, third trimester	Diagnosis	ICD-10-CM
O24919	Unspecified diabetes mellitus in pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O2492	Unspecified diabetes mellitus in childbirth	Diagnosis	ICD-10-CM
O2493	Unspecified diabetes mellitus in the puerperium	Diagnosis	ICD-10-CM
B97.7	Papillomavirus as the cause of diseases classified elsewhere	Diagnosis	ICD-10-CM
R87.81	High risk human papillomavirus (HPV) DNA test positive from female genital organs	Diagnosis	ICD-10-CM
R87.810	Cervical high risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-10-CM
R87.811	Vaginal high risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-10-CM
R87.82	Low risk human papillomavirus (HPV) DNA test positive from female genital organs	Diagnosis	ICD-10-CM
R87.820	Cervical low risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
R87.821	Vaginal low risk human papillomavirus (HPV) DNA test positive	Diagnosis	ICD-10-CM
T86.10	Unspecified complication of kidney transplant	Diagnosis	ICD-10-CM
T86.11	Kidney transplant rejection	Diagnosis	ICD-10-CM
T86.12	Kidney transplant failure	Diagnosis	ICD-10-CM
T86.20	Unspecified complication of heart transplant	Diagnosis	ICD-10-CM
T86.21	Heart transplant rejection	Diagnosis	ICD-10-CM
T86.22	Heart transplant failure	Diagnosis	ICD-10-CM
T86.40	Unspecified complication of liver transplant	Diagnosis	ICD-10-CM
T86.41	Liver transplant rejection	Diagnosis	ICD-10-CM
T86.42	Liver transplant failure	Diagnosis	ICD-10-CM
Z94.0	Kidney transplant status	Diagnosis	ICD-10-CM
Z94.1	Heart transplant status	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Z94.81	Bone marrow transplant status	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44	Other chronic obstructive pulmonary disease	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
L40.52	Psoriatic arthritis mutilans	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M04.2	Cryopyrin-associated periodic syndromes	Diagnosis	ICD-10-CM
M04.8	Other autoinflammatory syndromes	Diagnosis	ICD-10-CM
M04.9	Autoinflammatory syndrome, unspecified	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M35.1	Other overlap syndromes	Diagnosis	ICD-10-CM
M35.3	Polymyalgia rheumatica	Diagnosis	ICD-10-CM
M35.5	Multifocal fibrosclerosis	Diagnosis	ICD-10-CM
M35.8	Other specified systemic involvement of connective tissue	Diagnosis	ICD-10-CM
M35.9	Systemic involvement of connective tissue, unspecified	Diagnosis	ICD-10-CM
M36.8	Systemic disorders of connective tissue in other diseases classified elsewhere	Diagnosis	ICD-10-CM
A48.0	Gas gangrene	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
122.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
122.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
122.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
122.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
150.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
150.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
150.811	Acute right heart failure	Diagnosis	ICD-10-CM
150.812	Chronic right heart failure	Diagnosis	ICD-10-CM
150.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
150.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
150.82	Biventricular heart failure	Diagnosis	ICD-10-CM
150.83	High output heart failure	Diagnosis	ICD-10-CM
150.84	End stage heart failure	Diagnosis	ICD-10-CM
150.89	Other heart failure	Diagnosis	ICD-10-CM
150.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
161.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
161.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
161.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
161.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
161.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
161.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
161.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
161.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
161.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
163.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
163.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
163.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
163.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
163.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
163.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
163.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
163.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
163.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
163.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
163.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
163.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
163.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
163.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
163.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
163.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
163.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
163.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
163.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
163.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
163.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
163.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
163.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
163.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
163.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
163.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
163.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
163.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
163.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
163.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
163.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
163.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
163.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
163.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
163.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
163.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
163.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
163.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
163.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
163.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
163.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
163.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
163.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
163.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
163.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
163.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
163.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
163.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
163.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
163.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
163.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
163.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
163.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
163.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
163.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
163.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
163.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
163.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
163.8	Other cerebral infarction	Diagnosis	ICD-10-CM
163.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
165.01	Occlusion and stenosis of right vertebral artery	Diagnosis	ICD-10-CM
165.02	Occlusion and stenosis of left vertebral artery	Diagnosis	ICD-10-CM
165.03	Occlusion and stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
165.09	Occlusion and stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
165.1	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CM
165.21	Occlusion and stenosis of right carotid artery	Diagnosis	ICD-10-CM
165.22	Occlusion and stenosis of left carotid artery	Diagnosis	ICD-10-CM
165.23	Occlusion and stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
165.29	Occlusion and stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
165.8	Occlusion and stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
165.9	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
166.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I70.231	Atherosclerosis of native arteries of right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.232	Atherosclerosis of native arteries of right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.233	Atherosclerosis of native arteries of right leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.235	Atherosclerosis of native arteries of right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.238	Atherosclerosis of native arteries of right leg with ulceration of other part of lower right leg	Diagnosis	ICD-10-CM
I70.239	Atherosclerosis of native arteries of right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.241	Atherosclerosis of native arteries of left leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.242	Atherosclerosis of native arteries of left leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.243	Atherosclerosis of native arteries of left leg with ulceration of ankle	Diagnosis	ICD-10-CM
I70.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
I70.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
I70.248	Atherosclerosis of native arteries of left leg with ulceration of other part of lower left leg	Diagnosis	ICD-10-CM
I70.249	Atherosclerosis of native arteries of left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
I70.331	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
I70.332	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
I70.333	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
170.334	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.335	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.338	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.339	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.341	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.342	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.343	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.344	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.345	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.348	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.349	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.361	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.362	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.363	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.368	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.369	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.431	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.432	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.433	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.434	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
170.435	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.438	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.439	Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.441	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.442	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.443	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.444	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.445	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.448	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.449	Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.461	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.462	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.463	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.468	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.469	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.531	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.532	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.533	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.534	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.535	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
170.538	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.539	Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.541	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.542	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.543	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.544	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.545	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.548	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.549	Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.561	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.562	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.563	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.568	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.569	Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.631	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.632	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.633	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.634	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.635	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.638	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
170.639	Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.641	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.642	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.643	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.644	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.645	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.648	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.649	Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.661	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.662	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.663	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.668	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.669	Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
170.731	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.732	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf	Diagnosis	ICD-10-CM
170.733	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.734	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.735	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.738	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.739	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
170.741	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh	Diagnosis	ICD-10-CM
170.742	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf	Diagnosis	ICD-10-CM
170.743	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle	Diagnosis	ICD-10-CM
170.744	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot	Diagnosis	ICD-10-CM
170.745	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot	Diagnosis	ICD-10-CM
170.748	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg	Diagnosis	ICD-10-CM
170.749	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site	Diagnosis	ICD-10-CM
170.761	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg	Diagnosis	ICD-10-CM
170.762	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg	Diagnosis	ICD-10-CM
170.763	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs	Diagnosis	ICD-10-CM
170.768	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity	Diagnosis	ICD-10-CM
170.769	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity	Diagnosis	ICD-10-CM
172.4	Aneurysm of artery of lower extremity	Diagnosis	ICD-10-CM
173.01	Raynaud's syndrome with gangrene	Diagnosis	ICD-10-CM
173.9	Peripheral vascular disease, unspecified	Diagnosis	ICD-10-CM
174.3	Embolism and thrombosis of arteries of the lower extremities	Diagnosis	ICD-10-CM
174.4	Embolism and thrombosis of arteries of extremities, unspecified	Diagnosis	ICD-10-CM
179.1	Aortitis in diseases classified elsewhere	Diagnosis	ICD-10-CM
179.8	Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere	Diagnosis	ICD-10-CM
I96	Gangrene, not elsewhere classified	Diagnosis	ICD-10-CM
L97.101	Non-pressure chronic ulcer of unspecified thigh limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.102	Non-pressure chronic ulcer of unspecified thigh with fat layer exposed	Diagnosis	ICD-10-CM
L97.103	Non-pressure chronic ulcer of unspecified thigh with necrosis of muscle	Diagnosis	ICD-10-CM
L97.104	Non-pressure chronic ulcer of unspecified thigh with necrosis of bone	Diagnosis	ICD-10-CM
L97.105	Non-pressure chronic ulcer of unspecified thigh with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.106	Non-pressure chronic ulcer of unspecified thigh with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.108	Non-pressure chronic ulcer of unspecified thigh with other specified severity	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
L97.109	Non-pressure chronic ulcer of unspecified thigh with unspecified severity	Diagnosis	ICD-10-CM
L97.111	Non-pressure chronic ulcer of right thigh limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.112	Non-pressure chronic ulcer of right thigh with fat layer exposed	Diagnosis	ICD-10-CM
L97.113	Non-pressure chronic ulcer of right thigh with necrosis of muscle	Diagnosis	ICD-10-CM
L97.114	Non-pressure chronic ulcer of right thigh with necrosis of bone	Diagnosis	ICD-10-CM
L97.115	Non-pressure chronic ulcer of right thigh with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.116	Non-pressure chronic ulcer of right thigh with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.118	Non-pressure chronic ulcer of right thigh with other specified severity	Diagnosis	ICD-10-CM
L97.119	Non-pressure chronic ulcer of right thigh with unspecified severity	Diagnosis	ICD-10-CM
L97.121	Non-pressure chronic ulcer of left thigh limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.122	Non-pressure chronic ulcer of left thigh with fat layer exposed	Diagnosis	ICD-10-CM
L97.123	Non-pressure chronic ulcer of left thigh with necrosis of muscle	Diagnosis	ICD-10-CM
L97.124	Non-pressure chronic ulcer of left thigh with necrosis of bone	Diagnosis	ICD-10-CM
L97.125	Non-pressure chronic ulcer of left thigh with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.126	Non-pressure chronic ulcer of left thigh with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.128	Non-pressure chronic ulcer of left thigh with other specified severity	Diagnosis	ICD-10-CM
L97.129	Non-pressure chronic ulcer of left thigh with unspecified severity	Diagnosis	ICD-10-CM
L97.201	Non-pressure chronic ulcer of unspecified calf limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.202	Non-pressure chronic ulcer of unspecified calf with fat layer exposed	Diagnosis	ICD-10-CM
L97.203	Non-pressure chronic ulcer of unspecified calf with necrosis of muscle	Diagnosis	ICD-10-CM
L97.204	Non-pressure chronic ulcer of unspecified calf with necrosis of bone	Diagnosis	ICD-10-CM
L97.205	Non-pressure chronic ulcer of unspecified calf with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.206	Non-pressure chronic ulcer of unspecified calf with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.208	Non-pressure chronic ulcer of unspecified calf with other specified severity	Diagnosis	ICD-10-CM
L97.209	Non-pressure chronic ulcer of unspecified calf with unspecified severity	Diagnosis	ICD-10-CM
L97.211	Non-pressure chronic ulcer of right calf limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.212	Non-pressure chronic ulcer of right calf with fat layer exposed	Diagnosis	ICD-10-CM
L97.213	Non-pressure chronic ulcer of right calf with necrosis of muscle	Diagnosis	ICD-10-CM
L97.214	Non-pressure chronic ulcer of right calf with necrosis of bone	Diagnosis	ICD-10-CM
L97.215	Non-pressure chronic ulcer of right calf with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.216	Non-pressure chronic ulcer of right calf with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.218	Non-pressure chronic ulcer of right calf with other specified severity	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
L97.219	Non-pressure chronic ulcer of right calf with unspecified severity	Diagnosis	ICD-10-CM
L97.221	Non-pressure chronic ulcer of left calf limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.222	Non-pressure chronic ulcer of left calf with fat layer exposed	Diagnosis	ICD-10-CM
L97.223	Non-pressure chronic ulcer of left calf with necrosis of muscle	Diagnosis	ICD-10-CM
L97.224	Non-pressure chronic ulcer of left calf with necrosis of bone	Diagnosis	ICD-10-CM
L97.225	Non-pressure chronic ulcer of left calf with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.226	Non-pressure chronic ulcer of left calf with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.228	Non-pressure chronic ulcer of left calf with other specified severity	Diagnosis	ICD-10-CM
L97.229	Non-pressure chronic ulcer of left calf with unspecified severity	Diagnosis	ICD-10-CM
L97.301	Non-pressure chronic ulcer of unspecified ankle limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.302	Non-pressure chronic ulcer of unspecified ankle with fat layer exposed	Diagnosis	ICD-10-CM
L97.303	Non-pressure chronic ulcer of unspecified ankle with necrosis of muscle	Diagnosis	ICD-10-CM
L97.304	Non-pressure chronic ulcer of unspecified ankle with necrosis of bone	Diagnosis	ICD-10-CM
L97.305	Non-pressure chronic ulcer of unspecified ankle with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.306	Non-pressure chronic ulcer of unspecified ankle with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.308	Non-pressure chronic ulcer of unspecified ankle with other specified severity	Diagnosis	ICD-10-CM
L97.309	Non-pressure chronic ulcer of unspecified ankle with unspecified severity	Diagnosis	ICD-10-CM
L97.311	Non-pressure chronic ulcer of right ankle limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.312	Non-pressure chronic ulcer of right ankle with fat layer exposed	Diagnosis	ICD-10-CM
L97.313	Non-pressure chronic ulcer of right ankle with necrosis of muscle	Diagnosis	ICD-10-CM
L97.314	Non-pressure chronic ulcer of right ankle with necrosis of bone	Diagnosis	ICD-10-CM
L97.315	Non-pressure chronic ulcer of right ankle with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.316	Non-pressure chronic ulcer of right ankle with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.318	Non-pressure chronic ulcer of right ankle with other specified severity	Diagnosis	ICD-10-CM
L97.319	Non-pressure chronic ulcer of right ankle with unspecified severity	Diagnosis	ICD-10-CM
L97.321	Non-pressure chronic ulcer of left ankle limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.322	Non-pressure chronic ulcer of left ankle with fat layer exposed	Diagnosis	ICD-10-CM
L97.323	Non-pressure chronic ulcer of left ankle with necrosis of muscle	Diagnosis	ICD-10-CM
L97.324	Non-pressure chronic ulcer of left ankle with necrosis of bone	Diagnosis	ICD-10-CM
L97.325	Non-pressure chronic ulcer of left ankle with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.326	Non-pressure chronic ulcer of left ankle with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.328	Non-pressure chronic ulcer of left ankle with other specified severity	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
L97.329	Non-pressure chronic ulcer of left ankle with unspecified severity	Diagnosis	ICD-10-CM
L97.401	Non-pressure chronic ulcer of unspecified heel and midfoot limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.402	Non-pressure chronic ulcer of unspecified heel and midfoot with fat layer exposed	Diagnosis	ICD-10-CM
L97.403	Non-pressure chronic ulcer of unspecified heel and midfoot with necrosis of muscle	Diagnosis	ICD-10-CM
L97.404	Non-pressure chronic ulcer of unspecified heel and midfoot with necrosis of bone	Diagnosis	ICD-10-CM
L97.405	Non-pressure chronic ulcer of unspecified heel and midfoot with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.406	Non-pressure chronic ulcer of unspecified heel and midfoot with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.408	Non-pressure chronic ulcer of unspecified heel and midfoot with other specified severity	Diagnosis	ICD-10-CM
L97.409	Non-pressure chronic ulcer of unspecified heel and midfoot with unspecified severity	Diagnosis	ICD-10-CM
L97.411	Non-pressure chronic ulcer of right heel and midfoot limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.412	Non-pressure chronic ulcer of right heel and midfoot with fat layer exposed	Diagnosis	ICD-10-CM
L97.413	Non-pressure chronic ulcer of right heel and midfoot with necrosis of muscle	Diagnosis	ICD-10-CM
L97.414	Non-pressure chronic ulcer of right heel and midfoot with necrosis of bone	Diagnosis	ICD-10-CM
L97.415	Non-pressure chronic ulcer of right heel and midfoot with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.416	Non-pressure chronic ulcer of right heel and midfoot with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.418	Non-pressure chronic ulcer of right heel and midfoot with other specified severity	Diagnosis	ICD-10-CM
L97.419	Non-pressure chronic ulcer of right heel and midfoot with unspecified severity	Diagnosis	ICD-10-CM
L97.421	Non-pressure chronic ulcer of left heel and midfoot limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.422	Non-pressure chronic ulcer of left heel and midfoot with fat layer exposed	Diagnosis	ICD-10-CM
L97.423	Non-pressure chronic ulcer of left heel and midfoot with necrosis of muscle	Diagnosis	ICD-10-CM
L97.424	Non-pressure chronic ulcer of left heel and midfoot with necrosis of bone	Diagnosis	ICD-10-CM
L97.425	Non-pressure chronic ulcer of left heel and midfoot with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.426	Non-pressure chronic ulcer of left heel and midfoot with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.428	Non-pressure chronic ulcer of left heel and midfoot with other specified severity	Diagnosis	ICD-10-CM
L97.429	Non-pressure chronic ulcer of left heel and midfoot with unspecified severity	Diagnosis	ICD-10-CM
L97.501	Non-pressure chronic ulcer of other part of unspecified foot limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.502	Non-pressure chronic ulcer of other part of unspecified foot with fat layer exposed	Diagnosis	ICD-10-CM
L97.503	Non-pressure chronic ulcer of other part of unspecified foot with necrosis of muscle	Diagnosis	ICD-10-CM
L97.504	Non-pressure chronic ulcer of other part of unspecified foot with necrosis of bone	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
L97.505	Non-pressure chronic ulcer of other part of unspecified foot with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.506	Non-pressure chronic ulcer of other part of unspecified foot with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.508	Non-pressure chronic ulcer of other part of unspecified foot with other specified severity	Diagnosis	ICD-10-CM
L97.509	Non-pressure chronic ulcer of other part of unspecified foot with unspecified severity	Diagnosis	ICD-10-CM
L97.511	Non-pressure chronic ulcer of other part of right foot limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.512	Non-pressure chronic ulcer of other part of right foot with fat layer exposed	Diagnosis	ICD-10-CM
L97.513	Non-pressure chronic ulcer of other part of right foot with necrosis of muscle	Diagnosis	ICD-10-CM
L97.514	Non-pressure chronic ulcer of other part of right foot with necrosis of bone	Diagnosis	ICD-10-CM
L97.515	Non-pressure chronic ulcer of other part of right foot with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.516	Non-pressure chronic ulcer of other part of right foot with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.518	Non-pressure chronic ulcer of other part of right foot with other specified severity	Diagnosis	ICD-10-CM
L97.519	Non-pressure chronic ulcer of other part of right foot with unspecified severity	Diagnosis	ICD-10-CM
L97.521	Non-pressure chronic ulcer of other part of left foot limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.522	Non-pressure chronic ulcer of other part of left foot with fat layer exposed	Diagnosis	ICD-10-CM
L97.523	Non-pressure chronic ulcer of other part of left foot with necrosis of muscle	Diagnosis	ICD-10-CM
L97.524	Non-pressure chronic ulcer of other part of left foot with necrosis of bone	Diagnosis	ICD-10-CM
L97.525	Non-pressure chronic ulcer of other part of left foot with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.526	Non-pressure chronic ulcer of other part of left foot with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.528	Non-pressure chronic ulcer of other part of left foot with other specified severity	Diagnosis	ICD-10-CM
L97.529	Non-pressure chronic ulcer of other part of left foot with unspecified severity	Diagnosis	ICD-10-CM
L97.801	Non-pressure chronic ulcer of other part of unspecified lower leg limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.802	Non-pressure chronic ulcer of other part of unspecified lower leg with fat layer exposed	Diagnosis	ICD-10-CM
L97.803	Non-pressure chronic ulcer of other part of unspecified lower leg with necrosis of muscle	Diagnosis	ICD-10-CM
L97.804	Non-pressure chronic ulcer of other part of unspecified lower leg with necrosis of bone	Diagnosis	ICD-10-CM
L97.805	Non-pressure chronic ulcer of other part of unspecified lower leg with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.806	Non-pressure chronic ulcer of other part of unspecified lower leg with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
L97.808	Non-pressure chronic ulcer of other part of unspecified lower leg with other specified severity	Diagnosis	ICD-10-CM
L97.809	Non-pressure chronic ulcer of other part of unspecified lower leg with unspecified severity	Diagnosis	ICD-10-CM
L97.811	Non-pressure chronic ulcer of other part of right lower leg limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.812	Non-pressure chronic ulcer of other part of right lower leg with fat layer exposed	Diagnosis	ICD-10-CM
L97.813	Non-pressure chronic ulcer of other part of right lower leg with necrosis of muscle	Diagnosis	ICD-10-CM
L97.814	Non-pressure chronic ulcer of other part of right lower leg with necrosis of bone	Diagnosis	ICD-10-CM
L97.815	Non-pressure chronic ulcer of other part of right lower leg with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.816	Non-pressure chronic ulcer of other part of right lower leg with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.818	Non-pressure chronic ulcer of other part of right lower leg with other specified severity	Diagnosis	ICD-10-CM
L97.819	Non-pressure chronic ulcer of other part of right lower leg with unspecified severity	Diagnosis	ICD-10-CM
L97.821	Non-pressure chronic ulcer of other part of left lower leg limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.822	Non-pressure chronic ulcer of other part of left lower leg with fat layer exposed	Diagnosis	ICD-10-CM
L97.823	Non-pressure chronic ulcer of other part of left lower leg with necrosis of muscle	Diagnosis	ICD-10-CM
L97.824	Non-pressure chronic ulcer of other part of left lower leg with necrosis of bone	Diagnosis	ICD-10-CM
L97.825	Non-pressure chronic ulcer of other part of left lower leg with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.826	Non-pressure chronic ulcer of other part of left lower leg with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.828	Non-pressure chronic ulcer of other part of left lower leg with other specified severity	Diagnosis	ICD-10-CM
L97.829	Non-pressure chronic ulcer of other part of left lower leg with unspecified severity	Diagnosis	ICD-10-CM
L97.901	Non-pressure chronic ulcer of unspecified part of unspecified lower leg limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.902	Non-pressure chronic ulcer of unspecified part of unspecified lower leg with fat layer exposed	Diagnosis	ICD-10-CM
L97.903	Non-pressure chronic ulcer of unspecified part of unspecified lower leg with necrosis of muscle	Diagnosis	ICD-10-CM
L97.904	Non-pressure chronic ulcer of unspecified part of unspecified lower leg with necrosis of bone	Diagnosis	ICD-10-CM
L97.905	Non-pressure chronic ulcer of unspecified part of unspecified lower leg with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.906	Non-pressure chronic ulcer of unspecified part of unspecified lower leg with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
L97.908	Non-pressure chronic ulcer of unspecified part of unspecified lower leg with other specified severity	Diagnosis	ICD-10-CM
L97.909	Non-pressure chronic ulcer of unspecified part of unspecified lower leg with unspecified severity	Diagnosis	ICD-10-CM
L97.911	Non-pressure chronic ulcer of unspecified part of right lower leg limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.912	Non-pressure chronic ulcer of unspecified part of right lower leg with fat layer exposed	Diagnosis	ICD-10-CM
L97.913	Non-pressure chronic ulcer of unspecified part of right lower leg with necrosis of muscle	Diagnosis	ICD-10-CM
L97.914	Non-pressure chronic ulcer of unspecified part of right lower leg with necrosis of bone	Diagnosis	ICD-10-CM
L97.915	Non-pressure chronic ulcer of unspecified part of right lower leg with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.916	Non-pressure chronic ulcer of unspecified part of right lower leg with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.918	Non-pressure chronic ulcer of unspecified part of right lower leg with other specified severity	Diagnosis	ICD-10-CM
L97.919	Non-pressure chronic ulcer of unspecified part of right lower leg with unspecified severity	Diagnosis	ICD-10-CM
L97.921	Non-pressure chronic ulcer of unspecified part of left lower leg limited to breakdown of skin	Diagnosis	ICD-10-CM
L97.922	Non-pressure chronic ulcer of unspecified part of left lower leg with fat layer exposed	Diagnosis	ICD-10-CM
L97.923	Non-pressure chronic ulcer of unspecified part of left lower leg with necrosis of muscle	Diagnosis	ICD-10-CM
L97.924	Non-pressure chronic ulcer of unspecified part of left lower leg with necrosis of bone	Diagnosis	ICD-10-CM
L97.925	Non-pressure chronic ulcer of unspecified part of left lower leg with muscle involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.926	Non-pressure chronic ulcer of unspecified part of left lower leg with bone involvement without evidence of necrosis	Diagnosis	ICD-10-CM
L97.928	Non-pressure chronic ulcer of unspecified part of left lower leg with other specified severity	Diagnosis	ICD-10-CM
L97.929	Non-pressure chronic ulcer of unspecified part of left lower leg with unspecified severity	Diagnosis	ICD-10-CM
S91.321A	Laceration with foreign body, right foot, initial encounter	Diagnosis	ICD-10-CM
S91.322A	Laceration with foreign body, left foot, initial encounter	Diagnosis	ICD-10-CM
S91.329A	Laceration with foreign body, unspecified foot, initial encounter	Diagnosis	ICD-10-CM
S91.341A	Puncture wound with foreign body, right foot, initial encounter	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
S91.342A	Puncture wound with foreign body, left foot, initial encounter	Diagnosis	ICD-10-CM
S91.349A	Puncture wound with foreign body, unspecified foot, initial encounter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
B20	Human immunodeficiency virus [HIV] disease	Diagnosis	ICD-10-CM
B97.35	Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere	Diagnosis	ICD-10-CM
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status	Diagnosis	ICD-10-CM
D80.8	Other immunodeficiencies with predominantly antibody defects	Diagnosis	ICD-10-CM
D80.9	Immunodeficiency with predominantly antibody defects, unspecified	Diagnosis	ICD-10-CM
D81.0	Severe combined immunodeficiency [SCID] with reticular dysgenesis	Diagnosis	ICD-10-CM
D81.1	Severe combined immunodeficiency [SCID] with low T- and B-cell numbers	Diagnosis	ICD-10-CM
D81.2	Severe combined immunodeficiency [SCID] with low or normal B-cell numbers	Diagnosis	ICD-10-CM
D81.4	Nezelof's syndrome	Diagnosis	ICD-10-CM
D81.6	Major histocompatibility complex class I deficiency	Diagnosis	ICD-10-CM
D81.7	Major histocompatibility complex class II deficiency	Diagnosis	ICD-10-CM
D81.89	Other combined immunodeficiencies	Diagnosis	ICD-10-CM
D81.9	Combined immunodeficiency, unspecified	Diagnosis	ICD-10-CM
D82.0	Wiskott-Aldrich syndrome	Diagnosis	ICD-10-CM
D82.1	Di George's syndrome	Diagnosis	ICD-10-CM
D83.0	Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function	Diagnosis	ICD-10-CM
D83.1	Common variable immunodeficiency with predominant immunoregulatory T-cell disorders	Diagnosis	ICD-10-CM
D83.2	Common variable immunodeficiency with autoantibodies to B- or T-cells	Diagnosis	ICD-10-CM
D83.8	Other common variable immunodeficiencies	Diagnosis	ICD-10-CM
D83.9	Common variable immunodeficiency, unspecified	Diagnosis	ICD-10-CM
D84.8	Other specified immunodeficiencies	Diagnosis	ICD-10-CM
D84.9	Immunodeficiency, unspecified	Diagnosis	ICD-10-CM
D89.810	Acute graft-versus-host disease	Diagnosis	ICD-10-CM
D89.811	Chronic graft-versus-host disease	Diagnosis	ICD-10-CM
D89.812	Acute on chronic graft-versus-host disease	Diagnosis	ICD-10-CM
D89.813	Graft-versus-host disease, unspecified	Diagnosis	ICD-10-CM
L13	Other bullous disorders	Diagnosis	ICD-10-CM
L13.0	Dermatitis herpetiformis	Diagnosis	ICD-10-CM
L13.1	Subcorneal pustular dermatitis	Diagnosis	ICD-10-CM
L13.8	Other specified bullous disorders	Diagnosis	ICD-10-CM
L13.9	Bullous disorder, unspecified	Diagnosis	ICD-10-CM
L20	Atopic dermatitis	Diagnosis	ICD-10-CM
L20.0	Besnier's prurigo	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
L20.8	Other atopic dermatitis	Diagnosis	ICD-10-CM
L20.81	Atopic neurodermatitis	Diagnosis	ICD-10-CM
L20.82	Flexural eczema	Diagnosis	ICD-10-CM
L20.83	Infantile (acute) (chronic) eczema	Diagnosis	ICD-10-CM
L20.84	Intrinsic (allergic) eczema	Diagnosis	ICD-10-CM
L20.89	Other atopic dermatitis	Diagnosis	ICD-10-CM
L20.9	Atopic dermatitis, unspecified	Diagnosis	ICD-10-CM
L23	Allergic contact dermatitis	Diagnosis	ICD-10-CM
L23.0	Allergic contact dermatitis due to metals	Diagnosis	ICD-10-CM
L23.1	Allergic contact dermatitis due to adhesives	Diagnosis	ICD-10-CM
L23.2	Allergic contact dermatitis due to cosmetics	Diagnosis	ICD-10-CM
L23.3	Allergic contact dermatitis due to drugs in contact with skin	Diagnosis	ICD-10-CM
L23.4	Allergic contact dermatitis due to dyes	Diagnosis	ICD-10-CM
L23.5	Allergic contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L23.6	Allergic contact dermatitis due to food in contact with the skin	Diagnosis	ICD-10-CM
L23.7	Allergic contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM
L23.8	Allergic contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L23.81	Allergic contact dermatitis due to animal (cat) (dog) dander	Diagnosis	ICD-10-CM
L23.89	Allergic contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L23.9	Allergic contact dermatitis, unspecified cause	Diagnosis	ICD-10-CM
L24	Irritant contact dermatitis	Diagnosis	ICD-10-CM
L24.0	Irritant contact dermatitis due to detergents	Diagnosis	ICD-10-CM
L24.1	Irritant contact dermatitis due to oils and greases	Diagnosis	ICD-10-CM
L24.2	Irritant contact dermatitis due to solvents	Diagnosis	ICD-10-CM
L24.3	Irritant contact dermatitis due to cosmetics	Diagnosis	ICD-10-CM
L24.4	Irritant contact dermatitis due to drugs in contact with skin	Diagnosis	ICD-10-CM
L24.5	Irritant contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L24.6	Irritant contact dermatitis due to food in contact with skin	Diagnosis	ICD-10-CM
L24.7	Irritant contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM
L24.8	Irritant contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L24.81	Irritant contact dermatitis due to metals	Diagnosis	ICD-10-CM
L24.89	Irritant contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L24.9	Irritant contact dermatitis, unspecified cause	Diagnosis	ICD-10-CM
L25	Unspecified contact dermatitis	Diagnosis	ICD-10-CM
L25.0	Unspecified contact dermatitis due to cosmetics	Diagnosis	ICD-10-CM
L25.1	Unspecified contact dermatitis due to drugs in contact with skin	Diagnosis	ICD-10-CM
L25.2	Unspecified contact dermatitis due to dyes	Diagnosis	ICD-10-CM
L25.3	Unspecified contact dermatitis due to other chemical products	Diagnosis	ICD-10-CM
L25.4	Unspecified contact dermatitis due to food in contact with skin	Diagnosis	ICD-10-CM
L25.5	Unspecified contact dermatitis due to plants, except food	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
L25.8	Unspecified contact dermatitis due to other agents	Diagnosis	ICD-10-CM
L25.9	Unspecified contact dermatitis, unspecified cause	Diagnosis	ICD-10-CM
L40	Psoriasis	Diagnosis	ICD-10-CM
L40.0	Psoriasis vulgaris	Diagnosis	ICD-10-CM
L40.1	Generalized pustular psoriasis	Diagnosis	ICD-10-CM
L40.2	Acrodermatitis continua	Diagnosis	ICD-10-CM
L40.3	Pustulosis palmaris et plantaris	Diagnosis	ICD-10-CM
L40.4	Guttate psoriasis	Diagnosis	ICD-10-CM
L40.5	Arthropathic psoriasis	Diagnosis	ICD-10-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.52	Psoriatic arthritis mutilans	Diagnosis	ICD-10-CM
L40.53	Psoriatic spondylitis	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.8	Other psoriasis	Diagnosis	ICD-10-CM
L40.9	Psoriasis, unspecified	Diagnosis	ICD-10-CM
L50.0	Allergic urticaria	Diagnosis	ICD-10-CM
L50.1	Idiopathic urticaria	Diagnosis	ICD-10-CM
L50.2	Urticaria due to cold and heat	Diagnosis	ICD-10-CM
L50.3	Dermatographic urticaria	Diagnosis	ICD-10-CM
L50.4	Vibratory urticaria	Diagnosis	ICD-10-CM
L50.5	Cholinergic urticaria	Diagnosis	ICD-10-CM
L50.6	Contact urticaria	Diagnosis	ICD-10-CM
L50.8	Other urticaria	Diagnosis	ICD-10-CM
L50.9	Urticaria, unspecified	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D70.0	Congenital agranulocytosis	Diagnosis	ICD-10-CM
D70.4	Cyclic neutropenia	Diagnosis	ICD-10-CM
D71	Functional disorders of polymorphonuclear neutrophils	Diagnosis	ICD-10-CM
D72.0	Genetic anomalies of leukocytes	Diagnosis	ICD-10-CM
D76.1	Hemophagocytic lymphohistiocytosis	Diagnosis	ICD-10-CM
D76.2	Hemophagocytic syndrome, infection-associated	Diagnosis	ICD-10-CM
D76.3	Other histiocytosis syndromes	Diagnosis	ICD-10-CM
D81.4	Nezelof's syndrome	Diagnosis	ICD-10-CM
D82.0	Wiskott-Aldrich syndrome	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
D82.1	Di George's syndrome	Diagnosis	ICD-10-CM
D84.8	Other specified immunodeficiencies	Diagnosis	ICD-10-CM
D22.9	Melanocytic nevi, unspecified	Diagnosis	ICD-10-CM
D23.9	Other benign neoplasm of skin, unspecified	Diagnosis	ICD-10-CM
I78.1	Nevus, non-neoplastic	Diagnosis	ICD-10-CM
Q82.1	Xeroderma pigmentosum	Diagnosis	ICD-10-CM
C93.01	Acute monoblastic/monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.02	Acute monoblastic/monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.10	Chronic myelomonocytic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C93.11	Chronic myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.12	Chronic myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.31	Juvenile myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.32	Juvenile myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.90	Monocytic leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C93.91	Monocytic leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C93.92	Monocytic leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C93.Z0	Other monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.Z1	Other monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.Z2	Other monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.00	Acute erythroid leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C94.01	Acute erythroid leukemia, in remission	Diagnosis	ICD-10-CM
C94.02	Acute erythroid leukemia, in relapse	Diagnosis	ICD-10-CM
C94.20	Acute megakaryoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.21	Acute megakaryoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C94.22	Acute megakaryoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.30	Mast cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.31	Mast cell leukemia, in remission	Diagnosis	ICD-10-CM
C94.32	Mast cell leukemia, in relapse	Diagnosis	ICD-10-CM
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission	Diagnosis	ICD-10-CM
C94.41	Acute panmyelosis with myelofibrosis, in remission	Diagnosis	ICD-10-CM
C94.42	Acute panmyelosis with myelofibrosis, in relapse	Diagnosis	ICD-10-CM
C94.6	Myelodysplastic disease, not classified	Diagnosis	ICD-10-CM
C94.80	Other specified leukemias not having achieved remission	Diagnosis	ICD-10-CM
C94.81	Other specified leukemias, in remission	Diagnosis	ICD-10-CM
C94.82	Other specified leukemias, in relapse	Diagnosis	ICD-10-CM
C95.00	Acute leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.01	Acute leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.10	Chronic leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C95.11	Chronic leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.90	Leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C95.91	Leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C95.92	Leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.20	Malignant mast cell neoplasm, unspecified	Diagnosis	ICD-10-CM
C96.21	Aggressive systemic mastocytosis	Diagnosis	ICD-10-CM
C96.22	Mast cell sarcoma	Diagnosis	ICD-10-CM
C96.29	Other malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.4	Sarcoma of dendritic cells (accessory cells)	Diagnosis	ICD-10-CM
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
C96.A	Histiocytic sarcoma	Diagnosis	ICD-10-CM
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D00.00	Carcinoma in situ of oral cavity, unspecified site	Diagnosis	ICD-10-CM
D00.01	Carcinoma in situ of labial mucosa and vermilion border	Diagnosis	ICD-10-CM
D00.02	Carcinoma in situ of buccal mucosa	Diagnosis	ICD-10-CM
D00.03	Carcinoma in situ of gingiva and edentulous alveolar ridge	Diagnosis	ICD-10-CM
D00.04	Carcinoma in situ of soft palate	Diagnosis	ICD-10-CM
D00.05	Carcinoma in situ of hard palate	Diagnosis	ICD-10-CM
D00.06	Carcinoma in situ of floor of mouth	Diagnosis	ICD-10-CM
D00.07	Carcinoma in situ of tongue	Diagnosis	ICD-10-CM
D00.08	Carcinoma in situ of pharynx	Diagnosis	ICD-10-CM
D00.1	Carcinoma in situ of esophagus	Diagnosis	ICD-10-CM
D00.2	Carcinoma in situ of stomach	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
D01.3	Carcinoma in situ of anus and anal canal	Diagnosis	ICD-10-CM
D01.40	Carcinoma in situ of unspecified part of intestine	Diagnosis	ICD-10-CM
D01.49	Carcinoma in situ of other parts of intestine	Diagnosis	ICD-10-CM
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D01.7	Carcinoma in situ of other specified digestive organs	Diagnosis	ICD-10-CM
D01.9	Carcinoma in situ of digestive organ, unspecified	Diagnosis	ICD-10-CM
D02.0	Carcinoma in situ of larynx	Diagnosis	ICD-10-CM
D02.1	Carcinoma in situ of trachea	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
D02.3	Carcinoma in situ of other parts of respiratory system	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
D02.4	Carcinoma in situ of respiratory system, unspecified	Diagnosis	ICD-10-CM
D03.0	Melanoma in situ of lip	Diagnosis	ICD-10-CM
D03.10	Melanoma in situ of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D03.11	Melanoma in situ of right eyelid, including canthus	Diagnosis	ICD-10-CM
D03.12	Melanoma in situ of left eyelid, including canthus	Diagnosis	ICD-10-CM
D03.20	Melanoma in situ of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
D03.21	Melanoma in situ of right ear and external auricular canal	Diagnosis	ICD-10-CM
D03.22	Melanoma in situ of left ear and external auricular canal	Diagnosis	ICD-10-CM
D03.30	Melanoma in situ of unspecified part of face	Diagnosis	ICD-10-CM
D03.39	Melanoma in situ of other parts of face	Diagnosis	ICD-10-CM
D03.4	Melanoma in situ of scalp and neck	Diagnosis	ICD-10-CM
D03.51	Melanoma in situ of anal skin	Diagnosis	ICD-10-CM
D03.52	Melanoma in situ of breast (skin) (soft tissue)	Diagnosis	ICD-10-CM
D03.59	Melanoma in situ of other part of trunk	Diagnosis	ICD-10-CM
D03.60	Melanoma in situ of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.61	Melanoma in situ of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.62	Melanoma in situ of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D03.70	Melanoma in situ of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
D03.71	Melanoma in situ of right lower limb, including hip	Diagnosis	ICD-10-CM
D03.72	Melanoma in situ of left lower limb, including hip	Diagnosis	ICD-10-CM
D03.8	Melanoma in situ of other sites	Diagnosis	ICD-10-CM
D03.9	Melanoma in situ, unspecified	Diagnosis	ICD-10-CM
D04.0	Carcinoma in situ of skin of lip	Diagnosis	ICD-10-CM
D04.10	Carcinoma in situ of skin of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
D04.11	Carcinoma in situ of skin of right eyelid, including canthus	Diagnosis	ICD-10-CM
D04.12	Carcinoma in situ of skin of left eyelid, including canthus	Diagnosis	ICD-10-CM
D04.20	Carcinoma in situ of skin of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
D04.21	Carcinoma in situ of skin of right ear and external auricular canal	Diagnosis	ICD-10-CM
D04.22	Carcinoma in situ of skin of left ear and external auricular canal	Diagnosis	ICD-10-CM
D04.30	Carcinoma in situ of skin of unspecified part of face	Diagnosis	ICD-10-CM
D04.39	Carcinoma in situ of skin of other parts of face	Diagnosis	ICD-10-CM
D04.4	Carcinoma in situ of skin of scalp and neck	Diagnosis	ICD-10-CM
D04.5	Carcinoma in situ of skin of trunk	Diagnosis	ICD-10-CM
D04.60	Carcinoma in situ of skin of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.61	Carcinoma in situ of skin of right upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.62	Carcinoma in situ of skin of left upper limb, including shoulder	Diagnosis	ICD-10-CM
D04.70	Carcinoma in situ of skin of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
D04.71	Carcinoma in situ of skin of right lower limb, including hip	Diagnosis	ICD-10-CM
D04.72	Carcinoma in situ of skin of left lower limb, including hip	Diagnosis	ICD-10-CM
D04.8	Carcinoma in situ of skin of other sites	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
D04.9	Carcinoma in situ of skin, unspecified	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D06.0	Carcinoma in situ of endocervix	Diagnosis	ICD-10-CM
D06.1	Carcinoma in situ of exocervix	Diagnosis	ICD-10-CM
D06.7	Carcinoma in situ of other parts of cervix	Diagnosis	ICD-10-CM
D06.9	Carcinoma in situ of cervix, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
D07.1	Carcinoma in situ of vulva	Diagnosis	ICD-10-CM
D07.2	Carcinoma in situ of vagina	Diagnosis	ICD-10-CM
D07.30	Carcinoma in situ of unspecified female genital organs	Diagnosis	ICD-10-CM
D07.39	Carcinoma in situ of other female genital organs	Diagnosis	ICD-10-CM
D07.4	Carcinoma in situ of penis	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
D07.60	Carcinoma in situ of unspecified male genital organs	Diagnosis	ICD-10-CM
D07.61	Carcinoma in situ of scrotum	Diagnosis	ICD-10-CM
D07.69	Carcinoma in situ of other male genital organs	Diagnosis	ICD-10-CM
D09.0	Carcinoma in situ of bladder	Diagnosis	ICD-10-CM
D09.10	Carcinoma in situ of unspecified urinary organ	Diagnosis	ICD-10-CM
D09.19	Carcinoma in situ of other urinary organs	Diagnosis	ICD-10-CM
D09.20	Carcinoma in situ of unspecified eye	Diagnosis	ICD-10-CM
D09.21	Carcinoma in situ of right eye	Diagnosis	ICD-10-CM
D09.22	Carcinoma in situ of left eye	Diagnosis	ICD-10-CM
D09.3	Carcinoma in situ of thyroid and other endocrine glands	Diagnosis	ICD-10-CM
D09.8	Carcinoma in situ of other specified sites	Diagnosis	ICD-10-CM
D09.9	Carcinoma in situ, unspecified	Diagnosis	ICD-10-CM
D25.0	Submucous leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.1	Intramural leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.2	Subserosal leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.9	Leiomyoma of uterus, unspecified	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
D37.01	Neoplasm of uncertain behavior of lip	Diagnosis	ICD-10-CM
D37.02	Neoplasm of uncertain behavior of tongue	Diagnosis	ICD-10-CM
D37.030	Neoplasm of uncertain behavior of the parotid salivary glands	Diagnosis	ICD-10-CM
D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands	Diagnosis	ICD-10-CM
D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands	Diagnosis	ICD-10-CM
D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified	Diagnosis	ICD-10-CM
D37.04	Neoplasm of uncertain behavior of the minor salivary glands	Diagnosis	ICD-10-CM
D37.05	Neoplasm of uncertain behavior of pharynx	Diagnosis	ICD-10-CM
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity	Diagnosis	ICD-10-CM
D37.1	Neoplasm of uncertain behavior of stomach	Diagnosis	ICD-10-CM
D37.2	Neoplasm of uncertain behavior of small intestine	Diagnosis	ICD-10-CM
D37.3	Neoplasm of uncertain behavior of appendix	Diagnosis	ICD-10-CM
D37.4	Neoplasm of uncertain behavior of colon	Diagnosis	ICD-10-CM
D37.5	Neoplasm of uncertain behavior of rectum	Diagnosis	ICD-10-CM
D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D37.8	Neoplasm of uncertain behavior of other specified digestive organs	Diagnosis	ICD-10-CM
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified	Diagnosis	ICD-10-CM
D38.0	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-10-CM
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	Diagnosis	ICD-10-CM
D38.2	Neoplasm of uncertain behavior of pleura	Diagnosis	ICD-10-CM
D38.3	Neoplasm of uncertain behavior of mediastinum	Diagnosis	ICD-10-CM
D38.4	Neoplasm of uncertain behavior of thymus	Diagnosis	ICD-10-CM
D38.5	Neoplasm of uncertain behavior of other respiratory organs	Diagnosis	ICD-10-CM
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified	Diagnosis	ICD-10-CM
D39.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-10-CM
D39.10	Neoplasm of uncertain behavior of unspecified ovary	Diagnosis	ICD-10-CM
D39.11	Neoplasm of uncertain behavior of right ovary	Diagnosis	ICD-10-CM
D39.12	Neoplasm of uncertain behavior of left ovary	Diagnosis	ICD-10-CM
D39.2	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-10-CM
D39.8	Neoplasm of uncertain behavior of other specified female genital organs	Diagnosis	ICD-10-CM
D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified	Diagnosis	ICD-10-CM
D3A.00	Benign carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
D3A.010	Benign carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
D3A.011	Benign carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM
D3A.012	Benign carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
D3A.019	Benign carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
D3A.020	Benign carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
D3A.021	Benign carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
D3A.022	Benign carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
D3A.023	Benign carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
D3A.024	Benign carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
D3A.025	Benign carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
D3A.026	Benign carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
D3A.029	Benign carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
D3A.090	Benign carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
D3A.091	Benign carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
D3A.092	Benign carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
D3A.093	Benign carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
D3A.094	Benign carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
D3A.095	Benign carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
D3A.096	Benign carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
D3A.098	Benign carcinoid tumors of other sites	Diagnosis	ICD-10-CM
D3A.8	Other benign neuroendocrine tumors	Diagnosis	ICD-10-CM
D40.0	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-10-CM
D40.10	Neoplasm of uncertain behavior of unspecified testis	Diagnosis	ICD-10-CM
D40.11	Neoplasm of uncertain behavior of right testis	Diagnosis	ICD-10-CM
D40.12	Neoplasm of uncertain behavior of left testis	Diagnosis	ICD-10-CM
D40.8	Neoplasm of uncertain behavior of other specified male genital organs	Diagnosis	ICD-10-CM
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D41.3	Neoplasm of uncertain behavior of urethra	Diagnosis	ICD-10-CM
D41.4	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-10-CM
D41.8	Neoplasm of uncertain behavior of other specified urinary organs	Diagnosis	ICD-10-CM
D41.9	Neoplasm of uncertain behavior of unspecified urinary organ	Diagnosis	ICD-10-CM
D42.0	Neoplasm of uncertain behavior of cerebral meninges	Diagnosis	ICD-10-CM
D42.1	Neoplasm of uncertain behavior of spinal meninges	Diagnosis	ICD-10-CM
D42.9	Neoplasm of uncertain behavior of meninges, unspecified	Diagnosis	ICD-10-CM
D43.0	Neoplasm of uncertain behavior of brain, supratentorial	Diagnosis	ICD-10-CM
D43.1	Neoplasm of uncertain behavior of brain, infratentorial	Diagnosis	ICD-10-CM
D43.2	Neoplasm of uncertain behavior of brain, unspecified	Diagnosis	ICD-10-CM
D43.3	Neoplasm of uncertain behavior of cranial nerves	Diagnosis	ICD-10-CM
D43.4	Neoplasm of uncertain behavior of spinal cord	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code	Code Type
		Category	
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system	Diagnosis	ICD-10-CM
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified	Diagnosis	ICD-10-CM
D44.0	Neoplasm of uncertain behavior of thyroid gland	Diagnosis	ICD-10-CM
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland	Diagnosis	ICD-10-CM
D44.11	Neoplasm of uncertain behavior of right adrenal gland	Diagnosis	ICD-10-CM
D44.12	Neoplasm of uncertain behavior of left adrenal gland	Diagnosis	ICD-10-CM
D44.2	Neoplasm of uncertain behavior of parathyroid gland	Diagnosis	ICD-10-CM
D44.3	Neoplasm of uncertain behavior of pituitary gland	Diagnosis	ICD-10-CM
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct	Diagnosis	ICD-10-CM
D44.5	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-10-CM
D44.6	Neoplasm of uncertain behavior of carotid body	Diagnosis	ICD-10-CM
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia	Diagnosis	ICD-10-CM
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland	Diagnosis	ICD-10-CM
D45	Polycythemia vera	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.01	Cutaneous mastocytosis	Diagnosis	ICD-10-CM
D47.02	Systemic mastocytosis	Diagnosis	ICD-10-CM
D47.09	Other mast cell neoplasms of uncertain behavior	Diagnosis	ICD-10-CM
D47.1	Chronic myeloproliferative disease	Diagnosis	ICD-10-CM
D47.3	Essential (hemorrhagic) thrombocythemia	Diagnosis	ICD-10-CM
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)	Diagnosis	ICD-10-CM
D47.Z2	Castleman disease	Diagnosis	ICD-10-CM
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-10-CM
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-10-CM
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM

Appendix G. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology, Fourth Edition (CPT-4) Diagnosis and Procedure Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D48.3	Neoplasm of uncertain behavior of retroperitoneum	Diagnosis	ICD-10-CM
D48.4	Neoplasm of uncertain behavior of peritoneum	Diagnosis	ICD-10-CM
D48.5	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-10-CM
D48.60	Neoplasm of uncertain behavior of unspecified breast	Diagnosis	ICD-10-CM
D48.61	Neoplasm of uncertain behavior of right breast	Diagnosis	ICD-10-CM
D48.62	Neoplasm of uncertain behavior of left breast	Diagnosis	ICD-10-CM
D48.7	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-10-CM
D48.9	Neoplasm of uncertain behavior, unspecified	Diagnosis	ICD-10-CM
D49.0	Neoplasm of unspecified behavior of digestive system	Diagnosis	ICD-10-CM
D49.1	Neoplasm of unspecified behavior of respiratory system	Diagnosis	ICD-10-CM
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin	Diagnosis	ICD-10-CM
D49.3	Neoplasm of unspecified behavior of breast	Diagnosis	ICD-10-CM
D49.4	Neoplasm of unspecified behavior of bladder	Diagnosis	ICD-10-CM
D49.511	Neoplasm of unspecified behavior of right kidney	Diagnosis	ICD-10-CM
D49.512	Neoplasm of unspecified behavior of left kidney	Diagnosis	ICD-10-CM
D49.519	Neoplasm of unspecified behavior of unspecified kidney	Diagnosis	ICD-10-CM
D49.59	Neoplasm of unspecified behavior of other genitourinary organ	Diagnosis	ICD-10-CM
D49.6	Neoplasm of unspecified behavior of brain	Diagnosis	ICD-10-CM
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system	Diagnosis	ICD-10-CM
D49.81	Neoplasm of unspecified behavior of retina and choroid	Diagnosis	ICD-10-CM
D49.89	Neoplasm of unspecified behavior of other specified sites	Diagnosis	ICD-10-CM
D49.9	Neoplasm of unspecified behavior of unspecified site	Diagnosis	ICD-10-CM
Q85.00	Neurofibromatosis, unspecified	Diagnosis	ICD-10-CM
Q85.01	Neurofibromatosis, type 1	Diagnosis	ICD-10-CM
Q85.02	Neurofibromatosis, type 2	Diagnosis	ICD-10-CM
Q85.03	Schwannomatosis	Diagnosis	ICD-10-CM
Q85.09	Other neurofibromatosis	Diagnosis	ICD-10-CM

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Antineoplastic Effects	
Amlodipine besylate/atorvastatin calcium	Amlodipine-Atorvastatin
Amlodipine besylate/atorvastatin calcium	Caduet
Aspirin	Acuprin
Aspirin	Adult Aspirin
Aspirin	Adult Aspirin EC Low Strength
Aspirin	Adult Aspirin Regimen
Aspirin	Adult Low Dose Aspirin
Aspirin	Analgesic
Aspirin	Arthritis Pain Relief (ASA)
Aspirin	Asperdrink
Aspirin	Aspergum
Aspirin	Aspir-81
Aspirin	Aspirin
Aspirin	Aspirin (bulk)
Aspirin	Aspirin Child
Aspirin	Aspirin Childrens
Aspirin	Aspirin Extra Strength
Aspirin	Aspirin for Children
Aspirin	Aspirin Lite-Coat
Aspirin	Aspirin Low Dose
Aspirin	Aspirin Low-Strength
Aspirin	Aspirin Maximum Strength
Aspirin	Aspirina
Aspirin	Aspir-Low
Aspirin	Aspir-Trin
Aspirin	Baby Aspirin
Aspirin	Bayer 8-Hour
Aspirin	Bayer Advanced
Aspirin	Bayer Arthritis Pain Regimen
Aspirin	Bayer Aspirin
Aspirin	Bayer Chewable Aspirin
Aspirin	Child Aspirin
Aspirin	Children's Aspirin
Aspirin	Coprin
Aspirin	Durlaza
Aspirin	E.C. Prin
Aspirin	Easprin
Aspirin	EC Aspirin
Aspirin	Eco-10
Aspirin	Eco-5
Aspirin	Ecotrin
Aspirin	Ecotrin Low Strength
Aspirin	Ecotrin Maximum Strength
Aspirin	Empirin

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Aspirin	Encoprin
Aspirin	Encoprin Extra Strength
Aspirin	Entercote
Aspirin	Enteric Coated Aspirin
Aspirin	Extra Strength Bayer
Aspirin	Genacote
Aspirin	Genprin
Aspirin	Halfprin
Aspirin	Lite Coat Aspirin
Aspirin	Lo-Dose Aspirin
Aspirin	Low-Dose Aspirin
Aspirin	Miniprin
Aspirin	Minitabs
Aspirin	Ninoprin
Aspirin	Norwich Aspirin
Aspirin	Quality Aspirin
Aspirin	Regiprin
Aspirin	Ridiprin
Aspirin	Sloprin
Aspirin	St Joseph Aspirin
Aspirin	St. Joseph Aspirin
Aspirin	St. Joseph Aspirin Children
Aspirin	St. Joseph Low-Dose Aspirin
Aspirin	Stanback Headache Powder
Aspirin	Sureprin 81
Aspirin	Tasprin
Aspirin	Uni-Tren
Aspirin	Ysp Aspirin
Aspirin	Zero-Order Release Aspirin
Aspirin	Zorprin
Aspirin (calcium carb & magnesium buffers)/pravastatin	Pravigard Pac
Aspirin/acetaminophen	Goody's Body Pain
Aspirin/acetaminophen/caffeine	Added Strength Headache Relief
Aspirin/acetaminophen/caffeine	Added Strength Pain Relief
Aspirin/acetaminophen/caffeine	Added Strength Pain Reliever
Aspirin/acetaminophen/caffeine	Analgesic
Aspirin/acetaminophen/caffeine	Aspirin-Acetaminophen-Caffeine
Aspirin/acetaminophen/caffeine	Excedrin Extra Strength
Aspirin/acetaminophen/caffeine	Excedrin Menstrual Complete
Aspirin/acetaminophen/caffeine	Excedrin Migraine
Aspirin/acetaminophen/caffeine	Ex-Pain
Aspirin/acetaminophen/caffeine	Extra Pain Relief
Aspirin/acetaminophen/caffeine	Extra Strength Pain Relief
Aspirin/acetaminophen/caffeine	Extra Strength Pain Reliever
Aspirin/acetaminophen/caffeine	Extraprin

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Aspirin/acetaminophen/caffeine	Gelpirin
Aspirin/acetaminophen/caffeine	Genaced
Aspirin/acetaminophen/caffeine	Goody's Extra Strength
Aspirin/acetaminophen/caffeine	Goody's Migraine Relief
Aspirin/acetaminophen/caffeine	Headache Formula
Aspirin/acetaminophen/caffeine	Headache Formula Added Str
Aspirin/acetaminophen/caffeine	Headache Relief (ASA-Acet-Caf)
Aspirin/acetaminophen/caffeine	Migraine
Aspirin/acetaminophen/caffeine	Migraine Formula
Aspirin/acetaminophen/caffeine	Migraine Pain Reliever
Aspirin/acetaminophen/caffeine	Migraine Relief
Aspirin/acetaminophen/caffeine	Pain Relief (Acetamin-Asp-Caf)
Aspirin/acetaminophen/caffeine	Pain Relief Plus
Aspirin/acetaminophen/caffeine	Pain Reliever (Acetam-Aspirin)
Aspirin/acetaminophen/caffeine	Pain Reliever Added Strength
Aspirin/acetaminophen/caffeine	Pain Reliever Plus
Aspirin/acetaminophen/caffeine	Painaid Extra Strength Formula
Aspirin/acetaminophen/caffeine	Pain-Off
Aspirin/acetaminophen/caffeine	Pamprin Max
Aspirin/acetaminophen/caffeine	Super Pain Relief
Aspirin/acetaminophen/caffeine	Super Strength Pain Reliever
Aspirin/acetaminophen/caffeine	Super Strength Reliever
Aspirin/acetaminophen/caffeine	X-Str Pain Reliever
Aspirin/acetaminophen/caffeine/calcium	Supac
Aspirin/acetaminophen/caffeine/potassium	Goody's Headache Powder
Aspirin/acetaminophen/calcium carbonate	Excedrin Back and Body
Aspirin/acetaminophen/magnesium/aluminum hydroxide/caffeine	Vanquish
Aspirin/caffeine	AA and C
Aspirin/caffeine	Adult Analgesic
Aspirin/caffeine	Adult Strength Analgesic
Aspirin/caffeine	Adult Strength Pain Relief
Aspirin/caffeine	Adult Strength Pain Reliever
Aspirin/caffeine	Anacin
Aspirin/caffeine	Anacin Maximum Strength
Aspirin/caffeine	Analgesic (Aspirin/Caffeine)
Aspirin/caffeine	Analgesic Adult Strength
Aspirin/caffeine	Arthritis Pain Relief(ASA-Aaf)
Aspirin/caffeine	Aspircaf
Aspirin/caffeine	Aspirin-Caffeine
Aspirin/caffeine	Back and Body Pain Reliever
Aspirin/caffeine	Bayer Aspirin (with Caffeine)
Aspirin/caffeine	Bayer Back and Body
Aspirin/caffeine	BC
Aspirin/caffeine	BC Arthritis
Aspirin/caffeine	Biocin

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Aspirin/caffeine	CP-2
Aspirin/caffeine	Gensan
Aspirin/caffeine	Majorcin
Aspirin/caffeine	Pain Relief Fast Acting
Aspirin/caffeine	Q-Acin
Aspirin/caffeine	Stanback
Aspirin/caffeine/dihydrocodeine	Synalgos-DC
Aspirin/caffeine/dihydrocodeine bitartrate	Aspirin-Caffeine-Dihydrocodein
Aspirin/caffeine/dihydrocodeine bitartrate	Synalgos-DC
Aspirin/calcium carbonate	Aspirin Regimen Bayer/Calcium
Aspirin/calcium carbonate	Women's Aspirin with Calcium
Aspirin/calcium carbonate/magnesium	Aspirin Tri-Buffered
Aspirin/calcium carbonate/magnesium	Aspirin, Buffered
Aspirin/calcium carbonate/magnesium	Aspir-Mox
Aspirin/calcium carbonate/magnesium	Buffered Aspirin
Aspirin/calcium carbonate/magnesium	Bufferin
Aspirin/calcium carbonate/magnesium	Bufferin Analgesic
Aspirin/calcium carbonate/magnesium	Bufferin Arthritis Strength
Aspirin/calcium carbonate/magnesium	Bufferin Extra Strength
Aspirin/calcium carbonate/magnesium	Bufpirin
Aspirin/calcium carbonate/magnesium	Tri-Buffered Aspirin
Aspirin/calcium carbonate/magnesium	Tri-Buffered Bufferin
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Ascriptin
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Ascriptin A/D
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Ascriptin AP
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Ascriptin MS
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspercin
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspirin AD/Antacid
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspirin Plus Antacid
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspirin Tri Buffered
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspirin, Buffered
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspir-Lox
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspir-Lox AD
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspir-Mox LB
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspralum
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspralum E.B.
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Aspidrox
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Asprimox
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Asprimox ID
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Bayer Plus Extra Strength
Aspirin/calcium carbonate/magnesium/aluminum hydroxide	Bufferin Extra Str (Al Hydrox)
Aspirin/codeine phosphate	Aspirin-Codeine
Aspirin/codeine phosphate	Aspirin-Codeine #3
Aspirin/codeine phosphate	Aspirin-Codeine #4
Aspirin/diphenhydramine citrate	Bayer PM

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Aspirin/diphenhydramine HCl	Extra Strength Bayer PM
Aspirin/diphenhydramine/sodium bicarbonate/citric acid	Alka-Seltzer PM
Aspirin/dipyridamole	Aggrenox
Aspirin/dipyridamole	Aspirin-Dipyridamole
Aspirin/magnesium carbonate/dihydroxyaluminum aminoacetate	Gennin-FC
Aspirin/magnesium hydroxide/aluminum hydroxide	Arthritis Pain Formula
Aspirin/magnesium hydroxide/aluminum hydroxide	Arthritis Pain Formula Max St
Aspirin/magnesium hydroxide/aluminum hydroxide	Magnaprin
Aspirin/magnesium hydroxide/aluminum hydroxide/caffeine	Cope
Aspirin/meprobamate	Equagesic
Aspirin/meprobamate	Meprobamate-Aspirin
Aspirin/meprobamate	Micrainin
Aspirin/omeprazole	Yosprala
Aspirin/salicylamide/acetaminophen/caffeine	Back Pain-Off
Aspirin/salicylamide/acetaminophen/caffeine	Levacet
Aspirin/salicylamide/acetaminophen/caffeine	Pain Relief(with Salicylamide)
Aspirin/salicylamide/acetaminophen/caffeine	Painaid
Aspirin/salicylamide/acetaminophen/caffeine	Pain-Off Extra Strength
Aspirin/salicylamide/acetaminophen/caffeine	Rumalon
Aspirin/salicylamide/acetaminophen/caffeine	Saletto
Aspirin/salicylamide/caffeine	Arthritis Strength BC Powder
Aspirin/salicylamide/caffeine	BC
Aspirin/salicylamide/caffeine	BC Headache
Aspirin/salicylamide/caffeine	BC Headache Powder
Aspirin/sodium bicarbonate/citric acid	Alka-Seltzer
Aspirin/sodium bicarbonate/citric acid	Alka-Seltzer Extra Strength
Aspirin/sodium bicarbonate/citric acid	Alka-Seltzer Original
Aspirin/sodium bicarbonate/citric acid	Antacid and Pain Relief
Aspirin/sodium bicarbonate/citric acid	Antacid Pain Reliever
Aspirin/sodium bicarbonate/citric acid	Efferves Pain Relief Antacid
Aspirin/sodium bicarbonate/citric acid	Efferves Pain-Antacid Relief
Aspirin/sodium bicarbonate/citric acid	Effervescent
Aspirin/sodium bicarbonate/citric acid	Effervescent Antacid
Aspirin/sodium bicarbonate/citric acid	Effervescent Pain Relief
Aspirin/sodium bicarbonate/citric acid	Effervescent Pain Reliever
Aspirin/sodium bicarbonate/citric acid	Medi-Seltzer
Aspirin/sodium bicarbonate/citric acid	Zee-Seltzer
Atorvastatin calcium	Atorvastatin
Atorvastatin calcium	Lipitor
Bromfenac sodium	Bromday
Bromfenac sodium	Bromday Twinpack
Bromfenac sodium	Bromfenac
Bromfenac sodium	Bromfenac Sodium (bulk)
Bromfenac sodium	Bromsite
Bromfenac sodium	Prolensa

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Bromfenac sodium	Xibrom
Butalbital/aspirin/caffeine	Butalbital Compound
Butalbital/aspirin/caffeine	Butalbital-Aspirin-Caffeine
Butalbital/aspirin/caffeine	Farbital
Butalbital/aspirin/caffeine	Fiorinal
Butalbital/aspirin/caffeine	Fiortal
Butalbital/aspirin/caffeine	Fortabs
Carisoprodol/aspirin	Carisoprodol Compound
Carisoprodol/aspirin	Carisoprodol-Aspirin
Carisoprodol/aspirin	Soma Compound
Carisoprodol/aspirin/codeine phosphate	Carisoprodol Compound-Codeine
Carisoprodol/aspirin/codeine phosphate	Carisoprodol-ASA-Codeine
Carisoprodol/aspirin/codeine phosphate	Soma Compound with Codeine
Celecoxib	Celebrex
Celecoxib	Celecoxib
Celecoxib	Celecoxib (bulk)
Celecoxib/capsaicin/menthol	Capxib
Celecoxib/capsaicin/methyl salicylate/menthol	Nudroxipak
Celecoxib/lidocaine/menthol	Lidoxib
Chlorpheniramine mal/phenylephrine/d-methorphan hb/aspirin	Alka-Seltzer Plus C/C(PE,DM)
Chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Alka-Seltzer Plus Cold (PE)
Chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Cold Relief
Chlorpheniramine maleate/phenylephrine bitartrate/aspirin	Cold Relief Plus
Chlorpheniramine/phenylpropanolamine bitartrate/aspirin	Alka-Seltzer Plus Cold
Chlorpheniramine/phenylpropanolamine bitartrate/aspirin	Effervescent Cold
Cinnamedrine HCl/aspirin/caffeine	Menstrual
Cinnamedrine HCl/aspirin/caffeine	Midol Maximum Strength
Codeine phosphate/butalbital/aspirin/caffeine	Ascomp with Codeine
Codeine phosphate/butalbital/aspirin/caffeine	Butalbital Compound w/Codeine
Codeine phosphate/butalbital/aspirin/caffeine	Butalbital Compound-Codeine
Codeine phosphate/butalbital/aspirin/caffeine	Codeine-Butalbital-ASA-Caff
Codeine phosphate/butalbital/aspirin/caffeine	Fiorinal-Codeine #3
Codeine phosphate/butalbital/aspirin/caffeine	Fiortal/Codeine
Codeine/aspirin/salicylamide/acetaminophen/caffeine	Rid-A-Pain
Codeine/aspirin/salicylamide/acetaminophen/caffeine	Rid-A-Pain w/Codeine
Diclofenac epolamine	Flector
Diclofenac potassium	Cambia
Diclofenac potassium	Cataflam
Diclofenac potassium	Diclofenac Potassium
Diclofenac potassium	Zipsor
Diclofenac sodium	Diclo Gel
Diclofenac sodium	Diclofenac Sodium
Diclofenac sodium	Diclofenac Sodium (bulk)
Diclofenac sodium	Diclofono
Diclofenac sodium	Diclozor

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Diclofenac sodium	Dyloject
Diclofenac sodium	Klofensaid II
Diclofenac sodium	Pennsaid
Diclofenac sodium	Solaraze
Diclofenac sodium	Voltaren
Diclofenac sodium	Voltaren-XR
Diclofenac sodium	Vopac MDS
Diclofenac sodium, micronized	Diclofenac Sod, Micro (bulk)
Diclofenac sodium/benzalkonium chloride	Ds Prep Pak
Diclofenac sodium/capsaicin	Diclopak
Diclofenac sodium/capsaicin	Flexipak
Diclofenac sodium/capsaicin	Nudiclo Solupak
Diclofenac sodium/capsaicin	Nudiclo Tabpak
Diclofenac sodium/capsaicin/methyl salicylate/menthol	Nudroxipak DSDR-50
Diclofenac sodium/capsaicin/methyl salicylate/menthol	Nudroxipak DSDR-75
Diclofenac sodium/capsicum oleoresin	Dermacinrx Lexitral
Diclofenac sodium/capsicum oleoresin	Dermasilkrx Diclopak
Diclofenac sodium/capsicum oleoresin	Diclotral
Diclofenac sodium/capsicum oleoresin	Inflammacin
Diclofenac sodium/capsicum oleoresin	Previdolrx Plus Analgesic Pak
Diclofenac sodium/capsicum oleoresin	Sure Result DSS Premium Pack
Diclofenac sodium/capsicum oleoresin	Xelitral
Diclofenac sodium/capsicum oleoresin	Xenaflamm
Diclofenac sodium/kinesiology tape	Diclo Gel-Xrylix Sheet
Diclofenac sodium/kinesiology tape	Lexixryl
Diclofenac sodium/kinesiology tape	Xrylix
Diclofenac sodium/lidocaine HCl/kinesiology tape	Trixylyltral
Diclofenac sodium/menthol	Dithol
Diclofenac sodium/methyl salicylate/menthol	Diclopr
Diclofenac sodium/methyl salicylate/menthol/camphor	Inflamma-K
Diclofenac sodium/misoprostol	Arthrotec 50
Diclofenac sodium/misoprostol	Arthrotec 75
Diclofenac sodium/misoprostol	Diclofenac-Misoprostol
Diclofenac submicronized	Zorvolex
Ephedrine/aspirin/acetanilide/caffeine	Haysma
Etodolac	Etodolac
Etodolac	Etodolac (bulk)
Etodolac	Lodine
Etodolac	Lodine XL
Etodolac/capsaicin/methyl salicylate/menthol	Nudroxipak E-400
Ezetimibe/atorvastatin calcium	Liptruzet
Ezetimibe/simvastatin	Ezetimibe-Simvastatin
Ezetimibe/simvastatin	Vytorin 10-10
Ezetimibe/simvastatin	Vytorin 10-20
Ezetimibe/simvastatin	Vytorin 10-40

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Ezetimibe/simvastatin	Vytorin 10-80
Fenoprofen calcium	Fenoprofen
Fenoprofen calcium	Fenortho
Fenoprofen calcium	Nalfon
Fenoprofen calcium	Profeno
Fenoprofen calcium, dihydrate	Fenoprofen Calcium Dihyd(bulk)
Flurbiprofen	Ansaid
Flurbiprofen	Flurbiprofen
Flurbiprofen sodium	Flurbiprofen Sodium
Flurbiprofen sodium	Ocufen
Fluvastatin sodium	Fluvastatin
Fluvastatin sodium	Lescol
Fluvastatin sodium	Lescol XL
Hydrocodone bitartrate/aspirin	Alor
Hydrocodone bitartrate/aspirin	Damason-P
Hydrocodone bitartrate/aspirin	Lortab Asa
Ibuprofen	Advanced Pain Relief
Ibuprofen	Advil
Ibuprofen	Advil Liqui-Gel
Ibuprofen	Advil Migraine
Ibuprofen	A-G Profen
Ibuprofen	Backache
Ibuprofen	Bupranol FP
Ibuprofen	Caldolor
Ibuprofen	Cap-Profen
Ibuprofen	Child Ibuprofen
Ibuprofen	Children's Advil
Ibuprofen	Children's Ibu-Drops
Ibuprofen	Children's Ibuprofen
Ibuprofen	Children's Medi-Profen
Ibuprofen	Children's Motrin
Ibuprofen	Children's Motrin Jr Strength
Ibuprofen	Children's Profen IB
Ibuprofen	Childs Ibuprofen
Ibuprofen	Elixsure IB Suspension
Ibuprofen	Genpril
Ibuprofen	Ibu
Ibuprofen	Ibu-200
Ibuprofen	Ibu-Drops
Ibuprofen	Ibupain-200
Ibuprofen	Ibuprin
Ibuprofen	Ibuprofen
Ibuprofen	Ibuprofen (bulk)
Ibuprofen	Ibuprofen IB
Ibuprofen	Ibuprofen Jr Strength

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Ibuprofen	Ibuprofen M
Ibuprofen	Ibuprofen PMR
Ibuprofen	Ibutab
Ibuprofen	Ibu-Tab
Ibuprofen	Infant's Advil
Ibuprofen	Infants Ibu-Drops
Ibuprofen	Infant's Ibuprofen
Ibuprofen	Infant's Medi-Profen
Ibuprofen	Infant's Motrin
Ibuprofen	Infants Profenib
Ibuprofen	I-Prin
Ibuprofen	Medi-Profen
Ibuprofen	Menadol
Ibuprofen	Midol Max St Cramp Formula
Ibuprofen	Motrin
Ibuprofen	Motrin IB
Ibuprofen	Motrin Junior Strength
Ibuprofen	Motrin Migraine
Ibuprofen	Nuprin
Ibuprofen	Nuprin Menstrual Relief
Ibuprofen	Pediacare Fever
Ibuprofen	Profen IB
Ibuprofen	Provil
Ibuprofen	Q-Profen
Ibuprofen	Tab-Profen
Ibuprofen	Uni-Pro
Ibuprofen	Wal-Profen
Ibuprofen	Yaprofen
Ibuprofen lysine/PF	Ibuprofen Lysine (PF)
Ibuprofen lysine/PF	Neoprofen (Ibuprofen Lysn)(PF)
Ibuprofen/caffeine/vitamins b1, b2, b6, & b12	Ic400
Ibuprofen/caffeine/vitamins b1, b2, b6, & b12	Ic800
Ibuprofen/capsaicin/methyl salicylate/menthol	Nudroxipak I-800
Ibuprofen/dietary supplement,misc. Cb.11	Theraprofen-60
Ibuprofen/dietary supplement,misc. Cb.11	Theraprofen-90
Ibuprofen/diphenhydramine citrate	Advil PM
Ibuprofen/diphenhydramine citrate	Ibuprofen PM
Ibuprofen/diphenhydramine citrate	Ibuprofen-Diphenhydramine Cit
Ibuprofen/diphenhydramine citrate	Motrin PM
Ibuprofen/diphenhydramine HCl	Advil Pm Liqui-Gels
Ibuprofen/diphenhydramine HCl	Ibuprofen PM
Ibuprofen/diphenhydramine HCl	Ibuprofen-Diphenhydramine HCl
Ibuprofen/famotidine	Duexis
Ibuprofen/irritants counter-irritants combination no.2	Comfort Pac-Ibuprofen
Indomethacin	Indocin

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Indomethacin	Indocin Sr
Indomethacin	Indomethacin
Indomethacin sodium	Indocin
Indomethacin sodium	Indomethacin Sodium
Indomethacin, submicronized	Tivorbex
Ketoprofen	Actron
Ketoprofen	Frotek
Ketoprofen	Ketoprofen
Ketoprofen	Orudis
Ketoprofen	Orudis KT
Ketoprofen	Oruvail
Ketoprofen, micronized	Frotek
Ketoprofen, micronized	Ketoprofen, Micronized (Bulk)
Ketorolac tromethamine	Acular
Ketorolac tromethamine	Acular LS
Ketorolac tromethamine	Acular PF
Ketorolac tromethamine	Ketorolac
Ketorolac tromethamine	Ketorolac (bulk)
Ketorolac tromethamine	Readysharp Ketorolac
Ketorolac tromethamine	Sprix
Ketorolac tromethamine	Toradol
Ketorolac tromethamine/PF	Acuvail (PF)
Ketorolac/norflurane and pentafluoropropane (hfc 245fa)	Toronova I Suik
Ketorolac/norflurane and pentafluoropropane (hfc 245fa)	Toronova Suik
Lansoprazole/naproxen	Prevacid Naprapac
Lovastatin	Altacor
Lovastatin	Altoprev
Lovastatin	Lovastatin
Lovastatin	Mevacor
Meclofenamate sodium	Meclofenamate
Mefenamic acid	Mefenamic Acid
Mefenamic acid	Mefenamic Acid (bulk)
Mefenamic acid	Ponstel
Meloxicam	Meloxicam
Meloxicam	Meloxicam (bulk)
Meloxicam	Mobic
Meloxicam, submicronized	Vivlodex
Meloxicam/irritants counter-irritants combination no.2	Comfort Pac-Meloxicam
Methocarbamol/aspirin	Methocarbamol-Aspirin
Methocarbamol/aspirin	Robaxisal
Nabumetone	Nabumetone
Nabumetone	Nabumetone (bulk)
Nabumetone	Relafen
Nabumetone, micronized	Nabumetone, Micronized (bulk)
Nabumetone/capsaicin/methyl salicylate/menthol	Nudroxipak N-500

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Naproxen	EC-Naprosyn
Naproxen	Napro
Naproxen	Naproderm
Naproxen	Naprosyn
Naproxen	Naproxen
Naproxen	Romixen 500
Naproxen sodium	Aleve
Naproxen sodium	All Day Pain Relief
Naproxen sodium	All Day Relief
Naproxen sodium	Anaprox
Naproxen sodium	Anaprox DS
Naproxen sodium	Flanax (Naproxen)
Naproxen sodium	Mediproxen
Naproxen sodium	Midol (Naproxen)
Naproxen sodium	Naprelan
Naproxen sodium	Naprelan CR
Naproxen sodium	Naprelan CR Dose Card
Naproxen sodium	Naproxen Sodium
Naproxen sodium	Wal-Proxen
Naproxen sodium/diphenhydramine HCl	Aleve PM
Naproxen sodium/menthol	Napropak Cool
Naproxen/capsaicin/menthol	Napropax
Naproxen/capsaicin/menthol	Naproxenpax
Naproxen/capsaicin/menthol/methyl salicylate	Pain Relief Collection
Naproxen/dietary supplement,misc. Cb.11	Theraproxen
Naproxen/dietary supplement,misc. Cb.11	Theraproxen-90
Naproxen/esomeprazole magnesium	Vimovo
Naproxen/irritant counter-irritant combination no.2	Comfort Pac-Naproxen
Nepafenac	Ilevro
Nepafenac	Nevanac
Niacin/lovastatin	Advicor
Niacin/simvastatin	Simcor
Orphenadrine citrate/aspirin/caffeine	Norgesic
Orphenadrine citrate/aspirin/caffeine	Norgesic Forte
Orphenadrine citrate/aspirin/caffeine	Orphenadrine Compound
Orphenadrine citrate/aspirin/caffeine	Orphenadrine Compound Forte
Orphenadrine citrate/aspirin/caffeine	Orphenadrine Compound-DS
Orphenadrine citrate/aspirin/caffeine	Orphenadrine-ASA-Caffeine
Orphenadrine citrate/aspirin/caffeine	Orphengesic
Orphenadrine citrate/aspirin/caffeine	Orphengesic Forte
Oxaprozin	Daypro
Oxaprozin	Oxaprozin
Oxycodone HCl/aspirin	Endodan
Oxycodone HCl/aspirin	Oxycodone-Aspirin
Oxycodone HCl/aspirin	Percodan

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Oxycodone HCl/oxycodone terephthalate/aspirin	Endodan (Old Formula)
Oxycodone HCl/oxycodone terephthalate/aspirin	Oxycodone HCl-Oxycodone-ASA
Oxycodone HCl/oxycodone terephthalate/aspirin	Percodan
Oxycodone HCl/oxycodone terephthalate/aspirin	Roxiprin
Oxycodone/aspirin	Percodan Demi
Pentazocine HCl/aspirin	Talwin Compound
Phenylbutazone	Phenylbutazone (bulk)
Phenylephrine HCl/ketorolac tromethamine	Omidria
Phenylpropanolamine bitartrate/aspirin	Alka-Seltzer Plus Sinus
Phenylpropanolamine HCl/aspirin	BC Cold Powder/Cold-Sinus
Phenylpropanolamine HCl/aspirin/chlorpheniramine	BC Cold Powder/Cold-Sinus
Phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Cold
Phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Cold Medicine
Phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Cold Relief
Phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Nite Cold Relief
Phenylpropanolamine HCl/aspirin/chlorpheniramine	Effervescent Plus
Phenylpropanolamine HCl/aspirin/chlorpheniramine	Medi-Seltzer Plus
Phenylpropanolamine HCl/aspirin/chlorpheniramine/caffeine	Major-Stan
Phenylpropanolamine HCl/aspirin/diphenhydramine	Alka-Seltzer Plus Night-Time
Phenylpropanolamine HCl/aspirin/diphenhydramine	Cold Relief Nite
Phenylpropanolamine HCl/aspirin/diphenhydramine	Effervescent Cold Relief
Phenylpropanolamine HCl/aspirin/diphenhydramine	Effervescent Nite Cold Relief
Phenylpropanolamine HCl/aspirin/diphenhydramine	Effervescent Nite Relief
Phenylpropanolamine HCl/aspirin/diphenhydramine	Effervescent Plus Cold Nite
Phenylpropanolamine HCl/aspirin/diphenhydramine	Night Time Cold Medicine
Piroxicam	Feldene
Piroxicam	Piroxicam
Piroxicam	Piroxicam (bulk)
Piroxicam/dietary supplement,misc. Cb.11	Therafeldamine
Pitavastatin calcium	Livalo
Pitavastatin magnesium	Zypitamag
Pravastatin sodium	Pravachol
Pravastatin sodium	Pravastatin
Prednisolone acetate/bromfenac sodium	Prednisolone Acetate-Bromfenac
Prednisolone acetate/nepafenac	Prednisolone Acetate-Nepafenac
Prednisolone sodium phosphate/bromfenac sodium	Prednisolone Sod Ph-Bromfenac
Propoxyphene HCl/aspirin/caffeine	Darvon Compound 32
Propoxyphene HCl/aspirin/caffeine	Darvon Compound-65
Propoxyphene HCl/aspirin/caffeine	Pc-Cap
Propoxyphene HCl/aspirin/caffeine	Propoxyphene Compound-65
Pseudoephedrine HCl/aspirin/chlorpheniramine	Effervescent Cold Relief
Pseudoephedrine HCl/aspirin/chlorpheniramine	Effervescent Plus Cold Relief
Rofecoxib	Vioxx
Rosuvastatin calcium	Crestor
Rosuvastatin calcium	Rosuvastatin

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Simvastatin	Flolipid
Simvastatin	Simvastatin
Simvastatin	Simvastatin (bulk)
Simvastatin	Zocor
Sitagliptin phosphate/simvastatin	Juvisync
Sulindac	Clinoril
Sulindac	Sulindac
Suprofen	Profenal
Tolmetin sodium	Tolectin
Tolmetin sodium	Tolectin DS
Tolmetin sodium	Tolmetin
Tropicamide/proparacaine/phenylephrine/ketorolac in water	Mydriatic4(Trop-Prop-Pe-Ktrlc)
Valdecoxib	Bextra
Immunosuppressive: Glucocorticoids	
Triamcinolone acetonide	Kenalog
Acyclovir/hydrocortisone	Xerese
Alclometasone dipropionate	Aclovene
Alclometasone dipropionate	Alclometasone
Amcinonide	Amcinonide
Amcinonide	Cyclocort
Beclomethasone dipropionate	Beclovent
Beclomethasone dipropionate	Beclovent Refill
Beclomethasone dipropionate	Qvar
Beclomethasone dipropionate	Qvar Redihaler
Beclomethasone dipropionate	Vanceril
Beclomethasone dipropionate	Vanceril Double Strength
Benzoyl peroxide/hydrocortisone	Bencort
Benzoyl peroxide/hydrocortisone	Vanoxide-Hc
Benzoyl peroxide/hydrocortisone/skin cleanser comb no.14	Bencort
Benzoyl peroxide/hydrocortisone/skin cleanser comb no.14	Vanoxide-Hc
Betamethasone	Celestone
Betamethasone acetate and sodium phosph/norflurane/hfc 245fa	Betaloan Suik
Betamethasone acetate, micronized	Betamethasone Acet, Micro(bulk)
Betamethasone acetate/betamethasone sodium phosphate	Beta-1
Betamethasone acetate/betamethasone sodium phosphate	Betamethasone Acet, Sod Phos
Betamethasone acetate/betamethasone sodium phosphate	Celestone Soluspan
Betamethasone acetate/betamethasone sodium phosphate	Readysharp Betamethasone
Betamethasone dipropionate	Alphatrex
Betamethasone dipropionate	Betamethasone Dipropionate
Betamethasone dipropionate	Betamethasone, Augmented
Betamethasone dipropionate	Diprolene
Betamethasone dipropionate	Diprosone
Betamethasone dipropionate	Maxivate
Betamethasone dipropionate	Sernivo
Betamethasone dipropionate/propylene glycol	Betamethasone, Augmented

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Betamethasone dipropionate/propylene glycol	Diprolene
Betamethasone dipropionate/propylene glycol	Diprolene AF
Betamethasone sodium phosph in sterile water for injection	Betamethasone Sod Phosph-Water
Betamethasone sodium phosphate	Adbeon
Betamethasone sodium phosphate	Betamethasone Sodium Phosphate
Betamethasone sodium phosphate	Celestone
Betamethasone valerate	Betamethasone Valerate
Betamethasone valerate	Betatrex
Betamethasone valerate	Beta-Val
Betamethasone valerate	Luxiq
Budesonide	Budesonide
Budesonide	Entocort EC
Budesonide	Pulmicort
Budesonide	Pulmicort Flexhaler
Budesonide	Pulmicort Turbuhaler
Budesonide	Uceris
Budesonide, micronized	Budesonide, Micronized (bulk)
Budesonide/formoterol fumarate	Symbicort
Calcipotriene/betamethasone dipropionate	Calcipotriene-Betamethasone
Calcipotriene/betamethasone dipropionate	Enstilar
Calcipotriene/betamethasone dipropionate	Taclonex
Calcipotriene/betamethasone dipropionate	Taclonex Scalp
Chlorcyclizine HCl/hydrocortisone acetate	Mantadil
Chloroxylenol/benzocaine/hydrocortisone acetate	Myoxin
Chloroxylenol/benzocaine/hydrocortisone acetate	Trioxin
Ciclesonide	Alvesco
Ciprofloxacin HCl/dexamethasone	Ciprodex
Ciprofloxacin HCl/fluocinolone acetonide	Otovel
Ciprofloxacin HCl/hydrocortisone	Cipro Hc
Clioquinol/hydrocortisone	Ala-Quin
Clioquinol/hydrocortisone	Albaform Hc
Clioquinol/hydrocortisone	Clioquinol-Hydrocortisone
Clioquinol/hydrocortisone	Corque
Clioquinol/hydrocortisone	Iodochlorhydroxyquin-Hc
Clioquinol/hydrocortisone/emollient combination no.88	Dermasorb Af Complete Kit
Clioquinol/hydrocortisone/pramoxine	Pricort
Clobetasol propionate	Clobetasol
Clobetasol propionate	Clobevate
Clobetasol propionate	Clobex
Clobetasol propionate	Clodan
Clobetasol propionate	Cormax
Clobetasol propionate	Embeline
Clobetasol propionate	Impoyz
Clobetasol propionate	Olux
Clobetasol propionate	Temovate

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Clobetasol propionate/coal tar	Clobeta+Plus
Clobetasol propionate/coal tar	Clobetasol-Coal Tar
Clobetasol propionate/emollient base	Clobetasol-Emollient
Clobetasol propionate/emollient base	Embeline E
Clobetasol propionate/emollient base	Olux-E
Clobetasol propionate/emollient base	Olux-Olux-E
Clobetasol propionate/emollient base	Olux-Olux-E (100/10)
Clobetasol propionate/emollient base	Olux-Olux-E (50/50)
Clobetasol propionate/emollient base	Temovate E
Clobetasol propionate/skin cleanser combination no.28	Clodan Kit
Clocortolone pivalate	Clocortolone Pivalate
Clocortolone pivalate	Cloderm
Clotrimazole/betamethasone dipropionate	Clotrimazole-Betamethasone
Clotrimazole/betamethasone dipropionate	Lotrisone
Clotrimazole/betamethasone dipropionate/zinc oxide	Dermacinrx Therazole Pak
Cortisone acetate	Cortisone
Cortisone acetate	Cortone
Deflazacort	Emflaza
Desonide	Delonide
Desonide	Desonate
Desonide	Desonide
Desonide	Desowen
Desonide	Lokara
Desonide	Tridesilon
Desonide	Verdeso
Desonide, micronized	Desonide, Micronized (bulk)
Desonide/emollient combination no. 28	Desowen
Desonide/emollient combination no.3	Desonil
Desonide/emollient combination no.3	Desonil + Plus
Desonide/emollient combination no.30	Desowen Cream and Lotion
Desonide/emollient combination no.30	Desowen Ointment and Lotion
Desoximetasone	Desoximetasone
Desoximetasone	Desoximetasone (bulk)
Desoximetasone	Topicort
Desoximetasone	Topicort LP
Dexamethasone	Baycadron
Dexamethasone	Decadron
Dexamethasone	Decadron Dose Pack
Dexamethasone	Dexamethasone
Dexamethasone	Dexamethasone Intensol
Dexamethasone	Dexone
Dexamethasone	Dexpak 10 Day
Dexamethasone	Dexpak 13 Day
Dexamethasone	Dexpak 6 Day
Dexamethasone	Hexadrol

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Dexamethasone	Locort
Dexamethasone	Maxidex
Dexamethasone	Ozurdex
Dexamethasone	Taperdex
Dexamethasone	Zema-Pak
Dexamethasone	Zodex
Dexamethasone	Zonacort
Dexamethasone acetate	Adrenocot La
Dexamethasone acetate	Dalalone D.P.
Dexamethasone acetate	Dalalone La
Dexamethasone acetate	Decaject
Dexamethasone acetate	De-Sone La
Dexamethasone acetate	Dexacen La-8
Dexamethasone acetate	Dexamethasone Acetate
Dexamethasone acetate	Dexasone La
Dexamethasone acetate	Dexone La
Dexamethasone acetate	Solurex La
Dexamethasone acetate, micronized	Dexamethasone Ac, Micro (bulk)
Dexamethasone phosphate	Primethasone
Dexamethasone sod phosphate	Adrenocot
Dexamethasone sod phosphate	Ak-Dex
Dexamethasone sod phosphate	Cpc-Cort-D
Dexamethasone sod phosphate	Dalalone
Dexamethasone sod phosphate	Decadron
Dexamethasone sod phosphate	Decaject
Dexamethasone sod phosphate	Dexair
Dexamethasone sod phosphate	Dexamethasone Sod Phos (bulk)
Dexamethasone sod phosphate	Dexamethasone Sodium Phosphate
Dexamethasone sod phosphate	Dexasol
Dexamethasone sod phosphate	Dexasone 10
Dexamethasone sod phosphate	Dexasone 4
Dexamethasone sod phosphate	Dexone
Dexamethasone sod phosphate	Readysharp Dexamethasone
Dexamethasone sod phosphate	Solurex
Dexamethasone sodium phosphate in 0.9 % sodium chloride	Dexamethasone In 0.9 % Sod Chl
Dexamethasone sodium phosphate/lidocaine HCl	Lidocidex-I
Dexamethasone sodium phosphate/PF	Active Injection Kit D (PF)
Dexamethasone sodium phosphate/PF	Dexamethasone Sodium Phos (PF)
Dexamethasone sodium phosphate/PF	Doubledex (PF)
Dexamethasone sodium phosphate/PF	Mas Care-Pak (PF)
Dexamethasone, micronized	Dexamethasone, Micronized (bulk)
Dexamethasone/PF/norflurane/pentafluoropropane (hfc 245fa)	Dmt Suik
Diflorasone diacetate	Apexicon
Diflorasone diacetate	Diflorasone
Diflorasone diacetate	Florone

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Diflorasone diacetate	Maxiflor
Diflorasone diacetate	Psorcon
Diflorasone diacetate/emollient base	Apexicon E
Diflorasone diacetate/emollient base	Florone-E
Diflorasone diacetate/emollient base	Psorcon E
Difluprednate	Durezol
Diphenhydramine HCl/hydrocortisone	Hc Derma-Pax
Flunisolide	Aerobid
Flunisolide	Aerospan
Flunisolide/menthol	Aerobid-M
Fluocinolone acetonide	Capex
Fluocinolone acetonide	Derma-Smoothie/Fs
Fluocinolone acetonide	Derma-Smoothie/Fs Body Oil
Fluocinolone acetonide	Derma-Smoothie/Fs Eczema
Fluocinolone acetonide	Fluocinolone
Fluocinolone acetonide	Fs Shampoo
Fluocinolone acetonide	Iluvien
Fluocinolone acetonide	Retisert
Fluocinolone acetonide	Synalar
Fluocinolone acetonide	Synalar-Hp
Fluocinolone acetonide oil	Dermotic Oil
Fluocinolone acetonide oil	Fluocinolone Acetonide Oil
Fluocinolone acetonide, micronized	Fluocinolone Acet, Micro(Bulk)
Fluocinolone acetonide/emollient base	Derma-Smoothie/Fs Atopic Pak
Fluocinolone acetonide/emollient base	Synemol
Fluocinolone acetonide/emollient combination no.65	Synalar Cream Kit
Fluocinolone acetonide/emollient combination no.65	Synalar Ointment Kit
Fluocinolone acetonide/shower cap	Derma-Smoothie/Fs Scalp Oil
Fluocinolone acetonide/shower cap	Fluocinolone And Shower Cap
Fluocinolone acetonide/skin cleanser comb no.28	Synalar Ts
Fluocinolone acetonide/skin cleanser no.10/silicone, tape	Xilapak
Fluocinolone acetonide/urea/silicone, adhesive	Noxipak
Fluocinonide	Fluex
Fluocinonide	Fluocinonide
Fluocinonide	Lidex
Fluocinonide	Vanos
Fluocinonide/emollient base	Fluocinonide-E
Fluocinonide/emollient base	Fluocinonide-Emollient
Fluocinonide/emollient base	Lidex-E
Fluorometholone	Fluorometholone
Fluorometholone	Fluor-Op
Fluorometholone	Fml Forte
Fluorometholone	Fml Liquifilm
Fluorometholone	Fml S.O.P.
Fluorometholone acetate	Eflone

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Fluorometholone acetate	Flarex
Flurandrenolide	Cordran
Flurandrenolide	Cordran Patch
Flurandrenolide	Cordran Sp
Flurandrenolide	Cordran Tape Large Roll
Flurandrenolide	Cordran Tape Small Roll
Flurandrenolide	Flurandrenolide
Flurandrenolide	Nolix
Fluticasone furoate	Arnuity Ellipta
Fluticasone furoate/umeclidinium bromide/vilanterol trifenate	Trelegy Ellipta
Fluticasone furoate/vilanterol trifenate	Breo Ellipta
Fluticasone propionate	Armonair Respiclick
Fluticasone propionate	Cutivate
Fluticasone propionate	Flovent
Fluticasone propionate	Flovent Diskus
Fluticasone propionate	Flovent Hfa
Fluticasone propionate	Flovent Rotadisk
Fluticasone propionate	Fluticasone
Fluticasone propionate	Fluticasone Propionate (bulk)
Fluticasone propionate, micronized	Fluticasone Prop, Micro (bulk)
Fluticasone propionate/salmeterol xinafoate	Advair Diskus
Fluticasone propionate/salmeterol xinafoate	Advair Hfa
Fluticasone propionate/salmeterol xinafoate	Airduo Respiclick
Fluticasone propionate/salmeterol xinafoate	Fluticasone-Salmeterol
Gatifloxacin/prednisolone acetate	Gatifloxacin-Prednisolone
Gatifloxacin/prednisolone acetate/nepafenac	Gatifloxacin-Prednisol-Nepafen
Gentamicin sulfate/prednisolone acetate	Pred-G
Gentamicin sulfate/prednisolone acetate	Pred-G S.O.P.
Halcinonide	Halog
Halcinonide/emollient base	Halog-E
Halobetasol propionate	Halobetasol Propionate
Halobetasol propionate	Ultravate
Halobetasol propionate/ammonium lactate	Halac
Halobetasol propionate/ammonium lactate	Halonate
Halobetasol propionate/ammonium lactate	Halonate Pac
Halobetasol propionate/ammonium lactate	Ultravate Pac
Halobetasol propionate/lactic acid	Ultravate X
Hydrocortisone	Acticort 100
Hydrocortisone	Advanced Allergy Collect Kit
Hydrocortisone	Ala-Cort
Hydrocortisone	Ala-Scalp
Hydrocortisone	Albacort
Hydrocortisone	Anti-Itch (Hc)
Hydrocortisone	Anusol-Hc
Hydrocortisone	Aquanil Hc

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Hydrocortisone	Balneol For Her
Hydrocortisone	Beta-Hc
Hydrocortisone	Cetacort
Hydrocortisone	Colocort
Hydrocortisone	Complex A
Hydrocortisone	Cortaid
Hydrocortisone	Cortaid Faststick Max St
Hydrocortisone	Cortaid Intensive Therapy
Hydrocortisone	Cortaid Maximum Strength
Hydrocortisone	Cortef
Hydrocortisone	Cortenema
Hydrocortisone	Corticool
Hydrocortisone	Cortinal
Hydrocortisone	Cortisone (Hydrocortisone)
Hydrocortisone	Cortisone + Cooling Relief
Hydrocortisone	Cortizone For Kids
Hydrocortisone	Cortizone-10
Hydrocortisone	Cortizone-10 Anal Itch Relief
Hydrocortisone	Cortizone-10 Plus
Hydrocortisone	Cortizone-5
Hydrocortisone	Cotacort
Hydrocortisone	Dermacort
Hydrocortisone	Dermarest Eczema (Hydrocort)
Hydrocortisone	Dermolate Anti-Itch
Hydrocortisone	Dr. Smith's Anti-Itch
Hydrocortisone	Eczema Anti-Itch
Hydrocortisone	First-Hydrocortisone
Hydrocortisone	Hydrocortisone
Hydrocortisone	Hydrocortisone Plus
Hydrocortisone	Hydrocortisone Plus 12
Hydrocortisone	Hydrocortisone Scalp
Hydrocortisone	Hydrocortone
Hydrocortisone	Hydrocream
Hydrocortisone	Hydroskin
Hydrocortisone	Hytone
Hydrocortisone	Instacort
Hydrocortisone	Instacort Scalp
Hydrocortisone	Itch-X
Hydrocortisone	Itch-X Hc
Hydrocortisone	Lacticare-Hc
Hydrocortisone	Neosporin Anti-Itch
Hydrocortisone	Neutrogena T/Scalp
Hydrocortisone	Noble Formula Hc
Hydrocortisone	Nupercainal Hc
Hydrocortisone	Nutracort

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Hydrocortisone	Obagi Nu-Derm Tolereen
Hydrocortisone	P.P.C.
Hydrocortisone	Penecort
Hydrocortisone	Preparation H Hydrocortisone
Hydrocortisone	Proctocare-Hc
Hydrocortisone	Proctocort
Hydrocortisone	Proctocream-Hc
Hydrocortisone	Procto-Kit
Hydrocortisone	Procto-Med Hc
Hydrocortisone	Procto-Pak
Hydrocortisone	Proctosol Hc
Hydrocortisone	Proctozone-Hc
Hydrocortisone	Recort Plus
Hydrocortisone	Rederm
Hydrocortisone	Sarnol-Hc
Hydrocortisone	Scalacort
Hydrocortisone	Scalp Relief
Hydrocortisone	Scalp-Cort
Hydrocortisone	Scalpicin Anti-Itch
Hydrocortisone	Soothing Care (Hydrocortisone)
Hydrocortisone	Summer's Eve
Hydrocortisone	Texacort
Hydrocortisone	Yeast-X External
Hydrocortisone acetate	Anucort-Hc
Hydrocortisone acetate	Anudil Hc
Hydrocortisone acetate	Anu-Med
Hydrocortisone acetate	Anumed Hc
Hydrocortisone acetate	Anu-Med Hc
Hydrocortisone acetate	Anurx-Hc
Hydrocortisone acetate	Anusert Hc-1
Hydrocortisone acetate	Anusol Hc-1
Hydrocortisone acetate	Anusol-Hc
Hydrocortisone acetate	Anuzone-Hc
Hydrocortisone acetate	Cortaid (Hydrocortisone Acet)
Hydrocortisone acetate	Cortaid Maximum Strength
Hydrocortisone acetate	Corticaine
Hydrocortisone acetate	Corticreme
Hydrocortisone acetate	Cortifoam
Hydrocortisone acetate	Demarest Dricort
Hydrocortisone acetate	Grx Hicort 25
Hydrocortisone acetate	Gynecort
Hydrocortisone acetate	Gynecort Maximum Strength
Hydrocortisone acetate	Hc-1% Hemorrhoid
Hydrocortisone acetate	Hemmorex-Hc
Hydrocortisone acetate	Hemorrhoidal-Hc

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Hydrocortisone acetate	Hemril-30
Hydrocortisone acetate	Hemril-Hc
Hydrocortisone acetate	Hydrocortisone Acetate
Hydrocortisone acetate	Lanacort
Hydrocortisone acetate	Medi-Cortisone
Hydrocortisone acetate	Micort-Hc
Hydrocortisone acetate	Proctocort
Hydrocortisone acetate	Proctosert Hc
Hydrocortisone acetate	Proctosol
Hydrocortisone acetate	Proctozone H
Hydrocortisone acetate	Rectacort-Hc
Hydrocortisone acetate	Rectasol-Hc
Hydrocortisone acetate	Tucks Hydrocortisone
Hydrocortisone acetate/aloe polysaccharide/iodoquinol	Hydro-Iodoquinol 2-1
Hydrocortisone acetate/aloe polysaccharide/iodoquinol	Lodocortisone Aloe
Hydrocortisone acetate/aloe vera	Cortaid With Aloe
Hydrocortisone acetate/aloe vera	Cortalo
Hydrocortisone acetate/aloe vera	Hydrocortisone Acet-Aloe Vera
Hydrocortisone acetate/aloe vera	Hydrocortisone Acetate-Aloe
Hydrocortisone acetate/aloe vera	Lanacort
Hydrocortisone acetate/aloe vera	Nucort
Hydrocortisone acetate/aloe vera	Nuzon
Hydrocortisone acetate/iodoquinol/aloe polysaccharides no.2	Alcortin A
Hydrocortisone acetate/iodoquinol/aloe polysaccharides no.2	Hydrocortisone-Iodoquinol-Aloe2
Hydrocortisone acetate/iodoquinol/aloe vera	Hydrocortisone-Iodoquinol-Aloe
Hydrocortisone acetate/iodoquinol/aloe vera	Vytone
Hydrocortisone acetate/lidocaine HCl/aloe vera	Ana-Lex Hc
Hydrocortisone acetate/lidocaine HCl/aloe vera	Ana-Lex Kit
Hydrocortisone acetate/lidocaine HCl/aloe vera	Anamantle Hc
Hydrocortisone acetate/lidocaine HCl/aloe vera	Lidocaine-Hydrocortisone-Aloe
Hydrocortisone acetate/lidocaine HCl/aloe vera	Lidocort
Hydrocortisone acetate/lidocaine HCl/aloe vera	Peranex Hc
Hydrocortisone acetate/lidocaine HCl/aloe vera	Rectagel Hc
Hydrocortisone acetate/lidocaine HCl/skin cleanser no.6	Xyralid
Hydrocortisone acetate/lidocaine HCl/skin cleanser no.6	Xyralid Lp
Hydrocortisone acetate/pramoxine HCl	Analpram-Hc
Hydrocortisone acetate/pramoxine HCl	Analpram-Hc Singles
Hydrocortisone acetate/pramoxine HCl	Endaroid
Hydrocortisone acetate/pramoxine HCl	Enzone
Hydrocortisone acetate/pramoxine HCl	Epifoam
Hydrocortisone acetate/pramoxine HCl	Hc Pram
Hydrocortisone acetate/pramoxine HCl	Hc Pramoxine
Hydrocortisone acetate/pramoxine HCl	Hydrocortisone-Pramoxine
Hydrocortisone acetate/pramoxine HCl	Mezparox-Hc
Hydrocortisone acetate/pramoxine HCl	Novacort

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Hydrocortisone acetate/pramoxine HCl	Pramcort
Hydrocortisone acetate/pramoxine HCl	Pramosone
Hydrocortisone acetate/pramoxine HCl	Procort
Hydrocortisone acetate/pramoxine HCl	Proctocream-Hc(With Pramoxine)
Hydrocortisone acetate/pramoxine HCl	Proctofoam Hc
Hydrocortisone acetate/pramoxine HCl	Zone-A
Hydrocortisone acetate/pramoxine HCl	Zone-A Forte
Hydrocortisone acetate/pramoxine HCl/aloe polysaccharide	Hydropramox
Hydrocortisone acetate/pramoxine HCl/aloe polysaccharide	Novacort (With Aloe)
Hydrocortisone acetate/pramoxine HCl/emollient base	Pramosone E
Hydrocortisone acetate/pramoxine HCl/skin cleanser no.16	Pram-Hca
Hydrocortisone acetate/pramoxine HCl/skin cleanser no.16	Z-Pram
Hydrocortisone acetate/pramoxine HCl/skin cleanser no.16	Zypram
Hydrocortisone acetate/pramoxine/emollient/pramoxine cmb no1	Analpram E
Hydrocortisone acetate/pramoxine/emollient/pramoxine cmb no1	Hydrocortisone-Pramox-E-Pram#1
Hydrocortisone acetate/urea	Carmol Hc
Hydrocortisone acetate/urea	Keratol Hc
Hydrocortisone acetate/urea	U-Cort
Hydrocortisone butyrate	Hydrocortisone Butyrate
Hydrocortisone butyrate	Locoid
Hydrocortisone butyrate/emollient base	Hydrocortisone Butyr-Emollient
Hydrocortisone butyrate/emollient base	Locoid Lipocream
Hydrocortisone cypionate	Cortef (as Cypionate)
Hydrocortisone hemisuccinate	Hydrocortisone Hemisucc (bulk)
Hydrocortisone probutate	Pandel
Hydrocortisone sod phosphate	Hydrocortone
Hydrocortisone sod succinate	A-Hydrocort
Hydrocortisone sod succinate	Hydrocortisone Sod Succinate
Hydrocortisone sod succinate	Solu-Cortef
Hydrocortisone sodium succinate/PF	Solu-Cortef (PF)
Hydrocortisone valerate	Hydrocortisone Valerate
Hydrocortisone valerate	Westcort
Hydrocortisone/acetic acid	Acetasol Hc
Hydrocortisone/acetic acid	Hydrocortisone-Acetic Acid
Hydrocortisone/acetic acid	Otomycet Hc
Hydrocortisone/acetic acid	Otosol-Hc
Hydrocortisone/acetic acid	Vosol-Hc
Hydrocortisone/aloe polysaccharide/iodoquinol	Alcortin
Hydrocortisone/aloe vera	Cortisone with Aloe
Hydrocortisone/aloe vera	Cortizone-10 with Aloe
Hydrocortisone/aloe vera	Hydrocortisone Plus
Hydrocortisone/aloe vera	Hydrocortisone-Aloe Vera
Hydrocortisone/aloe vera	Hydroskin with Aloe
Hydrocortisone/aloe vera/vitamin e acetate/vitamins a and d	Anti-Itch (Hc) with Aloe-Vit E
Hydrocortisone/aloe vera/vitamin e acetate/vitamins a and d	Anti-Itch Plus

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Hydrocortisone/benzocaine/chloroxylenol	Oto-Care Hc
Hydrocortisone/colloidal oatmeal/aloe/vitamin e	Anti-Itch (Hc) With Oatmeal
Hydrocortisone/colloidal oatmeal/aloe/vitamin e	Aveeno Anti-Itch (Hydrocortsn)
Hydrocortisone/colloidal oatmeal/aloe/vitamin e	Hydrocortisone-Oatmeal-Aloe-E
Hydrocortisone/emollient combination no.45	Pediaderm Hc
Hydrocortisone/iodoquinol	Dermazene
Hydrocortisone/iodoquinol	Hydrocortisone-Iodoquinol
Hydrocortisone/iodoquinol	Iodoquinol-Hc
Hydrocortisone/iodoquinol	Vytone
Hydrocortisone/mineral oil/petrolatum,white	Hydrocortisone-Min Oil-Wht Pet
Hydrocortisone/pramoxine HCl/chloroxylenol	Aero Otic Hc
Hydrocortisone/pramoxine HCl/chloroxylenol	Cortane-B
Hydrocortisone/pramoxine HCl/chloroxylenol	Cortic
Hydrocortisone/pramoxine HCl/chloroxylenol	Cortic-Nd
Hydrocortisone/pramoxine HCl/chloroxylenol	Cyotic
Hydrocortisone/pramoxine HCl/chloroxylenol	Exotic-Hc
Hydrocortisone/pramoxine HCl/chloroxylenol	Genexotic-Hc
Hydrocortisone/pramoxine HCl/chloroxylenol	Ot-Ake Hc
Hydrocortisone/pramoxine HCl/chloroxylenol	Oticin Hc (Bak Free)
Hydrocortisone/pramoxine HCl/chloroxylenol	Oti-Med
Hydrocortisone/pramoxine HCl/chloroxylenol	Otix
Hydrocortisone/pramoxine HCl/chloroxylenol	Oto-End 10
Hydrocortisone/pramoxine HCl/chloroxylenol	Otomar
Hydrocortisone/pramoxine HCl/chloroxylenol	Otomar-Hc
Hydrocortisone/pramoxine HCl/chloroxylenol	Otomax-Hc
Hydrocortisone/pramoxine HCl/chloroxylenol	Otozone
Hydrocortisone/pramoxine HCl/chloroxylenol	Pramoxine-Hc
Hydrocortisone/pramoxine HCl/chloroxylenol	Tri-Otic
Hydrocortisone/pramoxine HCl/chloroxylenol	Zolene Hc
Hydrocortisone/pramoxine HCl/chloroxylenol	Zoto-Hc
Hydrocortisone/pramoxine HCl/chloroxylenol/water	Cortane-B Aqueous
Hydrocortisone/pramoxine HCl/chloroxylenol/water	Pramoxine-Hc
Hydrocortisone/pramoxine HCl/chloroxylenol/water	Zotane Hc
Hydrocortisone/pramoxine/chloroxylenol/benzalkonium	Alba-3 Hc
Hydrocortisone/pramoxine/chloroxylenol/benzalkonium	Hydro
Hydrocortisone/pramoxine/chloroxylenol/benzalkonium	Oticin Hc
Hydrocortisone/pramoxine/diosmin1/aloe polysac 1/policosanol	Analpram Advanced
Hydrocortisone/resorcinol/bismuth subgallate/zinc oxide	Anusol-Hc
Hydrocortisone/resorcinol/bismuth subgallate/zinc oxide	Hc-Bismuth Subgal-Znox-Resor
Hydrocortisone/resorcinol/bismuth subgallate/zinc oxide	Hemorrhoidal With Hc
Hydrocortisone/resorcinol/bismuth subgallate/zinc oxide	Hemorrhoidal-Hc (Bismuth-Zinc)
Hydrocortisone/salicylic acid/sulfur	Coraz
Hydrocortisone/salicylic acid/sulfur/shampoo no. 1	Scalacort Dk
Hydrocortisone/skin cleanser combination no.25	Aqua Glycolic Hc
Hydrocortisone/skin cleanser combination no.35	Dermasorb Hc Complete Kit

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Hydrocortisone/yerba santa	Earsol-Hc
Ketoconazole/hydrocortisone	Ketocon + Plus
Ketoconazole/hydrocortisone	Ketoconazole-Hydrocortisone
Ketoconazole/hydrocortisone	Xolegel Corepak
Lidocaine HCl/hydrocortisone acetate	Ana-Lex
Lidocaine HCl/hydrocortisone acetate	Anamantle Hc
Lidocaine HCl/hydrocortisone acetate	Anamantle Hc Forte
Lidocaine HCl/hydrocortisone acetate	Lidamantle Hc
Lidocaine HCl/hydrocortisone acetate	Lidazone Hc
Lidocaine HCl/hydrocortisone acetate	Lidocaine HCl-Hydrocortison Ac
Lidocaine HCl/hydrocortisone acetate	Lidocaine-Hc
Lidocaine HCl/hydrocortisone acetate	Peranex Hc
Lidocaine HCl/hydrocortisone acetate	Rectacreme Hc
Lidocaine HCl/hydrocortisone acetate	Senatec Hc
Lidocaine HCl/hydrocortisone acetate/psyllium husk	Xyralid Rc
Loteprednol etabonate	Alrex
Loteprednol etabonate	Lotemax
Medrysone	Liquifilm
Methylprednisolone	Medrol
Methylprednisolone	Medrol (Pak)
Methylprednisolone	Meprolone Unipak
Methylprednisolone	Methylpred
Methylprednisolone	Methylprednisolone
Methylprednisolone acetate	Adlone
Methylprednisolone acetate	Cpc-Depmed-40
Methylprednisolone acetate	Cpc-Depmed-80
Methylprednisolone acetate	Dep-Medalone 40
Methylprednisolone acetate	Dep-Medalone 80
Methylprednisolone acetate	Depoject-40
Methylprednisolone acetate	Depoject-80
Methylprednisolone acetate	Depo-Medrol
Methylprednisolone acetate	Depopred 40
Methylprednisolone acetate	Depopred 80
Methylprednisolone acetate	Depo-Predate
Methylprednisolone acetate	Medralone 40
Methylprednisolone acetate	Medralone 80
Methylprednisolone acetate	Methylcotolone
Methylprednisolone acetate	Methylprednisolone Acetate
Methylprednisolone acetate	P-Care D40
Methylprednisolone acetate	P-Care D80
Methylprednisolone acetate	Readysharp Methylprednisolone
Methylprednisolone acetate	Rep-Pred 40
Methylprednisolone acetate	Rep-Pred 80
Methylprednisolone acetate/bupivacaine HCl	Physicians Ez Use M-Pred
Methylprednisolone acetate/norflurane/hfc 245fa	Medroloan II Suik

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Methylprednisolone acetate/norflurane/hfc 245fa	Medroloan Suik
Methylprednisolone acetate/norflurane/hfc 245fa	P-Care D40g
Methylprednisolone acetate/norflurane/hfc 245fa	P-Care D80g
Methylprednisolone sodium succinate	A-Methapred
Methylprednisolone sodium succinate	Methylprednisol Sod Suc(bulk)
Methylprednisolone sodium succinate	Methylprednisolone Sodium Succ
Methylprednisolone sodium succinate	Solu-Medrol
Methylprednisolone sodium succinate/PF	Solu-Medrol (PF)
Methylprednisolone, micronized	Methylprednisolone, Mic (bulk)
Mifepristone	Korlym
Mometasone furoate	Asmanex Hfa
Mometasone furoate	Asmanex Twisthaler
Mometasone furoate	Elocon
Mometasone furoate	Mometasone
Mometasone furoate	Mometasone Furoate (bulk)
Mometasone furoate/ammonium lactate	Momexin
Mometasone furoate/formoterol fumarate	Dulera
Neomycin sulf/colistin sul/hydrocortisone ac/thonzonium brom	Coly-Mycin S
Neomycin sulf/colistin sul/hydrocortisone ac/thonzonium brom	Cortisporin-Tc
Neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone	Ak-Spore Hc
Neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone	Antibiotic Hc
Neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone	Cortisporin
Neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone	Cortomycin
Neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone	Neomycin-Bacitracin-Poly-Hc
Neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone	Neo-Poly-Bac-Hc
Neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone	Neo-Polycin Hc
Neomycin sulfate/bacitracin zinc/polymyxin b/hydrocortisone	Triple Antibiotic-Hc
Neomycin sulfate/colistin sulfate/hydrocortisone	Coly-Mycin S
Neomycin sulfate/dexamethasone sod phosphate	Ak-Neo-Dex
Neomycin sulfate/dexamethasone sod phosphate	Neo-Decadron
Neomycin sulfate/dexamethasone sod phosphate	Neo-Dex
Neomycin sulfate/dexamethasone sod phosphate	Neo-Dexair
Neomycin sulfate/dexamethasone sod phosphate	Neomycin-Dexamethasone
Neomycin sulfate/fluocinolone acetonide	Neo-Synalar
Neomycin sulfate/fluocinolone acetonide/emollient comb no.65	Neo-Synalar Kit
Neomycin sulfate/hydrocortisone	Neomycin-Hydrocortisone
Neomycin sulfate/polymyxin b sulfate/buffers/hydrocortisone	Pediotic
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Ak-Spore Hc
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Antibiotic Ear
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Antibiotic Hc
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Antibiotic Otic
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Aurobiotic-Hc
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Bio-Cot
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Cortatrigen
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Cort-Biotic

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Cortisporin
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Cortomycin
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Lazersporin-C
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Neomycin-Polymyxin-Hc
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Octigen
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Oticin Hc
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Otimar
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Otolidin
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Otocort
Neomycin sulfate/polymyxin b sulfate/hydrocortisone	Uad Otic
Neomycin sulfate/polymyxin b sulfate/prednisolone	Poly-Pred
Neomycin/bacitracin/polymyxin b/hydrocortisone	Cortisporin
Neomycin/polymyxin b sulfate/dexamethasone	Ak-Trol
Neomycin/polymyxin b sulfate/dexamethasone	Dexacidin
Neomycin/polymyxin b sulfate/dexamethasone	Dexacine
Neomycin/polymyxin b sulfate/dexamethasone	Dexasporin
Neomycin/polymyxin b sulfate/dexamethasone	Maxitrol
Neomycin/polymyxin b sulfate/dexamethasone	Methadex
Neomycin/polymyxin b sulfate/dexamethasone	Neo Poly Dex
Neomycin/polymyxin b sulfate/dexamethasone	Neomycin-Polymyxin B-Dexameth
Neomycin/polymyxin b sulfate/dexamethasone	Poly-Dex
Neomycin/polymyxin b sulfate/dexamethasone	W-Dnp
Nystatin/triamcinolone acetamide	Mycogen II
Nystatin/triamcinolone acetamide	Mycolog II
Nystatin/triamcinolone acetamide	Mycosone II
Nystatin/triamcinolone acetamide	Myco-Triacet II
Nystatin/triamcinolone acetamide	Mycozin
Nystatin/triamcinolone acetamide	Mytrex
Nystatin/triamcinolone acetamide	N T A
Nystatin/triamcinolone acetamide	N.G.T.
Nystatin/triamcinolone acetamide	Nta
Nystatin/triamcinolone acetamide	Nystatin-Triamcinolone
Nystatin/triamcinolone acetamide	Tri-Staton II
Oxytetracycline HCl/hydrocortisone acetate	Terra-Cortril
Polymyxin b sulfate/hydrocortisone	Otobiotic
Prednicarbate	Dermatop
Prednicarbate	Dermatop E
Prednicarbate	Prednicarbate
Prednisolone	Millipred
Prednisolone	Millipred Dp
Prednisolone	Prednisolone
Prednisolone	Prelone
Prednisolone acetate	Cotolone
Prednisolone acetate	Econopred
Prednisolone acetate	Econopred Plus

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Prednisolone acetate	Flo-Pred
Prednisolone acetate	Key-Pred
Prednisolone acetate	Omnipred
Prednisolone acetate	Pred Forte
Prednisolone acetate	Pred Mild
Prednisolone acetate	Predalone 50
Prednisolone acetate	Predicort-50
Prednisolone acetate	Prednisolone Acetate
Prednisolone acetate	Pri-Cortin 50
Prednisolone acetate	Uad Pred
Prednisolone acetate, micronized	Prednisolone Ac, Micro (Bulk)
Prednisolone acetate/nepafenac	Prednisolone Acetate-Nepafenac
Prednisolone sod phosphate	Ak-Pred
Prednisolone sod phosphate	Bubbli-Pred
Prednisolone sod phosphate	Inflamase Forte
Prednisolone sod phosphate	Inflamase Mild
Prednisolone sod phosphate	Millipred
Prednisolone sod phosphate	Orapred
Prednisolone sod phosphate	Orapred Odt
Prednisolone sod phosphate	Pediapred
Prednisolone sod phosphate	Predair Forte
Prednisolone sod phosphate	Prednisol
Prednisolone sod phosphate	Prednisolone Sodium Phosphate
Prednisolone sod phosphate	Veripred 20
Prednisolone sodium phosphate/peak flow meter	Asmalpred
Prednisolone sodium phosphate/peak flow meter	Asmalpred Plus
Prednisolone, micronized	Prednisolone, Micro (bulk)
Prednisone	Deltasone
Prednisone	Deltasone Dose Pack
Prednisone	Liquid Pred
Prednisone	Meticorten
Prednisone	Prednisone
Prednisone	Prednisone Intensol
Prednisone	Rayos
Prednisone	Sterapred
Prednisone	Sterapred Ds
Prednisone micronized	Prednisone Micronized (bulk)
Pyrilamine/pheniramine/chlorpheniramine/hydrocortisone	Derma-Pax-Hc
Rimexolone	Vexol
Sulfacetamide sodium/fluorometholone	Fml-S Liquifilm
Sulfacetamide sodium/prednisolone acetate	Ak-Cide
Sulfacetamide sodium/prednisolone acetate	Blephamide
Sulfacetamide sodium/prednisolone acetate	Blephamide S.O.P.
Sulfacetamide sodium/prednisolone acetate	Cetapred
Sulfacetamide sodium/prednisolone acetate	Isopto Cetapred

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Sulfacetamide sodium/prednisolone acetate	Metimyd
Sulfacetamide sodium/prednisolone acetate	Sulfacetamide-Prednisolone
Sulfacetamide sodium/prednisolone acetate	Vasocine
Sulfacetamide sodium/prednisolone sodium phosphate	Sulfacetamide-Prednisolone
Sulfacetamide sodium/prednisolone sodium phosphate	Sulfapred
Sulfacetamide sodium/prednisolone sodium phosphate	Sulster
Sulfacetamide sodium/prednisolone sodium phosphate	Supred
Sulfacetamide sodium/prednisolone sodium phosphate	Vasocidin
Tobramycin/dexamethasone	Tobradex
Tobramycin/dexamethasone	Tobradex St
Tobramycin/dexamethasone	Tobramycin-Dexamethasone
Tobramycin/loteprednol etabonate	Zylet
Triamcinolone	Aristocort
Triamcinolone	Aristo-Pak
Triamcinolone	Triamcinolone
Triamcinolone acetonide	Acetocot
Triamcinolone acetonide	Aristocort Hp
Triamcinolone acetonide	Aristocort Lp
Triamcinolone acetonide	Aristocort R
Triamcinolone acetonide	Arze-Ject-A
Triamcinolone acetonide	Azmacort
Triamcinolone acetonide	Cenocort A-40
Triamcinolone acetonide	Cinalog
Triamcinolone acetonide	Cinonide 40
Triamcinolone acetonide	Kenaject
Triamcinolone acetonide	Kenalog In Orabase
Triamcinolone acetonide	Oralone
Triamcinolone acetonide	P-Care K40
Triamcinolone acetonide	P-Care K80
Triamcinolone acetonide	Pod-Care 100k
Triamcinolone acetonide	Pro-C-Dure 5
Triamcinolone acetonide	Pro-C-Dure 6
Triamcinolone acetonide	Readysharp Triamcinolone
Triamcinolone acetonide	Tac-3
Triamcinolone acetonide	Triacet
Triamcinolone acetonide	Triam-A
Triamcinolone acetonide	Triamcinolone Acetonide
Triamcinolone acetonide	Triamcinolone Acetonide (bulk)
Triamcinolone acetonide	Triamonide 40
Triamcinolone acetonide	Trianex
Triamcinolone acetonide	Triderm
Triamcinolone acetonide	Tri-Kort
Triamcinolone acetonide	Zilretta
Triamcinolone acetonide/dimethicone	Ellzia Pak
Triamcinolone acetonide/dimethicone/silicone, adhesive	Dermacinrx Silapak

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Triamcinolone acetonide/dimethicone/silicone, adhesive	Dermasilkrx Sds
Triamcinolone acetonide/dimethicone/silicone, adhesive	Dermawerx Sds
Triamcinolone acetonide/dimethicone/silicone, adhesive	Nutriarx
Triamcinolone acetonide/dimethicone/silicone, adhesive	Sanadermrax
Triamcinolone acetonide/dimethicone/silicone, adhesive	Sure Result Tac Pak
Triamcinolone acetonide/dimethicone/silicone, adhesive	Tri-Sila
Triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm Tdpak
Triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm Trilasil Pak
Triamcinolone acetonide/emollient combination no.45	Pediaderm Ta
Triamcinolone acetonide/emollient combination no.86	Dermasorb Ta Complete Kit
Triamcinolone acetonide/lidocaine HCl	Ez Use Joint-Tunnel-Trigger
Triamcinolone acetonide/lidocaine HCl	Lidocilone I
Triamcinolone acetonide/lidocaine/prilocaine	Dermacinrx Cinlone-I Cpi
Triamcinolone acetonide/low sensitizing base	Aristocort A
Triamcinolone acetonide/PF	Triesence (PF)
Triamcinolone acetonide/silicones	Dermacinrx Silazone
Triamcinolone acetonide/silicones	Dermazone
Triamcinolone acetonide/silicones	Silazone-II
Triamcinolone acetonide/skin clnsr6/emollient 27	Zytopic
Triamcinolone diacetate	Amcort
Triamcinolone diacetate	Aristocort Forte
Triamcinolone diacetate	Aristocort Intralesional
Triamcinolone diacetate	Cenocort Forte Suspension
Triamcinolone diacetate	Cinalone 40
Triamcinolone diacetate	Triam Forte
Triamcinolone diacetate	Triamcinolone Diacetate
Triamcinolone diacetate	Triamcot
Triamcinolone diacetate	Tristoject
Triamcinolone diacetate	U-Tri-Lone
Triamcinolone hexacetonide	Aristospan Intra-Articular
Triamcinolone hexacetonide	Aristospan Intralesional
Triamcinolone hexacetonide	Triamcinolone Hexaceton (bulk)
Triamcinolone hexacetonide, micronized	Triamcin Hexacet, Micro (bulk)
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	P-Care K40g
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	P-Care K80g
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	Pod-Care 100kg
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	Triloan II Suik
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	Triloan Suik
Immunosuppressive: Treatment for Immune Disorders (Excluding Chemotherapy or Radiation)	
Abatacept	Orencia
Abatacept	Orencia Clickject
Abatacept/maltose	Orencia (With Maltose)
Adalimumab	Humira Pediatric Crohn's Start
Adalimumab	Humira Pen Crohn's-Uc-Hs Start
Adalimumab	Humira

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Adalimumab	Humira Pen
Adalimumab	Humira Pen Psoriasis-Uveitis
Alefacept	Amevive
Anakinra	Kineret
Auranofin	Ridaura
Aurothioglucose	Solganal
Aurothioglucose	Aurothioglucose
Azathioprine	Azathioprine
Azathioprine	Imuran
Azathioprine	Azathioprine (bulk)
Azathioprine	Azasan
Azathioprine sodium	Azathioprine Sodium
Azathioprine sodium	Imuran
Basiliximab	Simulect
Belatacept	Nulojix
Belimumab	Benlysta
Canakinumab/PF	Ilaris (PF)
Certolizumab pegol	Cimzia Powder for Reconst
Certolizumab pegol	Cimzia
Certolizumab pegol	Cimzia Starter Kit
Clofarabine	Clolar
Clofarabine	Clofarabine
Cyclosporine	Restasis Multidose
Cyclosporine	Restasis
Cyclosporine	Sandimmune
Cyclosporine	Cyclosporine
Cyclosporine	Cyclosporine (bulk)
Cyclosporine, modified	Gengraf
Cyclosporine, modified	Neoral
Cyclosporine, modified	Cyclosporine Modified
Cyclosporine, modified	Sangcya
Cyclosporine/chondroitin sulfate a	Cyclosporine in Klarity
Daclizumab	Zenapax
Daclizumab	Zinbryta
Eculizumab	Soliris
Efalizumab	Raptiva
Etanercept	Enbrel
Etanercept	Enbrel Sureclick
Etanercept	Enbrel Mini
Fingolimod HCl	Gilenya
Glatiramer acetate	Copaxone
Glatiramer acetate	Glatiramer
Glatiramer acetate	Glatopa
Gold sodium thiomalate	Aurolate
Gold sodium thiomalate	Myochrysine

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Gold sodium thiomalate	Gold Sodium Thiomalate (bulk)
Gold sodium thiomalate	Gold Sodium Thiomalate
Golimumab	Simponi
Golimumab	Simponi Aria
Hydroxyurea	Hydrea
Hydroxyurea	Droxia
Hydroxyurea	Hydroxyurea
Hydroxyurea	Hydroxyurea (bulk)
Hydroxyurea	Mylocel
Hydroxyurea	Siklos
Infliximab	Remicade
Infliximab-abda	Renflexis
Infliximab-dyyb	Inflectra
Interferon alfa-2a,recomb.	Roferon-A
Interferon alfa-2b,recomb.	Intron A
Interferon alfa-n3	Alferon N
Interferon alfacon-1	Infergen
Interferon beta-1a	Avonex
Interferon beta-1a/albumin human	Rebif (with Albumin)
Interferon beta-1a/albumin human	Rebif Rebidose
Interferon beta-1a/albumin human	Rebif Titration Pack
Interferon beta-1a/albumin human	Avonex (with Albumin)
Interferon beta-1b	Extavia
Interferon beta-1b	Betaseron
Interferon gamma-1b,recomb.	Actimmune
Leflunomide	Arava
Leflunomide	Leflunomide
Lenalidomide	Revlimid
Methylprednisolone	Medrol
Methylprednisolone	Medrol (Pak)
Methylprednisolone	Methylprednisolone
Methylprednisolone	Meprolone Unipak
Methylprednisolone	Methylpred
Methylprednisolone acetate	Depo-Medrol
Methylprednisolone acetate	Rep-Pred 40
Methylprednisolone acetate	Rep-Pred 80
Methylprednisolone acetate	Methylprednisolone Acetate
Methylprednisolone acetate	Depoject-40
Methylprednisolone acetate	Depoject-80
Methylprednisolone acetate	Depopred 40
Methylprednisolone acetate	Depopred 80
Methylprednisolone acetate	Dep-Medalone 40
Methylprednisolone acetate	Dep-Medalone 80
Methylprednisolone acetate	Methylcotolone
Methylprednisolone acetate	Medralone 40

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Methylprednisolone acetate	Medralone 80
Methylprednisolone acetate	Adlone
Methylprednisolone acetate	Depo-Predate
Methylprednisolone acetate	P-Care D40
Methylprednisolone acetate	P-Care D80
Methylprednisolone acetate	Readysharp Methylprednisolone
Methylprednisolone acetate	Cpc-Depmed-40
Methylprednisolone acetate	Cpc-Depmed-80
Methylprednisolone acetate in sodium chloride,iso-osmotic/PF	Methylpred Ac(PF)-NaCl,Iso-Osm
Methylprednisolone acetate in sterile water for injection	Methylprednisolone Acet-Water
Methylprednisolone acetate, micronized	Methylprednisolon Ac,Mic(Bulk)
Methylprednisolone acetate/bupivacaine HCl	Physicians Ez Use M-Pred
Methylprednisolone acetate/bupivacaine HCl in sterile water	Methylprednisol Ac-Bupivac-Wat
Methylprednisolone acetate/norflurane/hfc 245fa	P-Care D40g
Methylprednisolone acetate/norflurane/hfc 245fa	P-Care D80g
Methylprednisolone acetate/norflurane/hfc 245fa	Medroloan Suik
Methylprednisolone acetate/norflurane/hfc 245fa	Medroloan II Suik
Methylprednisolone sodium succinate	Solu-Medrol
Methylprednisolone sodium succinate	A-Methapred
Methylprednisolone sodium succinate	Methylprednisolone Sodium Succ
Methylprednisolone sodium succinate	Methylprednisol Sod Suc(bulk)
Methylprednisolone sodium succinate/PF	Solu-Medrol (PF)
Methylprednisolone, micronized	Methylprednisolone, Mic (bulk)
Muromonab-cd3	Orthoclone Okt3
Mycophenolate mofetil	Cellcept
Mycophenolate mofetil	Mycophenolate Mofetil
Mycophenolate mofetil HCl	Cellcept Intravenous
Mycophenolate mofetil HCl	Mycophenolate Mofetil HCl
Natalizumab	Tysabri
Nystatin/triamcinolone acetonide	Mycolog II
Nystatin/triamcinolone acetonide	Myco-Triacet II
Nystatin/triamcinolone acetonide	Nystatin-Triamcinolone
Nystatin/triamcinolone acetonide	Mycogen II
Nystatin/triamcinolone acetonide	Mytrex
Nystatin/triamcinolone acetonide	Tri-Statin II
Nystatin/triamcinolone acetonide	N T A
Nystatin/triamcinolone acetonide	N.G.T.
Nystatin/triamcinolone acetonide	Mycosone II
Nystatin/triamcinolone acetonide	Nta
Nystatin/triamcinolone acetonide	Mycozin
Palivizumab	Synagis
Pegademase bovine	Adagen
Peginterferon alfa-2a	Pegasys
Peginterferon alfa-2a	Pegasys Convenience Pack
Peginterferon alfa-2a	Pegasys Proclick

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Peginterferon alfa-2b	Pegintron
Peginterferon alfa-2b	Sylatron
Peginterferon alfa-2b	Sylatron 4-Pack
Peginterferon alfa-2b	Pegintron Redipen
Peginterferon beta-1a	Plegridy
Ribavirin/interferon alfa-2b,recomb.	Rebetron 1200/Mdv
Ribavirin/interferon alfa-2b,recomb.	Rebetron 1000/Mdv
Ribavirin/interferon alfa-2b,recomb.	Rebetron 600/Mdv
Ribavirin/interferon alfa-2b,recomb.	Rebetron 1200/Pak-3
Ribavirin/interferon alfa-2b,recomb.	Rebetron 1000/Pak-3
Ribavirin/interferon alfa-2b,recomb.	Rebetron 600/Pak-3
Ribavirin/interferon alfa-2b,recomb.	Rebetron 1200/3 Miu Pen
Ribavirin/interferon alfa-2b,recomb.	Rebetron 1000/3 Miu Pen
Ribavirin/interferon alfa-2b,recomb.	Rebetron 600/3 Miu Pen
Ribavirin/interferon alfa-2b,recomb.	Rebetron 1200
Rilonacept	Arcalyst
Sirolimus	Rapamune
Sirolimus	Sirolimus (bulk)
Sirolimus	Sirolimus
Tacrolimus	Hecoria
Tacrolimus	Tacrolimus
Tacrolimus	Prograf
Tacrolimus	Astagraf XI
Tacrolimus	Protopic
Tacrolimus	Tacrolimus (bulk)
Tacrolimus	Envarsus Xr
Tacrolimus anhydrous	Tacrolimus Anhydrous (bulk)
Tacrolimus, micronized	Tacrolimus Micronized (bulk)
Temsirolimus	Torisel
Temsirolimus	Temsirolimus
Teriflunomide	Aubagio
Thalidomide	Thalomid
Tocilizumab	Actemra
Triamcinolone	Triamcinolone
Triamcinolone	Aristocort
Triamcinolone	Aristo-Pak
Triamcinolone	Triamcinolone (bulk)
Triamcinolone acetoneide	Kenalog
Triamcinolone acetoneide	Kenalog In Orabase
Triamcinolone acetoneide	Aristocort Hp
Triamcinolone acetoneide	Azmacort
Triamcinolone acetoneide	Nasacort
Triamcinolone acetoneide	Nasacort Aq
Triamcinolone acetoneide	Triacet
Triamcinolone acetoneide	Triamcinolone Acetoneide

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Triamcinolone acetonide	Nasal Allergy
Triamcinolone acetonide	Cenocort A-40
Triamcinolone acetonide	Trianex
Triamcinolone acetonide	Kenaject
Triamcinolone acetonide	Triam-A
Triamcinolone acetonide	Triderm
Triamcinolone acetonide	Tri-Nasal
Triamcinolone acetonide	Triamonide 40
Triamcinolone acetonide	Acetocot
Triamcinolone acetonide	Aristocort Lp
Triamcinolone acetonide	Aristocort R
Triamcinolone acetonide	Triamcinolone Acetonide (bulk)
Triamcinolone acetonide	Tri-Kort
Triamcinolone acetonide	Cinonide 40
Triamcinolone acetonide	Cinalog
Triamcinolone acetonide	Children's Nasacort
Triamcinolone acetonide	24 Hour Nasal Allergy
Triamcinolone acetonide	P-Care K40
Triamcinolone acetonide	P-Care K80
Triamcinolone acetonide	Pod-Care 100k
Triamcinolone acetonide	Tac-3
Triamcinolone acetonide	Oralone
Triamcinolone acetonide	Readysharp Triamcinolone
Triamcinolone acetonide	Arze-Ject-A
Triamcinolone acetonide	Pro-C-Dure 5
Triamcinolone acetonide	Pro-C-Dure 6
Triamcinolone acetonide	Zilretta
Triamcinolone acetonide in 0.9 % sodium chloride	Triamcinolone Aceton-0.9% Nacl
Triamcinolone acetonide/0.9% sodium chloride/PF	Triamcinol Ac (PF) In 0.9%Nacl
Triamcinolone acetonide/bupivacaine/in 0.9% sodium chloride	Triamcinol Ace-Bupiv-0.9% Nacl
Triamcinolone acetonide/dimethicone	Ellzia Pak
Triamcinolone acetonide/dimethicone/silicone, adhesive	Dermacinrx Silapak
Triamcinolone acetonide/dimethicone/silicone, adhesive	Dermasilkrx Sds
Triamcinolone acetonide/dimethicone/silicone, adhesive	Dermawerx Sds
Triamcinolone acetonide/dimethicone/silicone, adhesive	Tri-Sila
Triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm Tdpak
Triamcinolone acetonide/dimethicone/silicone, adhesive	Whytederm Trilasil Pak
Triamcinolone acetonide/dimethicone/silicone, adhesive	Sure Result Tac Pak
Triamcinolone acetonide/dimethicone/silicone, adhesive	Nutriarx
Triamcinolone acetonide/dimethicone/silicone, adhesive	Sanadermrax
Triamcinolone acetonide/emollient combination no.45	Pediaderm Ta
Triamcinolone acetonide/emollient combination no.86	Dermasorb Ta Complete Kit
Triamcinolone acetonide/lidocaine HCl	Lidocilone I
Triamcinolone acetonide/lidocaine HCl	Ez Use Joint-Tunnel-Trigger
Triamcinolone acetonide/lidocaine/prilocaine	Dermacinrx Cinlone-I Cpi

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Triamcinolone acetonide/low sensitizing base	Aristocort A
Triamcinolone acetonide/moxifloxacin HCl/water/PF	Triamcinolon-Moxiflox-Watr(PF)
Triamcinolone acetonide/PF	Triesence (PF)
Triamcinolone acetonide/silicones	Dermacinx Silazone
Triamcinolone acetonide/silicones	Silazone-II
Triamcinolone acetonide/silicones	Dermazone
Triamcinolone acetonide/silicones	Silalite Pak
Triamcinolone acetonide/skin clnsr6/emollient 27	Zytopic
Triamcinolone diacetate	Cenocort Forte Suspension
Triamcinolone diacetate	Tristoject
Triamcinolone diacetate	Triam Forte
Triamcinolone diacetate	Triamcinolone Diacetate
Triamcinolone diacetate	Triamcot
Triamcinolone diacetate	Aristocort Forte
Triamcinolone diacetate	Aristocort Intralesional
Triamcinolone diacetate	Amcort
Triamcinolone diacetate	U-Tri-Lone
Triamcinolone diacetate	Cinalone 40
Triamcinolone diacetate	Triamcinolone Diacetate (bulk)
Triamcinolone diacetate in 0.9 % sodium chloride	Triamcinolone Diacet-0.9% Nacl
Triamcinolone diacetate in 0.9 % sodium chloride/PF	Triamcinolone Dia(PF)-0.9%Nacl
Triamcinolone diacetate, micronized	Triamcin Diacet, Micro (bulk)
Triamcinolone hexacetonide	Aristospan Intralesional
Triamcinolone hexacetonide	Aristospan Intra-Articular
Triamcinolone hexacetonide	Triamcinolone Hexaceton (bulk)
Triamcinolone hexacetonide, micronized	Triamcin Hexacet, Micro (bulk)
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	P-Care K40g
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	P-Care K80g
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	Pod-Care 100kg
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	Triloan Suik
Triamcinolone/norflurane and pentafluoropropane (hfc 245fa)	Triloan II Suik
Ustekinumab	Stelara
Photosensitizing Drugs: Aminoquinolines	
Chloroquine HCl	Aralen
Chloroquine phosphate	Aralen
Chloroquine phosphate	Aralen Phosphate
Chloroquine phosphate	Chloroquine Phosphate
Chloroquine phosphate	Chloroquine Phosphate (bulk)
Hydroxychloroquine sulfate	Hydroxychloroquine
Hydroxychloroquine sulfate	Hydroxychloroquine Sulf (bulk)
Hydroxychloroquine sulfate	Plaquenil
Hydroxychloroquine sulfate	Quineprox
Primaquine phosphate	Primaquine
Primaquine phosphate	Primaquine (bulk)
Tafenoquine succinate	Arakoda

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Photosensitizing Drugs: Amiodarone	
Amiodarone HCl	Cordarone Iv
Amiodarone HCl	Cordarone
Amiodarone HCl	Amiodarone
Amiodarone HCl	Pacerone
Amiodarone HCl/dextrose 5 % in water	Amiodarone in Dextrose 5 %
Amiodarone in dextrose, iso-osmotic	Nexterone
Amiodarone HCl	Amiodarone (bulk)
Photosensitizing Drugs: Macrolides	
Amphotericin b	Fungizone
Azithromycin	Azasite
Azithromycin	Azithromycin
Azithromycin	Azithromycin (bulk)
Azithromycin	Zithromax
Azithromycin	Zithromax Tri-Pak
Azithromycin	Zithromax Z-Pak
Azithromycin	Zmax
Azithromycin	Zmax Pediatric
Azithromycin hydrogen citrate	Azithromycin Hydrogen Citrate
Clarithromycin	Biaxin
Clarithromycin	Biaxin XI
Clarithromycin	Biaxin XI Pak
Clarithromycin	Clarithromycin
Clarithromycin	Clarithromycin (bulk)
Dirithromycin	Dynabac
Dirithromycin	Dynabac D5-Pak
Erythromycin base	E-Mycin
Erythromycin base	Eryc
Erythromycin base	Ery-Tab
Erythromycin base	Erythromycin
Erythromycin base	Ilotycin
Erythromycin base	Pce
Erythromycin base	Romycin
Erythromycin estolate	Erythromycin Estolate
Erythromycin estolate	Erythromycin Estolate (bulk)
Erythromycin estolate	Ilosone
Erythromycin ethylsuccinate	E.E.S. 200
Erythromycin ethylsuccinate	E.E.S. 400
Erythromycin ethylsuccinate	E.E.S. Granules
Erythromycin ethylsuccinate	Eryped
Erythromycin ethylsuccinate	Eryped 200
Erythromycin ethylsuccinate	Eryped 400
Erythromycin ethylsuccinate	Erythromycin Ethylsuccinate
Erythromycin ethylsuccinate/sulfisoxazole acetyl	Erythromycin-Sulfisoxazole
Erythromycin ethylsuccinate/sulfisoxazole acetyl	Erythro-Sul Ped

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Erythromycin ethylsuccinate/sulfisoxazole acetyl	Eryzole
Erythromycin ethylsuccinate/sulfisoxazole acetyl	Pediagen
Erythromycin ethylsuccinate/sulfisoxazole acetyl	Pediazole
Erythromycin lactobionate	Erythrocin
Erythromycin lactobionate	Erythromycin Lactobionate
Erythromycin stearate	Erythrocin (as Stearate)
Erythromycin stearate	Erythrocot
Erythromycin stearate	Erythromycin Stearate
Erythromycin stearate	My-E
Fidaxomicin	Dificid
Nystatin	Mycostatin
Nystatin	Nyamyc
Nystatin	Nyata
Nystatin	Nystatin
Nystatin	Nystex
Nystatin	Nystop
Nystatin	Pedi-Dri
Nystatin/emollient combination no.54	Pediaderm Af
Nystatin/emollient combination no.88	Nyata (with Curatin)
Troleandomycin	Tao
Photosensitizing Drugs: Methoxypsoralen	
Methoxsalen	Oxsoralen
Methoxsalen	Oxsoralen Ultra
Methoxsalen	8-Mop
Methoxsalen	Methoxsalen (bulk)
Methoxsalen	Methoxsalen
Methoxsalen	Uvadex
Photosensitizing Drugs: Retinoids	
Adapalene	Adapalene
Adapalene	Differin
Adapalene	Plixda
Isotretinoin	Absorica
Isotretinoin	Accutane
Isotretinoin	Amnesteem
Isotretinoin	Claravis
Isotretinoin	Isotretinoin
Isotretinoin	Myorisan
Isotretinoin	Sotret
Isotretinoin	Zenatane
Tazarotene	Avage
Tazarotene	Fabior
Tazarotene	Tazarotene
Tretinoin	Altinac
Tretinoin	Altreno
Tretinoin	Atralin

Appendix H. List of Generic and Brand Drug Names Used to Define Covariates in this Request

Generic Name	Brand Name
Tretinoin	Avita
Tretinoin	Retin-A
Tretinoin	Tretinoin
Tretinoin	Tretin-X
Tretinoin microspheres	Retin-A Micro
Tretinoin microspheres	Retin-A Micro Pump
Tretinoin microspheres	Tretinoin Microspheres
Tretinoin/emollient base	Refissa
Tretinoin/emollient base	Renova
Tretinoin/emollient base	Tretinoin (Emollient)
Tretinoin/emollient combination no.9/skin cleanser no.1	Tretin-X Cream Kit
Tretinoin/emollient combination no.9/skin cleanser no.1/gel	Tretin-X (Gel)

Photosensitizing Drugs: Tetracycline

Tetracycline	Tetracycline (bulk)
Tetracycline HCl	Achromycin
Tetracycline HCl	Achromycin V
Tetracycline HCl	Actisite
Tetracycline HCl	Brodspec
Tetracycline HCl	Emtet-500
Tetracycline HCl	Sumycin
Tetracycline HCl	Sumycin 250
Tetracycline HCl	Sumycin 500
Tetracycline HCl	Tetracycline
Tetracycline HCl	Tetracycline HCl (bulk)
Tetracycline HCl	Viabecline

Appendix I. Specifications used to Define Parameters for Outcome 1 (Basal Cell Carcinoma) in this Request

This request utilized the Cohort Identification and Descriptive Analysis (CIDA) module, version 7.0.3 with ad hoc programming to examine the association between exposure to hydrochlorothiazide (HCTZ)-containing products and incidence of non-melanoma skin cancer (NMSC) in the Sentinel Distributed Database (SDD).

Query Period: January 1, 2000 to August 31, 2018
Coverage Requirement: Medical and Drug Coverage
Enrollment Requirement: 183 days
Restrictions: Male and Female only
Age: <50, 50-59, 60-74, and 75+ years
Enrollment Gap: 45 days
Envelope Macro: Reclassify encounters during inpatient stay as inpatient
Never-exposed Cohort: None
Freeze Data: No

Secondary Analysis: Extended Risk - 180 Day

	Primary Analysis: Extended Risk		Outcome		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome	
Scenario	1		2		4		5	
Expected Output	Propensity Score Estimation Needed [due to new censoring criteria] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups		Propensity Score Estimation Needed [due to new analysis] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups		Propensity Score Estimation Needed [due to new analysis] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups		Propensity Score Estimation Needed [due to new analysis] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups	
Drug/Exposure								
Exposure/Comparator	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products
Stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling
Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any
Incident with Respect to:	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products
Incidence Criteria Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any
Washout	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)
Cohort Definition	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period

Appendix I. Specifications used to Define Parameters for Outcome 1 (Basal Cell Carcinoma) in this Request								
Secondary Analysis: Extended Risk - 180 Day								
Primary Analysis: Extended Risk		Outcome		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome		
Scenario	1		2		4		5	
Inclusion/Exclusion Criteria								
Criteria	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation
Type	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion
Evaluation Window	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0
Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any
Criteria	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products
Type	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion
Evaluation Window	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any
Follow-up Time								
Treatment Episode gap	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days
Treatment Episode Extension	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days
Maximum Exposure Episode Duration	----	----	----	----	----	----	----	----
Follow-up Truncation Criteria (for both follow-up time and dose calculation)	(1) Death (2) DP End Date (3) Query End Date (4) Disenrollment (5) Outcome (6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(1) Death (2) DP End Date (3) Query End Date (4) Disenrollment (5) Outcome (6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(1) Death (2) DP End Date (3) Query End Date (4) Disenrollment (5) Outcome (6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(1) Death (2) DP End Date (3) Query End Date (4) Disenrollment (5) Outcome (6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(1) Death (2) DP End Date (3) Query End Date (4) Disenrollment (5) Outcome (6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(1) Death (2) DP End Date (3) Query End Date (4) Disenrollment (5) Outcome (6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(1) Death (2) DP End Date (3) Query End Date (4) Disenrollment (5) Outcome (6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(1) Death (2) DP End Date (3) Query End Date (4) Disenrollment (5) Outcome (6) Non-outcome cancer DX, radiation, non-outcome chemotherapy

Appendix I. Specifications used to Define Parameters for Outcome 1 (Basal Cell Carcinoma) in this Request								
Secondary Analysis: Extended Risk - 180 Day								
Primary Analysis: Extended Risk		Outcome		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome		
Scenario	1		2		4		5	
Event/Outcome								
Event/Outcome <i>Outcome Definition:</i> Basal cell carcinoma (BCC) or squamous cell carcinoma (SCC).	BCC Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date	BCC Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date	BCC Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 180) to DX date. Date of DX as outcome date	BCC Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 180) to DX date. Date of DX as outcome date	BCC Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date	BCC Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date	BCC Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 60) to DX date. Date of DX as outcome date	BCC Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 60) to DX date. Date of DX as outcome date
Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any
Washout, Relative to Exposure	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)
Incidence Criteria	Any	Any	Any	Any	Any	Any	Any	Any
Blackout Period (days)	1	1	1	1	731	731	1	1
Effects of Blackout	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days, and minimum enrollment length of 732 days --Time at risk starts on day 731 --Remove episodes with outcome on day 0-731	--Minimum episode length of 2 days, and minimum enrollment length of 732 days --Time at risk starts on day 731 --Remove episodes with outcome on day 0-731	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0
Propensity Score Matching								
Covariates	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score

Appendix I. Specifications used to Define Parameters for Outcome 1 (Basal Cell Carcinoma) in this Request									
Secondary Analysis: Extended Risk - 180 Day									
Primary Analysis: Extended Risk		Outcome		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome			
Scenario	1		2		4		5		
Covariates	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation
Covariate Evaluation Window	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	
Matching Ratio	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	
Matching Caliper Settings	0.050	0.050	0.050	0.050	0.050	0.050	0.050	0.050	
Analysis Type	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	
Additional Covariates to Adjust	-----	-----	-----	-----	-----	-----	-----	-----	
Subgroup Analysis	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)

Appendix I. Specifications used to Define Parameters for Outcome 1 (Basal Cell Carcinoma) in this Request									
		Secondary Analysis: Extended Risk - 180 Day							
		Primary Analysis: Extended Risk		Outcome		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome	
Scenario		1		2		4		5	
Re-matching within Subgroup Restricted		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Effect Estimation		Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return
Kaplan Meier Plot		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM) and Current Procedural Terminology, Fourth Edition (CPT-4) codes are provided by Optum360. National Drug Codes (NDCs) are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."

Appendix J. Specifications used to Define Parameters for Outcome 2 (Squamous Cell Carcinoma) in this Request

This request utilized the Cohort Identification and Descriptive Analysis (CIDA) module, version 7.0.3 with ad hoc programming to examine the association between exposure to hydrochlorothiazide (HCTZ)-containing products and incidence of non-melanoma skin cancer (NMSC) in the Sentinel Distributed Database (SDD).

Query Period: January 1, 2000 to August 31, 2018
Coverage Requirement: Medical and Drug Coverage
Enrollment Requirement: 183 days
Restrictions: Male and Female only
Age: <50, 50-59, 60-74, and 75+ years
Enrollment Gap: 45 days
Envelope Macro: Reclassify encounters during inpatient stay as inpatient
Never-exposed Cohort: None
Freeze Data: No

	Primary Analysis: Extended Risk		Secondary Analysis: Extended Risk - 180 Day Outcome		Long-term Risk		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome		Short-term Risk	
Scenario	7		8		9		10		11		12	
Expected Output	Propensity Score Estimation Needed [due to new analysis] (1) Updated Dose IRRs (2) Angiotensin-converting enzyme inhibitor (ACEI) IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups		Propensity Score Estimation Needed [due to new analysis] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups		Propensity Score Estimation Needed [due to new censoring criteria] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups		Propensity Score Estimation Needed [due to new analysis] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups		Propensity Score Estimation Needed [due to new analysis] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups		Propensity Score Estimation Needed [due to new censoring criteria] (1) Updated Dose IRRs (2) ACEI IRs over variable follow-up (3) Full PSA report including overall HR and all subgroups	
Drug/Exposure												
Exposure/Comparator	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products
Stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling	All product stockpiling
Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any
Incident with Respect to:	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products or ACEI monotherapy or non-HCTZ ACEI combination products
Incidence Criteria Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any
Washout	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)	-183 days (via exclusion)

Appendix J. Specifications used to Define Parameters for Outcome 2 (Squamous Cell Carcinoma) in this Request												
	Primary Analysis: Extended Risk		Secondary Analysis: Extended Risk - 180 Day Outcome		Long-term Risk		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome		Short-term Risk	
Scenario	7		8		9		10		11		12	
Cohort Definition	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period	First valid incident treatment episode during the query period
Inclusion/Exclusion Criteria												
Criteria	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation	Any cancer diagnosis, any chemotherapy, radiation
Type	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion
Evaluation Window	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0
Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any
Criteria	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products	ACEI monotherapy or non-HCTZ ACEI combination products	Any HCTZ-containing products
Type	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion	Exclusion
Evaluation Window	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any
Follow-up Time												
Treatment Episode gap	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days
Treatment Episode Extension	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days	15 days
Maximum Exposure Episode Duration	----	----	----	----	----	----	----	----	----	----	731	731

Appendix J. Specifications used to Define Parameters for Outcome 2 (Squamous Cell Carcinoma) in this Request												
Scenario	Primary Analysis: Extended Risk		Secondary Analysis: Extended Risk - 180 Day Outcome		Long-term Risk		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome		Short-term Risk	
	7	7	8	8	9	9	10	10	11	11	12	12
Follow-up	(1) Death	(1) Death	(1) Death	(1) Death	(1) Death	(1) Death	(1) Death	(1) Death	(1) Death	(1) Death	(1) Death	(1) Death
Truncation Criteria (for both follow-up time and dose calculation)	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date	(2) DP End Date
	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date	(3) Query End Date
	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)
	Disenrollment	Disenrollment	Disenrollment	Disenrollment	Disenrollment	Disenrollment	Disenrollment	Disenrollment	Disenrollment	Disenrollment	Disenrollment	Disenrollment
	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome	(5) Outcome
	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy	(6) Non-outcome cancer DX, radiation, non-outcome chemotherapy
					(7) Comparator dispensing	(7) Comparator dispensing					(7) Comparator dispensing	(7) Comparator dispensing
					(8) Treatment episode end	(8) Treatment episode end					(8) Treatment episode end	(8) Treatment episode end
Event/Outcome												
Event/Outcome Outcome	SCC	SCC	SCC	SCC	SCC	SCC	SCC	SCC	SCC	SCC	SCC	BCC
<i>Definition: Basal cell carcinoma (BCC) or squamous cell carcinoma (SCC).</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 180) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 180) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 60) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 60) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date</i>	<i>Diagnosis AND (removal of tumor or evidence of topical chemotherapy) (0, 30) to DX date. Date of DX as outcome date</i>
Care Setting/PDX	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any
Washout, Relative to Exposure	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)	-183 days (via exclusion for any cancer)
Incidence Criteria	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any	Any
Blackout Period	1	1	1	1	731	731	731	731	1	1	1	1


Appendix J. Specifications used to Define Parameters for Outcome 2 (Squamous Cell Carcinoma) in this Request													
Scenario	Primary Analysis: Extended Risk		Secondary Analysis: Extended Risk - 180 Day Outcome		Long-term Risk		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome		Short-term Risk		
	7	8	9	10	11	12							
Effects of Blackout	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0	--Minimum episode length of 2 days --Time at risk starts on day 1 --Remove episodes with outcome on day 0
Propensity Score Matching													
Covariates	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score	Tool based: Age (continuous), sex, calendar year, healthcare utilization, prior combined comorbidity raw score

Appendix J. Specifications used to Define Parameters for Outcome 2 (Squamous Cell Carcinoma) in this Request												
Scenario	Primary Analysis: Extended Risk		Secondary Analysis: Extended Risk - 180 Day Outcome		Long-term Risk		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome		Short-term Risk	
	7	8	9	10	11	12						
Covariates	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation	Code based: Naevi, mole removal, immunosuppressive conditions, Xeroderma pigmentosum, Photosensitizing drugs, Alcohol use, Actinic Keratosis, Bowen's disease, Human papillomavirus, Arsenic exposure, diabetes, drugs with suggested antineoplastic effects Custom: UV radiation
Covariate Evaluation Window	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0	-183, 0
Matching Ratio	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1	1:1
Matching Caliper	0.050	0.050	0.050	0.050	0.050	0.050	0.050	0.050	0.050	0.050	0.050	0.050
Analysis Type	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional	Unconditional
Additional Covariates to Adjust for in Cox Model	----	----	----	----	----	----	----	----	----	----	----	----

Appendix J. Specifications used to Define Parameters for Outcome 2 (Squamous Cell Carcinoma) in this Request													
Scenario	Primary Analysis: Extended Risk		Secondary Analysis: Extended Risk - 180 Day Outcome		Long-term Risk		Extended Risk - 2 Year Blackout		Extended Risk - 60 Day Outcome		Short-term Risk		
	7	8	9	10	11	12							
Subgroup Analysis	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)	Race (5 categories) Sex (Male and Female) Age (<50 years, 50-60 years, 60-75 years and 75+ years) Cumulative Dose (<10,000mg; 10,000 - 24,999mg; 25,000 - 49,999mg; 50,000 - 74,999mg; 75,000 - 99,999mg and >100,000mg)
Re-matching within Subgroup Restricted to Matched	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Effect Estimation	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	Risk set level data return	
Kaplan Meier Plot	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	

International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM) and Current Procedural Terminology, Fourth Edition (CPT-4) codes are provided by Optum360. National Drug Codes (NDCs) are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."

Appendix K. Design Diagram for this Request



^aUp to 45-day gaps in medical or pharmacy enrollment allowed

^bSee Table 1 for list of baseline covariates

^cEarliest of outcome diagnosis, health plan disenrollment, study end date (August 31, 2018), end of data availability, diagnosis of non-outcome cancer, use of chemotherapy or radiation therapy, or death

ACEI: Angiotensin-converting enzyme inhibitor

HCTZ: Hydrochlorothiazide

BCC: Basal cell carcinoma

SCC: Squamous cell carcinoma